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Abstract 
 
The rapid development and dissemination of antibiotic resistance in pathogenic 
bacteria requires new strategies and new structural scaffolds of antimicrobial compounds 
to be investigated. A developing trend targets virulence factors rather than pathways 
essential for survival in an effort to neutralize pathogens while minimizing the risk of 
resistance. The thesis focuses on the design of new molecules from peptides to 
peptidomimetics aimed at disrupting the bacterial periplasmic oxidative system, a new 
antivirulence target.  
 
This thesis initially describes in chapter I the recent emergence of peptidomimetics 
in antimicrobial treatments aimed at well-known mechanisms as well as novel targets. 
Peptidomimetics may be particularly efficient for disrupting protein-protein interactions and 
have been successful for instance in preventing post-translational modifications or the 
formation of pili machinery. The thesis also highlights the mechanism and context of the 
interaction between DsbA and DsbB, both primary factors in the periplasmic oxidative 
system of gram-negative bacteria and the target proteins of this PhD. 
 
Developing inhibitors requires a solid screening pipeline of biophysical assays to 
measure binding parameters such as affinity, thermodynamics and kinetics. Chapter II 
highlights the building and optimization of such a pipeline by evaluating differential 
scanning fluorimetry, isothermal titration calorimetry, surface plasmon resonance, 
substrate oxidation assay and crystallography in order to characterize the designed 
peptide scaffolds.  
 
Chapter III focuses on the structure-activity relationship studies of 31 manually 
synthesized peptide sequences screened through this pipeline. Based on peptide length 
scouting, alanine scanning and rational substitution of specific residues, a final heptameric 
peptide was found to bind Escherichia coli DsbA with a Kd of 2.9 ± 0.3 µM. Moreover, the 
data suggest a probable disulfide bond formation between peptide and DsbA essential to 
the binding interface, while cysteine-free peptides present very weak affinity towards 
EcDsbA. This chapter generated a manuscript submitted to the Journal of Medicinal 
Chemistry. 
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In a slightly different strategy, Chapter IV evaluates this best heptamer peptide 
sequence against a newly characterized Proteus Mirabilis DsbA, a structurally related 
protein (59% similarity with E. coli DsbA) showing promise for co-crystallization. With the 
peptide showing the same affinity against wild type E. coli and P. mirabilis DsbA, a high-
resolution (1.6 Å) co-crystal structure of the heptamer peptide bound to a cysteine mutant 
of P. mirabilis DsbA was solved. This structure shows the peptide binding to the P. 
mirabilis DsbA active site in a similar fashion to the native E. coli DsbA/DsbB interaction 
and differently from E. coli DsbA substrates. In-depth analysis of the high-resolution 
structure identifies two binding anchors, a H-bond-rich region and a hydrophobic pocket, 
which can be optimized for tighter affinities. This chapter generated a manuscript 
submitted to the Journal of Biological Chemistry. 
 
Based on the peptide structure-activity relationship studies and the DsbA peptide 
complex structure reported in the two previous chapters, Chapter V describes the initial 
steps in designing novel peptidomimetic scaffolds. These molecules include cyclic 
peptides, irreversible peptide binders and a tripeptide scaffold designed to target a specific 
hydrophobic groove on both E. coli and P. mirabilis DsbA surface. The tripeptide scaffold 
was characterized through the screening pipeline, including an intensive co-crystallization 
optimization.  
 
In summary, this thesis has employed a variety of assays and techniques to take a 
significant step towards the development of the first inhibitors targeting the oxidative 
folding system essential for bacterial virulence. Formation of a disulfide bond proved to be 
critical for ligand binding, and thus intense biochemical and structural investigation was 
executed to develop a potent inhibitory scaffold. This has lead to the characterization of 
the very first non-covalent peptide-DsbA crystal structure. The outcome of this research 
expands our understanding of the DsbA-DsbB interaction in different pathogenic bacteria 
and provides a peptide scaffold with high specificity as well as the optimization steps to be 
undertaken towards a potent and specific antivirulent peptidomimetic. 
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I.1 Current state of the antibiotic pipeline 
 
The emergence of bacterial strains presenting resistance to most antibiotic treatments, 
including the most recently approved on the market, is now a widespread concern and identified as 
one of the major healthcare issues of the next decade (The Bacterial Challenge: time to react, 2010, 
ECDC/EMEA). The World Health Organization characterized this phenomenon as one of the three 
greatest threats to human health (The 10 x '20 Initiative: pursuing a global commitment to develop 
10 new antibacterial drugs by 2020, 2010, IDSA). Antimicrobial resistance has become a major 
threat to human health across the globe, resulting in ≈25,000 deaths per year in developed regions 
of the world such as Europe with associated costs of > $2 billion in healthcare expenses and 
productivity (The Bacterial Challenge: time to react, 2010, ECDC/EMEA). In the United States of 
America (USA) alone, the Center for Disease Control and Prevention (CDC) reported more than 2 
million infections annually by antimicrobial resistant pathogenic strains resulting in ≈25,000 deaths 
(Antibiotics Resistance Threats in the United States, 2013, 2013).   
 
Antibiotic resistance has been observed and described since the early 1940’s, when 
Staphylococcus aureus strains were found to be resistant to penicillin even before its large-scale use 
as a treatment (Plough, 1945, Miller & Bohnhoff, 1945). This was the starting point of a race 
between the introduction of new antibacterial drugs and the emergence of drug resistance by 
pathogenic strains (Figure 1.1).  
	  
Figure 1.1. Timeline of the deployment and appearance of resistance against the major antibiotic 
classes. XDR = Extremely Drug Resistant, PDR = Pan Drug Resistant. Modified from (Antibiotics 
Resistance Threats in the United States, 2013, 2013). 
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The appearance and spread of resistance is enhanced by many factors: high global population 
growth, increased mobility, limited access to health facilities in many countries, misuse and 
overprescription of antibiotics (e.g. for treating viral infections for which they are ineffective), 
overuse (such as in animal feeding (Aarestrup, 2005)), low quality drugs (degraded and counterfeit 
antibiotics, (Okeke et al., 1999)) and the habit of self prescription (Grigoryan et al., 2010). 
 
Multidrug-resistant (MDR) bacteria have been reported around the world, limiting the 
efficiency of medication against a large array of common diseases such as sepsis, skin, burn and 
urinary tract infections, leading to the term ‘superbugs’ being coined (Boucher et al., 2009). These 
MDR strains are also qualified as extremely drug resistant (XDR) and in the case of resistance to 
the entire array of antimicrobial treatment as pan drug resistant (PDR). The Antimicrobial 
Availability Task Force at the Infectious Disease Society of America highlighted especially 
Acinetobacter baumannii, the Aspergillus species, the extended spectrum ß-lactamase (ESBL)–
producing Enterobacteriaceae, the vancomycin-resistant Enterococcus faecium, Pseudomonas 
aeruginosa, and the methicillin-resistant Staphylococcus aureus (MRSA) as highest threats (Talbot 
et al., 2006). 
 
Two different mechanisms can be involved in resistance development: firstly non-specific 
intrinsic resistance is achieved through the expression of proteolytic enzymes (degrading 
antimicrobial compounds reaching the cytoplasm) and membrane efflux pumps (Li & Nikaido, 
2009, Cox & Wright, 2013) expelling antibacterial molecules from the cytoplasm. Second, adaptive 
resistance involves the gain of long-term immunity towards specific molecular scaffolds through 
prolonged exposure by physically neutralizing the antibacterial drug or altering the therapeutic 
target (Rodriguez-Rojas et al., 2013). In addition, inter-species transfer of newly gained drug 
resistance to other sensitive strains contributes to the rapid spread of MDR strains (Davies, 1994). 
 
At the same time there has only been approval of six new antibiotic scaffolds over the past 
three decades: pseudomonic acid (mupirocin) in 1985 (Casewell & Hill, 1987), oxazolidinones in 
2000 (Ford et al., 2001), lipopeptides (daptomycin) in 2003 (Alder, 2005), pleuromutilin in 2007 
(Novak & Shlaes, 2010), fidaxomicin in 2011 (Johnson & Wilcox, 2012) and bedaquiline in 2012 
(Palomino & Martin, 2013). Resistance is already known for most of them (Shaw & Barbachyn, 
2011, Thomas et al., 2010, Li et al., 2013, Miller et al., 2013). Compared to the frequency of MDR 
strains discovered, this antibiotic pipeline is currently unable to cope with the rising demand for 
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new treatments. This has occurred despite the rapid development of new drug discovery 
technologies in the same period of time. It is partially caused by the limited profits to be expected 
from antibiotics due to the non-chronic nature of infection, the short duration of treatment and the 
increasing cost of drug development, estimated at more than $1.8 billion to take a lead molecule to 
the market (Paul et al., 2010). New antimicrobial drugs revenue will also be limited because of 
health policies restraining antibiotic prescriptions to slow down generation of resistance. Overall, 
the quantity of antimicrobial drugs in the medical pipeline is in constant decrease (Spellberg et al., 
2004, Butler et al., 2013)) along with pharmaceutical companies cancelling their antibacterial drug 
discovery programs.  
 
Overall, progress towards new antibiotics that use different targets or different mechanisms of 
action to subvert resistance is slow, and there is a real threat of a worldwide spread of lethal drug-
resistant bacteria.  This was exemplified by the recent outbreak of the New Delhi Metallo-beta-
lactamase 1 (NDM-1) pandemic strain presenting strong resistance against every medical treatment 
currently available (Deshpande et al., 2010). The situation calls for innovation about designing new 
classes of antibiotics and limiting the resistance to medical treatments (Butler & Cooper, 2012). 
Large-scale initiatives are currently being undertaken to tackle the problem and fuel the antibiotic 
pipeline (Cooper & Shlaes, 2011). In this perspective, the purpose of my PhD is to investigate a 
novel drug target, DsbA, by designing inhibitors that could potentially lead to a new antimicrobial 
scaffold thwarting drug resistance. 	  
I.2 EcDsbA as a novel target for antivirulence drug design 
 I.2.1 Background 
 
 The current struggle in the antibiotic pipeline with the shortage of new efficient antibacterial 
drugs not only requires the investigation of novel scaffolds but also the validation of new 
antimicrobial targets. One suggested approach is to inhibit the virulence system in bacteria to 
reduce selective pressure compared with targeting pathways essential for survival, hence potentially 
leading to a diminished mutation rate towards drug resistance (Rasko & Sperandio, 2010, 
Clatworthy et al., 2007). Additionally, by specifically targeting virulence pathways, such a drug 
might not affect the host endogenous microbiota hence limiting side effects. Disulfide bond forming 
protein A (DsbA) has been highlighted as a key target in this endeavor against pathogenic Gram-
negative bacteria (Heras et al., 2009) and is described in the section below.  
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The process of oxidative folding, i.e. the catalysis of protein folding through disulfide bond 
formation, has been detected in most pathogenic members of the Enterobacteriaceae family and in 
other Gram-negative pathogenic species (Dutton et al., 2008). In the archetypal model of oxidative 
folding, the machinery includes a soluble thioredoxin-fold protein, DsbA, and a membrane-bound 
partner, DsbB, located in the oxidizing environment of the intermembrane space, or periplasm 
(Wunderlich & Glockshuber, 1993, Bardwell et al., 1991, Bardwell et al., 1993, Martin et al., 
1993). DsbA is the primary oxidizing enzyme triggering the introduction of disulfide bonds into 
unfolded substrates freshly translocated into the periplasm (Bardwell et al., 1991) while DsbB 
regenerates DsbA to its active oxidized form (Figure 1.2) (Regeimbal & Bardwell, 2002).  
 
 
Figure 1.2. Perisplasmic oxidative folding mechanism. DsbA (in its oxidized form) is a powerful 
oxidase catalyzing the formation of a disulfide bond between two free cysteines in a substrate 
molecule, leading to a functional folded protein. DsbA in the reduced form transfers electrons to the 
transmembrane partner DsbB and is regenerated into the oxidized active form. These electrons are 
then transferred to a ubiquinone molecule (UQ) and transported to the respiratory system. 
Modified from (Inaba & Ito, 2008).  
 
The first DsbA protein was discovered in Escherichia coli in 1991 (Bardwell et al., 1991) 
and the crystal structure solved in 1993 (Martin et al., 1993). Since then, many homologues from a 
variety of pathogenic Gram-negative bacteria have been structurally and functionally characterized 
(Kurth et al., 2013, Shouldice et al., 2011). Importantly, many substrates of DsbA are essential for 
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virulence pathways (Table 1.1) (Heras et al., 2009, Ha et al., 2003): for example mutation of 
Escherichia coli DsbA (EcDsbA) prevents pili and flagella formation (Jacob-Dubuisson et al., 
1994, Hultgren et al., 1993, Bringer et al., 2007, Dailey & Berg, 1993), assembly of the type III 
secretion complex (Miki et al., 2008), interaction with the host cell during infection (Vallance & 
Finlay, 2000, Bringer et al., 2007), and the functional (but not structural) integrity of the bacterial 
membranes (Ruiz et al., 2010). DsbA is also responsible for the correct folding of toxins, such as 
the enterolabile toxin in E. coli (Foreman et al., 1995, Wulfing & Rappuoli, 1997), the cholera toxin 
in Vibrio cholerae (Peek & Taylor, 1992, Yu et al., 1992) and pertussis toxin in Bordetella 
pertussis (Stenson & Weiss, 2002).  Therefore, it was suggested that silencing DsbA enzymatic 
activity might ultimately lead to the disruption of virulence factor maturation and consequently 
impede infection (Heras et al., 2009). To support this, a knock-out of dsbA/dsbB null uropathogenic 
E. coli (UPEC) cells are severely attenuated in a mouse infection model and unable to colonize the 
bladder though they remain viable (Totsika et al., 2009b), fitting the expected phenotype of the 
antivirulence strategy.  
 
 
Table 1.1. Selected substrates of DsbA involved in bacterial virulence. Modified from (Heras et 
al., 2009) 
 	  	  
Organism DsbA substrate Substrate function 
Adhesion   
Uropathogenic E. coli PapD Molecular chaperone of P fimbriae 
Enteropathogenic E. coli BfpA Major structural subunit of bundle-
forming pili 
Salmonella enterica PefA Major structural subunit of plasmid-
encoded fimbriae 
Toxin production and secretion   
Enterotoxigenic E coli ST8 Heat-stable enterotoxin 
Enterotoxigenic E. coli LT Heat-labile enterotoxin 
Bordetalla pertussis S1 and S2 Pertussis toxin A and B subunits  
Vibrio cholerae Unknown  
Type III secretion system (T3SS)   
Enteropathogenic E. coli EscC Outer membrane secretin of T3SS 
Salmonella enterica SpiA Outer membrane secretin of T3SS 
Motility   
E. coli Flgl Flagellar P-ring motor protein 
Outer membrane function   
E. coli  LptD Lipopolysaccharide transporter !
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I.2.2 Escherichia coli DsbA, structure and mechanism 
 
My project focuses primarily on developing inhibitors able to attenuate pathogenic strains of 
E. coli. From a potent scaffold against EcDsbA, derivatives could potentially be designed in the 
future targeting structurally similar DsbA enzymes from different pathogenic species or genus. 
Structurally, EcDsbA belongs to the thioredoxin related (TRX) protein family consisting of a 
classical thioredoxin domain with an inserted four α-helix domain (Figure 1.3) (Martin et al., 
1993). Residues 1 to 62 (β1-2, α1, β3) which harbor the catalytic site 30CPHC33 and residues 139 to 
189 (α6, β4-5, α7) which include the highly conserved cis-Pro loop region form the TRX domain, 
conferring the enzyme DsbA-like redox properties and its enzymatic reactivity (Charbonnier et al., 
1999). The α-helical domain comprises residues 63 to 138 (N-term α6, α2-5) and is embedded into 
the thioredoxin fold.  
 
Figure 1.3. Crystal structure of oxidized EcDsbA. The structure of EcDsbA (PDB code: 1DSB) is 
composed of a TRX domain (β1-5, α1, α6-7, in brown) and a α-helical domain (α2-5, in blue). The 
two thiolates from the catalytic cysteines Cys30 and Cys33 are shown as yellow spheres. The 
conserved cisPro loop region, contributing to the activity and stability of EcDsbA is located in the 
TRX domain between the α6 C-terminal end and ß4, in close proximity to the catalytic cysteines.  
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EcDsbA shares three typical properties with its homologues:  
1) A CXXC motif, in this case 30CPHC33, includes the two active site cysteines essential for 
catalysis of redox reactions (Walker et al., 1996). DsbA in its oxidized form presents an 
intramolecular disulfide bond between Cys30 and Cys33 that destabilizes the enzyme (Zapun et al., 
1993): the unfolding temperature of reduced EcDsbA is 8 K higher than that of the oxidized state 
(redEcDsbA: 350K, oxEcDsbA: 342 K Heras et al., 2008)). Two residues varying according to the 
bacterial species (in E. coli Pro31 and His32) separate the catalytic cysteines and provide an 
electrostatic contribution to the enzyme stability (Guddat et al., 1997). It was also shown that 
modification of these two intermediate residues shifts the pKa and the redox potential of DsbA 
(Kortemme et al., 1996, Chivers et al., 1997).  
2) A highly acidic and nucleophilic cysteine, here Cys30, presents an uncommonly low pKa 
of 3.3 in EcDsbA (Huber-Wunderlich & Glockshuber, 1998) (with an average of 3.5 over the DsbA 
family). Cysteine residues in most proteins have a pKa around 8.3 (Karala et al., 2010). This feature 
ensures that reduced Cys30 will always be in the anion thiolate form in physiological environment, 
thus able to perform nucleophilic attacks.   
3) A highly oxidizing potential, -122 mV for EcDsbA (Huber-Wunderlich & Glockshuber, 
1998), with the range for the DsbA protein family varying from -80 mV to -163 mV (Kurth et al., 
2013). In contrast, the redox potential of E. coli cytoplasmic thioredoxin Trx is much more reducing 
with a redox potential of -270 mV (Aslund et al., 1997). 
 
EcDsbA catalyzes the formation of a disulfide in unfolded substrates by using a bimolecular 
nucleophilic substitution reaction (Fernandes & Ramos, 2004, Inaba, Murakami, et al., 2006, Frech 
et al., 1996, Kadokura & Beckwith, 2009). A substrate thiolate group starts with a nucleophilic 
attack on oxidized EcDsbA Cys30, breaking the disulfide bond with EcDsbA Cys33 and leading to 
the formation of an intermolecular disulfide bond between enzyme and substrate (Figure 1.4). In 
the second phase, another substrate thiolate triggers nucleophilic attack on the first thiolate, forming 
a disulfide bond and folding the substrate while EcDsbA is released in its reduced and inactive 
form. The substrate binding site on EcDsbA can be considered as a therapeutic target, but since 
EcDsbA accepts hundreds of protein substrates the specificity and selectivity (and thus the interest 
in drug design) of this interaction is questionable.  
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Figure 1.4. Nucleophilic substitution between EcDsbA and a substrate protein, leading to the 
transfer of a disulfide bond to the substrate molecule. The nucleophilic attack of a substrate free 
cysteine thiolate functionality on EcDsbA Cys30 (left panel) leads to the formation of an 
intermolecular disulfide bond (center). Second nucleophilic attack from a neighboring free cysteine 
in the substrate triggers the release of EcDsbA in its reduced and inactivated form (right panel).  
 
Reduced EcDsbA with two free cysteines Cys30 and Cys33 then binds to the partner 
EcDsbB to regenerate the active oxidized form (Figure 1.2). EcDsbB has four transmembrane 
helices and mediates shuttling of EcDsbA between its reactive oxidized and inactive reduced state 
(Inaba, Murakami, et al., 2006). EcDsbB, which shows strict binding specificity for EcDsbA, 
possesses two periplasmic loops (P1 and P2) each containing one pair of cysteines (P1 = C41/C44, 
P2 = C130/ C104) (Inaba, Murakami, et al., 2006). Transfer of the disulfide bond to EcDsbA also 
occurs through a bimolecular nucleophilic substitution reaction: EcDsbA Cys30 starts a 
nucleophilic attack on oxidized EcDsbB Cys104, followed by nucleophilic attack of EcDsbA Cys33 
onto Cys30, restoring the disulfide bond and releasing EcDsbA in the oxidized form. The additional 
electrons on EcDsbB Cys104 are transferred to a ubiquinone molecule through concerted disulfide 
bond exchange with EcDsbB Cys130, Cys41 and Cys44 (Inaba, Takahashi, et al., 2006). The 
charged ubiquinone finally exchanges these electrons with the membrane bound respiratory system 
(Figure 1.2).  
 
Both EcDsbA-EcDsbB and EcDsbB-ubiquinone interactions are promising targets for drug 
discovery, as their inhibition might force EcDsbA to remain in its reduced hence inactive state. The 
EcDsbB-ubiquinone interaction is not addressed in this thesis. However, the EcDsbA-EcDsbB 
interaction offers great potential: the interaction may be more specific than the EcDsbA substrate 
binding site, and the structure of the EcDsbA-EcDsbB complex has already been reported (Inaba, 
Murakami, et al., 2006, Malojcic et al., 2008, Inaba et al., 2009b). To date no rational design of 
ligands towards DsbA has been reported (Shouldice et al., 2011) and structural scaffolds able to 
inhibit EcDsbA activity remain to be identified. Moreover, the protein-protein interaction provides 
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an interesting starting point for the design of peptides and peptidomimetics. A structure-based drug 
design strategy based on the EcDsbA-EcDsbB interaction was the focus of my PhD project. 
 
I.2.3 Characterization of the EcDsbB binding site on EcDsbA  
 
The EcDsbB-binding site on the EcDsbA surface is well known: three different co-crystal 
structures of the EcDsbA-EcDsbB complexes have been solved in the past seven years (Inaba et al., 
2009a, Malojcic et al., 2008, Inaba, Murakami, et al., 2006). Due to the brevity of the transitional 
state between EcDsbA and EcDsbB (Inaba et al., 2004, Inaba et al., 2005), it was necessary to 
engineer a stable complex bound by a non-resolvable intermolecular disulfide bond using cysteine 
mutants of one or both proteins (EcDsbB-C130S and/or EcDsbA-C33A, Figure 1.5) (Guilhot et al., 
1995, Kishigami et al., 1995).  
 
 
Figure 1.5. Formation of an irreversible DsbA/DsbB complex. Mutations of the second cysteine in 
the catalytic dyad of DsbA (Cys33Ala) and/or DsbB (Cys130Ser) prevented the resolution of the 
intermolecular disulfide bond and thus impeded the release of EcDsbA in its active form. The 
complex formed from the mutants was stable and suitable for co-crystallization. 
 
In the 3.7 Å resolution structure of EcDsbA-EcDsbB (PDB ID: 2ZUP) the EcDsbB 
periplasmic loop P2 98PSPFATCDFMVR109 binds within a hydrophobic groove between EcDsbA 
helixes α1 and α7 formed by aromatic residues Phe36, Phe174 and Tyr178 and aliphatic residues 
Leu40 and Ile42 (Figure 1.6). This region had been predicted to interact with partner or substrate 
proteins prior to the complex crystal structure (Martin et al., 1993). The EcDsbB P2 loop also 
interacts on the shallow surface of EcDsbA, next to the EcDsbA 30CPHC33 catalytic motif triggering 
formation of a disulfide bond between EcDsbB Cys104 and EcDsbA Cys30, and also interacts with 
the cisPro loop.  
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Figure 1. 6. Two representations of the EcDsbAC33A – EcDsbBC130S complex from the 3.7 Å 
resolution crystal structure by Inaba et al. (Inaba, Murakami, et al., 2006). A. The model showed 
the EcDsbB periplasmic loop (in blue) to bind on the surface of EcDsbA (in light brown) making 
contacts with helices α1 and α7 and the cisPro loop. B. The EcDsbB periplasmic loop P2 (in blue 
with residues labeled) binds into the EcDsbA hydrophobic pocket (in orange). A disulfide bond 
linking EcDsbA Cys30 to EcDsbB Cys104 (both in yellow) covalently locks the two mutants and the 
EcDsbAC33A and EcDsbB C130S mutations prevent the mixed disulfide bond from being resolved. 
The predicted hydrogen bond between EcDsbA Arg148 and EcDsbA Phe106 is shown as a blue 
dashed line and highlighted in blue.  
 
NMR studies of the complex showed that additional contacts are made by EcDsbB residues 
126ASGDCA131 with the EcDsbA β3-α2 loop next to the 30CPHC33 motif on the side opposite to the 
hydrophobic patch (Zhou et al., 2008). EcDsbA Met64 is suspected to play a role in the separation 
between EcDsbB Cys104 and Cys130 for binding to EcDsbA Cys30; mutation of this residue to 
Gly or Ala leads to a significant decrease of the enzyme kinetics (Inaba et al., 2009a). It is worth 
noting that the molecular mechanisms underlying the EcDsbA-DsbB interaction were interpreted 
based on a 3.7 Å crystal structure, therefore the initial working model might be slightly biaised. 
Submission of the EcDsbB-EcDsbA interface to the PDBsum server identifies interactions at the 
interface in addition to the EcDsbA Cys30 - EcDsbB Cys104 disulfide bond. Indeed, every residue 
from EcDsbB loop P2 sequence 98PSPFATCDFMVR109 presents hydrophobic contacts with the 
EcDsbA surface (Shouldice et al., 2011). A hydrogen bond is predicted between EcDsbB Phe106 
backbone and EcDsbA Arg148 backbone on the cisPro loop (Figure 1.6), suggesting there are more 
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interactions at play than the driving force of the disulfide bond that could be exploited for the 
development of a potent scaffold. 
 
I.2.4. Analysis of the additional DsbA-ligand complex structures  
 
A structure-based drug design strategy requires the analysis of the available DsbA-ligand 
crystal structures to provide additional information that can shed light on the ligand binding mode 
and specificity towards DsbA. The number of solved DsbA protein structures has rapidly increased 
within recent years, some of them including ligands. Two of these DsbA structures incorporate 
small molecules (Shouldice et al., 2010, Kurz et al., 2009, Crow et al., 2009) and two were solved 
with peptides bound (Rinaldi et al., 2009, Paxman et al., 2009b) (Figure 1.7). The small molecules 
(glycerol and polyethylene glycol) present little interest for drug design purposes.  
 
The recently characterized Xyfella fastidiosa DsbA was fortuitously cocrystallized (PDB ID: 
2REM) with an octamer peptide ligand (Rinaldi et al., 2009). Careful analysis reveals that the 
ligand binds within the hydrophobic pocket and close to the catalytic cysteine motif. Compared 
with the EcDsbA-EcDsbB structure, this polypeptide chain binds in a similar fashion to the EcDsbB 
P2 loop. However, the poor quality of the electronic density map only allowed fitting of an Ala-
Ala-Ala-Ala-Ala-Gly-Gly-Ala polypeptide chain, giving little information about the specific 
interaction between peptide side chains and the DsbA surface.  
 
In the second structure a known substrate peptide from autotransporter protein SigA was 
covalently linked by a thioether bond to EcDsbA Cys30 (PDB ID: 3DKS) (Paxman et al., 2009b). 
The peptide of sequence PIPFL(Hse)QKD adopts a conformation very different from the EcDsbB 
loop. The SigA peptide interacts at the interface with the thioredoxin and the α-helical domains of 
EcDsbA, in particular with EcDsbA Phe29, Phe63, Met64 and Arg148, but no interactions are 
present between the SigA peptide and the hydrophobic groove (Paxman et al., 2009b). 
Consequently, the binding mode differing from the EcDsbB loop presents limited interested in the 
design of inhibitors of the EcDsbA-EcDsbB interaction.  
 
 
	  	  	  Chapter	  I	  –	  General	  introduction	  	  	  
	   13	  
 
Figure 1.7. Surface representation of reported DsbA-ligand crystal structures. Top left, EcDsbA 
in light brown with the EcDsbB loop in green. Top center, Xyfella fastidiosa DsbA in black with an 
unknown peptide sequence in green. Top right, EcDsbA in pink with a SigA substrate derivative 
peptide in green. Bottom left, Wolbachia pipientis αDsbA1 in pink with a bound polyethylene glycol 
molecule in green. Bottom right, Pseudomonas aeruginosa DsbA in orange with two glycerol 
molecules in green. Catalytic cysteines are shown in yellow. Besides EcDsbB, the only reported 
ligand binding to the DsbA hydrophobic pocket is the polypeptide chain interacting with XfDsbA, 
but the poor resolution prevented the accurate modeling of residues.  
 
 Taken together, the best available structure from which to start designing peptidic inhibitors 
for the EcDsbB-binding site on EcDsbA is the 3.7 Å resolution EcDsbB-EcDsbA complex crystal 
structure itself. Although lacking a secondary structure, the disordered loop provided an amino acid 
sequence from which the initial ligands could be based, mimicking the binding properties to interact 
with EcDsbA. One approach is to use peptides that offer the possibility to reproduce the DsbB loop 
backbone and side chains. Moreover the development of peptides as drugs is an emerging field in 
the world of antibiotics and the recently acquired knowledge could prove useful to develop an 
inhibitor of the EcDsbA-EcDsbB interaction.  	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I.3 Peptides as antimicrobial drugs 	  
 
The EcDsbB periplasmic loop P2 provides a suitable starting point for the design of peptide 
sequences targeting the binding of EcDsbA. My project was to identify and optimize such peptide 
sequences. These peptides would also present an ideal basis for the development of 
peptidomimetics, an emerging field of antimicrobial molecules. The purpose of antimicrobial 
peptidomimetics is to improve the overall efficiency of a peptide scaffold and novel strategies are 
meeting growing success as described in the section below. In this project the design of 
peptidomimetics could potentially lead to novel scaffolds that trigger significant inhibition of the 
EcDsbA folding activity.  
 
I.3.1 Antimicrobial peptides (AMP) 
 
A promising field of research for new antibiotics focuses on natural antimicrobial peptides 
(AMP), particularly from eukaryotic organisms. AMPs are typically amino acid chains up to 50 
residues in length synthesized ribosomally (involving mRNA translation) rather than non-ribosomal 
‘natural products’ antibiotics, and featuring bactericidal and/or fungicidal properties. AMPs were 
initially characterized in the 1980s and proved to be a vital component of many organisms’ innate 
immune system (Antimicrobial Sequences Database). For detailed reviews on AMPs see (McPhee 
& Hancock, 2005, Powers & Hancock, 2003, Nguyen et al., 2011).  
 
The majority of AMPs act in an indiscriminate manner disrupting the bacterial and fungal 
membrane, hence differing from traditional antibiotics that have specific targets. The versatility of 
AMPs is very high, and the large reservoir of natural peptides available can lead to fruitful drug 
development though structure-activity relationship (SAR) studies. The amino acid sequence of 
membrane-disruptors is less relevant for antibacterial efficiency than the physicochemical 
properties, such as charge and hydrophobicity, which also regulate the specificity towards the 
bacterial membrane rather than the mammalian ones (Tossi et al., 2000). All membrane disrupting 
mechanisms identified to date involve interactions between positive charges on the antibiotic 
(“cationic” peptide) and the negatively charged lipid of the outer membrane, together with a 
hydrophobic moiety to interact with the fatty acyl chains, ultimately leading to membrane 
degradation. Many structural groups of AMPs have been defined (Figure 1.8).  
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Figure 1.8. Selected examples of natural AMPs. A. Structure of dermcidin (PDB code 2KSG), an 
AMP from human origin inducing membrane depolarization (Song et al., 2013). B. Structure of 
indolicidin (PDB code 1G89), a tryptophan-rich peptide from bovine origin triggering inner 
membrane polarization. (Falla et al., 1996) C. Structure of magainin 2 (PDB code 2MAG), an α-
helical AMP of amphibian origin forming pores in the membrane leading to cell lysis (Imura et al., 
2008). D. Structure of daptomycin, a cyclic AMP from bacterial origin that causes membrane 
aggregation and loss of membrane potential (Pogliano et al., 2012). 
 
For example, α-helical AMPs possess the ability to penetrate and span across the thickness of 
the lipid bilayer triggering the formation of pores or breaking off the membrane into micelles 
(Zasloff, 2002, Haney et al., 2009, Holt & Killian, 2010). β-sheet AMPs, composed of β-hairpin 
peptides, are able to form β-barrels in lipid bilayers as well as β-sheets on their surface, also 
disrupting the membrane structure (Tang & Hong, 2009). Extended AMPs incorporate a high 
percentage of selected residues, usually Arg and Trp, and cause membrane leakage through 
formation of ‘barrel-stave’ pores in the lipid bilayer (Chan et al., 2006).  
 
Some natural peptides are also cyclized to link the termini and/or residue side chains together, 
thereby limiting conformational flexibility. These structural restraints offer advantages in stability 
and specificity. Indeed, cyclic peptides are not substrates for proteases. Moreover, stabilized pre-
organized three-dimensional structure can result in high-affinity interactions with a target protein. 
Consequently, many cyclic peptides are membrane-inactive and instead target specific protein-
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protein interactions (PPI) essential for bacterial viability. Many antibiotics already in clinical use 
are cyclic peptides, such as colistin, polymyxin b and daptomycin.  Some antimicrobial peptides are 
polycyclic (two or more cycles) such as vancomycin, nisin and actinomycin D and are frequently 
used in the clinic (Baeriswyl & Heinis, 2013).  
 
AMPs promised a solution to the microbial resistance issue (Peschel & Sahl, 2006): instead of 
local mutations bacteria would need to substantially alter the composition of the lipid membrane 
thus compromising other essential pathways (Zasloff, 2002, Schroder, 1999, Hancock & Chapple, 
1999). However, this prediction about microbial resistance has since been criticized (Bell & 
Gouyon, 2003, Tzeng et al., 2005, Kraus & Peschel, 2006, 2008). A very large number of AMPs 
have been identified but apart from a few exceptions presently on the market (Leader et al., 2008) 
natural peptides offer little prospect as drug candidates for the following properties: 1) poor stability 
due to the sensitivity to proteases (with a lifetime of a few minutes in serum and tissues (Pollaro & 
Heinis, 2010)), 2) high sensitivity to pH and salts (Goldman et al., 1997, Bals et al., 1998, Rydlo et 
al., 2006, Lee et al., 1997), 3) their large size limiting large-scale manufacturing and 4) poor 
pharmacokinetics combined with high immunogenicity (Latham, 1999). These drawbacks have led 
to the generation of peptide analogues that can mimic AMP properties, so-called peptidomimetics.  
 
I.3.2 Emergence of peptidomimetics 
 
The term peptidomimetics embraces here any molecule derived from a peptide or a protein 
fragment, but not limited to the natural peptide backbone and the natural 20 α-amino acids. This 
includes de novo scaffolds, semi-synthetic peptides and even small molecules on which a peptide 
group was grafted. Here, I focus on artificial or synthetic modifications made to molecules of 
peptidic origin, and will not include natural products falling within this definition.  
 
Apart from the large reservoir of natural AMPs to use as starting points, a certain advantage 
of peptidomimetics as drug candidates compared to natural peptides is that they enable a broad 
array of variations for stability, activity, solubility or bioavailability as well as various secondary 
structures (e.g. helices, ß-sheets, etc) based on simple modifications of the peptide backbone or 
specific side chains (also called multidimensional optimization (Satyanarayanajois & Hill, 2011)). 
Structure-activity relationship (SAR) studies lead to the emergence of new structural classes of 
peptidomimetics: for example β-peptides incorporate an additional carbon atom in the peptide 
	  	  	  Chapter	  I	  –	  General	  introduction	  	  	  
	   17	  
backbone and are able to fold into secondary structures such as helices and ß-sheet-like structures 
(Figure 1.9). The different class of peptoids presents residues with side chains attached to the 
nitrogen atom of the backbone amide functionality rather than the α-carbon. These simple 
transformations confer a far greater resistance to peptidases (Zuckermann et al., 1994, Weinstock et 
al., 2012).  
 
 
Figure 1.9. Selected examples of peptide backbone modifications providing resistance against 
peptidases. A. ‘natural’ α-amino acid. B. Peptoid. C. β2-peptide. D. β3-peptide. E. β-peptoid. 
 
Beside the ability of AMP peptidomimetics to bind bacterial membranes, peptidomimetics 
have the ability to mimic protein-protein interactions (PPI).  Peptidomimetics can also adopt 
secondary structures such as ß-hairpins (Robinson, 2008), helices (Fischer et al., 2010) and ß-sheets 
(Hammond et al., 2006) to mimic recognition motifs specific to PPI (Figure 1.10).  
 
 
Figure 1.10. Selected examples of peptidomimetics adopting secondary structure motifs. A. 
Structure of a ß-hairpin mimetic. To contrast, a ‘natural’ ß-hairpin peptide relies on disulfide 
bonds to adopt such a conformation. B. Sequence and tridimensional model of an α-helix mimetic. 
Reproduced and modified from (Fischer et al., 2010). 
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Therefore, by developing inhibitors based on the structure of known partners, 
peptidomimetics might aim at novel targets not limited to the membrane. For drug design purposes, 
the possibility of conserving natural peptides antimicrobial activities with a much smaller molecular 
size also contributes to better druggability. Generally, small peptidomimetics (≤ 5 amino acids) fall 
into the set of Lipinski “rule of 5” (molecular weight ≤ 500 Da, LogP ≤ 5, ≤ 5 hydrogen donors, ≤ 
10 hydrogen acceptors (Lipinski et al., 2001))  adapted for antibiotics (O'Shea & Moser, 2008), and 
side chain variations offer convenient optimization options for them.  
 
The following sections highlight innovations that peptidomimetics can offer to help fight the 
new MDR pathogenic strains. Rather than an exhaustive list of antimicrobial peptidomimetics 
produced to date, it illustrates some important advantages of using peptidomimetics as novel 
antimicrobial scaffolds through selected successful drug design approaches not limited to 
membrane disruptors (Table 1.2). Additional reviews about antimicrobial peptidomimetics are 
available elsewhere (Niu et al., 2012, Ung & Winkler, 2011, Liskamp et al., 2011, Giuliani & 
Rinaldi, 2011, Rotem & Mor, 2009, Chongsiriwatana et al., 2008, Nguyen et al., 2011, Ahn et al., 
2002, Vaara, 2009, Bragonzi, 2010, Hatahet & Ruddock, 2009, Patch & Barron, 2002). The 
examples below were selected to demonstrate the diversity in the mechanisms of action that are part 
of the peptidomimetic weaponry.  
 
Table 1.2. Summary of the peptidomimetic targets and mechanisms approached in this chapter.  
Peptidomimetic Gram +/- Target specie(s) Mechanism Drug 
Phase 
reached 
PDF inhibitors Both 
E. coli, M. tuberculosis, S. 
aureus, P. aeruginosa, E. 
faecium 
Binding peptide deformylase 
to prevent post translational 
protein maturation 
BB-81384, 
LBM415 
Ongoing 
Phase I 
Oligoacyllysines 
(OAK) Both 
E. coli, S. aureus, S. enterica, 
K. pneumoniae, P. 
aeruginosa, P. mirabilis 
Membrane depolarization, 
DNA binding, / / 
ß-hairpin 
macrocycles Gram - P. aeruginosa Membrane disruption POL7080 
Completed 
Phase I 
Arylamides Both E. coli, S. aureus, P. aeruginosa, K. pneumoniae Membrane permeabilization 
PMX-30063 
(Briladicin) 
Completed 
Phase IIa 
Pilicides Gram - E. coli Inhibition of chaperones necessary for pili formation / / 
EP inhibitors Gram - P. aeruginosa Blocking efflux pumps / / 
G6PS inhibitors Both E. coli, S. aureus, B. subtilis Blocking cell wall synthesis / / 
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I.3.3 Improving potency and pharmacokinetics: bacterial peptide 
deformylase (PDF) inhibitors 
 
Some traditional antibiotic scaffolds directly target the bacterial translation mechanism (such 
as the ribosome subunits 16S and 50S (Lambert, 2012)), but an alternative way to prevent proteins 
from functioning is to inhibit post-translational modifications (Hatahet & Ruddock, 2009). 
Peptidomimetics have been developed to bind the bacterial peptide deformylase (PDF) (Huntington 
et al., 2000), an essential metalloenzyme present in most of the bacterial world and identified as a 
novel antimicrobial target (Mazel et al., 1994, Meinnel & Blanquet, 1994, Sharma et al., 2009). 
PDF specifically cleaves the N-terminal formyl moiety resulting from N-formylmethionine 
initiating ribosomal translation, hence allowing further maturation of the folding protein. The 
development of peptidomimetic BB-3497 that reached human clinical trials is a typical example of 
peptidomimetic design. 
 
 On the one hand, peptides and peptidomimetic molecules mimicking PDF substrates were 
screened using an activity assay to evaluate the simplest potent scaffold in vitro (Meinnel et al., 
1999). It resulted in dipeptide HS-CH2-Nle-Arg-OCH3 (Figure 1.11A) showing low micromolar 
affinity towards PDF in vitro (Kd 2.5 ± 0.5 µM) but poor antibacterial activity. On the other hand, 
screening of a large library of small compounds for PDF inhibitors identified actinonine (Chen et 
al., 2000) (Figure 1.11B) as a natural antibacterial agent. The antimicrobial activity of actinonine 
was recognized in the early 1960s but its mechanism of action was unknown then (Gordon et al., 
1962). Consequently, Clements et al. screened an in-house database of metalloenzyme inhibitors 
(Clements et al., 2001) resulting in one peptidomimetic hit, BB-3497, sharing striking structural 
similarities with both natural substrates of PDF and actinonine (Figure 1.11C). BB-3497 featured 
minimal inhibitory concentrations (MIC, the lowest concentration of an antimicrobial necessary to 
completely impede bacterial growth) and bioavailability more potent than actinonine (against 
different strains of E. coli 0.125 µg/mL ≤ MIC ≤ 8 µg/mL). The crystal structure of the BB-3497-
bound PDF was solved for SAR studies to further develop non-natural side chains on the peptidic 
backbone (Clements et al., 2001). The knowledge of the structure allowed investigation of essential 
positions on the BB-3497 scaffold (Figure 1.11D), thereby allowing modification for 
peptidomimetics.  
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Figure 1.11. Peptidomimetic inhibitors of bacterial PDF. A. dipeptide HS-CH2-Nle-Arg-OCH3 
from peptide designed against PDF. B. Natural antimicrobial actinonine was identified as a PDF 
inhibitor through a step of library screening. C. The metalloenzyme inhibitor BB-3497 shares 
structural similarities with actinonine and HS-CH2-Nle-Arg-OCH3. D. Peptide scaffold on which 
peptidomimetic inhibitors of PDF are synthesized and tested. E. The ‘hit’ peptidomimetic BB-81834 
derived from SAR (based on the scaffold in panel D) now in clinical trials. F. Macrocyclic scaffold 
based on BB-3497. G. Another PDF inhibitor LBM-415, also in clinical trials, presents similarities 
with BB-81834. Modified from (Meinnel et al., 1999, East et al., 2004, Azoulay-Dupuis et al., 2004, 
Anderegg & Jones, 2004, Clements et al., 2001, Chen et al., 2000). 
 
The N-formyl hydroxylamine functional group was replaced by similar metal binding groups 
(Smith et al., 2002) found in other metalloenzyme inhibitors. The optimal distance between the 
metal-binding group and the peptide residues was investigated (Davies, Ayscough, Beckett, Bragg, 
et al., 2003). The optimal side chains P1’ (Davies, Ayscough, Beckett, Bragg, et al., 2003), P2’ and 
P3’ (Davies, Ayscough, Beckett, Clements, et al., 2003, East et al., 2004) were identified, leading 
to the design of the peptidomimetic BB-81384 (Figure 1.11E). This compound had promising 
pharmacokinetics and oral bioavailability against a large array of bacterial strains including 
Staphylococcus aureus (Gross et al., 2004, Azoulay-Dupuis et al., 2004). Another standard 
peptidomimetic approach was also tested, using the cyclization of the side chains P2’ and P3’, 
resulting in an increase in potency and stability (Figure 1.11F) (Hu et al., 2003, Nguyen et al., 
2004). A second peptidomimetic inhibitor, LBM415 (previously NVP-PDF 713), whose design 
process has not been disclosed, presented a remarkably similar scaffold (Figure 1.11G) and 
demonstrated high potency towards a wide spectrum of pathogens (Credito et al., 2004, Ednie et al., 
2004, Anderegg et al., 2003, Anderegg & Jones, 2004, Gordon et al., 2003, Jones, Fritsche, et al., 
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2004, Jones, Moet, et al., 2004, Osborne et al., 2009).  Both BB-81384 and LBM415 are 
undergoing phase I clinical trials (Rolan et al., 2011). 
 
 In this first case the design of peptidomimetics is suited for the fusion of two different 
approaches - small molecule screening and rational peptide design – leading to improved potency 
regarding natural products, such as actinonine, and better pharmacokinetics that allowed two lead 
peptidomimetic molecules to enter clinical trials.  
 
I.3.4 Thwarting ‘adaptive’ resistance: β-peptides and peptoids 
 
Peptides and peptidomimetics can be inactivated by peptidases, seriously limiting their 
stability in serum. This can be overcome through simple peptide backbone alterations, such as the 
introduction of an extra carbon atom between the α-carbon and the amide moiety (β-peptides), the 
linkage of the side chain on the amide nitrogen atom (α-peptoids) or a combination of both (β-
peptoids). The effect of such backbone modifications goes beyond improved stability: recent studies 
suggest that such peptidomimetics evade traditional resistance mechanisms in MDR E. coli 
(Jahnsen et al., 2012), increase antibacterial activity and lower hemolytic properties 
(Chongsiriwatana et al., 2008).  
 
   
Figure 1.12. Examples of peptoid inhibitor alternatives of AMP sequences that evade AMP 
resistance in bacteria. A. Example of an active alternate α-amino acid/peptoid residue scaffold, 
while the α-amino acid sequence is no longer potent due to bacterial resistance. B. An example of 
amphiphilic cyclic peptoid, combining alternate hydrophobic (Phe) and positively charged (Lys) 
residues. Modified from (Jahnsen et al., 2012, Huang et al., 2012)  
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Pointing out that most peptidomimetic studies focus on side chain alterations specific to 
their mode of action, Jahnsen et al. analyzed backbone alterations on simple AMP mimetics 
(Jahnsen et al., 2012). From Ac-(Lys-Phe)8-NH2 AMP sequence (with typical AMP features 
combining alternative cationic –Lys- and hydrophobic –Phe- components), they designed and 
synthesized hybrid peptidomimetics incorporating only α-peptoids, β-peptoids or β-aminoacids or 
replacing every second residue with α-aminoacids (Figure 1.12A). They subsequently tested their 
antibacterial efficiency against three MDR strains of E. coli, two MDR strains of K. pneumoniae 
and MRSA. The resulting data show clear evidence of improved antibacterial activities towards E. 
coli for the hybrid peptidomimetics compared to natural α-L-residue sequences. While the α-L-
amino acid peptides and their α-D analogues have limited effects (MIC ≥ 128 µM), 
peptidomimetics especially α-aminoacid/α-peptoid hybrids showed great efficacy (2 µM ≤ MIC ≤ 8 
µM) against all E. coli MDR and laboratory strains. Activities against K. pneumoniae and MRSA 
were however unchanged (MIC ≥ 128 µM), which the authors justified by the selectivity of the Lys-
Phe sequence towards the E. coli membrane (Olsen et al., 2010).  
 
Barron et al. advanced that similar linear peptoids were able to act synergistically with 
AMPs, with both molecules using similar modes of actions (Chongsiriwatana et al., 2011). 
Moreover, Huang et al. argued that cyclic analogues of linear peptoids (Figure 1.12B) further 
increased antibacterial activity compared to their linear versions (Huang et al., 2012). A MRSA 
strain was found not to develop resistance against such a cyclic peptoid after 21 passages of 
bacteria. 
 
These examples of peptoids show how small modifications to the backbone, independently of 
the side chains and thus possibly of the specificity of the antibiotic for its target, allow 
peptidomimetics to overcome existing resistance mechanisms, including those targeting the AMPs 
from which they were derived. Therefore, the combination of higher efficiency by optimization of 
the side chains and lower resistance by modification of the backbone could possibly lead to very 
potent antibacterial agents.  
 
 
 
 
	  	  	  Chapter	  I	  –	  General	  introduction	  	  	  
	   23	  
 
I.3.5 Tuning physicochemical properties and selectivity: oligoacyllysines  
 
The secondary structure of AMPs has a crucial influence on antibacterial activity. For 
example, through the study of dermaseptin (a natural cationic AMP, 1.13A) a higher helical content 
leads to higher antibacterial activity (potentially through easier spanning across the membrane 
bilayer), although it also reduces selectivity towards targeted cells (Shalev et al., 2002). On the 
other hand, decreasing the hydrophobicity by truncating the AMP induced better selectivity 
between membrane types although coupled with reduced activity. According to these properties a 
structurally ordered dermaseptin analogue shaping as an amphipathic α-helix proved to be very 
potent against a broad spectrum of pathogens, but also possessed a very high hemolytic activity 
(Kustanovich et al., 2002, Navon-Venezia et al., 2002).  
 
 
Figure 1.13. Oligoacyllysines (OAK) membrane-disrupting peptidomimetics. A. Natural AMP 
dermaseptin, from amphibian origin. B. C12K-7α8. C. C12(ω7)K-β12. Modified from (Rotem & 
Mor, 2009, Epand et al., 2008, Sarig et al., 2010). 
 
Mor et al. turned to a peptidomimetic approach to improve selectivity while retaining 
antibacterial activity, and obtained a significant enhancement by replacing long N-terminal 
sequences with acyl groups (Marynka et al., 2007). Lysine-rich cationic peptidomimetics with acyl 
moieties were developed under the name of oligoacyllysines (OAKs). These offer the advantage of 
tuning the hydrophobicity of the peptidomimetic by varying acyl chain length for improved activity, 
while limiting formation of a secondary structure that could lead to lower selectivity and higher 
hemolytic activity. Thus, by screening physicochemical properties necessary for antibacterial 
activity, Mor et al. identified optimal parameters for minimal inhibitory concentrations against 
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different pathogens independently of the amino-acid sequence: for example a membrane disruptor 
against E. coli would require 50 % ± 2 % hydrophobicity and 6.5 ± 2 positive charges 
(Radzishevsky et al., 2008). Hemolytic activity, however, was strongly linked to the presence of 
secondary structure. Disordered OAKs with butyl- and octyl- acyl moieties had hemolytic activities 
above 100 times the MIC hence presenting a certain advantage over natural dermaseptin 
(Radzishevsky et al., 2007). To contrast, longer acyl chains (>11 carbon atoms) presented higher 
flexibility, spontaneous aggregation and formation of amphipathic structures perturbing the 
membrane of red blood cells.  
 
 The most potent OAK to date, C12K-7α8 (MIC: 3.1 µg/mL against E. coli, Figure 1.13B) 
disrupts the cytoplasmic membrane (Rotem et al., 2008, Epand et al., 2008, Radzishevsky et al., 
2007) and has the ability to act synergistically with traditional antibiotics, raising the sensitivity of 
MDR bacteria (Livne et al., 2010). Shorter peptidomimetics such as C12(ω7)K-β12 (Figure 1.13C) 
were also active, but the mode of action was different from longer OAKs with a bacteriostatic effect 
(Sarig et al., 2010) unlike most AMPs which are bactericidal. In fact, a single broad-spectrum OAK 
might present several distinct antibacterial mechanisms, depending on the pathogen species and 
strain. Against two different strains of E. coli, C16(ω7)K-β12 (similar to C12(ω7)K-β12 but with 4 
extra carbons on the N-terminal acyl chain) acted differently by triggering cell death through 
membrane depolarization or by impeding biosynthesis through directly binding DNA (Sarig et al., 
2011).  
 
Different modes of action for different OAKs also imply that different bacterial resistance 
mechanisms were triggered. Against gram-negative pathogens, C12K-7α8 was not affected by efflux 
pumps, while C12(ω7)K-β12 reportedly acted as a substrate of these pumps and its bacterial activity 
was consequently limited (Goldberg et al., 2013). However, C12(ω7)K-β12 was still efficacious in 
vitro and in vivo against gram-negative bacteria when used synergistically with another antibiotic 
substrate of efflux pumps, such as erythromycin (Goldberg et al., 2013). Finally, C12(ω7)K-β12 
also restored sensitivity of selected MRSA strains when used in combination with traditional 
antibiotics (Kaneti et al., 2013). A suggested mechanism for this restored sensitivity involved 
membrane depolarization by the OAK, thus facilitating entry of traditional compounds such as 
oxacillin. Importantly, this facilitated entry occurred without activation of membrane-bound 
proteins triggering antibiotic resistance pathways (in the case of oxacillin the β-lactamase receptor).  
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In summary, this drug design approach allowed exquisite optimization of the physicochemical 
properties from AMPs to bind bacterial membranes through the addition of acyl moieties to a poly-
lysine chain. Moreover, shortening the length of the acyl side chains impeded formation of 
secondary structure and consequently hemolytic activity and toxicity. OAKs possess different 
modes of action depending on the targeted pathogenic species, therefore the horizontal transfer of 
DNA coding for OAK resistance might not transfer the resistance to other pathogenic strains. OAKs 
also show great promise when synergistically used with traditional scaffolds to restore antibacterial 
activity.   
 
I.3.6 Mimicking ß-hairpin structures: lipposaccharide transport inhibitors  
 
Peptidomimetic substitutes for a polypeptide sequence that can also mimic their secondary 
structure conformation can be valuable for targeting protein-protein interactions (PPI). 
Consequently, there has been a great deal of effort focused on turn, helix and strand mimetics. For 
example, antimicrobial β-hairpin mimetics have been developed through an approach called Protein 
Epitope Mimetic (PEM). Protegrin I, a mammalian broad-spectrum and membrane-disrupting AMP 
(Kokryakov et al., 1993), presents a typical ß-hairpin motif though the formation of two disulfide 
bonds (Figure 1.14A). This scaffold was modified at the Swiss company Polyphor Ltd. into a 
macrocyclic peptidomimetic through the use of a stabilizing D-Pro-L-Pro motif (Shankaramma et 
al., 2002, Robinson et al., 2005) and optimized through iterative rounds of peptidomimetic library 
synthesis leading to the molecules POL7001 (Figure 1.14B) and POL7080 (structure not disclosed) 
(Srinivas et al., 2010). A particular feature of these ß-hairpin mimetics is the much-improved 
resistance to proteolysis by substitution of the Lys/Arg residues by diaminobutyric acid. The 
resulting molecules showed significantly enhanced minimal inhibitory concentrations (MIC = 0.008 
µg/mL) compared with the original AMP protegrin I (MIC = 0.5 µg/mL) (Steinberg et al., 1997).  
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Figure 1.14. β-Hairpin peptidomimetics that bind to membrane lipopolysaccharides. A. Natural 
AMP Protegrin-I forming a β-hairpin through the formation of two disulfide bridges. B. Structure 
of POL7001: the cyclic L-Pro-D-Pro motif stabilizes a structurally similar β-hairpin conformation 
to give a peptidomimetic scaffold with membrane disrupting activity. C. Structure of L27-11, 
showing that only W2 and W8 are essential for LptD binding. Consequently other residue positions 
might be improved to increase other properties such as stability or bioavaliability. Amino acids are 
represented by their one-letter-code and X = diaminobutyric acid. Modified from (Srinivas et al., 
2010) 
 
A consequence of their ß-hairpin structures was a more focused targeting of Pseudomonas 
strains and the discovery of a novel target, LptD. Protegrin I forms pores in the bacterial membrane, 
whereas bacterial lysis is much slower when using ß-hairpin peptidomimetics. Sequencing of 
Pseudomonas strain genomes selected for resistance to POL7001 and POL7080 revealed mutations 
in the gene coding for LptD (Srinivas et al., 2010), a membrane-bound protein involved in the 
assembly of lipopolysaccharides on the outer layer of the outer membrane of Gram-negative 
bacteria (Yuan et al., 2013). To date the action of POL7001 and 7080 onto LptD remains unclear. 
For further investigation on the binding mechanism to LptD, a third peptidomimetic structure from 
the same series, L27-11 (Figure 1.14C) was analyzed by NMR spectroscopy and SAR by alanine 
scanning, proving that the β-hairpin conformation was essential for interaction with LptD (Schmidt 
et al., 2013). Moreover, only two side chains (the indoles of tryptophan 2 and 8) were essential to 
retain strong antibacterial activity (Schmidt et al., 2013), hence leaving 10 amino acid sidechains 
free for further improvements. 
 
POL7001 and POL7080 demonstrated significant antibacterial activity in vivo with dose-
dependent acceleration of infection clearance in mice (Srinivas et al., 2010). POL7080 completed 
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phase I clinical trials in March 2013 for treating bacterial infections caused by Pseudomonas 
aeruginosa and Polyphor Ltd. was licensed to Roche in November 2013 for further clinical trials.  
 
These macrocyclic peptidomimetics are able to retain a secondary structure from the original 
AMP that was essential for antibacterial activity, but stability was not the only parameter improved. 
The MIC was significantly lowered whereas the targeted pathogenic spectrum substantially 
narrowed to Pseudomonas strains. These ß-hairpin mimetics are aimed at a new membrane target, 
LptD, with a mode of action yet to be defined. Moreover, the recent finding that only two side 
chains are essential for this interaction allows a high level of scope for further modifications 
without altering the backbone that maintains the essential β-hairpin conformation.  
 
I.3.7 Identifying a novel antibacterial mode of action: arylamides 
 
Simple modifications such as β-peptides (Liu & DeGrado, 2001, Porter et al., 2000) and self-
assembling cyclic peptides (Fernandez-Lopez et al., 2001) are sufficient to provide resistance 
against peptidases, while conserving broad-spectrum antibacterial efficacy. However, these are 
more costly to manufacture than simple peptides, especially when based around long peptide leads 
with multistep syntheses in large scale.  
 
Tew et al. chose a peptidomimetic approach to develop short, less expensive and synthesis-
friendly polymers based on natural AMPs that retain the antibacterial activity of longer peptides. 
From the common properties of cationic AMPs, an amphiphilic structure and a global positive 
charge, they developed a series of rigid arylamide polymers (Tew et al., 2002). Computational 
analysis based on crystal structures and molecular dynamics were used to determine the optimal 
length and torsion angles of the initial scaffold (Figure 1.15A). This arylamide scaffold, here 
named Aryl1, was easy to synthesize, presented a hydrophilic side chain able to bind negatively 
charged membrane-bound lipids and a rigid hydrophobic core able to insert within the bilayer and 
induce lethal leaking. These arylamide peptidomimetics were effective against different pathogens 
(MIC < 25 µg/mL for several strains of E. coli for example), although they also exhibited high 
hemolytic activity. SAR studies aimed at reducing toxicity led to the discovery that selectivity of 
arylamides towards bacterial membranes depended mostly on the amphiphilicity of the compound 
but was not related to antimicrobial activity (Liu et al., 2004).  
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Figure 1.15. Arylamide peptidomimetics. A. Aryl1: basic scaffold for polymeric arylamide-based 
AMP mimics. B. Aryl2: combination of hydrophobic (benzene rings and tert-butyl groups) and 
hydrophilic (arginine and aminoalkyl substituents) properties led to this highly selective and potent 
membrane disruptor. C. Rigidification of the scaffold here with pyrimidine moieties increased 
antibacterial activity by 10-fold compared to Aryl2-based compounds. D. PMX-30063, which 
achieved Phase IIa in clinical trials. Modified from (Tang et al., 2006, Liu et al., 2004, Tew et al., 
2002) 
 
From this study, an extended arylamide (Aryl2, Figure 1.15B) was found to retain a similar 
bacterial activity to Aryl1 compounds, but with reduced hemolytic activity (500-fold lower than the 
bactericidal MIC) due to the arginine groups on each terminus and the aminoalkyl substituent on the 
central ring.  Further studies linked antibacterial activity with the structural conformation; 
interestingly the more rigid core structure had more potent antibacterial activity (Choi et al., 2009). 
For instance, introduction of pyrimidine moieties replacing the central benzene ring rigidified the 
backbone through additional intramolecular hydrogen bonds and induced a ten-fold improvement in 
antibacterial activity (compared to compounds based on Aryl2) with MIC 0.8 µg/mL (Tang et al., 
2006) against E. coli (Figure 1.15C). Preliminary infection models in mice showed the potency of 
another pyrimidine arylamer peptidomimetics to be almost comparable to vancomycin (Choi et al., 
2009). Moreover, bacteria did not develop effective resistance against selected lead compounds 
from the SAR after 17 passages (Scott et al., 2008). This reinforced a controversial notion that it 
may be more difficult for bacteria to develop resistance to AMPs due to the absence of a specific 
target, and the requirement for a major change to the membrane composition (Zasloff, 2002).  
 
An intriguing property was the strikingly different mode of action from those reported for 
natural AMPs. The lead peptidomimetic PMX30016 did not induce a significant physical disruption 
of the membrane, with NMR data suggesting that it penetrated into the membrane bilayer by 
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insertion between the lipid headgroup and the acyl chains (Su et al., 2010). It was then thought to 
rotate to induce a change in the electric potential of the membrane, leading to dramatically 
increased permeabilization and cell death.  Consistent with this hypothesis, two novel arylamide 
compounds from different SAR studies, PMX 10070 and PMX 10072, were shown to induce 
defects in the translocating mechanisms by dissipating the electrochemical potential across the 
membrane leading to a greater permeabilization to ions (Mensa et al., 2011). Finally, the lead 
peptidomimetic PMX-30063 (Figure 1.15D) developed by the now defunct Polymedix company 
under the name Briladicin completed phase IIa clinical trials in early 2013, showing high 
antibacterial activity against MRSA.   
 
By investigating a cheaper alternative to AMP synthesis, DeGrado et al. have developed 
peptidomimetic polymers that increased antibacterial activity and also identified a novel mode of 
action for AMPs. These discoveries led to a peptidomimetic that reached phase IIb clinical trials 
against MRSA. This success suggested that peptidomimetic development might generate stable 
AMP analogues with novel modes of action. The lack of resistance development against these 
arylamide peptidomimetics to date, possibly due to the novel mechanism, is a consequent milestone 
in the strategy that de novo peptidomimetics can provide better scaffolds to transform the actual 
antibiotic pipeline.  
 
I.3.8 De novo scaffold: design of pilicides and curlicides 
 
Inhibiting adherence of pathogenic bacteria to host cells is another potential way to fight 
infection (Stephens & Shapiro, 1997). The pili formation process has been highlighted as a 
mechanism to target in order to limit bacterial motility and pattern recognition on the surface of 
host cells (Waksman & Hultgren, 2009). Pili have also been demonstrated as essential for the 
formation of biofilms, involved in colonization of host tissues and medical devices and in antibiotic 
resistance (Anderson et al., 2003). Pili formation involves thousands of proteins including two 
highly conserved adhesins PapG and FimH located at the very tip on the pilus (Kuehn et al., 1993). 
Pili assembly requires translocation of these adhesins to the periplasm by two chaperones PapD and 
FlimC. Peptidomimetics are particularly suitable candidates for the inhibition of the specific PPI 
between adhesins and chaperones that can be a promising target for antibacterial development.  
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Initial screening of peptide binding using enzyme-linked immunoabsorbant assay (ELISA) 
and NMR revealed that the C-terminal sequence of PapG (307MTMVLSFP314, Figure 1.16A) 
inhibited PapG-PapD complex formation (Karlsson et al., 1998). A 3.0 Å resolution PapD-PapG307-
314 complex crystal structure allowed the development of two peptidomimetic scaffolds using 
computational docking and surface plasmon resonance (Svensson et al., 2001). The first scaffold 
retained a peptide backbone and had non-natural side chains (Figure 1.16B), whereas the second 
incorporated a 2-pyridinone scaffold (Figure 1.16C, Amino methylated 2-pyridinone - Patent # 
US7915417).  
 
Figure 1.16. Structure of pilicide peptidomimetics from PapG C-terminal sequence. A. Sequence 
VLSFP of the PapG C-terminal tail binding to PapD. B. First peptidomimetic design based on the 
PapG C-terminus, with the peptide backbone conserved (highlighted with the dashed square). The 
Pro314 ring was opened with indol and phenol moieties to improve binding to PapD. C. Second 
approach for peptidomimetics based on a 2-pyridinone scaffold binding to PapD. D. Core 
pyridinone scaffold for peptidomimetic development. E. Example of pyridinone peptidomimetic 
including a triazole function. Modified from (Bengtsson et al., 2012, Svensson et al., 2001, Karlsson 
et al., 1998, Pemberton et al., 2004). 
 
An innovative method for the high-throughput synthesis of 2-pyridinone scaffolds, allowed 
the exploration of different functional groups on the 2-pyridinone ring (Figure 1.16D). Position R1 
and R2 favored aromatic groups and surface plasmon resonance evaluation suggested that position 
R2 played a large part in the specificity of binding to PapD (Chorell et al., 2011, Emtenas et al., 
2002, Emtenas et al., 2003). The importance of the pyridinone ring was illustrated by the dramatic 
loss of activity when the ring was opened (Berg et al., 2008) or the sulfide replaced by amine or 
oxygen atoms (Berg et al., 2008). However, adding aryl groups on the pyridone ring improved the 
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affinity of the compounds to give low micromolar potencies (Chorell et al., 2010), as did 
incorporating other heterocycles such as triazoles (Bengtsson et al., 2012) (Figure 1.16E). 
Likewise, the carboxylic acid scaffold on the pyridone ring, originating from mimicking the original 
peptides, was important for binding because replacing this group resulted in loss in activity (Aberg 
et al., 2005). A new synthetic method allowed the exploitation of position R3 for refining solubility 
(Pemberton et al., 2004) and bioavailability. Extensive work on position R3 to extend toward di- 
and tri- peptide mimetics resulted in an increased affinity towards PapD but a reduction in 
inhibition of pili formation (Berg et al., 2006, Aberg & Almqvist, 2007).  
 
Interestingly, NMR studies of peptidomimetics such as 6C and 6E showed three different 
binding locations on FlimC (Hedenstrom et al., 2005), all leading to a defect in pili formation by 
preventing correct folding of the chaperone or by interfering directly with the protein-protein 
interaction with FimH. These compounds successfully inhibited pili and curli (another bacterial 
fiber (Barnhart & Chapman, 2006)) formation (Cegelski et al., 2009, Chorell et al., 2012). No 
clinical or in vivo data appear to have yet been released regarding therapeutic efficiency (Barber et 
al., 2013). 
  
These pilicides based on 2-pyridinone scaffolds demonstrate how peptidomimetics can be 
used for the design of an entirely de novo mode of action. Indeed, no natural product has ever been 
found to specifically inhibit the formation of pili and curli to date. The versatility of 
peptidomimetics allowed retention of the essential binding components from the initial protein 
sequence involved in the PPI and rational design allowed non-peptidic optimization of the backbone 
and the remaining positions on the 2-pyridinone scaffold.  
 
I.3.9 Peptidomimetics with indirect antimicrobial activity: efflux pump 
inhibitors 
 
Because of their ability to mimic PPI, peptidomimetics can also be used for limiting 
resistance mechanisms by recovering the sensitivity of MDR pathogenic strains to traditional 
antibiotic drugs. An interesting example is the development of peptidomimetics targeting the efflux 
pumps in Pseudomonas aeruginosa, largely responsible for antibiotic resistance by expelling 
compounds out of the cytoplasm (Livermore, 2002, Piddock, 2006, Schweizer, 2003). Neutralizing 
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efflux pumps has been identified as a promising approach to restore antibiotic activity (Mahamoud 
et al., 2007).   
 
A screening study by Renau et al. to discover a scaffold that restored fluoroquinolone activity, 
particularly for levofloxacin, singled out a phenylalanine-arginyl β-naphthylamide dipeptide (MC-
207,110, Figure 1.17A) that was able to lower the MIC of levofloxacin (MIC = 2.5 µg/mL) (Renau 
et al., 1999, Lomovskaya & Watkins, 2001). This property was shown against a large range of 
pathogenic strains, promising broad-spectrum activity for an antibiotic cocktail. Nevertheless, the 
initial investigation of a series of derived peptides suggested that instability in serum was a major 
issue. This was solved by the use of peptidomimetics composed of D-amino-acids and non-natural 
side chains (homophenylalanine for phenylalanine, ornithine instead of arginine) and by swapping 
side chain positions (MC-002-595, Figure 1.17B) (Renau et al., 2001).  
 
 
Figure 1.17. Peptidomimetic inhibitors of efflux pumps in Pseudomonas aeruginosa. A. 
phenylalanine-arginyl β-naphthylamide dipeptide MC-207,110. B. Swapping side chain positions 
and replacing with non-natural residues such as ornithine for arginine and homophenylalanine for 
phenylalanine in MC-002,595 provided improved serum stability. C. Cyclization of the toxic 
ornithine function led to lower hemolytic activity for MC-04,124. Modified from (Renau et al., 
2003, Renau et al., 2001, Renau et al., 1999) 
 
Throughout animal studies, MC-002,595 proved to be stable but also highly toxic due to the 
presence of the ornithine group. Cyclization of the residue provided a peptidomimetic molecule 
with similar potency (5 µg/mL enhanced MIC of levoflaxin by 8-fold) and lower toxicity 
(MC04,124, Figure 1.17C) (Renau et al., 2003). It was reported that these inhibitors behave as 
efflux pump substrates and trigger competitive binding with antibiotics. The efflux pumps expelled 
peptidomimetics and the traditional antibiotics remained in the cytoplasm and disrupted essential 
pathways (Lomovskaya & Bostian, 2006). A considerable advantage is that the efflux pump 
mechanism is not altered, thus unlikely to trigger adaptive resistance by modification of the pump 
mode of action. However, the relatively low affinity and specificity of the peptidomimetic to the 
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efflux pump led to the requirement for higher doses to produce substantial activity in vivo, thus 
resulting in higher toxicity. Consequently, this first series of efflux pump inhibitors did not enter 
clinical trials.  
 
 Efflux pump inhibitors are interesting examples of peptidomimetic compounds that do not 
have direct antimicrobial activity, but are used for their peptide-mimicking properties to compete 
against resistance mechanisms. If used in a cocktail with traditional antibiotics, they are expected to 
increase the duration of drug efficacy (Kourtesi et al., 2013).   
  
I.3.10 Improving membrane permeation and bioavailability: glucosamine-
6-phosphate synthase inhibitors.  
 
Peptides have high membrane permeation rates enabling access to different cellular 
compartments. In the case of glucosamine-6-phosphate synthase inhibitors, peptidomimetics helped 
improve permeation by allowing inhibitors to reach their targeted cellular compartment. 
Glucosamine-6-phosphate synthase is essential in the initial steps of the peptidoglycan synthesis, 
crucial for the bacterial cell wall (Milewski, 2002). Analogues of the glutamine substrate, such as 
N3-(4-methoxyfumaroyl)-L-2,3-diaminopropanoic acid (FMDP, Figure 1.18A), have been reported 
as selective inhibitors in vitro (IC50 15 µM, Salmonella typhimurium) (Andruszkiewicz et al., 1986, 
Chmara et al., 1986). It binds to the active site cysteine in the enzymatic substrate-binding site, but 
this potential is nullified in whole cells due to the very poor permeation. By combining FMDP with 
a transporter peptide, thus forming a peptidomimetic molecule, the FMDP-peptide molecule is 
transported into the cytoplasm via permeases, before release of the FMDP “warhead” through 
cleavage by a peptidase (Chmara et al., 1998, Andruszkiewicz et al., 1987). This way, FMDP 
dipeptides combining residues Met, Ala, Leu, Nva (norvaline) or Nle (norleucine) demonstrated 
MIC as low as 0.4 µg/mL (Figure 1.18B and 1.18C) against whole bacterial cells (compared to no 
inhibition detected using FMDP alone) (Chmara et al., 1998).  
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Figure 1.18. Peptidomimetic inhibitors of glucosamine-6-phosphate synthase. A. N3-(4-
methoxyfumaroyl)-L-2,3-diaminopropanoic acid (FMDP) is an analogue of glucosamine-6-
phosphate synthase substrates featuring inhibitory activity but unable to cross membranes. B. Graft 
of a norvaline residue onto FMDP allowed translocation into the cytoplasm through binding to the 
Opp permease and inducing in vivo antibacterial activity. C. Graft of the norvaline group onto the 
carboxylic acid end of FMDP also led to translocation but with substantially lower antibacterial 
activity.  
 
FMDP dipeptides possess inhibitory potential against various pathogenic species (Escherichia 
coli, Staphylococcus aureus, Bacillus subtilis). The position of the peptide residue was also vital, 
with a substantial increase in activity when linked to the N-terminus rather than the C-terminus of 
FMDP. Parallel progress in peptide transporters studies reported conformational features, such as 
backbone torsions and angles, necessary for recognition by permeases Dpp, Opp or Tpp. Molecular 
modelling of the different active FMDP dipeptides and comparison with typical permease peptide 
substrates directly correlated the antibacterial activity of a peptidomimetic with the proportion of 
features favorably recognized by transporter proteins, such as terminal charges, backbone torsion 
angles and chirality (Marshall et al., 2003). A higher percentage of conformers matching these 
properties common to natural permease substrates resulted in higher antibacterial activity for the 
FMDP dipeptides. Moreover, the choice made for the peptide residue linked to FMDP, altering the 
backbone torsion of the peptidomimetic in different conformers, greatly influenced the permease 
responsible for transportation in the cytoplasm. The different lowest energy conformations of Tyr-
FMDP, Lys-FMDP and Nva-FMDP influenced recognition and transportation by different 
permeases Dpp, Tpp and Opp, respectively.  
 
 This approach presented another alternative for the use of peptides for indirect improvement 
of antimicrobial potency. The data showed that the rational addition of a single amino acid could 
greatly facilitate transport of a small non-peptide inhibitor to the cytoplasm. Moreover, the choice 
of this single residue directly influenced the permeation mechanism through different 
conformations. This is a feature that could improve pharmacokinetics and bioavailability for a large 
array of inhibitors with limited membrane permeability.  
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I.4 Discussion  
 
 The DsbA/DsbB interaction, being part of a hub for the maturation of multiple virulence 
factors, is a promising and exciting new target for developing inhibitors limiting the appearance of 
resistance. However, while the disulfide bond exchange mechanism has been thoroughly described 
and reported in the literature, information about the structural features of the interaction itself are 
still scarce. The only structures available of the EcDsbA/EcDsbB complex presented a resolution of 
3.7 Å, this limiting the possibilities for virtual tools that are usually a vital part of screening 
methods to identify inhibitory scaffolds and new ligands. Therefore, my PhD consisted in clarifying 
the mechanism underlying the interaction and to provide better structural insight. For this purpose, 
the design of peptides and peptidomimetics seemed an appropriate strategy to begin the EcDsbA 
inhibitor design program, and potentially develop molecules similar to AMPs.  
 
Antimicrobial AMPs are a natural reservoir of antibacterial compounds – broad-spectrum and 
narrow-spectrum – that has not revealed its full potential yet, as new sequences and novel modes of 
action are still being identified. Nevertheless, from 2,000 described AMP molecules to date 10 
peptides are undergoing clinical trials in different stages as of 2013 (Fox, 2013). Weaknesses of 
AMPs as drug candidates are now well known, including notably poor stability in serum and high 
toxicity, and the growing field of peptidomimetics is beginning to overcome some of these 
drawbacks. Far from only improving stability, selectivity and pharmacokinetics, peptidomimetics 
have also helped to discover new classes of antibiotics with scaffolds and modes of action quite 
different from the original AMPs, as exemplified above. The peptidomimetic concept also presents 
advantages for non-peptide antimicrobial compounds, with the example of glucosamine-6-
phosphate synthase inhibitors now able to reach their cytoplasmic target and induce an antibacterial 
effect in vivo. To further broaden the possibilities, the development of non-antibacterial 
peptidomimetics targeting existing specific mechanisms such as efflux pump inhibitors might be 
fruitful when used to complement antibiotic cocktails to recover sensitivity in MDR pathogenic 
strains. Additionally, the development of peptidomimetics, contrary to the traditional antibiotic 
pipeline, has taken advantage of the tremendous technologic progress of the past few decades (high-
throughput screening, computational docking and modelling, etc). The medical world might be 
lagging behind MDR strains in the race between treatments and drug resistance, but 
peptidomimetics might be the toolbox that will bring the antibiotic pipeline back on track. 
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The inhibition of the EcDsA-EcDsbB interaction is suitable to a peptidomimetic approach. 
The EcDsbA/EcDsbB complex is located in the periplasm, which is easily accessible by peptides 
and peptidomimetics. It is a specific protein-protein interaction that can possibly be mimicked best 
by a peptide providing similar properties in terms of charges, hydrophobicity and conformation as 
the EcDsbB loop. As described above, peptides present weaknesses that can be overcome by the 
transformation into peptidomimetics. Therefore, if an EcDsbB loop mimic peptide could benefit 
from the array of improvement available to peptidomimetics, it might be possible to develop a 
potent, stable and specific antivirulence scaffold inhibiting the bacterial oxidative folding.  
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I.5 Goals of this PhD 
 
 The overall aim of this PhD is to develop peptides and peptidomimetic ligands for the 
EcDsbB-binding site on the EcDsbA surface. The goal was to generate compounds competing with 
the EcDsbB periplasmic loop P2. The strategy behind this competition is to block the regeneration 
of EcDsbA in the oxidized active state, thus accumulating EcDsbA in a reduced state unable to fold 
virulence factors. Impeding this virulence pathway is predicted to lead to attenuated bacterial 
strains, unable to spread infection but still viable hence limiting drug resistance. To achieve this aim 
I had to develop robust tools to synthesize, screen and evaluate such peptides and peptidomimetics 
to design the most potent scaffold. Consequently, the specific aims of this PhD are:  
 
 
 (1) To assess and develop a robust in vitro screening pipeline including differential scanning 
fluorimetry, isothermal titration calorimetry, surface plasmon resonance and model substrate 
oxidation assays to characterize the binding affinity and DsbA inhibitory activity of synthesized 
molecules. This aim is addressed in chapter II. 
 
 (2) To create and enrich a database of peptide sequences binding to the E. coli EcDsbA 
groove ideally with a sub-micromolar affinity. This was to be done by identifying the key residues 
and properties to develop an optimal sequence. This aim is addressed in chapter III.  
 
 (3) To use biophysical methods such as soaking, cocrystallisation or NMR with the 
peptide/protein or peptidomimetic/protein complexes and solve the structures to characterize the 
interactions. This aim is addressed in chapter IV.  
 
 (4) To use these optimal peptide sequences to develop peptidomimetics that increase 
affinity, specificity, stability and bioavailability, potentially leading to a novel antibacterial scaffold. 
This aim is addressed in chapter V.  
 
 Finally, an overview of the outcome of this PhD is presented, along with discussion of the 
main data and future directions are suggested for the next steps to undertake in the development of 
an antivirulence drug.
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CHAPTER II 	  	  	  
Assembly and optimization of a screening pipeline to 
detect peptides that bind to EcDsbA 
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II.1 Overview of the screening pipeline 
 
 Rational drug discovery, in a similar fashion to traditional methods in drug design, requires 
a robust screening pipeline with which to evaluate the potency of new scaffolds towards the target 
of interest (Anderson, 2003, Mandal et al., 2009). In the early stages of development, potential 
inhibitors can be ranked according to affinity, activity, and kinetic and thermodynamic specificities 
of binding (Keseru & Makara, 2006). Concurrent structural characterization through structural 
biology techniques such as crystallography and nuclear magnetic resonance (NMR) can shed light 
on the ligand binding mode and guide future optimization of the scaffold (Verlinde & Hol, 1994). 
Once a potent in vitro inhibitor scaffold has been identified, optimization focuses initially on the 
selectivity for the target and long-term stability, and later on potency, toxicity and bioavailability in 
vivo.  
 
 An important goal of my PhD was to set up robust binding assays that would enable the 
detection of the binding and the characterization of novel scaffolds. I opted not to include high-
throughput screening of existing compound libraries but rather to focus on the rational design of 
peptides and peptidomimetics from existing biological and structural data. Therefore, a pipeline that 
enabled accurate detection of binding of compounds was favored over one that focused on a high 
rate of compound library screening. Ideally each tested compound would provide additional 
information, either biochemical or structural, that would inform the design of the next molecule in 
the series, enabling the iterative development of a final potent compound, or ‘hit’, suited to the 
inhibition of EcDsbA. As reported in the previous chapter, the starting point of this PhD was the 3.7 
Å resolution EcDsbA-EcDsbB complex crystal structure (Inaba et al., 2009a), using the EcDsbB 
loop bound to the EcDsbA groove to design the first peptide sequence. We hypothesized that this 
peptide would bind to EcDsbA and the optimization of the sequence would lead to a potent peptide 
or peptidomimetic with EcDsbA inhibitor activity that could be later tested in vivo.  
 
 The pipeline itself was designed to make use of the instrumentation available within the 
Institute for Molecular Bioscience. A flow chart for the ideal pipeline is shown (Figure 2.1). 
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Figure 2.1. Flow chart of the screening pipeline for the design and evaluation of inhibitors of 
EcDsbA. The pipeline includes three binding assays, one activity assay and structural biology 
experiments to characterize peptides in terms of binding affinity, thermodynamic and kinetic 
binding parameters, inhibitory activity and binding mode. Tm represents the melting temperature of 
EcDbsA.  
 
The design of the initial peptide sequence was based on available crystal structures. Virtual 
tools - such as docking experiments - were not included because of the difficulty of accurately 
predicting both the binding site on EcDsbA and the conformation of ≥7mer peptides due to the 
large number of rotatable bonds (Aloy & Russell, 2006, Gray, 2006). Only very recently specialized 
tools have been developed for peptide folding and docking (Raveh et al., 2011, Audie & Swanson, 
2013). Synthesis and purification of peptides were performed manually within the chemistry 
laboratory of co-supervisor Prof. David P. Fairlie. The first assay (differential scanning fluorimetry) 
was chosen because it is rapid and consumes small amounts of peptide and protein; it was intended 
to evaluate whether or not the peptide bound to EcDsbA by measuring changes in the EcDsbA 
melting temperature Tm. Non-binders, for which no significant shifts (< 0.2 ºC) in EcDsbA Tm 
were recorded, would not progress further. If concentration-dependent and significant shifts (> 0.2 
ºC) were measured, then the peptide progressed through to the next step, Isothermal Titration 
Calorimetry (ITC). ITC provides an accurate measurement of the thermodynamics, including a Kd 
value as well as enthalpy and entropy contributions. If the peptide had high affinity by ITC (Kd < 
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50 µM) or improved affinity compared with previous molecules tested, surface plasmon resonance 
was to be used to confirm the affinity by an independent method and to provide kinetics of the 
binding reaction. If the kinetic rates were acceptable (103 M-1.s-1 < kon < 109 M-1.s-1 and 10-6 s-1 < 
koff < 1 s-1, (Nunez et al., 2012)), the peptide was then progressed through to an activity assay that 
monitored the oxidase activity of EcDsbA using a fluorescent synthetic substrate. Finally, if the 
peptide inhibited EcDsbA activity (IC50 < 50 µM), co-crystallization trials were set up to solve the 
structure of the EcDsbA-peptide complex in order to map the peptide binding site and provide 
structural information about the binding mode. If any peptides or peptidomimetics became a ‘hit’, 
then its potency was to be tested using in vivo assays, but this was beyond the scope of the work 
reported.   
 
Overall, this pipeline provided two independent affinity measurements, as well as kinetic 
and thermodynamic characterization, assessment of inhibitory activity and structural 
characterization of binding conformations. This chapter reports my efforts to establish and optimize 
these screening methods; the outcomes of the design and characterization of DsbA peptidic 
inhibitors are presented in chapters III, IV and V.  
II.2 Experimental details of materials and methods for subsequent 
chapters 
II.2.1 DsbA expression and production 	  
 The expression and purification of EcDsbA and variants for the entire Martin lab use was 
jointly performed by myself, Dr Maria Halili, Mrs Stephanie Tay and Mr Fabian Kurth. Dr Stephen 
Shouldice engineered wild type EcDsbA and GST-tagged constructs. Mr Fabian Kurth developed 
the optimized expression and purification protocol used in this section.  
 
Wild type E. coli DsbA (GenBank® accession number X80762), without the sequence 
coding for the predicted signal sequence was cloned into a modified pMCSG7 (Midwest Center for 
Structural Genomics) vector for cytoplasmic expression. The sequence includes an N-terminal His6 
affinity-tag followed by a linker region containing a Tobacco Etch Virus (TEV) protease cleavage 
site. The EcDsbAC30S variant was generated from the wild type construct by Mr Fabian Kurth 
using the QuikChange® protocol (Agilent Technologies). The following primers were used to 
introduce the point mutation, FW- GTTTTTCTCTTTCTTCAGCCCGCACTGCTATCAG and 
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REV- CTGATAGCAGTGCGGGCTGAAGAAAGAGAAAAAC. Transformed BL21(DE3)pLys 
cells containing plasmids for either EcDsbA or EcDsbAC30S were grown in auto-induction media 
(Studier, 2005) in Erlenmeyer flasks for 16-20 h at 30ºC with a stirring speed of 220 rpm. After an 
initial centrifugation (10,000 rpm for 10 minutes at 4ºC, rotor JLA 10.500, Beckman Coulter), the 
bacterial pellet was resuspended in 25 mM Tris, 150 mM NaCl, 1:1000 protease inhibitor cocktail 
(BioPioneer Inc) and DNase (Roche). Lysis was executed using a Cell Disruptor (TS-Series, 
Constant Systems LTD) applying a constant pressure of 25 Kpsi. Cell debris was removed by 
centrifugation (18,500 rpm for 30 min at 4ºC, rotor JM-25.5, Beckman Coulter). Purification by 
metal ion affinity chromatography using TALON resin (Clontech) was used to bind His-tag 
EcDsbA, which was then eluted with a solution of 25 mM Tris, 150 mM NaCl and 200 mM 
imidazole (Figure 2.2A). The His6 affinity tag was removed by TEV cleavage using a 1:50 w/w 
ratio protein/TEV-protease incubated in a 50 ml tube overnight at 4ºC, leaving the EcDsbA with 
two additional amino acids (S–1 and N0) at the N-terminus. Removal of any remaining tagged 
EcDsbA and TEV was performed by reverse metal ion affinity chromatography using TALON 
resin.   
 
Figure 2.2. Purification profile of EcDsbA. A. SDS-PAGE gel of samples collected during the 
purification process, leading to the collection of pure EcDsbA fractions for screening experiments. 
The bands oberseved at ≈42 kDa in five of the final FPLC fractions were likely EcDsbA dimers and 
were excluded from the final pooled fractions. B. Elution profile of EcDsbA during the final 
purification step using a FPLC Superdex 75 column. Fractions of 5 mL eluted from 45 mL to 85 mL 
between the dashed lines were injected into the gel in A and only fractions 65 mL to 85 mL were 
kept for binding experiments.  
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A final size-exclusion chromatography step using a Superdex 75 16/60 column (GE 
Healthcare) injecting 5mL of concentrated protein in 25 mM Tris, 150 mM NaCl pH 7.4 that 
yielded high purity protein (≥ 95 %) verified by SDS-PAGE (Figure 2.2B). Protein was then 
concentrated and buffer exchanged into 25 mM HEPES, 150 mM NaCl pH 7.4. Quantitation was 
performed using a Nano-drop (thermo-Scientific) and revealed yields of 50-100mg of purified 
EcDsbA per liter of culture. EcDsbA was stored in 50 µL aliquots at 50 mg.mL-1 at -80ºC. GST-
EcDsbA was purified with the same protocol using a His-GST tagged construct, with the His-tag 
removed during purification.  
 
Prior to all experiments, EcDsbA was fully oxidized or fully reduced by incubation with 
respectively 25-molar excess of copper(II)1,10-phenanthroline or dithiothreitol (DTT) for 60 
minutes, followed by removal of the agent in a PD-10 desalting column (GE Healthcare). The redox 
state was confirmed by Ellman’s assay (Aitken, 2009). 
 
For substrate oxidation experiments E. coli DsbB (AAC74269) membrane extracts were 
prepared by Dr Halili as described previously (Bader et al., 1998) and resuspended in phosphate 
buffered saline (PBS, 137 mM NaCl, 2.7 mM KCl, Na2HPO4 10 mM and KH2PO4, pH = 7.4) 
containing 10 % glycerol. 	  
II.2.2 Peptide synthesis 
 
Synthesis of all peptides reported in this thesis was performed using classic Solid Phase 
Peptide Synthesis (SPPS) on resin with Fmoc-protected (Fluoroenylmethyloxycarbonyl) amino 
acids (Figure 2.3A). Peptides were synthesized on rink-amide MBHA resin (p-
methylbenzhydrylamine resin, ChemImpex International) with loading rates of 0.36 or 0.72 
mmol/g. The resin initially presents an amine protected by a removable Fmoc protection group 
(Figure 2.3B).  
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Figure 2.3. Schematic overview of the SPPS process. A. Overview of the Fmoc-based solid phase 
peptide synthesis. Residues are coupled sequentially onto the resin with deprotection steps in 
between to remove the Fmoc group protecting the N-terminal amine, hence allowing the following 
residue’s carboxylic acid to react. AAn = Amino Acid number n. B. Structure of the MBHA rink-
amide resin, with the necessary removal of the Fmoc protection group to begin synthesis.  
 
After swelling the dry resin in Dimethylformamide (DMF, Rci Labscan) for 15 minutes, the 
Fmoc protection group was removed according to the mechanism shown in Figure 2.4A in the 
presence of an excess of piperidine. This step was performed twice (5 min incubation time) 
separated by thorough DMF washing. The resin was then activated and ready for the first amino 
acid (AA) coupling. The principle of solid-phase synthesis relies on the step-wise addition of AAs 
sequentially from the peptide C-terminus to the N-terminus. Each AA presents a free backbone 
carboxylic acid group able to react with the resin-linked AA terminal amine to form an amide bond. 
The N-terminal Fmoc group on the newly added residue prevents the sequential addition of the 
same AA on a single growing peptide linked on the resin; in this way only one residue is added at a 
time onto each growing peptide (Figure 2.3A). Similarly, side chains likely to react with a 
carboxylic acid or the activation reagents are also orthogonally protected. The Fmoc-protected 
residue to be coupled on the resin was activated by O-Benzotriazole-N,N,N',N'-tetramethyl-
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uronium-hexafluoro-phosphate (HbTU, ChemImpex International) in the presence of an excess of a 
base, N,N-Diisopropylethylamine (DIPEA, Auspep) as shown in Figure 2.4B. After 5 minutes of 
activation the new residue was incubated with the resin for 30 minutes allowing binding to the N-
terminal amine of the resin-linked sequence. This deprotection/coupling step was repeated for each 
residue until the sequence was complete. The peptide was then capped on the N-terminus with 
acetic acid, using the same coupling conditions as above. Incorporation of amino acids with non-
natural side chains, such as L-homophenylalanine or L-homoserine, was performed using 
commercial reagents (all from ChemImpex International).  
 
 
Figure 2.4. Reactions of the amino acid coupling steps. A. General mechanism of Fmoc 
deprotection using an excess of piperidine, liberating the free amine for coupling with the available 
amino acid. B. Activation of an amino acid (R1) by HbTU followed by coupling onto an already 
immobilized residue (R2).  
 
The final sequence was cleaved from the resin using a 95:2.5:1.25:1.25 v/v mixture of 
trifluoroacetic acid (TFA), 1,2-ethanedithiol, triisopropylsilane (Sigma-Aldrich) and H2O 
respectively, resulting in the amidation of the C-terminal end. Cleaved peptides were dried using 
N2, washed with diethyl-ether (Ajax Finechem) and dissolved in an 80:20 v/v mix of 
acetonitrile/H2O (RCI Labscan) before purification on reverse phase HPLC. Purification was 
executed on a Luna C18 column (250 x 21 mm, Phenomenex) using a 20-100% gradient 90:9.9:0.1 
acetonitrile:H2O:TFA over 12 minutes, until the peptide reached > 90% purity. Peptides were 
lyophilized and characterized by analytical UHPLC on a Shimadzu Nexera system using an Agilent 
Zorbax R-ODS III column (2.0 mm i.d x 75 mm 1.6 mm) and a 2020 LCMS, and their mass 
measured with a high-resolution QSTAR Elite mass spectrometer (Applied Biosystems). Peptide 
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powder stocks were stored at -20 ºC in vials wrapped with parafilm. Peptides were dissolved in 100 
% DMSO to generate stock solutions between 200 mM and 500 mM according to the different 
screening assays.   
 
 Using this method, around a hundred unique peptides were manually synthesized during this 
PhD, targeting different DsbA proteins. By optimizing both the incubation and washing times I was 
able to synthesize a typical 10-residue peptide in the course of 48 hours, including cleavage and 
purification. With rare exceptions (i.e. because of very poor solubility), each of these peptides was 
tested in the screening pipeline, with the main outcomes presented in Chapter III. Peptides were 
also synthesized for collaborative projects in other studies on the DsbA proteins outlined in the 
Appendices B and C.  
 
II.2.3 Differential scanning fluorimetry 
 	   Once a new peptide or peptidomimetic was synthesized, the primary purpose of the first 
screening assay was to quickly and cheaply assess if it could bind to EcDsbA. The Differential 
Scanning Fluorimetry (DSF, also called thermal shift assay or Thermofluor) is a well-studied 
technique that can detect ligand binding in a short timeframe (< 1 hour) (Niesen et al., 2007, Lo et 
al., 2004).  DSF was initially developed to scout the stability of a protein in a broad range of 
different conditions (i.e. buffers, pH, metal ions, detergents, etc) (Ericsson et al., 2006). The 
stability of a protein is related to its Gibbs free energy of unfolding ΔGu: the higher ΔGu, the more 
stable the protein (Schellman, 1997). According to the definition of Gibbs free energy (ΔG = ΔH - 
TΔS), ΔG is directly related to the temperature: the higher the temperature necessary to trigger 
protein unfolding (∆𝐺!!" = 0), the higher the ΔGu associated with this protein and thus the higher its 
stability. Therefore, the melting temperature Tm of a protein, corresponding to the temperature at 
which ΔGU = 0 and half of the protein is unfolded, when measured under different conditions 
discriminates stabilizing factors from destabilizing factors. This principle can be extended to ligand 
screening; typically binding of a ligand to a macromolecule raises the overall free energy of a 
protein due to the solvation effect (Senisterra et al., 2006) and hence the Tm of a complex is higher 
than the Tm of the native protein (Vedadi et al., 2006). The difference between the complex Tm and 
the protein Tm is called the thermal shift (ΔTm). In this project, a positive ΔTm for EcDsbA in the 
presence of a peptide indicated that the peptide binds to EcDsbA, marking it for further testing in 
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the screening pipeline. To be significant, the ΔTm in the presence of a ligand must be at least twice 
as large as the standard deviation of the native protein Tm (Kranz & Schalk-Hihi, 2011).	  	  
 DSF measures the unfolding temperature using a fluorescent dye, typically SYPRO Orange 
(S-6650, Life Technologies). SYPRO Orange is quenched in aqueous solution but emits 
fluorescence when bound to hydrophobic residues. As the protein unfolds, the dye is able to access 
hydrophobic regions usually buried at the core of the macromolecule, hence triggering an increase 
in fluorescence that can be measured. Continuous fluorescent recording of a sample containing 
protein and dye along an incremental rise in temperature leads to the determination of the unfolding 
temperature from the resulting sigmoidal curve (Figure 2.5). The initial plateau of the curve is the 
background fluorescence of the quenched dye; the final plateau is reached when protein is entirely 
unfolded. It is usual to notice a decrease in fluorescence past the point of total unfolding caused by 
dye aggregation.  
 
Figure 2.5. Protein unfolding monitored with a fluorescent dye. The unfolding temperature Tm 
can be calculated from the inflection point of the sigmoidal section. LL = fluorescence lower limit, 
UL = fluorescence upper limit. Reproduced from Niesen et al. (Niesen et al., 2007). 
  
 Experiments were initially performed in a Microamp Optical 384-well reaction plate 
(Applied Biosciences) on a 7900HT real-time PCR instrument with an excitation wavelength of 490 
nm and an emission filter at 615 nm. RT-PCR systems offer the ability to increase temperature in a 
constant and monitored fashion although the Microamp instrument was not able to raise the 
temperature in incremental steps less than 1 ºC at a time, thus limiting the number of data points 
available to determine Tm values. Samples were set up in 5 technical replicates on the same plate in 
phosphate buffered saline (PBS) pH 7.4, with a final dye concentration of 5X (Life Technologies do 
not disclose the stock dye’s molar concentration and list it only as a X5000 concentrate) in 20 µL 
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sample volume per well. A reference sample that did not contain any peptide but which contained 
an equivalent concentration of DMSO was included in every plate to measure the unfolding 
temperature of native EcDsbA. Negative controls consisted of a mix of dye and peptide at every 
concentration used in the assay, and dye by itself. Two separate plates were tested as replicates for 
each experiment. 
 
Initial scouting of optimal DSMO concentration suggested that high concentrations of 
DMSO interfered with the dye, so I imposed an upper limit of 2 % DMSO v/v in any sample. On 
this instrument, EcDsbA concentration scouting showed that a concentration of 100 µM was 
necessary to obtain a strong fluorescent signal. Centrifuging the plate immediately prior to the 
fluorescent reading (2000 rpm, 60 sec, Beckmann Coulter rotor JS 5.3) was found to substantially 
increase signal intensity. Raw data were analyzed using Prism 6 (GraphPad) and fluorescence 
emission was fitted using the classic Boltzmann sigmoidal equation and the resulting inflection 
point was used as the unfolding temperature Tm value. Initial experiments revealed a high degree of 
variability between replicates from different plates, and no clear trend in ΔTm values for different 
concentrations of a single peptide (Figure 2.6A and 2.6B). Many peptides that gave significant 
binding in ITC experiments did not induce Tm shifts. Some peptides were also found to have a 
destabilizing effect upon EcDsbA inducing a reduction in Tm of up to 5 ºC. Differences in 
incubation times of EcDsbA with the peptide prior to the assay were shown to be partially 
responsible for this high degree of experiment to experiment variability; the longer the incubation 
(which were sometimes left overnight), the lower the shift. An incubation time of one hour 
appeared to favor larger ΔTm shifts, but the high standard deviations between replicates precluded 
definitive conclusions.  
 
 DSF proved unreliable until the availability of a new state-of-the-art RT-PCR instrument, 
the VIAA7 (Life Technologies), offered the possibility for protocol improvement. The temperature 
ramp rate could be set to 0.05 ºC.sec-1 (instead of incremental 1 ºC steps) and the measured 
fluorescence signal intensity was improved by 20-fold using a 585 ± 15 nm emission filter. EcDsbA 
was diluted 5-fold to a final concentration of 20 µM and incubated for 1 h with different peptides at 
concentrations ranging from 125 µM to 4 mM in two-fold increments. Using this instrument, 
resulting ΔTm values gave high reproducibility between replicates and concentration-dependent 
shifts (Table 2.1, Figure 2.6C and 2.6D). It is relevant to note that the ΔTm still increased beyond 
the peptide concentration that would saturate the EcDsbA molecules present in the samples; this 
phenomenon has been reported before, and is linked to an increase in the Gibbs free energy of the 
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system that arises from the interaction of free ligands in solution with the complexes, hence 
depending on the concentration of free ligands in the sample (Cimmperman et al., 2008).  
 
Figure 2.6. Example of positive thermal shift induced by the presence of peptide PWATCDS. A. 
Raw fluorescence measurement of EcDsbA unfolding in presence of increasing concentrations of 
peptide PSPWATCDF using the 7900HT instrument. The unfolding temperature Tm is calculated 
from the inflection point of the sigmoidal curve but the signals were small and inaccurate. B. First 
derivative of the raw fluorescence signal in A. The unfolding temperature is also represented by a 
peak in the first derivative of the sigmoidal curve, but data are too poor to calculate a Tm value 
using this method. C. Raw fluorescence measurement of EcDsbA unfolding in presence of 
increasing concentrations of peptide PWATCDF using the VIAA-7 instrument, allowing 
determination of Tm. D. First derivatives of the raw fluorescence in C, with the unfolding 
temperature represented by the peak of each concentration curve. All curves are here represented 
with the standard deviation from 5 technical replicates.  
 
Table 2.1. Example of thermal shift using peptide PWATCDS with concentrations ranging from 
125 µM to 4 mM. ΔTm values are presented as mean and standard deviation from 5 technical 
replicates. 
 
Peptide PWATCDS concentration 
 125 µM 250 µM 500 µM 1 mM 2 mM 4 mM 
∆Tm (ºC) +1.7 ± 0.1 + 3.3 ± 0.2 +3.7 ± 0.1 +5.0 ± 0.1 +6.9 ± 0.1 +9.8 ± 0.1 
 
  
56 58 60 62 64 66 68 70 72 74
0
2000
4000
6000
8000
10000
12000
Temperature (ºC)
Fl
uo
re
sc
en
ce
 s
ig
na
l d
er
iva
tiv
e 
(d
R
FU
)
DsbA control
0.5 mM
1 mM
2 mM  
3 mM
4 mM
30 40 50 60 70 80 90
0
200000
400000
600000
800000
Temperature (ºC)
Fl
uo
re
sc
en
ce
 S
ig
na
l (
Fu
)
DsbA control
Buffer control
4mM
2mM
1mM
0.5mM
0.25mM
0.125mM
Peptide Control
30 40 50 60 70 80 90
0
10000
20000
30000
40000
Temperature (ºC)
Fl
uo
re
sc
en
ce
 S
ig
na
l (
Fu
) DsbA control
0.5 mM
1 mM
2 mM  
3 mM
4 mM
Peptide Control
55 60 65 70 75
0
20000
40000
60000
80000
Temperature (ºC)
Fl
uo
re
sc
en
ce
 s
ig
na
l d
er
iva
tiv
e 
(d
R
FU
)
DsbA control
4mM
2mM
1mM
0.5mM
0.25mM
0.125mM
A
C
B
D
	  	  	  Chapter	  II	  –	  Assembly	  of	  the	  screening	  pipeline	  	  	  
	   50	  
 
Overall, the differential scanning fluorimetry assay required significant optimization to 
enable it to be used reliably to identify peptides and peptidomimetics that alter the EcDsbA Tm. The 
breakthrough to achieving this was the use of a more sensitive instrument. The final protocol 
allowed testing a peptide at different concentrations and five technical replicates in a 2-hour 
timeframe including incubation and data analysis. If thermal shifts were detected, the next step was 
to evaluate the affinity of these ligands.  
 
II.2.4 Isothermal Titration Calorimetry 
 
 Screening of inhibitors requires a robust assay to evaluate their affinity for the target and 
identify the best scaffolds, or ‘hits’, to progress further into potent and specific molecules. A label-
free assay, isothermal titration calorimetry (ITC) provides an accurate measurement of the energy 
released or captured upon a binding interaction (Perozzo et al., 2004, Leavitt & Freire, 2001). By 
titrating a target macromolecule with a binding ligand (here a peptide) one can directly deduce the 
binding affinity (Ka), the enthalpy change (ΔH), and the molar stoichiometry (n) of the target-ligand 
interaction. The total Gibbs free energy (ΔG) and entropy contribution (ΔS) are mathematically 
calculated from these direct measurements using the Gibbs equations ΔG = - R*T*ln(Ka) and ΔG = 
ΔH - TΔS. A titration experiment typically takes about two hours per ligand, and is thus poorly 
suited to high-throughput screening. However the robustness of the method and the usefulness of 
the thermodynamic information yielded (Ladbury, 2010, Holdgate, 2001) provide important details 
for a rational inhibitor design strategy such as this project. 
 
 ITC was initially performed using a manual MicroCal™ ITC200 instrument (GE 
Healthcare, USA). The sample cell was loaded with 200 µL of purified EcDsbA at 100 µM in 25 
mM HEPES pH 7.4, 50 mM NaCl 0.8 % DMSO. The syringe was filled with purified peptide in the 
same buffer solution. Titrations were initially conducted at 25 °C using 12 consecutive injections of 
2.8 µL with 180 s intervals and a stirring speed of 1000 rpm. In every experiment, an initial 0.5 µL 
of peptide was injected to avoid slow leakage of titrant that could interfere with the initial reading. 
Consequently, this initial data point was discarded for binding analysis. As a negative control, 
peptides were injected into a buffer solution lacking EcDsbA to measure the heat of dilution. The 
association constant (Ka = 1/Kd), enthalpy (ΔH) and entropy (ΔS) were calculated by fitting the data 
to a single-site binding model using the MicroCal™ Origin software (version 7.0552).  
	  	  	  Chapter	  II	  –	  Assembly	  of	  the	  screening	  pipeline	  	  	  
	   51	  
 
 
The first titrations with an EcDsbB derived peptide showed promising results, with a strong 
exothermic reaction indicated by a sharp decrease in the power supplied to the cell to keep the 
temperature constant (Figure 2.7A). However this phenomenon was only observed with freshly 
oxidized EcDsbA; titration of reduced EcDsbA by peptide sequences demonstrated insignificant 
energy release with no binding trends (Figure 2.7B) thus suggesting that the oxidation state of 
EcDsbA influenced peptide binding. Further discussion of these observations is presented in 
Chapter III, and unless stated otherwise all peptide sequences and peptidomimetic scaffolds in this 
PhD were tested in ITC against fully oxidized EcDsbA.  
 
For all peptides the 1:1 binding model provided the most accurate curve fitting, suggesting 
that only one peptide binds to the EcDsbA surface. Due to differences in estimated concentrations 
between different peptide sequences, the initial stoichiometry factor n ranged from 1.0 to 1.6. The 
origin of these differences comes from peptide synthesis, where the final peptide powder stock 
might include 10 to 40% salts and solvent, leading to batch-to-batch variation in the actual 
concentration of peptide. To restrain the impact of this variation on the analysis and thermodynamic 
calculations, the peptide concentration input in the software (originally 4 mM) was adjusted for 
each peptide to achieve a calculated n value of 1.0 ± 0.05. The ITC parameters for optimal curve 
fitting are typically represented by a unitless c-value representing the ratio of the protein 
concentration over the dissociation constant Kd, with a recommended range from 1 to 100. The 
calculated ITC c-values for the tested peptides varied from 2 to 50 therefore falling within the 
acceptable range. Each peptide was tested using three technical replicates, and the thermodynamic 
values were presented as mean and standard deviations from the separate analysis of each replicate.  
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Figure 2.7. Examples of Isothermal Titration Calorimetry profiles. A. Titration of oxidized 
EcDsbA with peptide PSPFATCD, leading to a strong exothermic reaction and saturation plateau. 
B. Titration of reduced EcDsbA by peptide PSPFATCDF, triggering a very low exothermic signal 
with no observed binding. Note the different scales in the energy release for each titration. 
 
 Curve-fitting could be optimized with an initial plateau for the first injections, and the ITC 
protocol was extended to 19 injections of 2 µL as smaller injection volumes would delay the 
saturation of EcDsbA, for no improvement (Figure 2.8A). It suggested the binding of peptides to 
EcDsbA occurred in a very short timeframe.  
 
 The installation of the MicroCal™Auto-ITC200 (GE Healthcare), an automated version of 
the earlier instrument, enabled a significant increase in the throughput of tested peptides because it 
allowed for a 96-well plate format (Figure 2.8). However, this improvement was at a cost of greater 
consumption of peptide (almost two-fold) and of EcDsbA.  
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Figure 2.8. Example of successful ITC experiment titrating oxidized EcDsbA with peptide 
PWATCDS using the automated ITC200 instrument. A. Titration of 4 mM PWATCDS into a 
solution of 100 µM EcDsbA. B. Negative control: titration of 4 mM PWATCDS into a buffer 
solution.  
  
 In conclusion, the isothermal titration calorimetry assay proved to be reliable for the study 
of EcDsbA binders, providing essential thermodynamic information. The main drawback was the 
very high consumption of reagents, requiring larger-scale synthesis of peptides and production of 
purified protein. Nevertheless, a large number of peptides synthesized for this PhD were tested 
resulting in more than three hundred ITC titrations performed. The main outcome of these 
experiments is presented in Chapter III for EcDsbA, Chapter IV for PmDsbA and in the Appendix 
for KpDsbA and MtbDsbA.  
 
II.2.5 Surface Plasmon Resonance 
 
 In the pipeline, the purpose of a surface plasmon resonance (SPR) experiment was to 
evaluate the kinetics of the peptide binding reaction to EcDsbA, and to provide a second affinity 
value independent of ITC. SPR is based on the alteration upon ligand binding of particle 
oscillations under a light beam (Homola et al., 1999). A BIAcore T200, the most sensitive of the 
BIAcore instruments from GE Healthcare, was available at the IMB. Briefly, a sensor chip includes 
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four independent flow paths coated with a dextran matrix upon a gold nanolayer. The target 
molecule (the ‘ligand’) can be immobilized onto the dextran matrix through a broad range of 
chemical couplings (Figure 2.9) (Jason-Moller et al., 2006). A light beam is directed towards the 
nanolayer on which polarized light will be reflected and the refractive angle measured by an optical 
detection unit. Injection of a molecule in solution (the ‘analyte’) triggers a mass change on the 
surface of the chip upon binding to the ligand, disturbing the gold nanolayer and shifting the local 
index of refraction. Measuring this shift under different concentrations of analyte provides the data 
used to calculate an affinity value (Kd) and kinetic rates (Karlsson, 2004, Andersson et al., 2006).  
 
The BIAcore refractive index is highly influenced by the molecular mass of the interactants: 
a large analyte binding to a smaller ligand immobilized onto the chip surface will result in a higher 
mass change than the same interaction in the reverse orientation, hence yielding a higher shift in the 
refractive index and a higher response in response units (RU). Therefore in the case of EcDsbA and 
peptides, the recommended method was to immobilize the peptides and peptidomimetics (Mw 500 
– 1500 Da) onto the chip (for example through capture using a streptavidin/biotin interaction) and 
inject EcDsbA (Mw 21170 Da) as analyte across the surface for each experiment. However, this 
approach requires individual labeling of every peptide for immobilization onto the chip. Moreover 
it also requires a high quantity of sensor chips as each flow path used for a specific peptide 
sequence cannot be reused, thus increasing the cost of the assay. Therefore, I initially decided to 
immobilize EcDsbA upon the chip and to inject peptides as analytes instead. The signal was 
expected to be low and therefore harder to detect, but if successful it would mean that an 
experimental series with all controls could be run on a single chip. This chip surface could be 
regenerated by peptide dissociation and with additional immobilization of EcDsbA when signal 
intensity decreased. A potential issue with this method was controlling the oxidation state of 
immobilized EcDsbA. Over a long period of time on the chip and through successive experiments 
the oxidation state of EcDsbA could change, with potential knock-on effects for peptide binding.  
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Figure 2.9. The different immobilization methods used in SPR for this project. A. Direct 
immobilization of ligand EcDsbA (in green) onto the dextran-coated surface through amine 
coupling. The peptides (in orange) are injected as analytes and the mass change on the chip surface 
results in a shift in the refractive index. B. Capture of labeled EcDsbA with a 6xHis or GST tag (in 
red) by a monoclonal antibody (in blue) previously immobilized by amine coupling. C. Capture of a 
biotin-tagged (purple) peptide onto a chip coated with streptavidin (in yellow). The peptide acts as 
ligand and the analyte is the native EcDsbA, which should give a larger refractive shift because of 
the larger mass change on the surface upon binding. This technique however only allows one 
peptide tested per chip. D. Similar method to C except the streptavidin is captured through 
nucleotide strand complementarity beforehand. This method enables regeneration by breaking the 
DNA double strand, thus releasing the entire complex and allowing the use of the same chip for 
different peptides 
 
II.2.5.1 Initial optimization: EcDsbA immobilization 
 
 EcDsbA and peptides for use in the SPR assays were diluted into the running buffer HBS-
EP (0.01 M HEPES pH 7.4, 0.15 M NaCl, 3 mM EDTA, 0.005% v/v Surfactant P20). 
Immobilization of EcDsbA could not be performed using standard thiol coupling onto a chip 
because the only two cysteines in the sequence are the two catalytic cysteines in the active site. 
Accordingly, the first attempts to immobilize EcDsbA onto a standard CM5 sensor chip (GE 
A B
C D
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Healthcare) utilized amine coupling between the activated surface and a free lysine residue of 
EcDsbA (Figure 2.9A). pH scouting of the immobilization buffer (sodium acetate 10mM, pH 4.0, 
4.5 and 5.0) demonstrated that optimal binding of EcDsbA occurred at pH 4.0 with a steep binding 
curve that reached saturation at 6,000 RU (flow rate 10 µL.min-1, contact time 60 sec, Figure 2.10). 
The surface was then regenerated with 10 mM glycine HCl pH 2.5 (flow rate 30 µL/min-1, contact 
time 30 sec). No pH values lower than 4.0 were tested because the dextran matrix on the chip 
surface is required to be negatively charged (pH > 3.5).  
 
 
Figure 2.10. pH scouting for EcDsbA immobilization onto a BIAcore CM5 chip. The first 
injection shows pH 4.0 (in red) to be optimal for EcDsbA binding while the second injection is a 
regeneration of the chip surface. At pH 5.0 (in blue) no binding is observed and at pH 4.5 (in 
green) saturation of the chip surface is not reached.  
 
 An optimal response signal (Rmax) for kinetics studies is between 50 and 100 response units 
(RU). A lower signal would be difficult to detect and a much greater response can result in 
misleading kinetics analysis. Knowing that the experimental response is usually lower than the 
theoretical equivalent due to nonspecific binding, the theoretical Rmax (RmaxT) was set to 150 RU. 
This allows calculation of the theoretical level of EcDsbA immobilization required to detect binding 
kinetics with the following equation: RmaxT = MwDsbA * Rl * S / Mwpeptide, with Rl the 
immobilization level of EcDsbA in RU, and S the molar stoichiometry. Based on a 1:1 
stoichiometry and the molecular weight of the EcDsbB peptide derivative PSPFATCD of 878.3 Da, 
I deduced that to achieve a 150 RU binding signal of PSPFATCD onto EcDsbA, the initial 
immobilization level of EcDsbA onto the chip had to be around 3,600 RU. 
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Immobilization of EcDsbA was achieved through activation of the chip dextran matrix with 
1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC, GE Healthcare) and N-hydroxysuccinimide 
(NHS, GE Healthcare) following steps outlined in the BIAcore software wizard (GE Healthcare). 
EcDsbA (25 µg.mL-1) was then injected onto the chip surface in pulses until the required 
immobilization level (here 3,600 RU) was reached (Figure 2.11). The remaining dextran matrix 
was then inactivated with ethanolamine to limit nonspecific binding in later experiments. Once 
EcDsbA had been immobilized and the baseline stabilized, different concentrations of peptide 
PSPFATCD (3 µM to 300 µM) were sequentially injected onto the chip, using different flow rates 
(10 µL.min-1 to 30 µL.min-1) to avoid the mass transport effect, and different contact times (60 to 
180 seconds) in case of low association rates. However, no significant binding signal was observed. 
The best conditions gave less than 10% of the theoretical response RmaxT. Neither altering buffer pH 
(over a range of 4.0 - 9.0) nor saturating the chip with immobilized EcDsbA (with an 
immobilization response up to 8,000 RU) improved the binding signal. At this point it was 
suspected that the chosen immobilization method, by facilitating high density protein 
immobilization or favouring particular protein conformations, may have occluded access to the 
peptide-binding pocket. Consequently, alternative immobilization approaches were investigated.  
 
Figure 2.11. Example of EcDsbA immobilization by amine coupling onto a BIAcore CM5 chip. 
Using consecutive pulses allowed reaching an immobilization level of 3,554 RU with a theoretical 
target of 3,600 RU. The pre-concentration loads the chip surface with ligand by electrostatic 
interactions, followed by dextran activation through injection of EDC and NHS preparations. 
EcDsbA is then injected in consecutive short pulses until the required immobilization is reached. 
Finally, the remaining active dextran matrix is blocked with ethanolamine to limit nonspecific 
binding of the analyte in the following experiments.  
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  II.2.5.2 EcDsbA capture approaches 
 
 To prevent covalent binding of EcDsbA upon the chip surface in a manner that might alter 
protein conformation and limit peptide binding, a ‘capture’ method of immobilization was used in 
which the ligand to be immobilized has a specific label captured by a high affinity antibody on the 
chip surface (Figure 2.9B). In this study, an N-terminal GST-tagged EcDsbA construct and a 
corresponding anti-GST tag polyclonal antibody (Life Technologies) were used. Native EcDsbA 
(immobilized via surface lysines as described above) and GST-EcDsbA (captured via the anti-GST 
antibody) were immobilized on different flow paths from the same chip along with controls to 
compare peptide binding between the two immobilization methods. The anti-GST tag antibody was 
immobilized through amine coupling at 30 µg.mL-1 in sodium acetate 10 mM pH 4.0 reaching 
immobilization levels up to 12,000 R (Figure 2.12A). GST-EcDsbA was then injected on the chip 
with a capture response 1,800 RU at the highest GST-EcDsbA concentration (4 mg.mL-1, flow rate 
10 µL.min-1, contact time 300 seconds, Figure 2.12B). To reach a similar density on the chip 
surface, native EcDsbA (1 mg.mL-1) was immobilized on a different flow path with an 
immobilization level of 1,000 RU (the molecular mass of EcDsbA being half the GST-EcDbsA 
construct, the immobilization level had to be halfed for a similar density).  However when peptide 
PSPFATCD was injected with concentrations ranging from 3 µM to 300 µM (flow rate 30 µL.min-
1, contact time 120 seconds and dissociation time 600 seconds) no significant binding was observed 
for either of the EcDsbA constructs (Figure 2.13). 
 
Figure 2.12. Immobilization of EcDsbA on a chip using the antibody capture method. A. 
Immobilization by amine coupling of an anti GST antibody saturating the chip surface. B. The 
injection of GST-EcDsbA into the flow path led to irreversible capture by the antibody already 
present on the chip, here resulting in EcDsbA immobilization of 1,800 RU. In this way, EcDsbA did 
not undergo any chemical reaction for immobilization that could have modified the state of the 
protein.   
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Figure 2.13. Absence of binding observed when injecting peptide PSPFATCD. A No response 
was observed with peptide concentrations ranging from 3 µM to 300 µM onto EcDsbA immobilized 
by amine coupling. B. No significant binding was observed when injecting the peptide at similar 
concentrations of the flow path with antibody-captured GST-EcDsbA. The sharp peaks observed at 
the start and the end of the injections are a consequence of slight buffer mismatches between the 
sample buffer and the washing buffer.  
 
Three possible reasons for the absence of signal are: 1) the peptide could not access the 
EcDsbA binding site, 2) the EcDsbA peptide binding was modified by the immobilization/capture 
process or 3) the peptide bound to EcDsbA but the mass change and thus the refractive index was 
too low for the sensitivity of the BIAcore instrument. An approach to prevent the first two issues 
was to immobilize the peptide as a ligand on the chip and to use EcDsbA as an analyte. This 
alternative allowed the use of native EcDsbA in solution solving issues 1) and 2), and binding of the 
21170 Da protein onto a 500-1500 Da peptide would lead to a high response signal, solving issue 
3). The main drawback was the cost and handling of many chips as each flow path can only be used 
once for each peptide sequence, which becomes a costly exercise when screening a high number of 
peptides. 
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  II.2.5.3 Peptide immobilization 
 
 To test the peptide immobilization approach, the sequence PSPWATCDF was biotinylated 
at the N- or the C- terminus with a spacer (EZ-Link Sulfo-NHS-LC-Biotin, Thermo Scientific) 
allowing flexibility and length for accessibility by EcDsbA on the chip surface (Figure 2.9C). 
These two peptides were injected on different flow paths of the same streptavidin-coated sensor 
chip (SA chip, GE Healthcare, 200 µg.mL-1, flow rate 10 µL.min-1, contact time 60 seconds) until 
surface saturation with an immobilization level of 420 RU for PSPWATCDF-biotin and 550 RU for 
biotin-PSPWATCDF was reached. For the binding measurements, EcDsbA was fully reduced or 
fully oxidized prior to the experiment using a molar excess of DTT or Cu(Phen) respectively. A 
PD-10 column (GE Healthcare) was used to remove the excess reducing or oxidising agent as well 
as buffer-exchanging EcDsbA into the HBS-EP running buffer (GE Healthcare). EcDsbA was then 
manually injected onto the peptide-coated chip at concentrations ranging from 0.5 mg.mL-1 to 5 
mg.mL-1 (flow rate 5 µL.min-1, contact time 120 seconds, dissociation time 120 seconds) and a 
concentration-dependent response was observed with a signal ranging from 100 RU to 1,300 RU 
(Figure 2.14). Unfortunately no negative controls (injection of EcDsbA on a flowpath with no 
peptide) were performed at this stage due to the shortage of free flow paths on the available chips. 
 
 
Figure 2.14. Oxidized EcDsbA binds in a concentration-dependent manner to PSPWATCDF 
immobilized on the surface of the streptavidin coated chip via either an N- or C-terminal biotin tag. 
Above each injection is indicated the concentration of EcDsbA injected in mg.mL-1. 
  
The sensorgram measured very high on-rate and off-rate, with EcDsbA binding and 
saturating the chip surface immediately after injection and dissociating very shortly after the end of 
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the injection. No residual EcDsbA remained on the chip with the signal immediately returning to 
baseline, and thus it was not necessary to include a regeneration step between injections. The 
sensorgrams suggested that EcDsbA (both oxidized and reduced) preferentially bound to the C-
terminally biotinylated peptide (PSPWATCDF-biotin) with a response level 30% higher than 
biotin-PSPWATCDF, despite a lower density of immobilized peptide. Oxidized EcDsbA binding 
also triggered a higher signal than that of reduced EcDsbA.  
 
A larger range of concentrations and a number of different peptide sequences needed to be 
tested but the requirement of a new chip per peptide substantially increased the cost and time 
efficiency of the assay. Recent progress in BIAcore technology from GE Healthcare provided a 
solution with the CAP sensor chip: the surface is coated with single-strand DNA on which a 
molecule composed of a streptavidin domain bound to the complementary DNA strand can bind at a 
high density. A biotin-labeled ligand (here a peptide) can then be immobilized on the streptavidin 
domain and experiments run with the analyte (here EcDsbA, Figure 2.9D).  Afterwards the chip 
surface can be entirely regenerated by breaking the DNA double strand, thus freeing the chip for 
immobilizing another ligand (here another peptide sequence). This way, only a single chip is 
necessary to test a large number of peptides. This new CAP chip was tested, on which streptavidin 
was immobilized (CAP reagent, GE Healthcare, flow rate 2 µL.min-1, contact time 300 sec) 
saturating the surface with a final immobilization level of 3,000 RU. The chip was then saturated 
with biotin-PSPWATCDF reaching an immobilization level of 64 RU (concentration 10 mM, flow 
rate 2 µL.min-1, contact time 300 seconds, dissociation time 120 seconds). Successive injections of 
oxidized EcDsbA triggered concentration-dependent binding response from 30 RU at 0.25 mg.mL-1 
to 376 RU at 4 mg.mL-1 in a similar fashion to that shown for the SA chip (Figure 2.14). As a 
negative control, the same solutions of oxidized EcDsbA were injected on flow paths only 
presenting the streptavidin reagent and no biotinylated peptide; a similar response was measured 
(Table 2.2). The data suggested that the observed binding of EcDsbA on the chip was non-specific 
and probably due to electrostatic interactions. This hypothesis explained the high on-rate and off-
rate as EcDsbA was simply washed away at the end of the injection with no dissociation from 
specific binding to the ligand.  
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Table 2.2. Binding signals for EcDsbA injection on a CAP in presence and absence of peptides. 
On one flow path biotin-PWATCDS peptide was immobilized on the streptavidin CAP reagent 
whereas on the second flow path only the CAP reagent was present. The binding responses (in RU) 
showed that EcDsbA bound to the chip the same way independently of the presence of peptide, 
suggesting a lack of specificity in the interaction with the chip. Due to the complexity of the chip, 
the experiment was executed in manual mode that does not provide clear graphic representation.   
 Injected EcDsbA concentration (mg.mL
-1) 
 0.25 0.5 1 2 4 
Biotin-PWATCDS +30 +58 +100 +192 +376 
Negative control +29 +60 +97 +190 +378 
 
  II.2.5.4 Discussion 
 
 The surface plasmon resonance assay transpired to be a major challenge to set up for 
EcDsbA. In all, four different methods of immobilization were investigated using a number of 
different labels, and the role of ligand and analyte swapped to overcome presumed steric hindrances 
and to amplify the change in the refractive index upon binding. Additionally flow, contact time, 
ligand and analyte concentrations, pH and running buffer composition were all scouted but no 
specific binding was observed between EcDsbA and peptides. The reasons behind the failure to 
detect specific binding are still unclear. One hypothesis is that immobilized EcDsbA undergoes a 
significant conformational change upon peptide binding thus modifying the refractive index of the 
protein in such a way that masks any shift due to specific peptide binding. However, such an 
explanation does not explain why EcDsbA when injected as an analyte seems to be unable to bind 
the immobilized peptide. Even with the long linker the peptide might be sterically hindered with the 
immobilization process substantially impeding binding by limiting the peptide flexibility. As a 
consequence of these issues and despite considerable efforts the SPR assay had to be abandoned 
and was removed from the peptide screening pipeline.  
 
II.2.6 Model Substrate Oxidation Assay 
 
DSF, ITC and SPR measure the affinity of EcDsbA towards the designed peptides but do 
not provide information about the inhibition of EcDsbA activity. Previous measurements of 
EcDsbA activity were performed by assessing the ability of EcDsbA to catalyze the reduction of 
insulin in the presence of DTT (Shouldice et al., 2010, Heras et al., 2010b, Heras et al., 2008b).  
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Briefly, insulin possesses two intramolecular disulfide bonds between chains A and B and their 
reduction leads to the precipitation of the insoluble B chain, inducing an increase in turbidity that 
can be measured with a spectrophotometer at 650 nm (Holmgren, 1979). However this assay is not 
an optimal way to evaluate EcDsbA activity not least because it is based on a reaction (transfer of a 
disulfide bond from oxidized substrate to reduced EcDsbA) that is the reverse of that which 
EcDsbA catalyses in vivo (transfer of a disulfide bond from oxidized EcDsbA to a reduced 
substrate).  
 
 An assay has since been developed by Assoc. Prof. Martin Scanlon at the Monash Institute 
of Pharmaceutical Sciences to assess the activity of DsbA proteins by monitoring their ability to 
catalyse the folding of a synthetic substrate peptide (Vivian et al., 2009). The peptide oxidation 
assay, hereafter referred to as the model substrate oxidation assay to avoid confusion between 
substrate peptide and inhibitor peptide, is based on a time-resolved fluorescence energy transfer 
phenomenon. The synthetic substrate peptide of EcDsbA of sequence CQQGFDGTQNSCK 
presents an N-terminal 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) group 
and a C-terminal methoxycoumarin amide (MCA) (Anaspec, Figure 2.15). The peptide is prepared 
in 2 mM stock in 100 mM imidazole pH 6.0 in the presence of 4mM of Europium3+ (Eu3+) to form a 
chelate complex with the DOTA scaffold. Upon disulfide bond formation between the two cysteine 
residues, the coumarin group is brought close to the Eu3+-DOTA fluorophore (Figure 2.15). 
Excitation of the coumarin moiety at 340 nm then leads to an energy transfer to the Eu3+-DOTA 
fluorophore and an increase in fluorescence emission at 615 nm. Continuous reading of 
fluorescence, in the presence of EcDsbA allows measuring the rate of folding of the substrate 
peptide and thus EcDsbA activity. EcDsbB is also included in the reaction to regenerate oxidised 
EcDsbA, thus increasing the timeframe of the experiment and allowing study of the influence of a 
ligand on the EcDsbB-EcDsbA interaction. The presence of an inhibitor that blocks the substrate-
EcDsbA, the EcDsbA-EcDsbB or the EcDsbB-ubiquinone interaction, would lead to a decrease in 
the substrate peptide folding rate and thus to a reduced fluorescence increase rate compared with 
EcDsbA activity in the absence of an inhibitor.  
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Figure 2.15. Model substrate oxidation mechanism. Folding of the peptide by formation of a 
disulfide bond between the two cysteines by EcDsbA enables energy transfer from the spatially 
close coumarin moiety to the Eu-DOTA moiety. EcDsbA activity - and the inhibitory power of any 
molecule impeding its activity – can be assessed by following the emission fluorescence at 615 nm 
over time. 
 
 The substrate oxidation assay was optimized in the laboratory at the IMB by Dr Maria Halili 
and I followed her procedure. Assays were performed in a white 384-well plate (Perkin Elmer 
OptiPlate-384, Part #: 6007290) in 50 mM MES, 50 mM NaCl and 2 mM EDTA at pH 5.5 buffer. 
Each sample well contained 80 nM EcDsbA, 1.6 µM EcDsbB in a membrane preparation (see 
section II.2.1), peptide or peptidomimetic at concentrations ranging between 64 nM to 1 mM, and 
10 µM synthetic substrate (added last to initiate the reaction and fluorescence signal) in a final 
volume of 50 µL. A positive control did not include any peptide or peptidomimetic. The three 
negative controls included mixing the substrate peptide with respectively EcDsbB, EcDsbA or the 
inhibitory peptide alone. Plates were read using a Synergy H1 multimode plate reader (BioTek). 
First fluorescence background measurement was performed before adding the substrate peptide 
triggering the reaction. Once the synthetic substrate was added, fluorescence emission at 615 nm 
was measured every 75 seconds, which was the minimal timeframe for the instrument to read every 
well on the plate once, for a total length of 4 hours. Every reaction was performed in three technical 
replicates.  
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 In the absence of inhibitors, the measured fluorescence increased rapidly, demonstrated by 
an initial steep curve. As the quantity of oxidized EcDsbB diminished, the rate of fluorescence 
signal showed an asymptotic behavior (Figure 2.16A, red curve) finally reaching absolute 
maximum fluorescence. In the presence of peptides the rate of fluorescence increase was 
substantially reduced from the beginning of the experiment, and the absolute maximum 
fluorescence was not reached within the experimental timeframe for the highest concentrations. The 
fluorescence rates were calculated based upon the first 15 minutes of the experiments before the 
asymptotic behavior. When plotted against the log of inhibitor concentrations, a dose-response 
sigmoidal curve can be fitted and an IC50 value calculated from the inflection point (Figure 
2.16B). 
 
Figure 2. 16. Example of significant inhibition of the peptide folding rate by peptide PWATCDS. 
A. Raw fluorescence measurements at 615 nm from wells containing increasing concentrations of 
PWATCDS from 64 nM to 1 mM. Lowest concentrations do not show any decrease in the rate of 
fluorescent signal increase compared to the positive control without peptide (red), while at the 
highest concentration (1 mM, in light blue) peptide folding is almost entirely prevented. Only half of 
the peptide concentrations tested in the assay is shown in this graph for clarity. Negative controls 
are not shown because their fluorescence is extremely low. B. Plotting the fluorescence increase 
rates against the log of the inhibitor concentration supports the fitting of a sigmoidal curve from 
which an IC50 can be calculated from the inflection point. Both graphs are presented with the 
standard deviation over three replicates.   
 
 Overall, the model substrate oxidation assay was an efficient tool to detect inhibitory 
activity from peptides and peptidomimetics that satisfied the previous binding assays. Importantly 
this assay consumed low amounts of both peptides and EcDsbA and experiments for up to three 
compounds at a time could be run over half a day. However, a limitation of this particular assay is 
that it does not differentiate if the inhibitor competes for EcDsbA binding against the substrate, or 
against EcDsbB, or both.  
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II.2.7 Crystallography  	   	  
 Crystallography was an essential component of this PhD project to provide structural 
understanding of the targeted site. However, co-crystallizing and solving the structure of a complex 
is not without challenges. There are three major strategies to achieve crystal complexes: 1) co-
expression of ligand and protein, 2) soaking of a ligand into a preformed protein crystal and 3) co-
crystallization of a mixture of protein and ligand (Hassell et al., 2007, Turnbull & Emsley, 2013, 
Danley, 2006, Schlichting, 2005).  The first possibility was not envisaged due to the difficulty of 
co-expressing the peptide sequence along with EcDsbA.  
 
Soaking is an attractive approach because the crystallization conditions of the protein alone 
are well known, although insertion of the ligand in the crystal depends on ligand size and 
conformation as well as crystal shape and the size of the solvent channels. In this technique, a 
ligand might not be able to access sites on the target that are available in solution. For co-
crystallization, the binding of a ligand, especially one as large as a peptide, can lead to significant 
protein conformational changes hence altering the crystal forms initially screened for the protein 
alone (Hassell et al., 2007). This can lead to the investigation and screening of entirely new 
crystallization conditions as well as the analysis of previously unreported crystal shapes for that 
protein. Moreover, the presence of a concentrated ligand was an additional consideration in the 
crystallization conditions, and ligand concentration might have to be scouted among other 
precipitants and additives. However this technique enables the possibility to saturate the protein 
with ligand thus resulting in a higher probability of finding a ligand molecule in the different 
protomers of the asymmetric unit of a crystal.  
 
Both soaking and co-crystal approaches were performed and are described in this section for 
solving a high-resolution co-crystal structure of a DsbA in complex with a peptide from the 
pipeline. The most interesting structure solved during this PhD is analyzed and discussed in chapter 
IV.  All crystallization trials were performed using the UQROCX (http://uqrocx.imb.uq.edu.au) 
diffraction facility. Diffraction data were collected at UQROCX and the Australian Synchrotron 
(http://www.synchrotron.org.au). 
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  II.2.7.1 Soaking trials  
 
 Soaking crystals with ligands is a popular technique, as the crystallization conditions of the 
protein alone are already known. The usual process is to immerse pre-formed crystals into 
stabilizing solutions with different concentrations of the desired ligand for different periods of time. 
The ligand can then access the crystal solvent channels to reach the protein binding site. The 
soaking trials were performed under the supervision of Dr Begoña Heras. In this case, diamond-
shaped crystals of EcDbsA were grown in 2 µL hanging drops containing 13%-18% PEG 8,000, 
100 mM cacodylate, 8% glycerol and 1 mM CuCl2. After 3 days, these crystals were transferred 
into 2 µL drops of a stabilizing solution (16% PEG 8,000, 100 mM cacodylate, 8% glycerol, 1 mM 
CuCl2) and peptides (PSPFATCD and PSPWATCDFM) at concentrations from 2 mM to 15 mM 
(with DMSO concentration up to 3% from the DMSO 100% peptide stock solution). However this 
treatment led to blunted edges and visible cracks in the crystals within 2 hours and the entire 
dissolution of crystals within 4 hours. X-ray diffraction of these crystals at incubation times of two 
and three hours revealed a drastic loss of diffraction resolution (Figure 2.17).  
 
 
Figure 2.17. Diffraction patterns of EcDsbA crystals soaked with or without peptides. A. 
Diffraction pattern with a resolution up to 1.7 Å of an EcDsbA crystal in stabilization solution for 2 
hours. B. Diffraction pattern of an EcDsbA crystal grown with identical conditions as A, and 
incubated for 2 hours in a stabilizing solution including peptide PSPFATCD at 12 mM 
concentration.  
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Interactions with EcDsbA (such as formation of an intermolecular disulfide bond with the 
catalytic cysteines) potentially accompanied with conformational change might have lead to the 
disruption of the crystal lattices on the crystal edges, ultimately leading to complete dissolution. 
This outcome suggested that soaking was not an appropriate technique in this case, even if it has 
been used successfully for smaller molecules (unpublished results), hence the co-crystallization 
approach was used for all subsequent experiments.  
 
  II.2.7.2 Co-crystallization  
 
 The co-crystallization approach requires the formation of a protein-ligand complex before 
setting the crystallization drops. This method has the advantage of allowing any conformational 
change on the protein caused by ligand binding to occur prior to the formation of lattice packing  (in 
contrast to soaking techniques where the protein is already in a rigid lattice), but these 
conformational changes may also lead to alterations in the conditions required for crystallisation. 
Therefore, when an inhibitor peptide or peptidomimetic satisfied the screening pipeline and was 
incorporated into the co-crystallization trials, the EcDsbA-peptide complex was tested for 
crystallogenesis both using the known EcDsbA protein crystallization conditions (13%-18% PEG 
8,000, 100 mM cacodylate, 8% glycerol, 1 mM CuCl2), as well as commercial screens to find new 
conditions.  
 
 The EcDsbA-peptide crystals were obtained by mixing EcDsbA at a final concentration 
ranging from 30 mg.mL-1 to 60 mg.mL-1 (1.5 mM to 3 mM) with a molar excess of peptide at 
concentrations ranging from 5 mM to 30 mM in a solution of 10 mM HEPES pH 7.4 (with a final 
DMSO concentration of 2 %). The solutions were then incubated on ice for an hour to facilitate 
complex formation. Crystallization trials were set up in 96-well plates mixing 200 nL of EcDsbA-
peptide complex with 200 nL of the crystallization condition using a Mosquito dispensing robot 
(TTP Labtech) and using the hanging drop vapor diffusion method. Trays were incubated and 
imaged at either 20 ºC or 8 ºC in a RockImager 1000 (Formulatrix). The commercial screening 
plates included Index, Peg/Ion and PegRX (Hampton Research), JCSG, Proplex, Morpheus and 
PACT (Molecular Dimensions), covering a broad array of common crystallization conditions 
(which implies a range of different solution compositions). 
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 A substantial number of peptide sequences were tested for co-crystallization but 
crystallogenesis with EcDsbA proved difficult. The original EcDsbA crystallization conditions gave 
poor-looking crystals upon the addition of a peptide. Commercial screens led to several promising 
crystal hits (Figure 2.18) but diffraction revealed these either to be salt crystals or of poor 
diffraction quality. Conditions giving poorly diffracting crystals were optimized by varying pH, 
EcDsbA and peptide ratios and concentrations, and temperature. Promising conditions were also 
subject to further testing with an additive screen. Trays were also set up using solutions generated 
from ITC experiments; after successful titrations, EcDsbA-peptide complexes were retrieved from 
the ITC instrument, concentrated and directly used to set up crystallization drops. The possibility 
that the peptide was binding through the formation of an intermolecular bond with EcDsbA 
catalytic cysteine (see Chapter III) suggested the peptide might be turned over. To prevent such 
potential release of the peptide from EcDsbA, an EcDsbA mutant was engineered (see section II.2.1 
of this chapter), substituting the catalytic Cys30 with Ser30 to prevent formation of any disulfide 
bond. Screening trays were set up with the EcDsbAC30S mutant to identify potential new ‘hit’ 
crystallization conditions, but only provided very poor and fragile crystals. Overall, the outcome of 
the co-crystallization attempts with EcDsbA was poor and no high-resolution co-crystal structures 
were solved.  
 
Figure 2.18. Examples of ‘hit’ co-crystallization conditions using EcDsbA and peptides. A. 
EcDsbA – PSPWATCD crystal in sodium citrate dibasic 0.1 M, 22 % PEG 3,350 and n-octyl-6-D-
glucoside 0.1 mM, which diffracted to low resolution (≥ 4.0 Å) B. EcDsbA – PSPWATCDF crystals 
in ammonium sulfate 2 M and citric acid 0.1 M, diffraction revealed the crystals to be salts.  C. 
EcDsbA-PWATCDS crystal in Tris 0.1M pH 7.8, PEG 3,350 24% and sodium chloride 0.2M which 
gave anisotropic diffraction. 
A B C 
D E F 
	  	  	  Chapter	  II	  –	  Assembly	  of	  the	  screening	  pipeline	  	  	  
	   70	  
 
An alternative protein was then trialled. The crystal structure of an EcDsbA homologue, 
Proteus mirabilis DsbA (or PmDsbA) had been solved within the lab by PhD student Fabian Kurth 
as part of another project investigating DsbA proteins in other pathogenic Gram-negative strains. 
PmDsbA shares many structural similarities with EcDsbA (see Chapter IV) and crystallization 
‘hits’ in commercial plates were far more numerous than for EcDsbA. ITC showed that PmDsbA 
also bound the synthesized peptides with an affinity range similar to EcDsbA (see Chapter IV). Co-
crystallization was therefore attempted using PmDsbA and a PmDsbAC30S mutant, giving a large 
number of crystal conditions (Figure 2.19).  
 
 
Figure 2.19. Examples of ‘hit’ co-crystallization conditions using PmDsbA and peptides. A. 
PmDsbA-PSPWATCDF crystals in PEG 3,350 19.50% and Sodium Malonate 0.4 M. The solved 1.7 
Å resolution structure did not include a peptide molecule.  B. PmDsbAC30S-PWATCDS crystal in 
PEG 3,350 28% and potassium thiocyanate 0.6 M. This crystal provided the 1.6 Å co-crystal 
structure described in Chapter IV. C. PmDsbAC30S-PSPWATCDFMV crystal gave anisotropic 
diffraction. 
 Crystallization trials were performed in collaboration with Fabian Kurth. Crystals that 
yielded a diffraction pattern with a resolution of 3 Å or higher during in-house screening at the UQ 
ROCX X-ray facility were subsequently tested at the Australian Synchrotron on beamlines MX1 or 
MX2. If the crystal diffracted to a resolution better or equal to 3 Å, diffraction images were 
A B C 
D E F 
	  	  	  Chapter	  II	  –	  Assembly	  of	  the	  screening	  pipeline	  	  	  
	   71	  
collected over 180º to 360º. Diffraction data were recorded with an ADSC Quantum 210r (MX1) or 
315r (MX2) detector controlled by BLU-ICE (McPhillips et al., 2002). Calculation of the density 
maps and refinements of the models were performed with the help and supervision of Dr 
Lakshmanane Premkumar. Reflections were indexed and integrated in Mosflm (Battye et al., 2011) 
or XDS (Kabsch, 2010), analyzed in Pointless (Evans, 2006) and scaled in SCALA (Evans, 2006) 
from the CCP4 suite (Winn et al., 2011). Molecular replacement (MR) was performed with 
PHASER (McCoy et al., 2007) respectively using EcDsbA as a template (PDB code 1DSB) for 
EcDsbA co-crystals, PmDsbA (PDB code 4OCE) for PmDsbA co-crystals and PmDsbAC30S 
(PDB code 4OCF) for PmDsbAC30S cocrystals. Iterative refinement of the final structures were 
performed with Phenix.refine (Adams et al., 2010) and Coot (Emsley et al., 2010) with the details 
for the successful co-crystal structure described in Chapter IV.  
 
 Systematic co-crystallization of EcDsbA and PmDsbA with different peptides through a 
broad range of conditions was the most reagent- and time-consuming element in this research 
project. This step demonstrated a bottleneck in the pipeline, with the co-crystallization trays of 
more potent peptides being postponed while the previous molecules were still under co-
crystallization optimization. However, this systematic approach provided the first reported high-
resolution (1.6 Å) co-crystal structure of a DsbA with a non-covalently bound peptide, in this case 
PmDsbAC30S with peptide PWATCDS, which is the focus of Chapter IV.  
II.3 Conclusion 
 
 From the initial ideal flowchart, the majority of the pipeline was successfully implemented; 
solid phase synthesis, DSF, ITC and model substrate oxidation assays were incorporated and used 
to synthesise and provide feedback on the characterization of peptides and peptidomimetics. 
Establishing a SPR assay was the major hurdle in this pipeline, and one that I was unable to 
overcome. Our collaborators have since reported similar difficulties in setting up an SPR assay for 
EcDsbA (M. Scanlon, personal communication). However, a potential solution has been found 
using a new EcDsbA construct using two 6xHis tags in tandem that optimizes the immobilization 
method. Using this construct specific binding of small molecules has been detected. The expression 
and purification of such a construct could be trialed for SPR analyses of specific binding from 
peptides and peptidomimetics. Systematic co-crystallization did not have the expected success due 
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to the strong influence of peptides upon the crystallization conditions but a high-resolution structure 
of a non-covalent DsbA-peptide structure was solved for the EcDsbA homologue from P. mirabilis.  
 
Besides the assays presented within the pipeline, additional techniques could be envisaged 
to provide additional information on the peptide binding mode. STD NMR analysis of peptide 
binding could identify EcDsbA residues affected by the binding event hence provide additional 
information for the design of future peptides. Microscale thermophoresis offers an alternative in 
affinity measurement for molecules with a major entropy contribution in binding (for which ITC 
has a limited sensitivity). Microscale thermophoresis does not require immobilization of the protein 
or peptide (unlike SPR) and does not use thermodynamic measurements to calculate the affinity 
(unlike ITC). However, this assay would only provide a Kd value and no thermodynamic or kinetic 
information. Finally mass spectrometry could be useful for detecting the formation of EcDsbA-
peptides complexes and the formation of covalent adducts (for example if the peptide forms an 
irreversible disulfide bond).  
 
 In summary the pipeline I established (excluding the SPR component) is able to characterize 
a newly designed molecule in a timeframe of 5 days, from synthesis to the first co-crystallization 
plates, and the outcomes of these experiments are presented in chapters III, IV and V.  
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CHAPTER III 
 
 
 
The following chapter is a manuscript submitted to the Journal of Medicinal Chemistry. 
Following the assembly of the screening pipeline as reported in Chapter II, a large number of 
peptides (based on the EcDsbA-EcDsbB interaction described in I.2.3) were synthesized and tested 
for binding and inhibition of the EcDsbA activity. A selection of 31 sequences was chosen to 
describe the interactions between these potential inhibitors and the EcDsbA binding site. The 
purpose of this structure-activity relationship (SAR) study is to identify the chemical moieties, 
residues and interactions essential for the binding and inhibition of EcDsbA. Peptides presenting 
weaknesses as druggable molecules (see Chapter I.3.1), the properties of the most advantageous 
peptide sequence (in terms of affinity, inhibition and ligand efficiency) will be used for the future 
design of peptidomimetic compounds. The supplementary information provided with the 
manuscript is available in Appendix C.  
 
This manuscript is also the result of fruitful collaboration with other contributors: the 
substrate oxidation peptide protocol (see section II.2.6) was provided by Dr Halili, who performed 
the assay for one peptide sequence while I applied for the others. Dr Halili also contributed to the 
production of EcDsbA protein samples for this work and provided the EcDsbB membrane 
preparations necessary for the substrate oxidation assay. Peptides were all synthesized according to 
a protocol provided by Dr Lindahl (see section II.2.2) with his advice and expertise for optimal 
yields. The final manuscript was reviewed and critically revised by Dr Halili, Dr Lindahl, Dr Reid, 
Prof. DP Fairlie and Prof. JL Martin.  	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Abstract 
Antibacterials with novel modes of action are desperately needed to address the increasing problem 
of antibiotic resistance. One approach is to develop drugs that interfere with bacterial virulence. A 
master regulator of virulence in Gram-negative bacteria is the oxidative folding machinery 
comprising DsbA and DsbB. DsbA introduces disulfide bonds into folding protein substrates while 
its partner protein DsbB maintains DsbA in the active oxidized form. Using crystal structure 
information on the DsbA:DsbB complex we evaluated structure-activity relationships for 31 
peptides using natural and unnatural amino acids, alanine substitutions and sequence length 
variation. Several peptides were found to bind oxidized DsbA (Kd 2.0 ± 0.3 µM) and inhibit its 
activity (IC50 5.1 ± 1.1 µM). A cysteine was essential for interaction of the peptide with DsbA 
suggesting that future peptidomimetic inhibitors should be designed to exploit this thiol interaction. 
Such inhibitors could provide the basis for antivirulence agents with a novel mechanism of action. 
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Introduction 
 
The rapid increase in antibiotic resistance (Boucher et al., 2009) combined with only a 
trickle of new antibiotics (Zurenko et al., 1997, Tally & DeBruin, 2000, Casewell & Hill, 1987, 
Novak & Shlaes, 2010) through the development pipeline has been described as a looming public 
health crisis (The Bacterial Challenge: time to react, 2010). One approach to generate new classes 
of antibacterial drugs is to target bacterial virulence traits rather than killing or inhibiting the growth 
of bacteria. This approach may induce less evolutionary pressure to develop resistance compared 
with current antibiotics (Clatworthy et al., 2007). Moreover, targeting virulence might limit the 
detrimental impact of drugs on host flora (Rasko & Sperandio, 2010).  
 
The Dsb periplasmic oxidative folding pathway of Gram-negative bacteria plays a master 
role in virulence (Heras et al., 2009). This process is essential for assembly of host cell adhesins 
(Jacob-Dubuisson et al., 1994), toxins (Wulfing & Rappuoli, 1997), type III secretion system 
systems (Miki et al., 2008), and motility machines (Dailey & Berg, 1993) among others. Bacterial 
strains lacking Dsb enzymes are viable but non-pathogenic (Totsika et al., 2009b), providing proof 
of principle that targeting this machinery may be a feasible antivirulence strategy. The archetypal 
system in Escherichia coli K12 comprises two enzymes, DsbA and DsbB. The dithiol oxidase E. 
coli DsbA (EcDsbA) (Bardwell et al., 1993, Bardwell et al., 1991) introduces disulfide bonds 
between cysteine residues in protein substrates by thiol exchange (Dutton et al., 2008) through a 
bimolecular nucleophilic reaction (Figure 3.1). EcDsbA is then re-oxidized by the membrane 
protein EcDsbB. The first step in re-oxidation is the formation of a mixed disulfide between 
EcDsbA Cys30 and EcDsbB Cys104 (located on a periplasmic loop of the EcDsbB membrane 
protein). This mixed disulfide is then subject to nucleophilic attack by EcDsbA Cys33 resulting in 
the release of oxidized EcDsbA (Kadokura & Beckwith, 2002). EcDsbB is highly specific for 
EcDsbA (Shouldice et al., 2011). 
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Figure 3.1. DsbA-induced disulfide bond transfer mechanism. 1. The nucleophilic attack of a 
substrate thiolate onto oxidized DsbA Cys30 leads to the formation of an intermolecular disulfide 
bond. 2. Nucleophilic attack on the disulfide by a second substrate thiolate induces substrate 
folding by formation of an intramolecular disulfide bond and releases DsbA in the inactive reduced 
state. 3. Reduced DsbA Cys30 forms a disulfide bond with membrane-bound oxidized DsbB Cys104. 
4. Nucleophilic attack by DsbA Cys33 on Cys30 results in disulfide bond formation in the DsbA 
active site. The additional electrons on the DsbB loop are subsequently transferred to ubiquinone 
and ultimately to the respiratory system. 
The present study was aimed at discovering whether peptides derived from EcDsbB would 
inhibit EcDsbA and thus be useful as the basis for future development of antivirulence compounds. 
The goal was to identify peptides that inhibit DsbA activity by interfering with the DsbB binding 
surface. In our peptide design, we made use of information from low-resolution crystal structures 
defining the EcDsbA-EcDsbB interaction (Inaba et al., 2009a, Malojcic et al., 2008, Inaba, 
Murakami, et al., 2006). The central interaction of the EcDsbB periplasmic P2 loop residues 
98PSPFATCDFMVR109 is the mixed disulfide formed between Cys104 of the EcDsbB P2 loop and 
EcDsbA Cys30 of the 30CPHC33 active site motif. However, additional interactions are also present. 
Specifically, residues 98PSPFAT103 interact with a hydrophobic groove on EcDsbA, which had been 
suggested previously as a potential peptide-binding groove (Martin et al., 1993). The groove is 
formed from aromatic and aliphatic residues (Phe36, Leu40, Ile42, Phe174 Tyr178) of EcDsbA 
helices α1 and α6 (Figure 3.2). In addition, the EcDsbA cisPro loop, a characteristic feature of the 
active sites of many thioredoxin-fold proteins (Qin et al., 1996, Nikkola et al., 1991), also 
participates in the interaction with EcDsbB through hydrogen bond formation with backbone atoms 
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of EcDsbA Arg148 and EcDsbB Phe106 (Figure 2). Taken together, the structural information 
suggested that interactions other than disulfide bond formation could be exploited for the 
development of an inhibitor scaffold targeting EcDsbA. 
 
 
Figure 3.2. EcDsbB P2 loop - EcDsbA interface from the 3.7 Å resolution EcDsbA-EcDsbB 
crystal structure by Inaba et al.(Inaba et al., 2009b) (PDB code 2ZUP). The EcDsbB loop is shown 
in blue with interacting residues at the interface labeled. The surface of EcDsbA is shown in beige 
with the hydrophobic pocket identified in orange. Both cysteines involved in a disulfide bond are 
shown in yellow. The predicted hydrogen bond between EcDsbB Phe106 and EcDsbA Arg148 is 
shown as a blue dashed line and its location highlighted in light blue. 
 
The EcDsbA-EcDsbB crystal structure was used to determine the initial synthetic peptide 
for these studies which corresponded to the sequence of the EcDsbB P2 loop that binds EcDsbA 
(Figure 2). A screening pipeline comprising thermal shift, isothermal titration calorimetry, and 
substrate oxidation assays was established to measure binding affinity for EcDsbA and inhibitor 
characteristics of a series of synthetic peptides. Structure-activity relationships for 31 synthetic 
peptides were assessed by varying length, using non-native amino acids, and by substituting side 
chains with alanine to identify critical components for activity. 
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Results 
 
EcDsbB-derived peptides bind to oxidized EcDsbA 
The sequence of peptide 1 was identified from the low-resolution crystal structure of the 
EcDsbA-EcDsbB crystal structure (Inaba et al., 2009a) (PDB code 2ZUP) and corresponds to 
residues 98PSPFATCDF106 of the EcDsbB periplasmic loop P2 that interact with EcDsbA. We first 
assessed the ability of this synthetic 9-residue peptide to interact with EcDsbA using a thermal shift 
assay that required small quantities of protein and peptide and which can be performed rapidly. The 
free energy contribution of peptide binding increases the Gibbs free energy of protein unfolding, 
which is measured as an increase in the protein melting temperature, Tm (Kranz & Schalk-Hihi, 
2011). Peptide 1 was found to markedly affect the EcDsbA melting temperature (Figure 3.3 and 
S1), with ΔTm 1.5 ± 0.1 ºC at the lowest concentration used ([PSPFATCDF] 125 µM) and 7.5 ± 0.1 
ºC at the highest concentration ([PSPFATCDF] 4 mM) (Table 3.1). These results suggested that 
this short synthetic peptide sequence, corresponding to a single loop fragment of EcDsbB, did 
indeed have significant binding affinity for EcDsbA.  
 
 
Figure 3.3. PSPFATCDF binds to EcDsbA. Sigmoidal curves can be fitted onto unfolding 
fluorescence readings where an inflexion point indicates Tm (see Supplementary figure S1). Tm is 
here shown as a peak in the first derivative of the sigmoidal curve for each peptide concentration. 
Tm values are determined from fitting the sigmoidal curve between 56°C and 72°C and values are 
shown here above the derivative curves according to each peptide concentration.  	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Table 3.1. Shifts in EcDsbA melting temperature observed in thermal shift assay for peptides 1, 23 
and 31.  
ATm (ºC) represents the unfolding temperature and ΔTm (ºC) is the difference between the Tm 
for EcDsbA in the presence and absence of the peptide. 
 
To investigate binding further, isothermal titration calorimetry (ITC) was used to assess the 
affinity and thermodynamics of the interaction. ITC profiles of PSPFATCDF binding to oxidized 
EcDsbA revealed an exothermic reaction with a significant release of energy (2.4 µcal.sec-1) for the 
first injection (Figure S2). The absence of an initial plateau, despite varying the peptide 
concentration, protein concentration and injection volumes (not shown), suggested a very fast on-
rate (kon) for the peptide binding to EcDsbA. The ITC profile is typical of a 1:1 stoichiometry, and 
we therefore concluded that one peptide molecule bound to one molecule of EcDsbA and curve-
fitting analysis parameters were configured appropriately. Using these parameters, peptide 1 had a 
Kd 4.0 ± 1.5 µM for EcDsbA, with a strong enthalpic component to binding (ΔH = -9.9 ± 0.1 
kcal.mol-1) and a relatively unfavorable entropy (ΔS = -8.3 ± 2.9 cal.mol-1.deg-1) (Table 3.2), an 
observation that is common for binding of linear peptides (Temussi et al., 1989). This binding 
affinity equates to a Binding Efficiency Index (BEI) of 5.3 (BEI is used to assess the interaction 
quality as the mass of the ligand changes (Abad-Zapatero & Metz, 2005) with higher values being 
better; see materials and methods). ITC did not detect binding of peptide 1 to reduced EcDsbA 
(where the CXXC active site was in the dithiol form) (Figure S2). All subsequent peptide binding 
assays were performed using oxidized EcDsbA. Peptide 2, PSPFATCD, which differed from 1 only 
in the removal of the C-terminal Phe9 residue, had a 4-fold lower affinity for EcDsbA (Kd 16.2 ± 
1.8 µM, Table 2) but a slightly increased BEI of 5.5. The reduced enthalpy of binding of 
octapeptide 2 compared with nonapeptide 1 is likely a consequence of the loss of a hydrogen bond 
between the backbone atoms of the additional C-terminal Phe9 in peptide 1 with EcDsbA 
Arg148(Shouldice et al., 2011) of the cisPro loop (see Figure 3.2). 
 
    Peptide Concentration 
    0 µM 125 µM 250 µM 500 µM 1 mM 2 mM 4 mM 
Nº Peptide TmA ΔTmA ΔTm ΔTm ΔTm ΔTm ΔTm 
1 PSPFATCDF 61.4 ± 0.1 +1.5 ± 0.1 +2.3 ± 0.1 +3.4 ± 0.1 +4.5 ± 0.1 +6.0 ± 0.1 +7.5 ± 0.1 
23 PWATCDS 61.4 ± 0.1 +1.7 ± 0.1 + 3.3 ± 0.2 +3.7 ± 0.1 +5.0 ± 0.1 +6.9 ± 0.1 +9.8 ± 0.1 
31 PWATSDS 61.4 ± 0.1 +0.1 ± 0.1 + 0.2 ± 0.2 +0.2 ± 0.3 +0.6 ± 0.1 +1.5 ± 0.1 +2.9 ± 0.1 
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Table 3.2. Isothermal titration calorimetry analysis of peptides 1 to 31 binding oxidized EcDsbA. 
Calculated values are stoichiometry (N), affinity (Kd), enthalpy change (ΔH) and entropy change 
(ΔS). Total free energy (ΔG) is calculated according to the equation ΔG = ΔH – TΔS, with T the 
temperature set up for the ITC experiment. The Binding Efficiency Index (BEI) is calculated with 
the following equation: BEI = -pKd / Mw, where Mw is the molecular weight of the ligand in kDa. 
In bold are shown residues differing from the original EcDsbB peptide sequence. N/A indicates 
weak binding preventing analysis. hf = homophenylalanine, 1dip = Ala-1-Diphenol, pip = pipecolic 
acid, thiq = tetrahydroisoquinolone, hs = Homoserine and nve = Norvaline.   
  
N Kd ΔH ΔS ΔG Mw BEI 
N° Sequence 
 
(μM) (kcal/mol) (cal/mol/°) (kcal/mol) (Da) 
 
1 PSPFATCDF 1.0 ± 0.1 4.0 ± 1.5 -9.9 ± 1.1 -8.3 ± 2.9 -7.4 ± 0.2 1025 5.3 
2 PSPFATCD 1.1 ± 0.1 16.2 ± 1.8 -8.4 ± 0.1 -6.1 ± 0.5 -6.5 ± 0.1 878 5.5 
3 PSPWATCDF 1.1 ± 0.1 2.9 ± 0.3 -11.1 ± 0.2 -12.1 ± 0.4 -7.6 ±  0.1 1064 5.2 
4 PSPWATCD 1.0 ± 0.1 10.7 ± 0.7 -11.8 ± 0.2 -17.0 ± 0.5 -6.8 ± 0.2 917 5.4 
5 PSPWATC 1.1 ± 0.1 18.0 ± 0.7 -8.6 ± 0.2 -7.2 ± 0.6 -6.5 ±  0.1 802 5.9 
6 PSPhfATC 1.0 ± 0.1 14.9 ± 2.2 -9.1 ± 0.8 -8.4 ± 2.8 -6.6 ±  0.1 776 6.2 
7 PSP1dipATC 1.1 ± 0.1 9.7 ± 1.8 -8.7 ± 0.7 -6.5 ± 2.3 -6.8 ± 0.1 838 6.0 
8 PSpipWATC 1.1 ± 0.1 12.0 ± 2.6 -8.6 ± 0.7 -6.2 ±2.4 -6.7 ± 0.2 815 6.0 
9 PSthiqWATC 1.0 ± 0.1 13.1 ± 3.0 -11.1 ± 0.9 -15.6 ± 3.5 -6.5 ± 0.5 866 5.7 
10 ASPWATCDF 1.1 ± 0.1 2.7 ± 1.0 -11.6 ± 1.5 -13.5 ± 4.1 -7.6 ± 0.3 1038 5.4 
11 PAPWATCDF 1.0 ± 0.1 2.8 ± 0.2 -9.5 ± 0.9 -6.4 ± 2.9 -7.6 ± 0.1 1048 5.3 
12 PSAWATCDF 1.0 ± 0.1 5.5 ± 1.5 -8.5 ± 0.3 -4.5 ± 0.3 -7.2 ± 0.2 1038 5.1 
13 PSPAATCDF 1.0 ± 0.1 5.8 ± 0.8 -11.7 ± 0.6 -15.4 ± 2.2 -7.4 ± 0.2 949 5.5 
14 PSPWAACDF 1.1 ± 0.1 11.3 ± 2.3 -7.4 ± 0.5 -2.3 ± 1.6 -6.7 ± 0.1 1034 4.8 
15 PSPWATADF N/A     1032  16 PSPWATCAF 1.0 ± 0.1 3.1 ± 1.1 -13.0 ± 0.5 -18.3 ± 1.7 -7.6 ± 0.3 1020 5.4 
17 PSPWATCDA 1.0 ± 0.1 4.4 ± 0.7 -14.9 ± 1.3 -25.7 ± 4.6 -7.3 ± 0.1 988 5.4 
18 PSPWATCDFMV 1.0 ± 0.1 2.5 ± 0.7 -12.5 ± 0.4 -16.1 ± 1.9 -7.7 ±  0.2 1295 4.3 
19 PSPWATCDFM 1.2 ± 0.1 2.0 ± 0.3 -12.6 ± 1.8 -16.2 ± 6.0 -7.8 ±  0.1 1195 4.8 
20 SPWATCDF 1.0 ± 0.1 2.2 ± 0.1 -15.6 ± 0.8 -26.7 ± 2.7 -7.6 ± 0.2 967 5.8 
21 PWATCDF 1.0 ± 0.1 3.0 ± 0.1 -14.3 ± 0.5 -22.6 ± 2.8 -7.5 ± 0.3 880 6.3 
22 PWATCDS 1.0 ± 0.1 5.7 ± 0.4 -13.6 ± 0.1 -21.6 ± 3.5 -7.1 ± 0.1 820 6.4 
23 PhFATCDS 1.0 ± 0.1 8.3 ± 0.4 -11.8 ± 0.3 -16.2 ± 0.9 -6.9 ± 0.1 795 6.4 
24 PSPWATSDF N/A     1048  25 PSPWAThs N/A     801  26 PSPWATN N/A     813  27 PSPWATVDF N/A     1060  28 PSPWATIDF N/A     1074  29 PSPWATnve N/A     799  30 PSPWATM N/A     830  31 PWATSDS N/A     804  
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Modification of residues that interact with the EcDsbA hydrophobic groove 
An attractive starting point for optimization of peptide ligands is the Phe4 residue of 
nonapeptide 1 (PSPFATCDF), the residue equivalent to EcDsbB Phe101. In the crystal structure of 
the EcDsbA-EcDsbB complex, Phe101 is buried in a hydrophobic pocket within the groove of 
EcDsbA (Figure 3.2). The binding interactions for this residue are exclusively hydrophobic, 
suggesting that a bulkier hydrophobic side chain might increase interactions with EcDsbA (residues 
Phe36 and Phe174). We investigated the effect of modifying this side chain. When Phe4 was 
substituted with the bulkier residue Trp (PSPWATCDF, peptide 3), a slightly improved affinity was 
observed (Kd 2.9 ± 0.3 µM) (Table 2) but this corresponded to a reduced BEI value (5.2). The same 
replacement in peptide 2 (ie PSPWATCD, peptide 4) gave an improvement in binding affinity (Kd 
10.7 ± 0.7 µM) and a similar BEI (5.4). 
 
To circumvent difficulties encountered during the synthesis of peptides 6 to 9 containing 
unnatural amino acid residues (Figure 3.4), the C-terminus was truncated by not including residues 
Asp8 and Phe9. The reference compound for this series was heptapeptide 5, PSPWATC, which is 
related to peptide 1 by the removal of these two C-terminal residues and by using Trp in place of 
Phe4. Peptide 5 had a slightly reduced Kd (18.0 ± 0.7 µM) compared to peptides 1 and 4, but this 
lower affinity was offset by the smaller size of peptide 5, so that it had an improved BEI (5.9) 
towards oxidized EcDsbA. The binding of peptide 5 was associated with a lower enthalpy 
contribution (ΔH -8.6 ± 0.2 kcal.mol-1) and a more favorable entropy change (ΔS -7.2 ± 0.6 cal.mol-
1.deg-1) in comparison to peptides 1 and 4.  
 
Next, the Phe4 residue was replaced with the unnatural amino acid homophenylalanine 
(PSP(hF)ATC, peptide 6, Figure 4). Compared with peptide 5 (PSPWATC), the hPhe substitution 
improved the affinity to a small degree (Kd 14.9 ± 2.2 µM, Table 2) and also improved the 
thermodynamics (ΔH -9.1 ± 0.8 kcal.mol-1, ΔS -8.4 ± 2.8 cal.mol-1.deg-1). Importantly, the longer 
side chain resulted in an improved BEI (6.2 compared with 5.9). Alternative substitution at the 4 
position with a diphenylmethyl group (peptide 7, Figure 4) increased the bulk of the side chain and 
improved affinity for EcDsbA almost two-fold (Kd 9.7 ± 1.8 µM, Table 2) relative to peptide 5 
(PSPWATC). However, the larger side chain translated into only a small improvement in BEI (6.0). 
Overall, the phenylethyl side chain at position 4 was a slightly better option than the 
diphenylmethyl group, though for further exploration of peptide SAR the natural amino acid Trp 
was maintained at this position. 
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Figure 3.4. Structure of the peptide scaffold of PSPFATCDF (peptide 1) and the modified 
positions in selected subsequent peptides. Non-natural side chains are highlighted in grey.  
We next sought to investigate the effect of substituting Pro3, the residue preceding Trp4 in 
peptide 5 that corresponds to Pro100 in EcDsbB and which binds in the same hydrophobic groove 
of EcDsbA as Phe101. Pro3 was replaced by two non-native residues pipecolic acid (Pip) and 
tetrahydroisoquinoline-3-carboxylic acid (Thiq) (peptides 8 and peptide 9 respectively, Figure 4) to 
probe the space available in the groove. Both PS(Pip)WATC (peptide 8) and PS(Thiq)WATC 
(peptide 9) gave a moderate improvement in affinity (Kd 13.1 ± 3.0 µM and 12.0 ± 2.6 µM, 
respectively) over peptide 5, however their BEI values indicated no overall improvement in the 
quality of the interaction (5.9, 6.0, and 5.7, respectively for peptides 5, 8 and 9). Moreover the 
binding entropy for peptide 9 (ΔS -15.6 ± 3.5 cal.mol-1.deg-1) suggested an unfavorable binding 
conformation. 
 
Alanine substitution and importance of Cys in peptide binding 
The limited improvement in BEI observed upon substituting Pro3 and Trp4, residues 
corresponding to Pro100 and Phe101 in EcDsbB, suggested that other residues of the peptide might 
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contribute to EcDsbA binding. We therefore performed a focused alanine scan with the aim of 
identifying residues that were critical for interaction. We evaluated the 9-residue peptide 
PSPWATCDF (peptide 3, BEI 5.2), substituting each residue in turn with alanine. Using the BEI 
values as a guide, we found that peptides 10 (Pro1Ala) and 11 (Ser2Ala) had slightly improved BEI 
values, indicating that their sidechains probably contributed little to the binding interaction. Peptide 
12 (Pro3Ala, BEI 5.1) had a slightly reduced BEI value indicating a loss in binding relative to Pro3. 
This is supported by the EcDsbA-EcDsbB crystal structure showing that the corresponding Pro100 
of EcDsbB interacts with the EcDsbA hydrophobic groove. Interestingly, peptide 13 (Trp4Ala) had 
a similar BEI of 5.5 compared with peptide 1. However, the binding thermodynamics were strongly 
affected, the entropy contribution being more unfavorable (ΔS -15.4 ± 2.2 cal.mol-1.deg-1), 
suggesting that this peptide adopted a conformation with little shape complementarity for EcDsbA. 
Peptide 14 (Thr6Ala) exhibited a large reduction in BEI (Table 3.2) compared with 3, suggesting 
that this sidechain should be retained. The reduction in affinity of peptide 13 (PSPWAACDF) for 
EcDsbA was surprising given that the EcDsbA-EcDsbB crystal structure showed the EcDsbB 
Thr103 side chain oriented away from EcDsbA. Therefore, the role of Thr6 in the binding 
mechanism remained unclear.  
 
Replacement of the C-terminal residues Asp8 and Phe9 with alanine (peptides 16 and 17) 
resulted in an increase of the BEI value (5.4), indicating that these side chains contribute little to the 
binding interaction. Indeed, removal of these two residues (peptide 5) improved the BEI 
considerably (5.9), although the crystal structure suggested the presence of hydrogen bond 
formation between the backbone atoms of the corresponding EcDsbB Phe106 residue and the 
EcDsbA cisPro loop, as well as π-stacking interactions between EcDsbB Phe106 and EcDsbA 
Phe63. The entropic contribution to the interaction of peptides 16 and 17 was very unfavorable (ΔS 
-18.3 ± 1.7 cal.mol-1.deg-1and -25.7 ± 4.6 cal.mol-1.deg-1, respectively) suggesting that the 
corresponding residues Asp105 and Phe106 may play a role in pre-ordering the loop conformation 
in EcDsbB for binding to EcDsbA. 
 
Replacement of Cys7 with alanine (peptide 15, PSPWATADF) abolished binding as 
determined by ITC. This suggested that nucleophilic attack of EcDsbA Cys30 by the peptide to 
form a mixed disulfide bond is critical for interaction of this synthetic peptide series corresponding 
to the EcDsbB loop residues 98-106. This result indicated that the peptides form a covalent 
interaction with EcDsbA. This is consistent with the activity of EcDsbA enzyme to interact with 
reduced proteins and is supported by the data described above showing that peptide 1 
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(PSPFATCDF) binds to oxidized EcDsbA (forming a mixed disulfide) and weakly, if at all, to 
reduced EcDsbA. 
 
In summary, the alanine substitution experiments showed that Cys7 was critical and that the 
Trp4 and Thr6 side-chains were most important for interacting with EcDsbA. 
 
Effect of peptide length  
We explored the effect of peptide length to identify residues that could be truncated without 
impacting greatly on affinity. For this purpose, a series of seven peptides with sequence lengths 
ranging from 6 to 11 residues was generated. Peptides 18 (PSPWATCDFMV) and 19 
(PSPWATCDFM) included residues that correspond to residues Met107 and Val108 in DsbB that 
made hydrophobic interactions with EcDsbA in the crystal structure complexes with EcDsbB 
(Inaba et al., 2009a, Inaba, Murakami, et al., 2006, Malojcic et al., 2008). However, both peptides 
had considerably lower BEI values than peptide 3 (PSPWATCDF) indicating that these additional 
residues were dispensable (Table 3.2). As described above, an addition of phenylalanine to peptide 
4 (PSPWATCD) giving peptide 3 (PSPWATCDF) also reduced the BEI value. However, Phe9 in 
peptide 3 corresponds to Phe106 of DsbB which forms a backbone hydrogen bond with Arg148 of 
the cisPro loop of EcDsbA in the crystal structure. Therefore, we investigated the effect of reducing 
the side chain size of this residue (below). Similarly, the addition of aspartate to peptide 5 
(PSPWATC) giving peptide 4 (PSPWATCD) was associated with an increase in affinity (Kd 18.0 ± 
0.7 µM to 10.7 ± 0.7 µM) but a decreased BEI value (5.9 to 5.4). In the crystal structure, EcDsbB 
Asp105 appears to form a salt bridge with EcDsbB Arg109 and a hydrogen bond to EcDsbB 
Thr103. These intramolecular interactions may structurally organize the EcDsbB loop although this 
wasn’t apparent in the entropy changes observed for the shorter peptides. 
 
We next investigated N-terminal truncation. In the 3.7 Å resolution crystal structure both 
Pro98 and Ser99 of EcDsbB are located outside of the hydrophobic groove and make few if any 
contacts with EcDsbA (Shouldice et al., 2011). Removing the corresponding Pro1 from peptide 3 
gave peptide 20 (SPWATCDF) with similar binding affinity (Kd 2.2 ± 0.1 µM, Table 3.2), an 
improved BEI (5.8 compared with 5.2), and increased enthalpy (ΔH -15.6 ± 0.8 kcal.mol-1) but 
more unfavourable entropy (ΔS -26.7 ± 2.7 cal.mol-1.deg-1). Removing both Pro1 and Ser2 to give 
peptide 21 (PWATCDF) gave similar binding affinity and thermodynamic properties to peptide 20, 
and a further increase in BEI to 6.3. However, peptide 21 had low water solubility. To address this, 
Phe7 was replaced with Ser7 to give peptide 22 in an attempt to increase solubility without affecting 
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affinity. This peptide had the highest BEI value of all peptides in this study (6.4) and much 
improved aqueous solubility. Combining the two peptide sequences with the best BEI (peptide 8 
and 22) gave peptide 23 (P(hF)ATCDS) which showed a slightly lower affinity (Kd 8.3 ± 0.4 µM) 
but a similar BEI (6.4) with a decreased enthalpy (ΔH -11.8 ± 0.3 kcal.mol-1) and more favorable 
entropy (ΔS -16.2 ± 0.9 cal.mol-1.deg-1).   
 
Overall, peptides with the most favorable affinity/length ratio and best solubility were the 7-
residue peptides 22 and 23, PWATCDS (Kd 5.7 ± 0.1 µM) and P(hF)ATCDS (Kd 8.3 ± 0.4 µM). In 
comparison with peptide 1 (PSPFATCDF), these two peptides increased BEI from 5.3 to 6.4. 
 
Evaluation of peptides lacking a cysteine 
The formation of a covalent disulfide bond between peptide Cys7 and EcDsbA Cys30 may 
not be desirable in viable drug-like antivirulence agents targeting EcDsbA. We then investigated 
whether non-covalent binding of a peptide to EcDsbA could be achieved by replacing the cysteine 
side chain. A logical substitution for the Cys7 thiol side chain is the hydroxyl side chain of Ser7 
(PSPWATSDF, peptide 24), due to its similar size and the potential to form hydrogen bonds 
through its hydroxyl group with the cisPro loop. However peptide 24 bound weakly, if at all, to 
EcDsbA based upon ITC measurements (Table 3.2). To investigate the possibility that the hydroxyl 
side chain of Ser7 may be too short to form hydrogen bonds with EcDsbA, peptide 25 was 
synthesized with a homoserine (Figure 3.4) at position 7 (PSPWAThS). Again, there was no 
evidence of binding using ITC. Similarly, replacement of Cys7 with Asn7 (PSPWATN, peptide 26) 
resulted in no detectable binding. We then sought to replace Cys7 with hydrophobic residues Val7, 
Ile7, Norvaline7 and Met7 (PSPWATVDF, 27; PSPWATIDF, 28; PSPWAT(Nve), 29; 
PSPWATM, 30) to potentially capture interactions with the hydrophobic surface of EcDsbA. Once 
again these peptides gave no detectable binding with EcDsbA (Table 3.2).  
 
ITC is best used for detecting enthalpy-driven binding rather than lower energy hydrophobic 
interactions. We therefore attempted to detect binding of the Cys-replacement peptides using 
thermal shift.  For this analysis, we chose the peptide with the highest BEI, PWATCDS (peptide 22, 
BEI 6.4) as the reference, and then synthesized the Cys5Ser substituted peptide PWATSDS (peptide 
31). As expected, we were unable to detect binding of peptide 31 to EcDsbA using ITC (Table 3.2). 
We did, however, detect evidence of binding in the thermal shift assay. The reference cysteine-
containing peptide 22, PWATCDS, induced significant shifts in the unfolding temperature Tm of 
EcDsbA of +1.7 ± 0.1 ºC at 125 µM and up to +9.8 ± 0.1 ºC at 4mM peptide 22 (Table 3.1). For 
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peptide 31, where the cysteine was replaced with serine, we also detected statistically significant 
shifts in Tm though at higher peptide concentrations (DTm 0.6 ± 0.1 ºC at 1 mM peptide 31 to 2.9 ± 
0.1 ºC at 4 mM peptide 31). These findings suggest that peptide 31 lacking a cysteine binds to 
oxidized EcDsbA with millimolar affinity.  
 
EcDsbB-derived peptides inhibit the oxidase activity of EcDsbA 
ITC and thermal shift both indicated that the peptides bound to EcDsbA. To address whether 
they inhibited EcDsbA activity, we made use of an enzyme inhibitor assay that measures disulfide 
bond catalysis. In this assay, oxidation of cysteines in a model substrate was detected as increased 
fluorescence as two chromophores moved into close proximity after folding. The aim was to 
determine whether EcDsbA activity in this assay was inhibited in the presence of the DsbB-derived 
peptides. 
 
The tightest-binding cysteine-containing peptides all inhibited EcDsbA activity with IC50 
values similar to their Kd values. For example, peptide 1 (PSPFATCDF, Kd 4.0 µM) yielded an IC50 
value of 6.7 ± 1.1 µM (Figure 3.5A and 3.5B).  Peptide 3 (PSPWATCDF, Kd 2.9 µM) gave IC50 5.1 
± 1.1 µM. The shorter peptides 22 (PWATCDS, Kd 5.7 ± 0.4 µM) and 23 (P(hF)ATCDS, Kd = 8.3 ± 
0.4 µM) resulted in IC50 values of 8.8 µM and 19.2 µM, respectively. Peptide 31 lacking a cysteine 
(PWATSDS) (Figure 5C) did not exhibit any measurable effect on EcDsbA activity, even at the 
highest concentrations tested. These results demonstrated that although peptide 31 bound to 
EcDsbA, it did not compete effectively with EcDsbB or the synthetic substrate to block enzyme 
activity. 
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Figure 3.5. Inhibition of EcDsbA activity. A. Raw fluorescence measurement for the peptide 
oxidation assay in the presence of increasing concentrations of PSPFATCDF (peptide 1). B. 
Average increase in fluorescence over the first 15 minutes of the reaction plotted against the log of 
PSPFATCDF concentration. Sigmoidal curve-fitting allows the estimation of an IC50 of 6.7 ± 1.1 
µM. C. Raw fluorescence measurement for the peptide oxidation assay in the presence of increasing 
concentrations of PWATSDS (peptide 31) lacking a cysteine. No significant inhibition was detected. 
On both panels A and C 12 peptide concentrations between 0.5 µM and 1 mM were tested but only 
8 are displayed for clarity. 
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Discussion 
 
Inhibitors of the enzyme DsbA have potential as a new class of antivirulence drugs to treat 
bacterial infections(Heras et al., 2009). We have focused here on identifying peptides that bound to 
DsbA, using information from the crystal structure of the EcDsbA:EcDsbB complex as the starting 
point. Peptides have limitations as drugs but are valuable starting points in drug design, and 
substantial progress has been made towards improving their stability, resistance to 
peptidases/proteases, cell permeability and bioavailability (Nguyen et al., 2011, Liskamp et al., 
2011, Vaara, 2009, Rotem & Mor, 2009) through modifications that generate peptidomimetics. 
 
The reference point was a 9-residue peptide PSPFATCDF corresponding to residues 98-106 
from the EcDsbB periplasmic loop. This peptide 1 interacted with oxidized EcDsbA with a Kd value 
of 4.0 ± 1.5 µM. A total of 30 peptide derivatives were assessed in comparison to this reference 
peptide in terms of enhanced affinity and BEI values. This led to peptide sequences PWATCDS (Kd 
5.7 ± 0.4 µM) and P(hF)ATCDS (Kd 8.3 ± 0.4 µM) both having the best BEI value of 6.4.  
 
Alanine substitution revealed that Cys104 of the peptide was critical for binding to EcDsbA. 
The cysteine-containing peptides interacted strongly with oxidized EcDsbA, but not with the 
reduced form of the enzyme, and inhibited the activity of EcDsbA in an in vitro assay. Peptides 
lacking a cysteine interacted weakly with EcDsbA and did not inhibit EcDsbA activity. These 
findings support the notion that disulfide bond formation occurs between EcDsbA Cys30 and 
peptide Cys104.  
 
Three scenarios are possible for the cysteine peptide interaction with EcDsbA. First, the 
peptides may bind irreversibly to EcDsbA, acting as “suicide” ligands through formation of an 
unresolved mixed disulfide bond with EcDsbA. If so, inhibition of the oxidation assay would result 
from progressive inactivation of EcDsbA rather than competitive binding with the substrate. A 
second possibility is that after formation of a mixed disulfide between the peptide and EcDsbA, the 
Cys7 of a second peptide attacks the disulfide to form a disulfide-bonded dimer peptide thereby 
releasing EcDsbA in the reduced inactive state. This scenario reflects the catalytic mechanism of 
the enzyme (Kadokura & Beckwith, 2009, Frech et al., 1996) (Figure 1) but is unlikely because 
only one peak was observed in the thermal shift assay, rather than two peaks indicative of the 
different Tm values for oxidized and reduced EcDsbA. A third possibility is that the mixed disulfide 
is resolved by nucleophilic attack of EcDsbA Cys33 on EcDsbA Cys30, releasing the peptide and 
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restoring EcDsbA in its oxidized state. This scenario would qualify the peptides as reversible 
binders.  
 
The finding that the peptide cysteine is essential for strong interaction with EcDsbA 
suggests the potential for the development of “suicide” inhibitors that bind irreversibly to the 
enzyme. For example, α-difluoromethylornithine forms a covalent pyrrole adduct to the mammalian 
ornithine decarboxylase through alkylation of the active site Cys360(Poulin et al., 1992) and 
dipeptide diazoketones with Michael acceptor C-termini are inhibitors of cathepsin C that target the 
active site Cys234(Laine & Busch-Petersen, 2010). Many irreversible cysteine protease inhibitors 
have been reported(Powers et al., 2002) that target the active site cysteine and have been carried 
through to clinical trials(Abbenante & Fairlie, 2005). 
 
Similar approaches could be considered to generate peptidic inhibitors targeting EcDsbA 
Cys30 and Cys33. A ‘warhead’ targeting the more accessible catalytic Cys30 could be linked to a 
peptidic scaffold such as those described here. For example, a halomethyl ketone or an epoxide 
group incorporated in the peptide could generate a thioether covalent adduct to EcDsbA Cys30. 
Alternatively azapeptides could acylate EcDsbA through nucleophilic attack by Cys30 on the 
carbonyl group of the aza-amino acid. A nitrile functionality on the peptide in place of the cysteine 
might lead to formation of a covalent thioimidate adduct. However, the challenge would be to 
design peptides with exquisite specificity towards EcDsbA. 
 
In summary, this SAR study has provided the first evidence that peptides designed to target 
EcDsbA can bind and inhibit activity of the enzyme. A cysteine residue in the peptide was essential 
for activity, highlighting the possibility that a covalent interaction occurs between the peptide and 
the EcDsbA catalytic cysteine. The generation of more potent and selective irreversible inhibitors 
based on this peptide scaffold could lead to a new class of antivirulence drugs to treat antibiotic 
resistant infections. 
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Material and methods 
 
Protein expression and purification 
Wild type E. coli DsbA (GenBank® accession number X80762), without the sequence 
coding for the predicted signal sequence was cloned into a modified pMCSG7 (Midwest Center for 
Structural Genomics) vector for cytoplasmic expression. The sequence includes an N-terminal His6 
affinity-tag followed by a linker region containing a Tobacco Etch Virus (TEV) protease cleavage 
site. EcDsbA was expressed in the cytoplasm of E. coli BL21 (DE3) pLysS strain grown in auto-
induction media(Studier, 2005) (1L) in erlenmeyer flasks for 16-20 h at 30ºC with a stirring speed 
of 220 rpm. After an initial centrifugation (10,000 rpm for 10 minutes at 4ºC, rotor JLA 10.500, 
Beckman Coulter, Brea, CA), the bacterial pellet was resuspended in 25 mM Tris, 150 mM NaCl, 
1:1000 protease inhibitor cocktail (BioPioneer Inc., San Diego, CA) and DNase (Roche, Australia). 
Lysis was executed using a Cell Disruptor (TS-Series, Constant Systems LTD., UK) applying a 
constant pressure of 25 Kpsi. Cell debris was removed by centrifugation (18 500 rpm for 30 min at 
4ºC, rotor JM-25.5, Beckman Coulter, Brea, CA). Purification by metal ion affinity 
chromatography using TALON resin (Clontech, Australia) was used to bind His-tag EcDsbA, 
consequently eluted with a solution of 25 mM Tris, 150 mM NaCl and 200 mM imidazole. The 
His6 affinity tag was removed by TEV cleavage using a 1:50 ratio (protein/TEV-protease, in mg.ml-
1) incubated in a 50 ml tube overnight at 4ºC, leading to two additional non-native residues Ser and 
Asn at the N-terminus of EcDsbA. Removal of the remaining tagged EcDsbA and TEV was 
performed by reverse metal ion affinity chromatography using TALON resin.  Final size-exclusion 
chromatography step using a Superdex 75 16/60 column (GE Healthcare, USA) injecting 5mL of 
concentrated protein in 25 mM Tris, 150 mM NaCl pH 7.4 yielded high purity protein (≥ 95 %) 
verified by SDS-PAGE. Protein was then concentrated and buffer exchanged into 25 mM HPES, 
150 mM NaCl pH 7.4. Quantitation using a Nano-drop (thermo-Scientific) revealed a final yield of 
50 mg of pure EcDsbA per liter of culture. EcDsbA was stored in 50 µL aliquots at 50 mg.mL-1 at -
80ºC. Prior to experiments EcDsbA was fully oxidized or fully reduced using a 25-molar excess of 
copper(II)1,10-phenanthroline or dithiothreitol (DTT), respectively, followed by removal of the 
agent in a PD-10 desalting column (GE Healthcare) and the redox state confirmed by Ellman assay 
(Aitken, 2009).  
 
E. coli membrane preparations containing over-expressed EcDsbB (GenBank® accession 
number AAC74269) were produced as previously reported(Bader et al., 1998), and resuspended in 
PBS buffer containing 10% glycerol. 
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Peptide synthesis  
Peptide synthesis was conducted using standard Fmoc-protected amino acids in solid-phase 
peptide synthesis (SPPS) on rink-amide MBHA resin (p-methylbenzhydrylamine resin, ChemImpex 
International, USA). AA (Amino-acids) were loaded after 5 minutes of preactivation using 4 eq of 
HBTU (O-Benzotriazole-N,N,N',N'-tetramethyl-uronium-hexafluoro-phosphate, ChemImpex 
International, USA) 500 mM and 5 eq of DIPEA (N,N-Diisopropylethylamine, Auspep, Australia) 
before coupling to the deprotected resin for 60 min. Fmoc removal was performed using a 80/20 v/v 
mix of dimethylformamide/piperidine (Rci Labscan, Thailand / Auspep, Australia) for 2 x 5 min. 
Peptides 6, 7, 8, 9, 23, 25 and 29 were synthesized using their respective unnatural AA Fmoc-L-
homophenylalanine, Fmoc-3,3-diphenyl-L-alanine, Fmoc-L-pipecolic acid, Fmoc-L-1,2,3,4-
tetrahydroisoquinoline-1-carboxylic acid, Fmoc-O-trityl-L-homoserine and Fmoc-L-norvaline (all 
Chem Impex International, USA). After final AA coupling all peptides were N-capped by 
acetylation. Peptides were released using a cleavage mixture (95/2.5/1.25/1.25 v/v mix of 
respectively Trifluoroacetic acid / Ethanedithiol / Triisopropylsilane / H2O, Sigma-Aldrich, USA) 
resulting in a C-terminal amide group. Cleaved peptides were dried using N2, precipitated with 
diethyl ether (Ajax Finechem, Australia) and dissolved into a 80/20 v/v mix of acetonitrile/H2O 
(RCI Labscan, Thailand) before purification by reversed phase HPLC (Waters). Purification was 
executed on a Luna C18 column ((250 x 21 mm, Phenomenex, USA) using a 20-100% gradient 
90/9.9/0.1 acetonitrile/H2O/TFA in 12 minutes until peptide reached > 95% purity. Peptides were 
lyophilized and characterised by analytical UHPLC on a Shimadzu Nexre using an Agilent Zorbax 
R-ODS III column (2.0 mm i.d x 75 mm 1.6 mm) and mass measured with a LCMS 2020 
(Shimadzu) and a high-resolution QSTAR Elite mass spectrometer (Applied Biosystems). Retention 
times and m/z ratios are available in Figure S3 and HPLC profiles of the most active peptides 6, 21, 
22 and 23 are available in the supplementary information (Figures S4 and S5).   
 
Thermal Shift Assay 
EcDsbA was diluted to a final concentration of 20 µM in phosphate buffered saline (PBS) 
pH 7.4 and incubated for 1 h with peptides PSPFATCDF, PWATCDS and PWATSDS at 
concentrations ranging from 125 µM to 4 mM in two-fold increments. SYPRO® orange (S-6650, 
Life Technologies Australia, Australia) was added at a final 5X concentration (from a X5000 stock 
provided by Life Technologies) to a final volume of 20 µL per sample. Controls were set up in the 
absence of peptide (positive control) or EcDsbA (negative control). The assay was conducted in a 
translucent Microamp Optical 384-well reaction plate (Applied Biosciences) with 5 replicates per 
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condition. Plates were sealed with optically clear seal and centrifuged immediately prior to use. 
Fluorescence emission was monitored throughout the course of an incremental temperature ramp 
from 25 °C to 95 °C (ramp rate = 0.05 °C.sec-1) using a VIAA7 Real-Time PCR instrument (Life 
Technologies Australia, Australia) with a 585 ± 15 nm emission filter. Raw data were analyzed 
using Prism 6 (GraphPad, CA, USA). Fluorescence emission was fitted using the classic Boltzmann 
sigmoidal equation and the resulting inflexion point was used as the unfolding temperature Tm 
value. To calculate ΔTm (shift in unfolding temperatures), Tm values for EcDsbA were subtracted 
from Tm values of EcDsbA-peptide complexes. In table 1, shifts are presented as mean and standard 
deviation from the 5 replicates per experiment. ΔTm is significant when it is larger than twice the 
standard deviation of the native protein Tm(Kranz & Schalk-Hihi, 2011).  
 
Isothermal Titration Calorimetry (ITC) 
ITC was performed using a MicroCal™ Auto-iTC200 instrument (GE Healthcare, USA). 
The sample cell was loaded with 200 µL of purified EcDsbA (fully oxidized or reduced beforehand) 
at 100 µM in 25 mM HEPES pH 7.4, 50 mM NaCl 0.8 % DMSO. The syringe was filled with 
purified peptide in the same buffer solution. Titrations were conducted at 25 °C using 19 
consecutive injections of 2 µL or 15 injections of 2.6 µL with 180 s intervals and a stirring speed of 
1000 rpm. In every experiment, an initial 0.5 µL of peptide was injected to avoid slow leakage of 
titrant which can interfere with the initial reading. Consequently, this initial data point was 
discarded for binding analysis. The association constant (Ka = 1/Kd), enthalpy (ΔH) and entropy 
(ΔS) were calculated by fitting the data to a single-site binding model using the MicroCal™ Origin 
software (Origin 7.0 SR4 v7.0552 beta) and adjusting the peptide concentration to give a 
stoichiometry parameter of ~1.0. Every peptide was tested in triplicate and the values given 
represent mean and standard deviation from these triplicate analyses.  
 
A ligand efficiency measurement Binding Efficiency Index (BEI) was used to compare the 
quality of binding. BEI is defined by both the measured binding affinity of a ligand for its target and 
the molecular weight of the ligand (Abad-Zapatero & Metz, 2005). The BEI is calculated as 
follows, with the dissociation constant Kd in M and the molecular weight Mw in kDa: 
 
The BEI value of an idealized ligand of molecular weight 0.333 kDa (which is the mean value of 
the molecular weight of marketed drugs (Vieth et al., 2004)) and affinity Kd 1 nM is 27.  
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Model Substrate Oxidation Assay 
The ability of the peptides to inhibit the activity of EcDsbA was evaluated using a model 
substrate oxidation assay(Kurth et al., 2013). Briefly, a synthetic peptide substrate of EcDsbA 
(CQQGFDGTQNSCK) with an N-terminal europium-DOTA (1,4,7,10-tetraazacyclododecane-
1,4,7,10-tetraacetic acid), a C-terminal methylcoumarin and two cysteine residues (AnaSpec, USA) 
does not fluoresce in the reduced state. Introduction of a disulfide bond by DsbA brings the 
europium-DOTA and coumarin moieties into close proximity triggering an energy transfer and a 
measurable signal upon excitation and allowing fluorescence emission to be monitored at 615 nm. 
Inhibition of EcDsbA activity is assessed as a reduction in the fluorescence rate in the presence of 
the peptide, corresponding to a decrease in substrate oxidation. Lyophilized synthetic substrate 
peptide was dissolved in 100 mM imidazole pH 6.0 at a final concentration of 2 mM. 100 mM of 
europium trifluoromethanesulfonate (Sigma Aldrich, Australia) was added to the synthetic substrate 
peptide at a molar ratio of 2:1 and incubated for 5 min at room temperature to allow europium 
chelation. Assays were performed using a Synergy H1 multimode plate reader (BioTek, USA) as 
described previously(Walden et al., 2012). The time-resolved fluorescence of substrate peptide 
folding (excitation λ = 340 nm and emission λ = 615 nm) was measured in a white 384-well plate 
(Perkin Elmer OptiPlate-384, Part #: 6007290) in 50 mM MES, 50 mM NaCl and 2 mM EDTA at 
pH 5.5 buffer. Total reaction volume was 50 µL solution in each well including 80 nM EcDsbA, 1.6 
µM EcDsbB, peptide 1, 3, 22, 23 or 31 at concentrations ranging from 0.5 µM to 5 µM and 10 µM 
substrate peptide was added last to initiate the reaction. Samples containing buffer only, EcDsbA 
without peptide inhibitor, or peptide inhibitor without EcDsbA were used as controls. Data were 
measured for three replicates and values for the mean and standard deviation reported. Fitting of a 
sigmoidal dose-response curve with peptide concentrations in a logarithmic scale allows to 
calculate an IC50 value from the inflexion point. To allow plotting of the positive control (EcDsbA 
only), the peptide concentration is considered negligible (10-10 M) rather than 0.   
	  	   	  Chapter	  III	  –	  Peptides	  inhibitors	  of	  the	  E.	  coli	  DsbA/DsbB	  interface	  	  	  
	   94	  
Supporting information available 
Additional figures for the thermal shift and isothermal titration calorimetry assays as well as 
peptide characterization data are included into the supporting information. This material is available 
free of charge via the Internet at http://pubs.acs.org. 
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CHAPTER IV 
 
The following chapter is a manuscript submitted to the Journal of Biological Chemistry. The 
structure-activity relationship study in Chapter III highlighted the difficulties in describing the set of 
interactions necessary for the specificity of the EcDsbA-EcDsbB or the EcDsbA-peptide binding 
mode. The systematic substitution of side chains located in the hydrophobic pocket did not alter the 
affinity while the only critical residue for binding was the cysteine. The formation of a disulfide 
bond between peptide and EcDsbA is the favored explanation for the formation of an EcDsbA-
peptide complex. To progress further in designing potent inhibitors of EcDsbA, high-resolution 
structural information was highly required. This manuscript describes the efforts provided in 
obtaining and solving the crystal structure of a peptide non-covalently bound to a DsbA protein 
from a different organism, Proteus mirabilis, which proved much easier to crystallize than EcDsbA. 
This resulted in a 1.6 Å resolution PmDsbAC30S-PWATCDS peptide structure. The structural 
information observed from the complex structure would be invaluable to the future design of 
peptidomimetic molecules.   
 
This manuscript resulted from collaboration with Mr Fabian Kurth, sharing the co-first 
authorship. The biochemistry and crystal structure characterization of native PmDsbA was 
performed by Mr Kurth as part of his own PhD project, whereas I performed all assays linked to 
peptide binding and characterization. The co-crystallization and structure characterization of a 
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manuscript was reviewed and critically revised by Dr Premkumar, Prof. Schembri, Prof. DP Fairlie 
and Prof. JL Martin.  
 
 
	  	   	  Chapter	  IV	  –	  PmDsbA-­‐PWATCDS	  crystal	  structure	  	  	  
	   96	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Running title: DsbA:peptide interactions as the basis for novel antimicrobials 
 
Background: DsbA enzymes assemble bacterial virulence factors and are targets for a new drug 
class. 
Results: Proteus mirabilis DsbA was characterized and its structure determined. 
Conclusion: The crystal structure for this DsbA with a non-covalently bound active site peptide 
provides a basis for future inhibitor design. 
Significance: New drugs to treat superbugs are urgently needed. DsbA inhibitors could have 
antivirulence activity against bacterial pathogens. 
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The disulfide bond forming DsbA enzymes and their DsbB interaction partners are 
attractive targets for development of antivirulence drugs because both are essential for 
virulence factor assembly in Gram-negative pathogens. Here we characterize PmDsbA from 
Proteus mirabilis, a bacterial pathogen increasingly associated with multidrug resistance. 
PmDsbA exhibits the characteristic properties of a DsbA, including an oxidizing potential, 
destabilizing disulfide, acidic active site cysteine, and dithiol oxidase catalytic activity. We also 
evaluated a peptide PWATCDS derived from the partner protein DsbB and showed by 
thermal shift and ITC that it binds to PmDsbA. The crystal structures of PmDsbA, and the 
active site variant PmDsbAC30S were determined to high resolution. Analysis of these 
structures allows categorization of PmDsbA into the DsbA class exemplified by the archetypal 
Escherichia coli DsbA enzyme. Other members of this DsbA subclass include enzymes from 
Salmonella enterica subtype Typhimurium and Klebsiella pneumoniae. A third crystal 
structure of PmDsbAC30S in complex with the PWATCDS peptide reveals non-covalent 
binding to this variant, potentially providing a platform for future peptidomimetic design. 
Introduction 
Proteus mirabilis is a significant Gram-negative extra-intestinal human pathogen that 
belongs to the Enterobacteriaceae family, which also includes other important pathogens such as 
Escherichia coli, Klebsiella pneumonia, and Enterobacter cloacae. Together, the 
Enterobacteriaceae account for the vast majority of community-acquired and nosocomial urinary 
tract infections (UTIs) (Guay, 2008, Ronald, 2003). P. mirabilis is a frequent cause of both 
complicated and catheter- associated UTIs (Jacobsen et al., 2008, Jacobsen & Shirtliff, 2011). 
Multidrug resistant strains of clinical pathogenic P. mirabilis have been reported for several 
decades (Guay, 2008). For example clinical isolates of P. mirabilis resistant to streptomycin, 
tetracycline, kanamycin, chloramphenicol and polymyxin B were described in the 1960s (Coetzee 
& Sacks, 1960, Sabath, 1969) and reports of antibiotic resistance have increased since then (Pearson 
et al., 2008, Hitchings, 1973, Wellington et al., 2013, Wang et al., 2009, Elsea et al., 1992, Tibbetts 
et al., 2008, Mehtar et al., 1991, Franklin & Rownd, 1973, Coetzee, 1975, Zhao & Hu, 2013). 
 
DsbA enzymes from Gram-negative bacteria are targets for the development of anti-
virulence drugs that could represent an entirely new class of antimicrobial agents (Heras et al., 
2009, Kurth et al., 2013). Drugs that target bacterial virulence could minimize the selective pressure 
that generates antibiotic resistance and simultaneously preserve the endogenous host microbiome 
(Rasko & Sperandio, 2010). DsbA is a key target for such drugs because it is essential for the 
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correct folding or assembly of multiple virulence factors, including toxins, fimbrial adhesins, 
flagella, and type II and type III secretion systems (Heras et al., 2009). The mutation of dsbA results 
in the attenuation of virulence factor production in multiple pathogens (Heras et al., 2009) some 
examples include Proteus mirabilis (Burall et al., 2004), uropathogenic E. coli (Totsika et al., 
2009a) and Burkholderia pseudomallei (Ireland et al., 2014), Vibrio cholerae (Peek & Taylor, 
1992), Shigella flexneri (Yu, 1998) and Salmonella enterica serovar Typhimurium (Lin et al., 
2008). 
 
DsbA enzymes are thioredoxin fold proteins (Martin et al., 1993) localized to the periplasm 
of Gram-negative bacteria where they catalyze oxidative folding (Bardwell et al., 1991). This 
reaction involves the transfer of a disulfide bond from the active site 30CXXC33 motif of DsbA to 
cysteine thiols in newly translocated proteins (Shouldice et al., 2011). Through this disulfide-
exchange reaction, the active site cysteines of DsbA become reduced. The enzymatic cycle is 
completed through oxidation of DsbA by the inner membrane partner protein, DsbB (Inaba, 
Murakami, et al., 2006). DsbA from E. coli (EcDsbA) is a highly promiscuous enzyme, that 
catalyzes disulfide bond formation in many cysteine-containing proteins (Shouldice et al., 2011). In 
contrast, EcDsbB has a very strict binding specificity for EcDsbA (Inaba, Murakami, et al., 2006). 
The interaction between EcDsbA and EcDsbB involves the formation of a mixed disulfide between 
Cys30 of the 30CXXC33 motif of EcDsbA and Cys104 of EcDsbB in the P2 periplasmic loop, which 
has the sequence 98PSPFATCDF106 (Inaba et al., 2009b). The crystal structure of the complex 
between EcDsbA and EcDsbB also revealed non-covalent binding of EcDsbB P2 loop residues to 
the EcDsbA hydrophobic groove (Inaba et al., 2009a). The P2 periplasmic loop sequence of P. 
mirabilis DsbB (PmDsbB) is identical to that of EcDsbB, suggesting a similar interaction occurs 
between PmDsbA and PmDsbB.  
 
Here we characterize PmDsbA from P. mirabilis, which shares 59% sequence identity with 
EcDsbA. We confirm that its redox and enzymatic properties classify it as a bona fide DsbA 
enzyme. We demonstrate that the heptapeptide PWATCDS, derived from the DsbB P2 loop 
sequence, binds to wild type PmDsbA and to a C30S active site variant (PmDsbAC30S). We report 
high-resolution crystal structures of PmDsbA and PmDsbAC30S. We also report the crystal 
structure of the PmDsbAC30S:PWATCDS complex, which represents to our knowledge the first 
reported example of peptide bound non-covalently to a DsbA structure. This structure can provide 
the basis for future drug design efforts to generate anti-virulence agents targeting 
Enterobacteriaceae DsbAs. 
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Experimental procedures 
Protein production and molecular biology – Codon-optimized wild type P. mirabilis dsbA 
(GenBank® accession number CAR45574), lacking the sequence coding for the predicted signal 
peptide (amino acids 1-19), was cloned into a modified pMCSG7 (Eschenfeldt et al., 2009) vector 
using ligation-independent cloning. The cytoplasmic expressed PmDsbA contained an N-terminal 
His6 affinity-tag followed by a linker region including a Tobacco Etch Virus (TEV) protease 
cleavage site. The PmDsbAC30S variant was generated from the wild type construct using 
QuikChange® (Agilent Technologies). The following primers were used to introduce the point 
mutation, FW-GAATTTTTCTCATTTTATTCTCCGCATTGTTACC and REV-
GGTAACAATGCGGAGAATAAAATGAGAAAAATTC. Transformed BL21(DE3)pLys cells 
containing plasmids for either PmDsbA or PmDsbAC30S were grown (1 L) at 30 °C in 2.5 L 
baffled shaker flasks for 16-20 h using autoinduction media (Studier, 2005). Cells were resuspended 
in 25 mM Tris, 150 mM NaCl (10 g cells per 100 mL buffer) and protease inhibitor cocktail 
(diluted 1 in 1000 into the lysate) (BioPioneer Inc., San Diego, CA) and DNase (1300 U per 100 
mL Lysate) (Roche, Australia) added. Lysis was performed in a Cell Disruptor (TS-Series, Constant 
Systems LTD., UK) applying a single run with a constant pressure of 25 Kpsi. Cell debris was 
removed by centrifugation (18500 rpm, 30 min, 4 ºC, rotor JM-25.5, Beckman Coulter, Brea, CA). 
The proteins were further purified by immobilized metal ion affinity chromatography (IMAC) using 
12 mL / 1 L cells of equilibrated Talon (Clontech, Australia) and eluted with 25 mM Tris, 150 mM 
NaCl, 200 mM imidazole after incubation of 30 min at RT. Total protein amount was determined at 
280 nm with a NanoDrop™ 2000c (Thermo Fisher Scientific, USA). The His6 affinity tag was 
removed by tobacco etch virus protease (TEV) cleavage using a 50:1 (w/w) ratio (protein/TEV-
protease) incubated in a 50 mL falcon tube including 1 mM β-mercaptoethanol for 2 h on a rotary 
mixer at room temperature. After cleavage, the PmDsbA proteins had an additional two non-native 
residues (Ser-2Asn-1) at the N-terminus. To remove imidazole, the mixture was rapidly buffer-
exchanged into 25 mM Tris, 150 mM NaCl using a Sephadex G-25 fine 16/60 column connected to 
an ÄKTA system (GE Healthcare, USA). The His6-tagged TEV protease was removed by reverse 
IMAC using Talon resin (0.5 mL resin / 2 mg TEV protease) (Clontech, Australia) and the 
PmDsbA proteins were recovered in the flow through. The final step of purification was performed 
using a Superdex S75 gel-filtration column (GE Healthcare, USA). Peak fractions were then 
combined and the protein was oxidized using copper(II) 1,10-phenanthroline at 1.7 mM final 
concentration or reduced using DTT at 25x molar excess. To remove oxidizing or reducing agent, 
the mixture was then buffer-exchanged into 10 mM HEPES pH 7.4 using a Sephadex G-25 fine 
16/60 column. Finally, the protein was concentrated to 100 mg/mL using Amicon Ultra filter 
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devices with a 10-kDa cutoff (Millipore, USA). Yield was generally 120-150 mg per L culture. 
Protein quality was assessed by SDS-PAGE (NuPAGE® system, 4-12% Bis-Tris gel, Invitrogen, 
Australia). Molar protein concentrations were determined from calculated extinction coefficients 
derived from ProtParam (Gasteiger E., 2005). 
 
Purified EcDsbA (GenBank® accession number CAA56736) and EcDsbC (GenBank® 
accession number AAA83074), lacking the periplasmic leader signal were expressed and purified as 
described above for PmDsbA. Yields were generally 120 mg and 80 mg per L culture, respectively. 
E. coli membrane extracts containing over-expressed EcDsbB (GenBank® accession number 
AAC74269) were prepared as described previously (Bader et al., 1998), and resuspended in PBS 
buffer containing 10% glycerol. 
 
EcDsbA complementation – E. coli ΔdsbA (JCB817) and ΔdsbA/ΔdsbB (JCB818) non-motile 
strains were used for motility assays as described previously (Shouldice et al., 2010). The gene 
sequence coding for mature PmDsbA (lacking the periplasmic signal sequence) was cloned into 
pBAD33 under an arabinose inducible promoter with an N-terminal EcDsbA signal sequence 
(Guzman et al., 1995). As a positive control, EcDsbA was expressed within the same pBAD33 
vector background. 2x106 non-motile E. coli ΔdsbA (JCB817) and ΔdsbA/ΔdsbB (JCB818) double-
mutant (JCB818) (Bardwell et al., 1991) cells harboring pBAD33(EcDsbA) or pBAD33(PmDsbA)  
were spotted onto the center of a soft M63 minimal agar plate containing 40 mg/mL of each amino 
acid (except L-cysteine) and 0.1% arabinose. Plates were incubated at 37 ºC and cell motility was 
monitored after 4-5 h using a Molecular Imager® Gel Doc™ system from BIO-RAD (CA 94547, 
USA). Complementation experiments were performed as biological triplicates. 
 
Cysteine Thiol Oxidation Assay – A synthetic peptide substrate of EcDsbA (CQQGFDGTQNSCK) 
with a europium DOTA (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid) group amide-
coupled to the N-terminus and a methylcoumarin amide-coupled to the ε-amino group of the C-
terminal lysine was purchased from AnaSpec (Fremont, CA) and prepared as previously reported 
(Vivian et al., 2009).  
Assays were performed using a Synergy H1 multimode plate reader (BioTek, USA) as 
described previously (Walden et al., 2012). In brief, fluorescence (excitation λ = 340 nm and 
emission λ = 615 nm) corresponding to disulfide formation in the substrate peptide was measured in 
a white 384-well plate (Perkin Elmer OptiPlate-384, Part #: 6007290) in 50 mM MES, 50 mM 
NaCl and 2 mM EDTA at pH 5.5 buffer. Total reaction volume in each well was 50 µL, containing 
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40, 80 or 160 nM PmDsbA or EcDsbA, 1.6 µM EcDsbB membrane and 8 µM peptide substrate 
(added last to initiate the reaction). Samples containing DsbA proteins, EcDsbB and buffer were 
used as controls. For every biological replicate (3 in total), the values derived from three technical 
replicates were averaged. The slope (reaction rate) for each sample was calculated for the first 8 
min of reaction. The reaction rates were plotted including the S.D. calculated combining data of 
three biological replicates.  
 
Thermal Stability of PmDsbA– Temperature-induced unfolding of native PmDsbA was recorded by 
far-UV circular dichroism as previously reported for other DsbA enzymes (Heras et al., 2008a) 
using a Jasco J-810 spectropolarimeter (Jasco, USA). The initial redox state of PmDsbA was 
confirmed by Ellman’s assay (Ellman, 1959). The maximum difference in CD signal was 
determined by subtraction of the CD-spectra of the folded protein (25 ºC) from the unfolded (95 °C) 
protein, for the oxidized and the reduced forms of the protein. Unfolding of oxidized PmDsbA (210 
nm) and reduced PmDsbA (213 nm) was monitored in a 1-mm quartz cuvette using a heating rate of 
1 ºC/min from 25 ºC to 95 ºC. Measurements were carried out using 10 µM protein in a buffer 
containing 100 mM NaH2PO4 / Na2HPO4, 1 mM EDTA, pH 7.0. To ensure PmDsbA remained 
reduced throughout the entire measurement, reduced samples contained 0.75 mM DTT. Data were 
fitted to a two-state unfolding model and errors calculated using Prism 6 (GraphPad, CA, USA) as 
described previously (Kurz et al., 2009)  
 
Redox properties of PmDsbA – The standard redox potential of PmDsbA was measured utilizing the 
intrinsic fluorescence of tryptophan residues in PmDsbA, similar to the method used for EcDsbA 
(Wunderlich & Glockshuber, 1993). In brief, oxidized PmDsbA was equilibrated for 3 h at 25 ºC in 
degassed 100 mM NaH2PO4 / Na2HPO4, pH 7.0, 1 mM EDTA, 298K containing 1 mM oxidized 
glutathione (GSSG) and a range of reduced glutathione (GSH) concentrations (0–2000 µM). 200 µL 
of PmDsbA from each redox condition was dispensed into a 96-well plate (TPP AG, Switzerland 
#92096) and tryptophan fluorescence measured (excitation wavelength 280 nm, emission 332 nm) 
using a Synergy H1 microplate reader and Gen5 2.0 software (Biotek, USA). Data were analyzed in 
Prism 6 (GraphPad, CA, USA) and the redox potential calculated as described previously for 
EcDsbA (Wunderlich & Glockshuber, 1993). 
 
Determination of Cys30 pKa  – Absorbance at 240 nm of the catalytic thiolate anion is pH-
dependent allowing the equilibrium between protonated and deprotonated Cys30 to be measured 
(Nelson & Creighton, 1994) using a UV/VIS spectrophotometer (CARY 50, Agilent Technologies). 
	  	   	  Chapter	  IV	  –	  PmDsbA-­‐PWATCDS	  crystal	  structure	  	  	  
	   102	  
Absorbance at 240 nm and 280 nm were measured over pH values starting at 6.5 and decreasing to 
2.0, in 0.25 pH unit increments. Samples contained either oxidized or reduced PmDsbA (40 µM) in 
composite buffer (10 mM Tris, 10 mM sodium citrate, 10 mM K2HPO4, 10 mM KH2PO4, 200 mM 
KCl, and 1 mM EDTA) at 22 ºC. The pKa value was calculated from the fitted curves using the 
Henderson Hasselbalch equation (pH = pKa - log ([A240 ⁄A280]red ⁄ [A240 ⁄A280]ox)). Average and 
standard deviation from the mean derived from triplicate measurements are plotted.   
 
Disulfide Reductase Activity – DsbA enzymes can reduce the intermolecular disulfide bonds 
between insulin chains A and B under mild reducing conditions (Bardwell et al., 1991). Disulfide 
bond reduction of insulin can be followed spectrophotometrically at λ = 650 nm (OD650nm). The 
OD650nm value gives a measure of turbidity, which occurs as a result of the increase in production of 
insoluble B-chain of insulin (Holmgren, 1979). Samples were prepared in 1-cm cuvettes containing 
10 µM of protein (PmDsbA, EcDsbA or EcDsbC), 0.33 mM DTT and 2 mM EDTA in 100 mM 
NaH2PO4 / Na2HPO4 pH 7.0. Catalysis was initiated by the addition of 0.131 mM insulin (I0516, 
Sigma-Aldrich, Australia) to the mixture. The assay was repeated three times and the mean values 
are plotted including the standard deviations of the measurement at each time point. 
 
Peptide Synthesis – Peptides were synthesized using solid-phase peptide synthesis (SPPS) on rink-
amide (4-methyl)benzhydrylamine (MBHA) resin (ChemImpex International, Wood Dale USA) 
with a loading of 0.65 mmol/g. De-protection of the resin and amino acids was performed using an 
80 / 20 v/v mix of dimethylformamide/piperidine (Rci Labscan, Bangkok Thailand / Auspep, 
Australia) for 2 x 5 min. L-aminoacids (ChemImpex International, Wood Dale USA) were activated 
using 4 resin equivalents (eq) and 4 eq of HbtU (O-Benzotriazole-N,N,N',N'-tetramethyl-uronium-
hexafluoro-phosphate, ChemImpex International, Wood Dale USA) 500 mM and 5 eq of DIPEA 
(N,N-Diisopropylethylamine, Auspep, Australia) for 5 min before coupling to the de-protected resin 
for 60 min. After final coupling, all peptides were acetylated at the N-terminus using 4 eq of acetic 
acid (Chem Supply, Australia), 4 eq of HbtU and 5 eq of DIPEA (Auspep, Australia) for 30 min. 
Cleaving was executed using a 95/2.5/1.25/1.25 v/v mix of trifluoroacetic acid (TFA)/ethane-dithiol 
(EDT)/triisopropylsilane (TIPS)/water (H2O) (chemicals from Sigma-Aldrich, Saint Louis USA). 
Cleaved peptides resulted in an amidated C-terminus from the resin rink amide and were dried 
using N2 gas, washed with diethyl ether (DEE, Ajax Finechem, Sydney Australia) and dissolved in 
a 80/20 v/v mix of acetonitrile/H2O (RCI Labscan, Bangkok Thailand) before purification on 
HPLC. Purification was executed on a C18 column (Phenomenex, Torrance USA) using a gradient 
from 20% to 80% of acetonitrile and TFA 0.1%. Fractions were analyzed by mass spectrometry 
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(Waters Micromass LCT, Milford USA) and the purified peptide was lyophilized using a freeze 
drier (Christ, Osterode am Harz, Germany). 
 
Peptide-Induced Thermal Shift Measurements – 25 µM of PmDsbA in phosphate buffered saline 
(PBS) pH 7.4 was incubated with peptide PWATCDS at concentrations ranging from 125 µM to 4 
mM for 1 h. Then Sypro orange (S-6650, Life Technologies, Australia) was added to a 5X final 
concentration (stock concentration 5000X). Controls contained either no peptide, no DsbA or the 
dye alone. Measurements were conducted in a white 384-well plate (Perkin Elmer OptiPlate-384, 
Part #: 6007290) with 5 replicates. Fluorescence emission from Sypro Orange binding to unfolded 
protein was measured following a temperature time course increasing from 25°C to 95°C (heat rate 
= 0.05 °C/sec) using a VIAA7 Real-Time PCR system (Life Technologies, Australia) with a l = 585 
± 15 nm wavelength filter. Raw data were analyzed using Prism 6 (GraphPad, CA, USA). 
Fluorescence emission was fitted to a classic Boltzmann sigmoidal curve, and the inflexion point 
was used as the melting temperature, Tm. To determine ΔTm (the shift in melting temperature in the 
presence of peptide), the Tm value for the wild type protein was subtracted from the Tm value for 
PmDsbA-PWATCDS and the Tm value for the variant PmDsbAC30S was subtracted from the Tm 
value for PmDsbAC30S-PWATCDS. ΔTm values are presented as the mean and standard deviation 
from 5 replicates. A significant ΔTm is considered to be greater than two times the standard 
deviation of the Tm value for the protein in the absence of ligand (Kranz & Schalk-Hihi, 2011). 
 
Isothermal Titration Calorimetry – Evaluation of affinity and thermodynamics of binding between 
PWATCDS and PmDsbA or PmDsbAC30S were assessed by Isothermal Titration Calorimetry 
(ITC) using an Auto-iTC200 instrument (MicroCal™, GE Healthcare, USA). The sample cell was 
loaded with 200 µL of purified protein (oxidized PmDsbA or untreated PmDsbAC30S) at 100 µM 
concentration in 25 mM HEPES pH 7.4, 50 mM NaCl 0.8% DMSO (ITC buffer). The syringe was 
filled with purified peptide PWATCDS in ITC buffer at a concentration of 4 mM. Titrations were 
conducted at 25 °C using 19 consecutive injections of 2 µL each delayed by 180 seconds with a 
stirring speed of 1000 rpm. In every experiment an initial 0.5 µL of peptide was injected to avoid 
slow leakage of titrant and this data point was discarded for binding analysis. As a control for 
background noise, titration of PWATCDS into a solution containing ITC buffer only was 
performed. The association constant (Ka = 1/Kd), free energy (ΔG) and enthalpy change (ΔH) were 
calculated by fitting the data to a single-site binding model using the MicroCal™ Origin software 
(Origin 7.0 SR4 v7.0552 beta) and correcting peptide concentrations to adjust the stoichiometry 
parameter close to 1.0. Entropy change (ΔS) was deduced from the standard free energy equation 
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ΔG = ΔH – TΔS. Parameters reported include the mean and standard deviation across three 
replicates. The calculated c-value for these measurements is 12.  
 
Crystallization, structure determination and structural analysis – Crystallization screening was 
performed at the UQ ROCX diffraction facility (http://uqrocx.imb.uq.edu.au). Protein 
crystallization trials were performed in 96-well plates using the hanging drop vapor diffusion 
method at 8 ºC or 20 ºC. In general, purified protein (200 nL) was mixed with crystallization 
solution (200 nL) using a Mosquito crystallization robot (TTP Labtech, UK), and trays were 
incubated and imaged in a RockImager 1000 (Formulatrix, USA). Wild type PmDsbA was 
crystallized by mixing 0.5 µL of 3 mM (60 mg/mL) purified PmDsbA including 10 mM of 
PSPWATCDF peptide (1:3 protein:peptide ratio) dissolved in DMSO (final concentration = 2% 
DMSO) with 0.5 µL of an optimized crystallization condition consisting of PEG3350 15% and 0.4 
M sodium malonate pH  5.0. The presence of the peptide permitted crystallization but no density 
was evident for the peptide in the phased data; the final refined structure from this condition is 
referred to as native PmDsbA. Crystals were harvested in cryo solution (PEG3350 25%, 0.4 M 
sodium malonate pH 5.0, 20% PEG400) and immediately flash frozen in liquid nitrogen. 
 
PmDsbAC30S crystals appeared overnight at 8 ºC in 0.2 M KSCN, PEG3350 23% and 30 
mg/mL of protein and 15 mM of PWATCDS (both final concentrations); again the presence of 
peptide permitted crystallization but there was no evidence of peptide binding in the electron 
density maps. The cryo solution used was 0.2 M KSCN, PEG3350 25% and 20% PEG400. The 
structure of the protein derived from this condition is referred to as PmDsbAC30S. 
 
PmDsbAC30S:PWATCDS co-crystals grew at 20 ºC using a 12-fold molar excess of 
peptide (30 mM) over protein (60 mg/mL), with the two components incubated on ice for 1 h prior 
to crystallization. The protein:peptide solution was then mixed with crystallization solution, which 
contained 0.2 M KSCN, 22% PEG3350, 0.2 M non-detergent sulfobetaine (NDSB-221). 
Differences in crystallization conditions in comparison to PmDsbC30S, included the use of NDSB-
221 and incubation of plates at 20 ºC. Crystals were flash frozen in cryo solution consisting of 
PEG3350 30%, 0.3 M KSCN and PEG400 20%.  
 
Diffraction data for all three crystal structures were measured at the Australian Synchrotron 
MX2 beamline at a wavelength of 0.9537 Å, and recorded with an ADSC Quantum 315r detector 
controlled by BLU-ICE (McPhillips et al., 2002). Reflections were indexed and integrated in 
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Mosflm (Battye et al., 2011) or XDS (Kabsch, 2010), analyzed in Pointless (Evans, 2006) and 
scaled in SCALA (Evans, 2006) from the CCP4 suite. (Winn et al., 2011). Phases for PmDsbA 
were obtained by molecular replacement (MR) using PHASER (McCoy et al., 2007) with EcDsbA 
as a template (PDB code 1FVK, sequence identity 59%). PmDsbAC30S: PWATCDS were solved 
using the wild type PmDsbA structure as the template. Initial electron density maps from PHASER 
were improved by cycles of iterative refitting of the model by using the program COOT (Emsley et 
al., 2010) and PHENIX.refine (Adams et al., 2010). The refinement of the complex structure was 
stalled at R-factor/R-free: 30% / 33%. Phenix.xtriage analysis indicated that the diffraction data was 
twinned with a twinning fraction of 0.49. The twin target function implemented in PHENIX was 
applied in further refinement cycles with the twinning operator -h+k, k, -l. The final R-factor/R-free 
was 17.2% / 19.9%. For PmDsbAC30S:PWATCDS, density corresponding to bound peptide was 
modeled for all seven residues including N-terminal acetylation and C-terminal amidation. In 
addition, a malonate anion was modeled into the crystal structure of PmDsbA and four SCN 
molecules were modeled into the PmDsbAC30S:PWATCDS crystal structure with one pair in each 
protomers A and C. One thiocyanate molecule is buried between α1 and β2 of protomers A/C, 
while the second molecule binds between Pro and PmDsbAC30S helix α1, possibly forming a weak 
hydrogen bond with the Pro backbone carbonyl (distance N:O = 3.4 Å). Thiocyanate molecules do 
not appear to influence peptide binding, since the peptide binding site and conformation is identical 
in protomer B which lacks a bound thiocyanate. 
 
 Data processing and refinement statistics for all three crystal structures are provided in 
Table 4.1. Molecular figures were generated using PyMOL (The PyMOL Molecular Graphics 
System, Version 1.6.0.0 Schrödinger, LLC) and figures of the electrostatic potential were generated 
using APBS (Baker et al., 2001). RMSD calculations and structural alignments were conducted in 
PyMOL and FATCAT (Ye & Godzik, 2003). Interaction analyses were conducted with the program 
COOT (Emsley et al., 2010) and the PDBePISA (Krissinel & Henrick, 2007) and Cocomaps servers 
(Vangone et al., 2011). 	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Table 4.1. X-ray data collection and refinement statistics  
 
Data collection PmDsbA (4OCE) 
PmDsbAC30S 
(4OCF) 
PmDsbAC30S:  
PWATCDS 
(4OD7) 
Wavelength (Å) 0.95369 0.95369 0.95370 
Resolution range (Å) 42.64 - 1.77 57.22 - 1.98 64.13 – 1.60  
Highest resolution shell (Å) 1.77 - 1.86 1.98 – 2.09 1.60 – 1.68 
Space group P 43212 P21 P32 
Unit cell dimensions    
    a (Å) 37.8 37.9 74.06 
    b (Å) 37.8 80.2 74.06 
    c (Å) 298.4 114.4 93.27 
    α, β, γ (º) 90, 90, 90 90, 91, 90 90, 90, 120 
Total reflections 303398 176891 839517  
Unique reflections  22817 47865 74969 
Multiplicity 13.3 (13.6)a 3.7 (3.6)a 11.2 (10.2)a 
Completeness (%) 100 (100) 99.7 (98.9) 98.6 (93.9) 
Mean <I>/<σI> 16.1 (4.8) 14.3 (8.4) 16.3 (2.4) 
Rmergea 0.127 (0.587) 0.073 (0.155) 0.080 (0.973) 
Rp.i.m. 0.035 (0.157) 0.044 (0.095) 0.026 (0.327) 
Refinement statistics     
    Rfree (%) 16.9 (21.9) 21.1 (24.0) 19.9 (29.2) 
    Rwork (%) 14.8 (17.3) 15.2 (15.2) 17.2 (30.3) 
    Unique reflections  22686 47846 74969 
    Number of non-H atoms    
      Protein 1492 5841 4506 
      Water 268 
 
542 
    Protein residues 189 
 
561 
    RMSD Bond lengths (Å) 0.009 0.012 0.017 
    RMSD Bond angles (º) 1.152 1.240 1.555 
    Ramachandran    
      Favoured (%) 98.4 98.5 98.9 
      Outliers (%) 0 0 0 
    Average B-factor (Å2) 14.6 12.8 25.7 
    Wilson B-factor (Å2) 16.0 10.3 22.1 
    Molprobityb    
      Clashscore (percentile) 1.03 [100th, (839)] 2.32 [100th, (714)] 4.25 [97th, (699)] 
      Score (percentile) 0.80 [100th, (11193)] 
1.01 [100th, (12309)] 
1.21 [98th,(6780)] 
 
a The values in parentheses refer to the highest resolution shell 
b 100th Molprobity (Chen et al., 2010) percentile is the best among the structures of comparable resolution. 	  
749 
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Results 
 
PmDsbA catalyzes disulfide formation in vitro and in vivo – DsbA enzymes catalyze oxidative 
folding, or the introduction of disulfide bonds into proteins. To assess whether PmDsbA has dithiol 
oxidase activity we assessed its activity in an in vitro peptide oxidation assay. A europium labeled 
peptide (CQQGFDGTQNSCK) fluoresces when the two cysteines are oxidized, but not when the 
cysteines are reduced (Vivian et al., 2009). We found that PmDsbA, like EcDsbA, catalyzed 
peptide thiol oxidation as evident by an increase in the reaction rate comparing three different 
concentrations of both enzymes (Figure 4.1A). The reaction rate reflects the kinetics of the peptide 
turnover within the first 8 min of catalysis. At the same enzyme concentrations PmDsbA catalysis 
was a little slower than that of EcDsbA. This slightly reduced activity may reflect the use of a 
peptide derived from an EcDsbA substrate. Nonetheless, the results establish that PmDsbA 
catalyses dithiol oxidation in a model substrate. 
 
We also assessed the ability of PmDsbA to complement EcDsbA in vivo. E. coli strains 
deficient in the P-ring protein FlgI fail to assemble functional flagella (Ohnishi et al., 1987). 
Moreover, E. coli strains lacking EcDsbA, EcDsbB or both, have the same phenotype (Dailey & 
Berg, 1993) because FlgI requires a disulfide bond to function. The non-motile strains E. coli 
ΔdsbA (JCB817) and ΔdsbA / ΔdsbB (JCB818) were therefore used for in vivo DsbA 
complementation experiments. When EcDsbA or PmDsbA were expressed in JCB817 following 
arabinose induction, full rescue of motility was observed in JCB817 (Figure 4.1B). However cells 
from the double knockout (JCB818) remained non-motile for both PmDsbA and EcDsbA. These 
results demonstrate that PmDsbA can replace EcDsbA functionally in vivo in the context of flagella 
assembly. Since EcDsbB was also essential for complementation in this experiment, the results 
confirm that PmDsbA and EcDsbB can form a functionally competent system. This was expected 
since the P2 loop sequence from PmDsbB is identical to that of EcDsbB. Furthermore, the P. 
mirabilis FlgI homologue shares 74% sequence identity with EcFlgI including two conserved 
cysteine residues. 
 
PmDsbA shares the same characteristic redox properties as EcDsbA – DsbA enzymes exhibit 
unique properties that contribute to their ability to catalyze disulfide bond formation (Pogliano et 
al., 1997, Shouldice et al., 2011). We next established whether these characteristics are shared by 
PmDsbA. First, we investigated the relative thermostability of the oxidized and reduced forms of 
the enzyme. In most DsbAs, the reduced form of the CXXC active site is more stable than the 
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oxidized form. For instance, the melting temperature of reduced EcDsbA is almost 10 K higher than 
that of the oxidized form (Heras et al., 2008b). Similarly, we found that reduced PmDsbA (Tmred 
348.4 ± 0.1 K) is 10 K more stable than oxidized PmDsbA (Tmox 338.4 ± 0.2 K) (Figure 4.1C).  
 
DsbAs are also highly oxidizing. The redox potential of EcDsbA is -122 mV (Wunderlich & 
Glockshuber, 1993) and the range of values reported for other DsbAs varies from -80 mV for 
NmDsbA1 (Vivian et al., 2009) to -163 mV for WpDsbA (Kurz et al., 2009). Nevertheless, closely 
related (> 80% sequence identity) homologues of EcDsbA such as SeDsbA and KpDsbA have 
redox potential values very similar to that of EcDsbA (-126 mV, -116 mV respectively). We 
determined the redox potential of PmDsbA to be -129 mV (Figure 4.1D), which is consistent with 
those of other Enterobacteriaceae DsbAs. 
 
The oxidizing nature of DsbA proteins is thought to be a consequence of the highly acidic 
cysteine in the CXXC active site motif. The pKa of 3.3 for this nucleophilic cysteine Cys30 for 
EcDsbA is unusually low for a cysteine (pKa 9.0) (Huber-Wunderlich & Glockshuber, 1998). 
Values reported for other DsbAs vary from 3.0 (NmDsbA1) (Lafaye et al., 2009) to 5.1 (VcDsbA) 
(Ruddock et al., 1996). We measured the pKa of the equivalent cysteine in PmDsbA, by pH-
dependent specific absorbance at λ = 240 nm, and determined the value to be 4.0 (Figure 4.1E). 
Thus, the nucleophilic cysteine of PmDsbA, like that of other DsbAs, is likely to be in the thiolate 
form at physiological pH when the enzyme is reduced. 
 
Although DsbA proteins are dithiol oxidases they can catalyse disulfide reduction in the 
presence of mild reducing agents such as DTT. Typically, insulin is used as a substrate to study in 
vitro disulfide bond reduction. The two chains of insulin are linked by three disulfide bonds, which 
can be rapidly reduced by disulfide reductases such as the disulfide isomerase EcDsbC. This 
reduction leads to separation of the insulin A and B chains, and precipitation of the insoluble B 
chain. Reduction can be followed by measuring the increase in turbidity of the solution over time. 
We found that PmDsbA is able to reduce the disulfide bonds of insulin as rapidly as EcDsbA 
(Figure 4.1F), but more slowly than the specialist reductant EcDsbC.  
 
In summary, the redox properties of PmDsbA reported here place it in the same class as 
EcDsbA and other Enterobacteriaceae DsbAs such as Salmonella enterica DsbA (SeDsbA) and 
Klebsiella pneumoniae DsbA (KpDsbA) (Kurth et al., 2013). 
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Figure 4.1. Redox Properties of PmDsbA. A. In vitro disulfide catalysis. Plot shows increase in 
reaction rates as a consequence of peptide disulfide formation catalyzed by EcDsbA or PmDsbA in 
the presence of EcDsbB. Rates reflect the kinetics of the catalysis within the first 8 min. As controls 
rates derived from DsbA proteins / buffer alone are displayed in the right. B. In vivo disulfide 
catalysis. ΔdsbA knock-out or ΔdsbA/B double knock-out cells are non-motile due to their inability 
to fold FlgI. Expression of PmDsbA or EcDsbA restores motility in ΔdsbA, but not in ΔdsbA/B. C. 
Thermal melting curves of oxidized and reduced PmDsbA shows that reduced PmDsbA (Tmred 348.4 
± 0.1 K) is more stable than its oxidized counterpart (Tmox 338.4 ± 0.2 K). D. Measurement of 
PmDsbA redox potential. PmDsbA was equilibrated in glutathione (GSSG/GSH) redox buffers to 
measure the equilibrium constant Keq (187. 5 ± 6 µM) which corresponds to a redox potential of -
129 mV. E. Absorbance of the catalytic thiolate anion is pH-dependent and this property was used 
to determine that the pKa of PmDsbA Cys30 is 4.0 F. Disulfide reductase activity measured by 
following OD650nm. PmDsbA has activity similar to that of EcDsbA, and much lower than that of the 
isomerase EcDsbC. For panels A and C-F, data are shown as mean and standard deviation from 
three replicates. 
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PWATCDS binding to PmDsbA and PmDsbAC30S – We were interested to understand how 
peptides interact with PmDsbA, as the basis for future peptidomimetic inhibitor development. The 
low resolution crystal structures and the NMR characterization of the EcDsbB:EcDsbA complex 
revealed that the EcDsbB periplasmic loop P2 forms a mixed disulfide with the nucleophilic 
cysteine of EcDsbA and binds to a hydrophobic groove near the active site (Inaba et al., 2009a, 
Inaba, Murakami, et al., 2006, Malojcic et al., 2008, Sperling et al., 2013). The peptide sequence of 
the EcDsbB P2 loop 98PSPFATCDF106 is conserved in PmDsbB (99PSPFATCDF107) suggesting that 
a similar interaction occurs between PmDsbA and PmDsbB. From the sequence of this P2 loop 
peptide, we developed a shorter, modified peptide PWATCDS optimized for solubility and binding 
affinity with EcDsbA (details of design reported elsewhere). Briefly, from an initial peptide of 
sequence PSPFATCDF an alanine scanning, peptide length scouting and substitution of specific 
residues showed that the PWATCDS sequence had the optimal affinity-to-mass ratio (or binding 
efficiency) to bind oxidized EcDsbA. Moreover, PWATCDS was shown to limit EcDsbA substrate 
folding activity in a competition assay. We hypothesized that this peptide would also interact with 
PmDsbA, and therefore evaluated its binding using two complementary methods, thermal shift and 
isothermal titration calorimetry (ITC).   
 
Tm values for PmDsbA and PmDsbAC30S (a variant in which the nucleophilic cysteine was 
replaced by serine) were measured in the presence and absence of the peptide PWATCDS, with 
varying peptide concentrations. Tm values of +2.0, +4.1 and +5.0 K were observed at peptide 
concentrations of 1, 2 and 4 mM respectively (Figure 4.2A), suggesting that PWATCDS binds to 
PmDsbA. These data show that the Tm shift continued with increasing peptide concentration 
beyond saturation, as is commonly observed in this assay (Cimmperman et al., 2008). When the 
variant PmDsbAC30S was used, thermal shifts (ΔTm > + 0.3 K) were detectable at concentrations 
of PWATCDS ranging from 250 µM to 4 mM. However the maximum ΔTm at 4 mM was 
significantly lower than that at the same concentration for PmDsbA (ΔTm +1.5 K, compared with 
5.0 K, respectively) (Figure 4.2A). This difference in ΔTm suggests the possibility of different 
binding modes. 
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Figure 4.2. Peptide PWATCDS interacts with PmDsbA. A. Values of ΔTm upon addition of 
increasing PWATCDS peptide for PmDsbA and PmDsbAC30S. Data are shown as mean and 
standard deviation from 5 replicates. B. ITC data titrating PWATCDS into PmDsbA. The reaction 
is exothermic suggesting a dominant enthalpic contribution to binding. C. ITC data titrating 
PWATDCS into PmDsbAC30S. The binding reaction is also exothermic but the energy released is 
less than that for native PmDsbA. Saturation of binding was not achieved in this case. Panels B and 
C show a representative example from the three replicates. 
 
 
Table 4.2. Stoichiometry (N), affinity (Kd) and thermodynamic (ΔH, ΔS and ΔG) parameters 
from ITC for binding of PWATCDS.  
Protein N Kd (uM) ΔH (kcal/mol) ΔS (cal/mol/deg) ΔG (kcal/mol) 
PmDsbA1 wt 1.0 ± 0.1 8.3 ± 0.4 -13.7 ± 0.3 -22.3 ± 1.1 -6.9 ± 0.1 
 
N, Kd, ΔH and ΔS are reported as means ± standard deviation from 3 titrations of PWATCDS into 
PmDsbA. ΔG is calculated from ΔG = ΔH –TΔS with T the temperature at which the titration took place 
 
We also investigated the interaction using isothermal titration calorimetry (ITC). An 
exothermic reaction was observed when titrating PWATCDS into PmDsbA (Figure 4.2B). Analysis 
of the raw data using a 1:1 binding model revealed a binding affinity KD of 8.3 ± 0.4 µM (Table 
4.2) with a high enthalpic contribution (ΔH = -13.7 ± 0.3 kcal/mol) and an unfavorable entropy of 
binding (ΔS = -22.3 ± 1.1 cal/mol/deg). When PmDsbAC30S was used, the energy exchange was 
much lower (first injection peaks at -0.8 µcal/sec instead of -2.5 µcal/sec) and saturation was not 
reached (Figure 4.2C). Curve-fitting was not optimal and a key enthalpic contribution was lost 
compared to the binding to native PmDsbA. The Cys30Ser mutation affected peptide binding and 
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PWATCDS presented a weaker affinity towards PmDsbAC30S. This is consistent with the 
observations from the thermal shift experiments.  
 
Crystal structure of PmDsbA - To investigate the different binding modes further, we attempted to 
determine the crystal structures of PmDsbA and PmDsbAC30S, in the presence of the peptide 
PWATCDS. We were unable to generate a crystal of a stable complex of PmDsbA with 
PWATCDS. However, crystals of PmDsbA and PmDsbAC30S without peptide, and PmDsbAC30S 
with peptide yielded high-resolution diffraction data (PmDsbA, 1.77 Å resolution; PmDsbAC30S, 
1.98 Å resolution; and PmDsbAC30S-PWATCDS, 1.6 Å resolution).  
 
PmDsbA crystallized in a tetragonal crystal system and was solved (PDB:4OCE) by 
molecular replacement using the EcDsbA structure (PDB: 1FVK) as a template. One protein chain 
is present in the asymmetric unit, and this has a typical DsbA-like architecture, comprising a TRX 
core domain (β1, β 2, α1, β3, C-terminal region of α6, β4, β 5 and α7), interrupted by an α-helical 
domain (α2- α5, and the N-terminal region of α6). This PmDsbA structure is structurally similar to 
other Enterobacteriaciae DsbAs including EcDsbA (PDB: 1FVK (Guddat et al., 1997)), KpDsbA 
(PDB: 4MCU (Kurth et al., 2013)) and SeDsbA (PDB: 3L9S (Heras et al., 2010a)) (Figure 4.3A). 
This is reflected in the RMSD of 1.0–1.2 Å comparing 177 Cα atoms from equivalent positions of 
these enzymes. Figure 4.3B shows a structure based sequence alignment of PmDsbA with 
homologous DsbA proteins from clinically relevant pathogens that share > 59% sequence identity. 
Sequences are highly conserved, especially at the active site CPHC motif. Sequence identity 
translates into overall structural similarity between DsbA proteins from these pathogens. 
 
The sequence and structure of the active site motif (CPHC) and the cisPro loop are identical 
in these DsbA homologues. However, helix α1 and the loops connecting β1 and β2, and α3 and α4 
differ in their relative positions. Most importantly loop L3 that connects β3 and helix α7 varies 
across the structures. The EcDsbA L3 residues D167, T168 and S169 are positioned closer to the 
active site helix α1 than the equivalent residues (A167, K168, S169) in PmDsbA. This region is 
relatively hydrophobic in both PmDsbA and EcDsbA, though more basic in PmDsbA than in 
EcDsbA due to presence of Lys159 in the former and Q160 in the latter. Overall these differences 
in structure are relatively minor compared to the structures of other DsbA proteins, such as 
Pseudomonas aeruginosa DsbA (25% identity with PmDsbA, RMSD 2.2 Å, 175 Cα, PDB: 3H93 
(Shouldice et al., 2010)), and Wolbachia pipientis DsbA1 (16% identity with PmDsbA, RMSD 3.6 
Å, 151 Cα, PDB: 3F4R (Kurz et al., 2009)) 
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Figure 4.3. Crystal structure of PmDsbA and its comparison with close homologues. A. 
Structural comparison of four closely related DsbA homologues, PmDsbA (4OCE) in cyan, EcDsbA 
(1FVK protomer B) in white, KpDsbA (4MCU protomer E) in orange and SeDsbA in green. 
Conserved structural regions are annotated; the catalytic cysteines are shown as yellow spheres. B. 
Structure based sequence alignment of EcDsbA (1FVK, chain A), SeDsbA (3L9S, chain A), KpDsbA 
(4MCU, chain F), and PmDsbA (4OCE, chain A). Sequence identity with EcDsbA is shown on the 
left, conserved residues are black, differing residues are red. The TRX domain is highlighted in 
light grey, and the helical domain in dark grey. Red squares mark the three loop regions L1/2/3. 
Amino acid conservation code is shown beneath the sequences. The active site CXXC motif is 
highlighted in blue, and the cisPro region in green. Secondary structure elements are indicated 
above the sequences. Residues underlined in EcDsbA bind to the EcDsbB P2 loop peptide (PISA 
server analysis). C. CXXC active site of PmDsbA. D. CXXC active site of 
PmDsbAC30S:PWATCDS. For panels C and D, the electron density is from 2F0 - Fc FFT maps 
generated in Phenix (Adams et al., 2010) and contoured at 1.0 σ. 
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Crystal structure determination of PmDsbAC30S and PmDsbAC30S:PWATCDS – We solved the 
structure of the active site mutant PmDsbAC30S (PDB:4OCF). The crystals grew in the presence of 
peptide, but no bound peptide was evident in the electron density map. We therefore used this 
structure of PmDsbAC30S to assess whether replacement of Cys30 with Ser30 induced any 
structural changes. The mutant crystallized in a monoclinic crystal system, containing 4 protomers 
in the asymmetric unit. The structure was solved by molecular replacement using the coordinates of 
PmDsbA described above. The average RMSD for comparison of the 6 combinations of the 4 
protomers ranges from 0.3–0.7 Å for 177 equivalent Cα atoms (residues 6-181).  
 
PmDsbAC30S in complex with the peptide PWATCDS crystallized in a trigonal crystal 
system, containing 3 protomers in the asymmetric unit. The complex was solved by molecular 
replacement using PmDsbA (PDB:4OD7) as the template. All three protomers (A, B and C) reveal 
strong electron density corresponding to bound PWATCDS. The average RMSD for the 3 
comparisons of the protomers in this crystal structure range from 0.4–0.6 Å for 177 equivalent Cα 
atoms (residues 6-181). The RMSD for comparison of PmDsbAC30S with PmDsbAC30S-
PWATCDS range from 0.5–0.9 Å (177 Cα) for the 12 combinations. Similarly, comparison of the 
wild type PmDsbA structure with PmDsbAC30S and PmDsbAC30S-PWATCDS gave RMSD 
values of 0.3–0.9 Å (177 Cα). This result indicates there is no major re-organisation of the 
PmDsbAC30S structure upon interaction with PWATCDS. However, there is evidence of rigid 
body shifts for helix 1 and side chain adjustments for residues on helix 1 (His32, Tyr34, Gln 35, 
Phe36, Ser37) and the flexible loop 3 (Ile165, Ser166) that together form part of the peptide binding 
site.  
 
Active site structure is conserved after peptide binding – A comparison of the active site motifs 
(CPHC, CPHS) and the Val150/Pro151 residues of the cisPro loop across all the protomers in the 
PmDsbA, PmDsbAC30S and PmDsbAC30S-PWATCDS crystal structures reveals a high degree of 
structural conservation. The active site cysteines Cys30 and Cys33 in the native PmDsbA structure 
were modeled as a mixture of oxidized and reduced (ratio 0.7:0.3). In the oxidized state the two 
sulfurs (Figure 4.3C) are 2.2 Å apart, reflecting the typical length of a covalent disulfide bond 
found in other oxidized DsbA structures (eg. EcDsbA and SeDsbA, S-S distance 2.0 Å) (Martin et 
al., 1993, Heras et al., 2010a). The dithiol form of the cysteines is likely a consequence of 
radiation-induced disulfide reduction. The distance between the dithiol sulfurs is 3.4 Å. In the 
PmDsbAC30S and PmDsbAC30S:PWATCDS structures, the distance between the hydroxyl 
oxygen of Ser30 and the sulfur atom of Cys33 varies between 3.3–3.5 Å (Figure 3D). These 
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distances are in agreement with those of other reduced DsbA structures (eg. KpDsbA 3.3-3.8 Å) 
(Kurth et al., 2013). Overall, there is no apparent change in the active site upon binding of the 
peptide. 
 
Peptide binding mode and interaction with PmDsbAC30S – The binding mode of the peptide 
(Figure 4.4A and 4.4B) is highly conserved across the three protomers (RMSD 0.1–0.2 Å over all 
82 atoms). The electron density from this high-resolution structure provides strong evidence for 
both the position and conformation of the bound peptide (Figure 4.4C). The binding site for 
PWATCDS (residues 1 to 7) includes the hydrophobic groove and the active site regions (CXXC 
and cisPro motif) of the enzyme. As expected, the hydrophobic residues Pro1 and Trp2 (italics 
indicate peptide residues) interact with the hydrophobic groove, and the C-terminal residues interact 
with the cisPro region of the active site.  
 
However, the observed binding mode was not entirely as predicted. On the basis of the 
EcDsbA:EcDsbB covalent complex, Cys5 of the peptide should interact with PmDsbAC30S residue 
30 (mutated from Cys to Ser). This was not the case. In all three complexes in the asymmetric unit, 
Asp6 and not Cys5 interacts with PmDsbAC30S Ser30 (Figure 4.4D). The acidic side chain of Asp6 
is within hydrogen bond contact distance of Ser30 and His32. Moreover, the backbone amide of 
Asp6 forms hydrogen bonds with the backbone amide of Val149 of the PmDsbAC30S cisPro loop 
(Figure 4D). 
 
Comparison of peptide binding mode with DsbA-DsbB complexes – The EcDsbB P2 loop (sequence 
PSPFATCDF) and the synthetic peptide we used, (PWATCDS), share the same binding location on 
EcDsbA and PmDsbAC30S, respectively. The EcDsbA-EcDsbB complex (3.7 Å resolution (Inaba 
et al., 2009a)), revealed one possible hydrogen bond between P2 and the enzyme (backbone oxygen 
of Arg148 of the EcDsbA cisPro loop with the backbone nitrogen of EcDsbB Phe106). All other 
interactions with the P2 loop, aside from the covalent disulfide, are hydrophobic (Shouldice et al., 
2011).  
 
As indicated above, no interaction was observed between Cys5 and Ser30 of PmDsbAC30S. 
Instead, hydrogen bond interactions with Asp6 and hydrophobic interactions with Trp2 appear to 
dominate the PWATCDS binding mode. Residues between these two anchor points - Cys5, Thr4 
and Ala3 - protrude out of the binding site relative to the equivalent EcDsbB loop residues (Figure 
4.4E, F). 
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Figure 4.4. Analysis of the interaction between peptide PWATCDS and PmDsbAC30S. A. 
Superposition of the PWATCDS peptides from all three protomer:peptide complexes in the 
asymmetric unit. Note the peptide includes an N-terminal acetyl and a C-terminal amide group. 
Carbon atoms are shown in cyan, oxygens in red, nitrogens in blue and sulfurs in yellow. B. 
Location of the bound PWATCDS peptide on the surface of PmDsbAC30S (protomer A shown, in 
grey). Peptide residues are labeled and colored as for panel A. The yellow patch indicates the 
location of Ser30. C. Electron density map of PWATCDS (chain F) at the interface with 
PmDsbAC30S (chain B). The 2F0-Fc map was generated in Phenix (Adams et al., 2010) and is 
contoured at 1.0 σ. PmDsbAC30S residues forming the binding site are labeled. D. Interactions 
between the peptide (D-F, in cyan) and protein (chains A-C, in grey) are shown: hydrogen bonds 
are indicated as black dashed lines; a circle highlights the stacking interaction between Trp2 and 
PmDsbAC30S Tyr173. E. Superposition of the EcDsbB P2 periplasmic loop (PSPFATCD, orange, 
black letters, PDB code 2ZUP) with PmDsbAC30S-PWATCDS (red letters, backbone in cyan). F. 
Schematic representation of the interactions formed between EcDsbB P2 loop binding to EcDsbA 
(top) in comparison to PWATCDS binding to PmDsbAC30S (bottom), showing the comparative 
shift in register. Covalent bonds are shown as black lines, hydrogen bonds are indicated with red 
dashed lines and hydrophobic interactions with black dotted lines. 
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The RMSD for comparison of PWATCDS with the EcDsbB P2 loop conformation is 
relatively high (2.2 Å for 28 backbone atoms), because of the bulge in the peptide conformation. 
Binding of PWATCDS results in an average buried surface area (i.e. surface that becomes 
inaccessible to solvent) of 955 ± 12 Å or 9.0% ± 0.1% of the total surface of PmDsbAC30S (values 
are means and S.D. generated from the three molecules in the asymmetric unit). This is similar in 
area to the EcDsbA buried surface upon binding of the EcDsbB P2 loop (924 Å2) (Inaba et al., 
2009a). In both structures a major feature is the binding of an aromatic residue in the hydrophobic 
groove. EcDsbB P2 loop residue Phe101 forms a T-shaped π-π stacking interaction with EcDsbA 
Phe174 whereas Trp2 of the PWATCDS peptide forms a parallel π-π stacking interaction with 
PmDsbAC30S Tyr173 and possible edge interactions with enzyme residues Pro170 and Tyr40. 
Discussion 
 
The increasing incidence of infections caused by multidrug resistant pathogens represents a 
serious global human health issue. Indeed, the emergence of carbapenem-resistant 
Enterobacteriaceae threatens to make common infections such as UTIs untreatable (Totsika et al., 
2012). Antibiotic resistance is spreading rapidly and treatment options are becoming increasingly 
limited. One possible approach to address the paucity of new antimicrobials in the developmental 
pipeline lies in the generation of novel anti-virulence drugs (Rasko & Sperandio, 2010, Clatworthy 
et al., 2007).  
 
The Gram-negative DsbA/B system has been proposed as a target for the development of 
novel anti-virulence drugs (Heras et al., 2009). Targeting DsbA/B for development of inhibitors 
could be beneficial in many ways. First DsbA is not essential for bacterial survival (Bardwell et al., 
1991) though it plays an essential role in virulence (Heras et al., 2009). Thus, inhibiting DsbA/B 
would not kill bacteria and this property may reduce the selective pressure to develop resistance. 
Second, structures of several DsbA homologues have been solved (Kurth et al., 2013, Shouldice et 
al., 2011, Premkumar et al., 2013) providing a framework for structure-based drug design. Third, 
DsbA structures and properties are more highly conserved than the structures and sequences of 
virulence factors across pathogens (Kurth et al., 2013). Therefore, inhibitors that target one DsbA 
enzyme within a subclass are likely to block DsbAs within the sub-class offering the possibility of 
medium-spectrum inhibitors (Kurth et al., 2013). 
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Designing an inhibitor to block a protein-protein interface such as that of a DsbA requires a 
comprehensive knowledge of its binding interactions. Here we have used an innovative approach to 
define the interaction surface of PmDsbA by using knowledge from the low resolution crystal 
structure of EcDsbA-EcDsbB. We characterized a peptide derived from the sequence of DsbB, 
showed that it bound PmDsbA and co-crystallized it in a non-covalent complex with 
PmDsbAC30S. This provides the first example of a high-resolution crystal structure of a DsbA in 
complex with a non-covalently bound peptide. Two previously published structures of DsbA in 
complex with bound peptides include (i) EcDsbA bound covalently with a substrate SigA derived 
peptide (Paxman et al., 2009a); and (ii) Xyfella fastidiosa DsbA also bound covalently with a 
peptide that co-crystallized fortuitously (Rinaldi et al., 2009). The SigA peptide was covalently 
linked to EcDsbA and interestingly showed a binding conformation differing from the DsbB loop or 
the present peptide, with the binding to EcDsbA Cys30 the only shared feature. For the second 
structure, the electron density of the peptide bound to XfDsbA was poor, only allowing the fitting 
of a poly-Ala chain and therefore not suitable for comparison with the present high-resolution 
structure.  
The high resolution of the new PmDsbAC30S-PWATCDS crystal structure allows 
investigation of finer binding features that can be exploited for inhibitor design. However, due to 
the alteration in the binding environment around the catalytic site with the Cys to Ser mutation (thus 
replacing a lipophilic residue with a hydrophilic amino acid), the binding peptide conformation 
might not be entirely representative of the binding to the wild type DsbA in this region, as hinted by 
the peptide residue shifts (Figure 4.4.E and 4.4.F) and Cys5 pointing outside of the DsbA suface. 
Neighboring regions however are very conserved and could be used as template for rational drug 
design, particularly the hydrophobic pocket.   
 
P. mirabilis associated infections are often difficult to treat due to its propensity to form 
biofilms (Jacobsen & Shirtliff, 2011). Two cell surface organelles associated with P. mirabilis 
biofilm formation, mannose-resistant Proteus-like (MR/P) fimbriae (Jansen et al., 2004) and 
flagella (which mediate swarming) (Jacobsen & Shirtliff, 2011), require DsbA for their correct 
assembly. Taken together, our data show that PmDsbA exhibits redox, functional and structural 
properties typical of the DsbA class Ia enzymes (McMahon et al., 2014) which extends to all 
DsbAs characterized to date from Enterobacteriaceae (Kurth et al., 2013). We expect that the 
structural details of the peptide binding mode and the interactions observed will likely hold true for 
all of these enzymes. Specifically, the hydrophobic groove and the cisPro loop provide key points 
of interaction that could be exploited further. The high-resolution crystal structure of the non-
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covalent complex between PmDsbAC30S and peptide may provide an important platform for the 
development of peptidomimetic antivirulence compounds targeting PmDsbA and by extension the 
DsbAs from all Enterobacteriaceae. 
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V.1 Introduction 
 
Peptides were characterized in my PhD project to investigate the potential optimization of 
the scaffold using natural residues and a few non-natural side chains (see Chapter III), and the 
highest affinity-to-mass-ratio peptide (PWATCDS) was crystallized with PmDsbAC30S to obtain a 
high-resolution crystal structure (see Chapter IV) providing insight into the binding features of this 
sequence. From this work, the next logical step was to develop peptidomimetics as better inhibitors 
of EcDsbA. This could be done by a broad range of chemical transformations to improve potency, 
stability, resistance to proteases and bioavailability.  
 
The first goal was to improve the affinity for EcDsbA to the submicromolar or nanomolar 
range, in order to reach potency closer to typical ‘druggable’ compounds. The second aim was to 
develop an inhibitor that did not rely on the formation of a covalent disulfide bond with EcDsbA. 
Otherwise, the possibility of nucleophilic attack by substrate molecules or EcDsbB onto Cys30 
might trigger the release of the disulfide-bond linked inhibitory peptide, hence limiting its 
efficiency.  
 
Many approaches can be used to develop a peptide sequence into a peptidomimetic scaffold 
retaining and/or enhancing antimicrobial properties (see section I.3). Substitution with non-natural 
side chains has briefly been explored in Chapter III, and this chapter focuses on efforts to move 
away from natural amino acids and peptides, using techniques such as backbone cyclization, 
addition of covalent ‘warheads’ and virtual screening to target the hydrophobic pocket neighboring 
the catalytic cysteines.  
 
Cyclic peptides are already present in the natural reservoir of antibiotics and AMPs. For 
instance, vancomycin and cyclosporine are all cyclic peptides. Generally, cyclic peptides are 
divided into three categories: peptides for which cyclization relies on disulfide bridges, such as 
tachyplesin (Nakamura et al., 1988), peptides that do not include disulfide bonds, such as 
Gramicidin S (two pentapeptides cyclized head-to-tail (Mogi & Kita, 2009)) and peptides that 
possess both disulfides bonds and a head-to-tail backbone cyclization, such as cyclotides (Craik et 
al., 2006). Peptides not including disulfide bonds can be cyclized head-to-tail such as Gramicidin S 
or through their side chains such as Actinomycin D. In a different approach, engineered cyclic 
peptides such as D,L-α-residue hybrids are even able to self-assemble into nanotubes with potent 
bactericidal properties in vivo (Dartois et al., 2005). Generally, peptide cyclization confers 
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additional stability by restraining the peptide conformation in solution and provides proteolytic 
resistance (Katsara et al., 2006). Another advantage of cyclization is that the restrained 
conformation decreases the energetic penalty of binding to the target by minimizing entropy losses 
(Clardy & Walsh, 2004). This way, the preorganization of a peptide into a conformational shape 
complementing the surface of the target through cyclization might also raise its potency. It was 
hypothesized that the transformation of DsbA-binding peptides into cyclic peptidomimetics might 
produce compounds that better complement the EcDsbA hydrophobic pocket. However, cyclization 
must not be induced by a disulfide bond because of the weak reductase activity of DsbA, and will 
instead require cross-linking of side chains together.  
 
A second strategy consisted of targeting the domains neighboring the catalytic cysteines that 
would still prevent EcDsbB periplasmic loop P2 from fitting onto the EcDsbA surface, without 
forming a disulfide bridge with Cys30. The peptide SAR in chapter III suggested that such a goal 
would be difficult due to the importance of the disulfide bond formation in the EcDsbA-peptide 
interaction; the crystal structure of peptide PWATCDS in a non-covalent complex with the 
PmDsbAC30S mutant in Chapter IV suggested possible clues to develop new binding interactions. 
Moreover the high resolution of the crystal structure highlighted the molecular features of peptide 
binding, including the π-stacking interaction between PmDsbAC30S Tyr174 and peptide Trp2 in 
the hydrophobic pocket. This hydrophobic patch is a feature shared by EcDsbA (see Chapter IV) 
and the EcDsbB periplasmic loop has been localised within this hydrophobic groove in the three 
crystal structures available (Inaba, Murakami, et al., 2006, Inaba et al., 2009b, Malojcic et al., 
2008). Therefore it was decided that the PmDsbAC30S-PWATCDS crystal structure could be used 
as a starting point for the development of small peptidomimetic compounds that would be more 
specific to the hydrophobic groove. The hypothesis was that the presence of such peptidomimetics 
might decrease the stability of a EcDsbA-EcDsbB complex, or prevent the interaction altogether 
thus restraining the disulfide bond exchange necessary for EcDsbA activity. As outlined in the 
following material and methods, a virtual docking of peptidomimetic libraries based on the 
PmDsbAC30S-bound PWATCDS structure was performed to provide the initial scaffolds. From an 
initial scaffold, derivatives were synthesized and tested according to the pipeline described in 
Chapter II.  
 
A third approach relied on the design of irreversible inhibitors of EcDsbA. The peptide SAR 
in Chapter III revealed the importance of disulfide bond formation in the binding mechanism to 
EcDsbA. This feature is not favorable in the drug design process as EcDsbA might be able to 
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release the inhibitor peptide following nucleophilic attack of Cys33 on Cys30, restoring the 
disulfide bond in the catalytic site and thus re-enabling EcDsbA folding activity. A new strategy 
would be to switch to a ‘suicide’ inhibitor strategy, in which the inhibitor is irreversibly linked to 
the target through a ‘warhead’ moiety. While this approach might provide better efficiency (the 
inhibitor is not released from its target and the latter can not resume activity) and lower dosages (the 
drug can not be out-competed by increasing concentration of substrate), it also presents a strong 
disadvantage as reactive moieties able to form covalent bonds can potentially bind other off-target 
proteins (Singh et al., 2011, Potashman & Duggan, 2009, Johnson et al., 2010). Such a compound 
requires extreme specificity to limit side effects in vivo. Nevertheless, previous successful examples 
of drug molecules following this ‘suicide’ strategy are available (Guterman, 2011). 
 
 In this project, the target for the ‘warhead’ was the EcDsbA Cys30, as the primary residue 
involved in the first step of disulfide bond exchange (see Chapter I). There is a broad array of 
moieties known to react with thiol groups including nitriles (Powers et al., 2002), 
halomethylketones (Cohen et al., 2005, Cohen et al., 2007), haloacetamides (Sako et al., 2008), 
vinyl sulfones (Chalker et al., 2009), epoxides (Johnson et al., 2010), maleimides (Kim et al., 2008) 
and Michael acceptors (Fry et al., 1998).Each of those would form a stable covalent bond with the 
sulfide atom of a free cysteine (Figure 5.1). The first peptidomimetics were synthesized with a 
nitrile or an aldehyde moiety as a ‘warhead’ to covalently bind EcDsbA Cys30.  
 
 
Figure 5.1. Examples of reactive functionalities capable of forming irreversible covalent bonds 
with thiol groups. A. Nitrile. B. Halomethylketone. C. Haloacetamide. D. Vinyl sulfone. E. 
Epoxide. F. Maleimide. G. An aldehyde group as an example of Michael acceptor. 
 
 These three approaches - macrocyclic peptides, peptidomimetics targeting the hydrophobic 
pocket and irreversibles binders - are described separately below in their respective material and 
methods and results sections. 
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V.2 Material and methods 	  
V.2.1 Macrocyclic peptidomimetics 
  
The initial approach was to synthesize cyclic versions of the sequence PSPWATC. The 
alanine scanning performed in Chapter III demonstrated that residues Ser2 and Ala5 were not 
involved in the binding interactions with EcDsbA and thus could be used for other purposes such as 
cyclization. According to the EcDsbA-EcDsbB and the PmDsbAC30S:PWATCDS structures, a 
large macrocycle on the peptide N-terminus might occupy most of the hydrophobic pocket and 
increase hydrophobic contacts with aromatic residues Phe36, Phe174 and Tyr178 and aliphatic 
residues Leu40 and Ile42 compared to linear PSPWATC.  
 
The usual method for cyclization involves an amine coupling reaction between a free 
carboxylic acid and a free amine functional groups, in a fashion similar to the usual amino-acid 
coupling used in solid phase peptide synthesis (see section II.2). This technique requires that all 
other functional groups on the peptide to be protected to prevent side reactions. To this end, the 
PSPWATC sequence was modified substituting Ser2 and Ala5 with Lys and Asp residues to give 
sequences PDPWKTC and PKPWDTC to attempt a ‘side chain-to-side chain’ macrocyclization. 
The macrocycle is anticipated to bring structural restraint and alter the conformation of the peptide, 
potentially adding stability but also limiting the flexibility of the peptide to fit EcDsbA hydrophobic 
pocket. In order to screen for different conformations, the Lys5 residue (including 4 carbon atoms 
in the side chain) was replaced with ornithine (Orn) and 2,4-diaminobutyric acid (Dab) presenting 
shorter side chains leading to different macrocycle sizes (Figure 5.2). The length of the side chain 
might also influence the yield of the cyclization reaction depending on its accessibility by the Asp 
residue.  
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Figure 5.2. Structure of different cyclic peptides to be synthesized. A. PDPWKTC as a 17-atom 
macrocycle. B. PDPW(Dab)TC as a 15-atom macrocycle. C. PDPW(Orn)TC as a 16-atom 
macrocycle.  
 
 Cyclization was initiated with the classic solid phase synthesis of PDPWKTC, PKPWDTC, 
PDPW(Orn)TC and PDPW(Dab)TC as described in section II.2, however using Fmoc-Lys, Fmoc-
Asp, Fmoc-Orn and Fmoc-Dab residues orthogonally protected by 4-methyltrityl (Mtt) moieties. 
Peptides still linked on the resin were incubated in TFA 2% in DCM for 30 minutes, which 
successfully removed the Mtt protection groups while keeping the remaining residues intact (with 
orthogonal protections resisting up to TFA 90%). The resin was then washed thoroughly with DMF 
and DCM before incubation with 4 equivalents of Benzotriazol-1-yloxy-
tris(dimethylamino)phosphonium hexafluorophosphate (BOP) or otriazol-1-yl-
oxytripyrrolidinophosphonium hexafluorophosphate (PyBOP) with excess of DIPEA. Incubation 
time was screened from 1 hour to 24 hours to identify the time needed for optimal cyclization yield. 
The resin was then washed again with DMF and DCM before cleaving from the resin and analysis 
by mass spectrometry. 
 
V.2.2 Targeted peptidomimetics 
 
Virtual Docking – The starting point for the docking study was the 1.6 Å resolution crystal structure 
of the PmDsbAC30S:PWATCDS peptide complex. The bound peptide was removed and hydrogen 
atoms were added using the Hermes interface in GoldSuite 5.1 (Verdonk et al., 2003). Additionally 
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the indole ring system of Trp2 of the bound peptide was separately stored in the same XYZ 
coordinate space to serve as a template file for the template docking mode within GOLD. The PWA 
tripeptide was replaced with a small targeted library of 10 compounds based on both D- and L-
Tryptophan cores, and both hydrophobic and hydrophilic C- and N-terminal capping groups. These 
candidate virtual ligands were prepared from 2D ChemDraw (CS ChemBioDraw Ultra 12.0) 
representations via SMILES strings, and minimum energy conformers were prepared using 
OMEGA2 v2.4.6 (OMEGA, Hawkins et al., 2010, Hawkins & Nicholls, 2012) and the mmff94s 
forcefield. Docking with GOLD 5.1 was performed using the standard precision settings and the 
default CHEMPLP scoring function. Docking results were visualized in Pymol (Schrodinger, 
2010a, b, c). The virtual docking was performed by Dr Martin Stoermer. 
 
Peptidomimetic synthesis – The initial material Boc-Trp-OH (1.00 mmol) was dissolved in 10 mL 
of dioxane in a nitrogen environment. Carbonyldiimidazole (1.02 mmol) was added in a stepwise 
manner and the resulting mixture was stirred for 3 h at room temperature followed by heating at 50 
ºC for 30 min. Aniline (1.03 mmol) was added to the reaction mixture at room temperature and the 
solution stirred for 48 h (Figure 5.3). The solvent was removed using a rotary evaporator and 
product was extracted with ethyl acetate (3 x 20ml). The organic extracts were washed with 1 M 
hydrochloric acid (15 mL), saturated sodium bicarbonate solution (15 mL) and water (15 mL). The 
extracts were then dried over anhydrous MgSO4 and the solvent was removed using a second rotary 
evaporator step. The final compound was dissolved in H2O (1 mL) in which was added aniline 
(2.00 mmol). The solution was cooled to 0 OC prior to the addition of TFA (30.00 mmol). After 
stirring for 1 h at 0 OC, the reaction mixture was warmed to room temperature and stirring was 
continued for 12 h. The reaction mixture was then diluted with ethyl acetate (15 mL) and washed 
with saturated sodium bicarbonate solution (15 mL), water (15 mL) and brine solution (15 mL) and 
dried over anhydrous MgSO4. The solvent was removed using a rotary evaporator.  
 
 
Figure 5.3. Synthesis route of the tripeptide peptidomimetics tested in this chapter. 
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The compound with the free amine was dissolved in dichloromethane (5 mL) in which was added 
carbonyldiimidazole (1.2 mmol) in a nitrogen environment. After stirring for 3 h, morpholine or 1-
Boc-piperazine (1.55 mmol) was added to the reaction mixture and the solution stirred for another 
12 h at room temperature. The solvent was removed using a rotary evaporator, diluted with ethyl 
acetate (15 mL) and washed with 1 M hydrochloric acid (15 mL), saturated sodium bicarbonate 
solution (15 mL), brine solution (15 mL) and dried over anhydrous MgSO4. Crude product was then 
purified by preparative HPLC (Gradient 0 to 100% of 95/5 acetonitrile/water solution over 25 min) 
and freeze-dried. The 10 compounds presented in this section were synthesized by Dr Prabhakar 
Bachu. 
 
Differential Scanning Fluorimetry – All protein thermal shift assays were performed on a ViiA™ 7 
Real-Time PCR instrument (Life Technologies™, Applied Biosystems™ Division) using 384 well 
MicroAmp Clear Optical Plates (Life Technologies™, Invitrogen™ Division). Oxidised EcDsbA 
(25 mM HEPES pH 7.4, 50 mM NaCl) was prepared at a final concentration of 2.5 µM, in the 
presence of either 5 % (v/v) DMSO (reference) or 2, 1, 0.5, 0.25, 0.125 or 0.0625 mM of the test 
compound (also in a final concentration of 5% DMSO (v/v.)) A x 5000 stock of SYPRO® Orange 
Protein Gel Stain (Life Technologies™, Invitrogen™ Division) was diluted to a final concentration 
of x 5. The final reaction volume was 20 µL. For each condition, five technical replicates were 
included. Non-protein control reactions (DMSO or compound, and dye in the absence of EcDsbA) 
were also included to monitor compound-dye interactions respectively. Plates were sealed with 
Axygen Ultra Clear Pressure Sensitive Sealing Film (Fisher Biotec) and immediately prior to 
analysis centrifuged (1000 x rpm, 2 min) to draw down all liquid and break any bubbles. A standard 
melt curve analysis was conducted using a temperature ramp from 25 °C to 99 °C at a rate of 0.05 
°C/s. Fluorescence was detected using the in built ‘m4’ filter set (excitation λ 470±15 nm, emission 
λ 586±10 nm) and data analysed using Prism Software. Tm was determined by fitting a Boltzmann 
equation to the data. The DSF experiments in this section were performed by Dr Roisin McMahon. 
 
Isothermal titration calorimetry - Oxidized EcDsbA was diluted to 50 µM in 25 mM HEPES pH 
7.4, 50 mM NaCl and 5% DMSO. Compounds were dissolved in 100% DMSO, and then diluted to 
a final concentration of 2 mM into 25mM HEPES pH 7.4 50mM NaCl with a final DMSO 
concentration of 5%. All experiments were performed using the MicroCalTM Auto-ITC200 
instrument (GE Healthcare, USA), loading 200 µL of EcDsbA in the sample cell and 40 µL of 
compound in the syringe. Titrations were set up at 25 ºC with 19 injections of 2 µL separated by 
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180 seconds and a constant stirring speed of 1000 rpm. A preliminary injection of 0.5 µL was added 
to avoid slow leakage of titrant in the sample cell before the first 2 µL injection and the 
corresponding datapoint excluded from analysis. Every compound was tested with three technical 
replicates. An additional titration of compound into buffer only (25 mM HEPES pH 7.4, 50 mM 
NaCl and 5% DMSO) was performed to measure the background heat of dilution. Analysis was 
performed with the MicroCal™ Origin software (version 7.0552). 
 
Model Substrate Oxidation assay – To prepare the model substrate, lyophilized EcDsbA synthetic 
substrate (CQQGFDGTQNSCK) which contains a C-terminal methylcoumarin and a N-terminal 
DOTA functional groups (Anaspec, USA) was dissolved in 100 mM imidazole pH 6.0. 100 mM of 
europium trifluoromethanesulfonate (Sigma Aldrich, Australia) was added to the synthetic substrate 
peptide at a molar ratio of 2:1 and incubated for 5 min at room temperature to allow europium 
chelation. Experiments were performed in a white 384-well plate (Perkin Elmer OptiPlate-384, Part 
#: 6007290) in 50 mM MES, 50 mM NaCl and 2 mM EDTA pH 5.5 buffer. Each well contained 80 
nM EcDsbA, 1.6 µM EcDsbB, one of the tested compounds at concentrations ranging from 16 µM 
to 2 mM and 10 µM synthetic substrate peptide (added last to initiate the reaction). Positive controls 
were set up replacing compound by buffer, and negative controls lacked EcDsbA or EcDsbB. 
Fluorescence emitted by substrate folding was measured with a Synergy H1 multimode plate reader 
(excitation λ = 340 nm and emission λ = 615 nm). Analysis was performed using the Prism 
software. To allow plotting the activity of the positive control (the native EcDsbA activity without 
compound) on a logarithmic scale of compound concentration, a very low compound concentration 
value was used (100 nM). The substrate oxidation assay experiments presented in this section were 
performed by Mrs Stephanie Tay. 
 
V.2.3 Irreversible peptidomimetics 
 
Two peptidomimetic molecules were designed from peptide PWATCDS including 
respectively a nitrile (PWATnitDS) and an aldehyde warhead (PWATaldDS) replacing the Cys5 
residue. Synthesis of PWATnitDS was attempted through the direct coupling of an amino acid with 
a cyanoalanine side chain (Figure 5.4A, synthesized by Dr Bachu) and through the dehydration of 
an Asn α-aminoacid.  
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Figure 5.4. Residues used in the synthesis of covalent peptide binders. A. Fmoc-beta-
cyanoalanine for the synthesis of PWAT(nit)DS. B. Fmoc-beta-dimethoxyalanine for the synthesis 
of PWAT(ald)DS, which upon action of TFA will be converted into an aldehyde functionality.   
 
Synthesis of PWATaldDS was executed using a residue presenting two methoxy groups on 
the side chain (Figure 5.4B, synthesized by Dr Bachu), which was converted into an aldehyde 
group under the action of TFA during the resin cleaving process. This peptidomimetic was tested in 
ITC according to section II.2.4. 
V.3 Results 	  
V.3.1 Macrocyclic peptidomimetics 
 
The cyclization of four different peptide sequences (PDPWKTC, PKPWDTC, 
PDPW(Orn)TC, PDPW(Dab)TC) was attempted using amine coupling to form macrocycles of 
different sizes. Only limited cyclization was detected for peptides PDPWKTC and PKPWDTC 
despite consecutive coupling rounds in the presence of excess of BOP or PyBOP. Attempts to 
catalyse the reaction with a series of microwave pulses yielded no improvement. Mostly the final 
products were of the major non-cyclized peptides. The peptides were also washed with benzene to 
prevent potential stacking and aggregation, but with no yield improvement. To address the 
possibility the N-terminal Pro1 was inducing steric hindrance and limiting access of Asp2 to Lys5 
(or Lys2 to Asp5), the same synthesis strategy was attempted on sequences Fmoc-DPWKTC and 
Fmoc-KPWDTC before the final coupling, with no success (Figure 5.5). To investigate the 
hypothesis that a high-loading resin might be encouraging intermolecular coupling and formation of 
peptide polymers, these experiments were repeated with low-loading MBHA rink-amide resin (0.36 
mmol.g-1 instead of 0.72 mmol.g-1) again with no enhancement in the cyclization yield. The same 
strategies were applied on peptides PDPW(Orn)TC and PDPW(Dab)TC but no cyclization was 
observed. Therefore the synthesis of macrocycles was abandoned.  
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Figure 5.5. Mass spectrometry measurements of Fmoc-DPWKTC and Fmoc-KPWDTC peptides. 
A. The mass spectrometry analysis of Fmoc-DPWKTC showed that the peptide was still linear (Mw 
= 970 Da) rather than cyclic (Mw =952 Da) despite the cyclization rounds. B. In a similar fashion, 
peptide PKPWDTC cyclization was not successful and the final synthesis product remained linear 
(Mw = 970 Da).  
 
It is known that the linear conformation of L-peptide precursors before cyclization greatly 
influences the cyclization yield due to allylic strain (White & Yudin, 2011). For ‘tail-to-side chain’ 
macrocycles such as DPWKTC (with N-term Asp) and KPWDTC (with N-term Lys), the ring size 
is known in this case to be important (White & Yudin, 2011) and a potential explanation for the 
low-yield is the relatively small size of the macrocycle. The linear peptides PDPWKYC and 
PKPWDTC have been tested with ITC on EcDsbA and presented Kd values (≈ 30 µM) 8-fold 
weaker than the original EcDsbB peptide derivative PSPFATCDF (Kd = 4.0 ± 1.5 µM). 
 
V.3.2 Targeted peptidomimetics 
 
Virtual docking and synthesis. The virtual docking was performed using the PmDsbAC30S-
PWATCDS complex as a template, focusing on the interaction of PWATCDS Trp2 with 
PmDsbAC30S Tyr173 in the hydrophobic pocket.  Evaluation of the 10 compounds from the 
library was based on the PWATCDS Trp2 indole moiety (Figure 5.6). The initial docking was 
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carried out with the template constraint set to the default values, and progressively reduced to allow 
for better induced fit docking, not to overly bias in favour of the observed crystal structure bound 
conformation of the Trp. As the backbone amine and carbonyl of the Trp2 residue in the bound full 
length peptide are not involved with hydrogen bonds to the protein (See Chapter IV), this allowed 
exploration of whether simpler small molecules could bind in the "opposite" direction to the full 
length peptide, with only the indole ring of Trp2 being used as a hydrophobic anchor. The steady 
reduction in the template constraint also allowed subtle changes to arise which may provide 
additional interactions in the case of smaller molecules which would reasonably be assumed to 
adopt multiple possible binding conformations. Indeed if the constraint is reduced completely, other 
conformations were observed (up to 4 out of 10 docking poses), some of which included extra H-
bonds with the protein, particularly with the charged molecules. However the dominant interactions 
in this portion (PWA) of the full (PWATCDS) peptide were the hydrophobic interactions of the Pro 
and Trp side chains, and these hydrophobic patches are the typical targets of druglike molecules.   
 
The compound that fitted best, here named compound 1, is a tripeptide consisting of a 
tryptophan residue flanked by a C-terminal morpholine functional group and a N-terminal benzyl 
moiety (Figure 5.7). Apart from the pi-stacking interaction between the Trp indole and 
PmDsbAC30S Tyr173, the docking modeled the oxygen atom of the morpholine group at similar 
distances from the PmDsbAC30S Pro150 backbone amide, His32 imidazole ring amines and 
Asn162 side chain amide (≈ 4.5 Å). In choosing compound 1 as the favoured compound we took 
into account several factors. Docking runs were performed with Goldscore, Chemscore and 
ChemPLP. Compound 1 performed well with all 3 scoring functions. Secondly, consideration was 
given to medicinal chemistry factors such as regard for a balance between aqueous solubility and 
"druglike" properties (e.g. compound 1 has a CLogP of 2.6, 6 rotatable bonds, 3 hydrogen bond 
acceptors, 3 hydrogen bond donors, a molecular weight of 406 Da, and is neutral at physiological 
pH). Ultimately, however, it was the ability of compound 1 to extend both the indole ring in the 
Trp-binding pocket, and the benzylamide group to make hydrophobic interactions in the same 
region as the Proline of the full peptide, as well as the morpholine ring to dock in the groove that 
made it an attractive synthetic target.  
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Figure 5.6. Comparison of a docked peptidomimetic with the EcDsbA-EcDsbB and 
PmDsbAC30S-PWATCDS crystal structures. A. Detail of the EcDsbA-EcDsbB crystal structure 
(PDB code 2ZUP, (Inaba et al., 2009b)) with EcDsbB Phe101 binding in the EcDsbA hydrophobic 
pocket. B. Detail of the PmDsbAC30S-PWATCDS crystal structure (PDB code 4OD7, see chapter 
IV) with Trp2 binding into PmDsbAC30S hydrophobic groove. C. Detail of the virtual docking 
outcome with the three conformations of compound 1 shown in shades of green binding to 
PmDsbAC30S. In orange are shown the PmDsbAC30S residues interacting with compound 1.  
 
 From compound 1 nine additional derivatives were synthesized (Figure 5.7) to explore the 
binding groove and exploit potential optimization possibilities. Compound 2 had a piperazine 
moiety replacing the morpholine group to present a hydrogen bond donor instead of an acceptor in 
order to bind with EcDsbA Asn142. Compound 3 was similar to compound 2 with an additional 
tert-butyloxycarbonyl (Boc) group on the piperazine moiety to extend the peptidomimetic in the 
groove for potential additional interactions with the cisPro loop residues Asn147, Gly148 and 
Val149. Compounds 4 and 5 investigated the importance of the distance between the benzyl group 
and the Trp residue by respectively replacing the benzyl by phenyl and phenethyl moieties in 
compound 1 to effectively expand hydrophobic contacts. Compound 6 presented an extra methyl 
group for additional hydrophobic interactions. On the benzyl ring of compounds 7 and 8 a 
trifluoromethyl moiety was attached in the ortho position and a trimethoxyfluoride moiety on the 
para position respectively; these groups were chosen for their strong electronegativity and their 
potential as hydrogen bond acceptors. Finally compounds 9 and 10 presented two methoxy moieties 
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in the ortho/para and meta/para positions respectively to improve the solubility of the scaffold and 
to further probe for additional hydrogen bonds contacts with EcDsbA.  
 
Figure 5.7. Structure of the 10 peptidomimetic compounds synthesized and tested in this section. 
Compound 1 was the initial hit from the virtual docking, from which derivatives 2-10 were 
designed.  
 
Differential scanning fluorimetry. The peptidomimetic compounds were first evaluated using DSF 
to detect any binding through a concentration-dependent increase (∆Tm) of EcDsbA melting 
temperature Tm. The peptidomimetics were tested with a concentration range from 64 µM to 2mM 
and initially checked for potential compound-dye interferences that could lead to background 
fluorescence. When mixed with SYPRO orange on a temperature gradient from 25 ºC to 99 ºC, 
compounds 7 and 8 indicated strong background fluorescence at 0.5 mM, 1 mM and 2 mM 
concentrations. Compounds 1, 3, 4 and 5 showed limited interaction at the highest concentration 
(2mM) for which fluorescence decreased to background level before the temperature of 50 ºC was 
reached. Finally, compounds 2, 6, 9, and 10 did not demonstrate substantial fluorescence from 
interaction with the dye. Measuring the melting temperature of EcDsbA in the presence of each of 
these compounds did not indicate substantial shift expected from strong ligands (Figure 5.8). To be 
significant, a thermal shift ∆Tm has to be at least twice as large as the standard deviation of the 
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native protein Tm, in this case 0.1 ºC. However, most of the measured ∆Tm were lower than 0.2 ºC, 
and the compounds also failed to demonstrate a concentration-dependent effect. 
 
 
Figure 5.8. Measurement of the melting temperature of EcDsbA in presence of compound 6 (not 
interfering with the dye). Each concentration is shown here as an average of 5 technical replicates 
with their respective standard deviations. No significant differences are observed compared to 
EcDsbA only, suggesting the compound does not bind strongly to EcDsbA.  
 
 This data suggested that these peptidomimetic compounds do not bind strongly to EcDsbA, 
but results can be biased by the intrinsic affinity of the compounds for the dye, by virtue of their 
hydrophobicity. To further identify the potential of this series of peptidomimetic, their affinity was 
also evaluated by isothermal titration calorimetry, a label-free approach lacking a dye that could 
interfere in the binding process or the read out.  
 
Isothermal titration calorimetry. The affinity and thermodynamics of the 10 compounds were 
measured with ITC in order to investigate differences with the original peptide sequence 
PWATCDS. Titration of EcDsbA with compound 1 revealed poor binding potential with low 
release of energy (-0.60 µcal.sec-1 for the highest peak against -1.6 µcal.sec-1 for PWATCDS) and 
no sign of EcDsbA saturation (Figure 5.9).  
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Figure 5.9. Isothermal titration calorimetry profile of EcDsbA titrated with compound 1, showing 
low energy release and poor EcDsbA saturation suggesting compound 1 is not a strong binder.    
 
Similarly for derivatives 2-10 no binding significant enough for accurate curve fitting was 
detected (Figure 5.10). The EcDsbA binding sites in the sample cells are not saturated and the 
profiles are similar to the negative controls. These data suggest two hypotheses: either EcDsbA 
demonstrated a very weak (in the millimolar range) affinity for these compounds, or the amount of 
energy released by the binding reaction was very low and thus difficult to measure with ITC. This 
second hypothesis is a possibility for binding reactions characterized by a major entropic 
contribution (Gaisford, 2006). Given that the compounds were designed to target the hydrophobic 
pocket of EcDsbA and that no atoms were predicted to be in range for the formation of hydrogen 
bonds, it is likely that ITC is not an optimal screening technique to rank these compounds according 
to their affinity towards EcDsbA. Screening techniques for hydrophobic binding are scarce, and 
thus it was decided that compounds to try to rank the compounds by their potential inhibitory 
activity rather than their binding affinity.  
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Figure 5.10. Raw isothermal titration calorimetry profiles of EcDsbA titrated with compounds 2 
to 10, for which none demonstrated binding with the parameters used. This could also be due to the 
interaction being mainly hydrophobic for which ITC has limited sensitivity.  
 
Model substrate oxidation assay – The model substrate oxidation assay had the advantage of being 
independent from the peptide binding mode (unlike ITC) and not using a dye was likely to interact 
with the compound (unlike thermal shift). Inhibition of the EcDsbA substrate folding activity 
demonstrated a reduced rate of total fluorescence increase, indicating a diminution in substrate 
folding. This signified that the peptidomimetic compound was competing either with the EcDsbA-
substrate interaction, the EcDsbA-EcDsbB interaction or the EcDsbB-ubiquinone electron 
exchange. When tested, compounds 1-9 did not have a strong influence on EcDsbA activity at the 
concentrations used (Figure 5.11) whereas compound 10 showed significant reduction in the 
fluorescence signal at the highest concentrations (1 mM and 2 mM, Figure 5.12A). Plotting 
concentrations against the fluorescence signal increase rate provided an estimated IC50 of 1.1 mM 
for compound 10 (Figure 5.12B), which was approximately 200-fold lower than the original 
EcDsbB sequence (PSPFATCDF, 6.7 ± 1.1 µM) and peptide PWATCDS (5.7 ± 0.4 µM, see 
Chapter III). Taken together, these peptidomimetic compounds were poor inhibitors of EcDsbA 
activity with IC50 values estimated in the high millimolar range.  
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Figure 5.11. Raw fluorescence measurements of the substrate folding by EcDsbA in presence of 
compounds 1 to 9 at concentrations ranging from 16 µM to 2 mM. None of these compounds 
induced a significant reduction in the fluorescence and so had no effect on EcDsbA activity.   
 
 
Figure 5.12. Compound 10 possessed weak inhibitory activity. A. Compound 10 was the only 
peptidomimetic to show detectable inhibition at the concentrations used in this assay with a 
significantly lower EcDsbA activity at the highest concentration. B. Plotting the log of the 
concentration against the fluorescence increase rate allowed fitting of a sigmoidal curve and an 
IC50 of approximately 1.1 mM was estimated.   
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Taken together, a virtual docking of peptidomimetic libraries based on the PmDsbAC30S-
PWATCDS structure and focusing on the hydrophobic pocket provided one hit (compound 1) from 
which nine derivatives were synthesized (compounds 2-10) to further explore the binding site. We 
were not able to detect concentration-dependent shifts in the melting temperature of EcDsbA using 
differential scanning fluorimetry and compounds did not demonstrate strong binding using ITC. 
The model substrate oxidation assay indicated very weak inhibition with the best compound 10 
showing an IC50 of 1.1 mM. Overall, these compounds presented a significant loss in affinity and 
inhibition compared with the starting peptide PWATCDS used in the virtual docking. 
V.3.3 Irreversible inhibitors 
 
The two compounds, PWAT(nit)DS and PWAT(ald)DS were expected to bind irreversibly 
to EcDsbA. The synthesis of PWAT(nit)DS proved to be difficult; each attempted synthesis 
experiment showed very low efficiency in the coupling of the nitrile amino acid, even in the 
presence of large excess (4 equivalents or higher) of the amino acid in multiple consecutive steps. 
Moreover presence of contaminants that could not be separated by HPLC prevented the production 
of a purified product (Figure 5.13A). The synthesis of PWATnitDS was then outsourced to an 
external commercial company that was also unable to produce the expected peptidomimetic 
compound after three months of trials. Therefore efforts towards peptides with a nitrile ‘warhead’ 
were abandoned. 
 
Figure 5.13. Mass spectrometry measurements of the final products from PWAT(nit)DS and 
PWAT(ald)DS synthesis. A. Attempts to synthesize PWAT(nit)DS (of mass 780 Da) mostly resulted 
in a product of mass 699 Da corresponding to the PWATDS sequence. B. Synthesis of 
PWAT(ald)DS (of mass 815 Da) proved to be more successful, and the expected product was 
present in the final cleaved mixture.  
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On the other hand, I was able to synthesize PWAT(ald)DS (Figure 5.13B). The 
peptidomimetic was tested using ITC to evaluate the reactivity towards oxidized and reduced 
EcDsbA. However the titrations demonstrated poor binding with a low signal and no saturation of 
EcDsbA binding sites (Figure 5.14).  
 
Figure 5.14. Isothermal titration calorimetry experiments using covalent binder PWAT(ald)DS to 
titrate EcDsbA oxidized (A) and reduced (B) which showed limited affinity. 
 
 NMR experiments performed concomitantly by Dr Brad Doak and Assoc Prof. Martin 
Scanlon at the Monash Institute of Pharmaceutical Sciences on small molecules targeting EcDsbA 
showed that most of the reputedly irreversible thiol binders tested (for example 
fluoromethylketones, acrylamides and maleimide) were in fact turned over and released from 
EcDsbA (Doak, 2012). The turnover began within 24 hours and EcDsbA was able to restore its 
former folding activity. In total 42 covalent binders were synthesized and tested but none resulted in 
irreversible binding onto EcDsbA, demonstrating the unique reactivity of EcDsbA and its ability to 
break covalent bonds for which no enzyme-mediated resolution has been previously reported. The 
reactivity of the EcDsbA catalytic cysteines is such that designing a functional group able to form a 
stable and irreversible bond with Cys30 is a major challenge. 
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V.4 Discussion 
 
The interactions between peptides and the EcDsbA binding site are quite unusual: 1) the 
peptide SAR indicated that the disulfide bond was a necessary component for binding but 2) we 
obtained a structure of a peptide bound in a non-covalent fashion to PmDsbAC30S and 3) deleting 
the peptide side chains binding to the EcDsbA hydrophobic groove did not alter affinity (See 
chapter III). However this hydrophobic patch still seems to play an important role as seen in the 
crystal structure of EcDsbA/EcDsbB and PmDsbAC30S-PWATCDS. Therefore, the development 
of the first series of peptidomimetics provided the opportunity to investigate the role of this binding 
site further. 
 
The formation of macrocycles to target the EcDsbA hydrophobic pocket was unsuccessful 
due to low yields and purity issues, probably due to the small size of the cycle. A solution to this 
issue would be to cyclize the full peptide sequence using both termini in a similar fashion as 
cyclopeptides (Craik et al., 2006), although such an approach would substantially increase the 
molecular mass of the molecule away from ‘drug-like’ properties.  
 
Targeting the hydrophobic pocket was a strategy aimed at thwarting the disulfide bond 
formation mechanism in order to develop a reversible binder. The 1.6 Å resolution PmDsbAC30S-
PWATCDS structure provided the basis for virtual docking, resulting in an in silico hit. However, 
the evaluation of this hit along with nine derivatives demonstrated limited affinities in vitro and 
these compounds were not able to compete effectively with the EcDsbB periplasmic loop. The 
inability of these compounds to bind EcDsbA however provides more insight on the role of the 
EcDsbA hydrophobic pocket and the choice of the drug design strategy. The EcDsbB periplasmic 
loop binds within this hydrophobic pocket in the three crystal structures solved (Malojcic et al., 
2008, Inaba, Murakami, et al., 2006, Inaba et al., 2009a) and EcDsbB-derived peptide PWATCDS 
also interacts with residues from the PmDsbAC30S hydrophobic pocket (see Chapter IV). However 
according to the data provided by the peptidomimetic screening above, the hydrophobic pocket by 
itself is not a target potent enough to prevent DsbA folding activity, which suggests two hypotheses. 
First, the compounds synthesized in this study can access the binding site, but they might be easily 
driven out by a substrate molecule or the DsbB loop binding onto the catalytic site. This suggests 
that the hydrophobic contacts in the groove alone are not strong and specific enough to compete 
with a substrate molecule or EcDsbB. Second, the peptidomimetic might bind into the groove (and 
the ITC sensitivity to screen them is limited due to the major entropic component), but the catalytic 
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disulfide bond transfer between EcDsbA/substrate and EcDsbA/EcDsbB can happen despite this 
hindrance. In both cases, I suggest that the role of the hydrophobic pocket as a drug target by itself 
seems limited. Further investigation can lead to the optimization of a future inhibitory scaffold for 
additional stability of the complex with EcDsbA, but most likely the inhibitor would need to 
primarily affect the nearby catalytic site. Therefore, the design of the next inhibitors should 
comprise interactions with the EcDsbA catalytic cysteines to possess inhibitory activity. For 
example, a reactive moiety specific to the cysteines could be integrated in the peptide design. 
 
 The next step was the insertion of a ‘warhead’ able to form a covalent bond with EcDsbA 
Cys30, in this case a nitrile and an aldehyde moieties. The synthesis of a nitrile peptide was 
particularly difficult, and no final purified product was obtained. The peptide presenting the 
aldehyde moiety indicated a weak affinity for EcDsbA. Moreover the work from Dr Doak and Pr 
Scanlon showed that moieties known to irreversibly bind thiol groups were turned over and released 
when binding to EcDsbA in vitro (Doak, 2012). The suggested mechanism involved a nucleophilic 
attack of Cys33 on the Cys30 linked to the inhibitor scaffold, triggering the restoration of the 
disulfide bond and the release of the adduct from EcDsbA. An innovative solution would be to 
target not only Cys30 but engineer a peptidomimetic in such a way that a second ‘warhead’ would 
lock onto Cys33 as well, hence preventing any disulfide bond transfer and peptidomimetic release. 
This would be a delicate process as Cys33 is buried deeper in the thioredoxin fold compared to 
Cys30. The main drawback is that such a compound including two reactive ‘warheads’ would be 
even more likely to trigger side reactions in vivo, hence increasing toxicity.  
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 The primary purpose of this PhD was to develop a potent peptide or peptidomimetic 
scaffold inhibiting the DsbA-DsbB interaction in Escherichia coli to impede the bacterial oxidative 
system in vivo. The inhibition of EcDsbA is thought to offer a novel means of preventing 
maturation of a broad range of virulence factors, leading to an attenuated but viable bacterial 
phenotype. Such a novel mode of action is expected to provide a new weapon to fight against MDR 
and pan resistant pathogenic bacterial strains and to limit the appearance of resistance by keeping 
the bacteria viable (Clatworthy et al., 2007, Rasko & Sperandio, 2010). The only starting point for 
the structure-based drug design of these inhibitors was the 3.7 Å resolution crystal structure of the 
EcDsbA-EcDsbB complex (Inaba et al., 2009a). 
Outcome of the screening pipeline assembly 
 
 The first goal was to develop a robust screening pipeline able to characterize the designed 
peptides and peptidomimetics by measuring their affinity and their inhibitory activity for EcDsbA. 
It had to also include crystallographic trials to provide structural data necessary to accurately 
interpret the biochemical data provided by the pipeline. Such a pipeline was successfully 
implemented using differential scanning fluorimetry (DSF), isothermal titration calorimetry (ITC) 
and model substrate oxidation assays as well as crystallography. A major hurdle arose in the 
development of a surface plasmon resonance assay, and that approach had to be abandoned during 
my thesis research due to the absence of binding signals. The final optimized pipeline was able to 
provide all the binding data for a single compound in five days from the beginning of the manual 
synthesis to the starting of the co-crystallization trials.  
 
 A major issue in this pipeline was the lack of a technique for accurate characterization of 
compounds for which binding involves a major contribution from hydrophobic interactions. DSF 
would demonstrate a high fluorescence background for the dye because it would bind to the 
hydrophobic moieties of the inhibitor; hence potentially hiding the fluorescence increase linked to 
the unfolding of EcDsbA or complexes. Moreover, DSF would not be able to provide a Kd value. 
Similarly, ITC would be limited, as the enthalpy contribution would be minimal. Model substrate 
oxidation assay do not discriminate between binding modes, but would provide an IC50 value and 
not a binding affinity. A suitable assay to overcome this issue would be saturation transfer 
difference nuclear magnetic resonance (STD NMR), a technique that would identify peptide and 
peptidomimetic residues involved in the binding process (Viegas et al., 2011). Through a 
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competition assay with another peptide of known affinity, STD-NMR can also provide a Kd value 
(Angulo et al., 2010). A second possibility is microscale thermophoresis, a recently developed 
assay that relies on the motion of molecules in temperature gradients (Seidel et al., 2013). This 
label-free assay is able to determine Kd values independently of the binding mode, thus would suit 
the screening of hydrophobic compounds. Instruments for both techniques are now available and 
might be used for follow-up research on EcDsbA inhibitors.  
 
Structure-activity relationship and hypothesis for peptide binding mechanism 
 
 The screening pipeline was successfully used to characterize peptide binding (see Chapter 
III) to identify the key residues in the interaction with EcDsbA. Interestingly the outcome of the 
alanine scanning showed that only the substitution of the peptide Cys residue resulted in a drastic 
loss of affinity. It suggested that no other residues are as critical for binding of the peptide to 
EcDsbA. Concurrently, there was no binding of the same peptides to reduced EcDsbA (thus unable 
to form disulfide bridges). Therefore, the evidence tends to suggest the formation of a disulfide 
bond between peptide and DsbA that would be the critical feature for binding. However, it also 
seems that the disulfide bond might be the only binding force behind the DsbA-DsbB interaction, 
therefore providing restricted specificity. If this was the case, oxidized active EcDsBA would not be 
able to differentiate between a substrate to be oxidized and reduced EcDsbB, therefore reduced 
EcDsbB would be a competitor for EcDsbA folding activity). This scenario is unlikely hence we 
cannot rule out the possibility that a mechanism intrinsic to EcDsbB prevents the binding of 
OxEcDsbA, hence responsible for the specificity of the DsbB-DsbA interaction and still remains to 
be observed (Figure 6.1A). This mechanism, that may involve a role from other regions of the 
perisplasmic loop P2, would not be featured in the peptides tested to date (Figure 6.1B).   
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Figure 6.1. Difference in the disulfide bond formation between the DsbA/DsbB and the DsbA-
peptide complexes. A. After regeneration of reduced DsbA in its active oxidized state, the reverse 
reaction with oxidized DsbA binding DsbB would be unproductive; there might be another feature 
preventing the backward reaction. B. In the proposed peptide binding model, the peptide binds to 
oxidized DsbA and forms an intramolecular disulfide bond – thus in a different context than the 
native DsbA-DsbB interaction.  
 
On the other hand, all peptides tested against oxidized EcDsbA presented a strongly 
unfavorable entropic contribution, suggesting the peptide conformations do not match the EcDsbA 
surface. This is consistent with the hypothesis that the disulfide bond is the only force driving the 
binding mode. It could be suggested that EcDsbB domain might adopt a conformation not present 
in the short and flexible peptide derivatives tested, but this is also unlikely for a disordered 
perisplamic loop such as EcDsbB P2. Moreover, the role of the hydrophobic residue (in EcDsbB 
Phe101) binding into the EcDsbA hydrophobic groove remains unclear as peptide affinity is not 
altered upon deletion of the hydrophobic side chain. In contrast, the solved structure of peptide 
PWATCDS binding non-covalently to the mutant PmDsbAC30S (i.e. without intermolecular 
disulfide bond) demonstrates the hydrophobic Trp2 residue interacting with PmDsbAC30S 
hydrophobic patch. A technique to evaluate the importance of a residue in soluble proteins is site-
directed mutagenesis, mutating the specific residue into a Gly or Ala. However EcDsbB being a 
membrane protein it would take considerable efforts to engineer a mutant (such as F101A), obtain a 
quantity of pure protein sufficient for ITC experiments and solve the membrane protein stability 
issues.  
 
My hypothesis is that the peptide, and possibly the EcDsbB loop, binding mode occurs in 
two consecutive steps with different kinetics. The first step is the nucleophilic attack of the peptide 
cysteine thiolate onto DsbA Cys30 (or DsbA Cys30 thiolate onto DsbB Cys104), forming the 
disulfide bond as per the EcDsbA native mechanism (Figure 6.2). This is a rapid reaction measured 
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by ITC followed by an entropically unfavorable contribution suggesting the peptide is in a 
disordered state on the surface of the EcDsbA. The peptide now anchored on EcDsbA has limited 
flexibility and after a period of time the peptide Trp or Phe residue would lock into the EcDsbA 
hydrophobic pocket. This second phase might be much slower than the first as the peptide might not 
readily adopt the favorable confirmation that would lead the Trp or Phe residue inside the pocket.  
 
 
Figure 6.2. Suggested binding mechanism of peptide PWATCDS to EcDsbA. The binding is 
initiated by the nucleophilic attack of Cys5 thiolate onto EcDsbA Cys30 (1), in a fashion similar to 
substrate binding. This interaction would occur with fast on-rate. Second, the peptide anchored to 
EcDsbA by the disulfide bond is stabilized by binding to the neighboring hydrophobic pocket (2) 
through hydrophobic contacts and π-stacking interaction with Phe173. Finally, the nucleophilic 
attack of EcDsbA Cys33 onto Cys30 might restore the intramolecular disulfide bond and release 
the peptide (right panel). This last event has been observed only for covalent binders by Doak et al. 
and has not been investigated in this thesis for peptides (Doak, 2012). However, if EcDsbA is able 
to turn over irreversible binders, it is very likely that the same phenomenon applies to peptides only 
bound by a disulfide bridge.  
 
The different timeframes of the binding experiments - DSF and model substrate oxidation 
requires over an hour incubation before measurements, ITC is instantaneous and crystallogenesis 
takes days – made the study of this binding mode difficult, depending on the kinetics of each step. 
Within this hypothesis, the role of the interaction between the EcDsbB loop Phe101 and the 
EcDsbA hydrophobic patch might involve additional stability of the complex to allow the disulfide 
bond exchange to occur. Another possibility presumes that the binding of EcDsbB loop into the 
EcDsbA hydrophobic groove restrains the flexibility of the periplasmic loop; this event could 
prevent the unproductive backward reaction in which DsbB Cys130 (on the same loop) attacks the 
intermolecular disulfide bond, releasing EcDsbA in the inactive state. With the peptide derivatives, 
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the hydrophobic interaction occurs as well even if the disulfide bond exchange process is never 
achieved due to the peptide lacking a second cysteine. Molecular dynamics studies might help to 
shed some light on this hypothesis, but it would require additional complex structures with the 
peptide anchored to EcDsbA by a disulfide bond, such as EcDsbA-PSPFATCDF and EcDsbA-
PWATCDS.  
Structural analysis of the DsbA-peptide interaction 
 
 The co-crystallization trials performed in this project were successful when a mutant, 
PmDsbAC30S, was used. No peptides were ever detected in crystals generated with wild type 
EcDsbA or PmDsbA. This was probably because the peptides were released following restoration 
of the Cys30-Cys33 disulfide bond before crystallogenesis occurred. Although providing crucial 
data about peptide binding to DsbA, the conformation of the PWATCDS peptide bound to 
PmDsbAC30S mutant might not reflect the native interaction as the catalytic cysteine has been 
substituted. As seen in Chapter IV, the peptide Cys was shifted and the consecutive Asp residue 
interacted with the catalytic site. Moreover, the inhibitory activity of PWATCDS towards this 
PmDsbA mutant cannot be evaluated as PmDsbAC30S does not possess a redox potential and 
cannot fold substrates. Consequently, additional structures of DsbA-peptide complexes with 
different mutants or the native protein might be needed to understand the peptide conformation on 
DsbA accurately.  
 
A simple way to cross-link the peptide to DsbA would be to engineer a DsbA mutant with 
the second cysteine in the catalytic site (Cys33) substituted with an inactive residue such as alanine 
(C33A). If the peptide indeed forms a disulfide bond with EcDsbA, it would then be trapped to 
EcDsbA as Cys33 would not be able to restore the disulfide bond and release the peptide. This is a 
strategy similar to the one applied to the formation of a stable EcDsbA-EcDsbB complex (see 
section I.2.2), and should be the next step in the structural part of the larger program. Moreover, 
such a structure might provide the starting point necessary for molecular dynamics experiments to 
study the peptide binding mechanism hypothesis described above.  
Future directions in inhibitor design 
 
During this PhD it appeared that EcDsbA is an extremely potent oxidase, able to turn over 
all the tested thiol-targeting reactive groups that are thought to form stable and irreversible covalent 
bonds with cysteine residues. This is a serious hurdle for drug design targeting DsbA as the 
	  	   	  	  Chapter	  VI	  -­‐	  Conclusions	  	  	  
	   148	  
interaction with Cys30 seems to be the primary force driving the binding. Consequently, the interest 
in ‘suicide’ inhibitors is limited by the timeframe during which the inhibitor stays anchored to 
EcDsbA before release. Moreover Doak et al. suggested that the released ‘suicide’ inhibitor might 
lose the ‘warhead’ in the process, thus being inactivated by EcDsbA (Doak, 2012). If this is correct, 
these ‘suicide’ binders would be worse than reversible binders as they could not bind back onto 
another EcDsbA molecule. Designed peptidomimetics focusing on the nearby hydrophobic pocket 
had weak potencies. Therefore, a successful inhibitor of the EcDsbA activity must not only bind 
EcDsbA but also neutralize the interaction between the two catalytic cysteines.  
 
To date, there are no reports in the literature of ligands able to bind two cysteines in the 
same active site. Such an inhibitor should include two thiol-reactive groups side by side (Figure 
6.3). These reactive groups must not interact with each other to avoid partial cyclization of the 
peptide. If both reactive groups connect with Cys30 and Cys33, then theoretically the peptide could 
be irreversibly bound to EcDbsA.  
 
Figure 6.3. Suggested peptidomimetic scaffold for future studies of EcDsbA inhibitors. The 
molecule should include a thiol-reactive group to irreversibly bind EcDsbA Cys30 (in blue) and a 
second similar moiety to bind EcDsbA Cys33 (in orange), which is buried deeper in the active site. 
A peptide backbone must be conserved in the residue on the C-terminal side to trigger hydrogen 
bond(s) with EcDsbA cisPro loop (Arg149, Pro150). On the N-terminus, the peptidomimetic should 
include at least one phenyl or indole moiety for π-stacking interactions with EcDsbA Phe173 (in 
red). The entire N-terminus of the peptide can also be replaced by a non-peptidic design that would 
fit the EcDsbA hydrophobic pocket better (in purple). X represents here an irreversible thiol-
reactive group to bind DsbA catalytic cysteines.  
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Once we know the structure of such an irreversible peptidomimetic, efforts could then be 
directed toward the rigidification of the peptide backbone into a conformation that matches EcDsbA 
binding site interface to improve the thermodynamics of the reaction, and thus the potency, of the 
peptidomimetic series. Once a potent in vitro peptidomimetic is designed, it would need to be tested 
for membrane permeability and E. coli motility inhibition. Assuming that the peptidomimetic 
efficiently inhibits bacterial swarming, a mouse infection model will then be the obvious next step 
to evaluate the effect of an antivirulence drug candidate in vivo.  
 
Conclusion 
 
Taken together, EcDsbA proved to be a challenging target to inhibit due to the lack of 
specificity and the high potency of its intrinsic enzymatic mechanism. However, substantial 
progress has been made in the understanding of the binding mode of peptides on the EcDsbA 
surface. An optimal inhibitor 7-mer peptide was identified with a Kd 5.7 ± 0.4 µM (and a binding 
efficiency index BEI of 6.4) involving the formation of a disulfide bond with EcDsbA Cys30. The 
same inhibitor showed an inhibitory activity (IC50 8.8 µM) in vitro. The first high-resolution 
structure of a peptide non-covalently bound to a DsbA was obtained, shedding light on the peptide 
binding mode. The first attempts at designing novel peptidomimetic scaffolds were unsuccessful but 
paved the way for new approaches.  
 
Overall, this PhD provides the first steps in the design of the first peptide inhibitors targeting 
a dithiol oxidase, and the acquired knowledge might be applied to other enzymes of similar 
function. If, based on the preliminary work performed in this thesis, the future design of a 
peptidomimetic compound bears fruit, it will also offer another argument in favor of the 
peptidomimetic weaponry in the current effort to relieve the current struggle in the antibiotic 
pipeline. Moreover, as aimed towards one of the first antivirulence targets, this potentially novel 
antimicrobial scaffold could be part of a new generation of antibiotics that could limit the 
appearance of new extremely-drug resistant strains.   
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APPENDIX 
 
 The following appendices includes two additional publications to which I contributed during 
the course of this PhD for the better understanding of the DsbA protein family and to investigate the 
possibility of designing a broad-spectrum antibiotic that might bind DsbA in different pathogenic 
species. Appendix A presents the characterization of Klebsiella pneumoniae DsbA and the outline 
of a first subclass of DsbA proteins in Enterobacteriaceae (including EcDsBA), for which a 
common inhibitor scaffold might be designed. I performed peptide binding experiments (ITC) using 
sequences I synthesized both against EcDsBA and specifically against KpDsbA. Appendix B 
characterizes a DsbA from a different subclass, originating from Mycobacterium tuberculosis, and 
shows that significant structural differences compared with EcDsbA suggest a different inhibitory 
scaffold would have to be designed. Here again, I synthesized and tested (with ITC) a series of 
specific peptides that were proved to bind and inhibit MtbDsbA. 
 
 Second, Appendix C presents all the supplementary information provided with the 
manuscript of the EcDsbA-peptides SAR publication (Chapter III). This includes the peptide 
characterization data as well as additional ITC and DSF graphs.  	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APPENDIX A 
	  	  	  	  	  	    
&RPSDUDWLYH6HTXHQFH6WUXFWXUHDQG5HGR[$QDO\VHVRI
.OHEVLHOODSQHXPRQLDH'VE$6KRZ7KDW$QWL9LUXOHQFH
7DUJHW'VE$(Q]\PHV)DOOLQWR'LVWLQFW&ODVVHV
)DELDQ.XUWK.LHUDQ5LPPHU/DNVKPDQDQH3UHPNXPDU%LVZDUDQMDQ0RKDQW\:LONR'XSUH]0DULD
$+DOLOL6WHSKHQ56KRXOGLFH͞D%HJRxD+HUDV͞E'DYLG3)DLUOLH0DUWLQ-6FDQORQ-HQQLIHU/
0DUWLQ
'LYLVLRQRI&KHPLVWU\DQG6WUXFWXUDO%LRORJ\,QVWLWXWHIRU0ROHFXODU%LRVFLHQFH7KH8QLYHUVLW\RI4XHHQVODQG%ULVEDQH4XHHQVODQG$XVWUDOLD)DFXOW\RI
3KDUPDF\DQG3KDUPDFHXWLFDO6FLHQFHV0HGLFLQDO&KHPLVWU\0RQDVK,QVWLWXWHRI3KDUPDFHXWLFDO6FLHQFHV0RQDVK8QLYHUVLW\3DUNYLOOH9LFWRULD$XVWUDOLD
$5&&HQWUHRI([FHOOHQFHIRU&RKHUHQW;UD\6FLHQFH0RQDVK8QLYHUVLW\3DUNYLOOH9LFWRULD$XVWUDOLD
$EVWUDFW
%DFWHULDO 'VE$ HQ]\PHV FDWDO\]H R[LGDWLYH IROGLQJ RI YLUXOHQFH IDFWRUV DQG KDYH EHHQ LGHQWLILHG DV WDUJHWV IRU
DQWLYLUXOHQFHGUXJV+RZHYHU'VE$HQ]\PHVFKDUDFWHUL]HGWRGDWHH[KLELWDZLGHVSHFWUXPRIUHGR[SURSHUWLHVDQG
GLYHUJHQW VWUXFWXUDO IHDWXUHV FRPSDUHG WR WKH SURWRW\SLFDO 'VE$ HQ]\PH RI (VFKHULFKLD FROL 'VE$ (F'VE$
1RQHWKHOHVVVHTXHQFHDQDO\VLVVKRZVWKDW'VE$VDUHPRUHKLJKO\FRQVHUYHGWKDQWKHLUNQRZQVXEVWUDWHYLUXOHQFH
IDFWRUVKLJKOLJKWLQJ WKHSRWHQWLDO WR LQKLELWYLUXOHQFHDFURVVD UDQJHRIRUJDQLVPVE\ WDUJHWLQJ'VE$)RUH[DPSOH
6DOPRQHOODHQWHULFD W\SKLPXULXP 6H'VE$VHTXHQFH LGHQWLW\ WR(F'VE$ VKDUHVDOPRVW LGHQWLFDO VWUXFWXUDO
VXUIDFH DQG UHGR[ SURSHUWLHV 8VLQJ FRPSDUDWLYH VHTXHQFH DQG VWUXFWXUH DQDO\VLV ZH SUHGLFWHG WKDW ILYH RWKHU
EDFWHULDO 'VE$V ZRXOG VKDUH WKHVH SURSHUWLHV 7R FRQILUP WKLV ZH FKDUDFWHUL]HG .OHEVLHOOD SQHXPRQLDH 'VE$
.S'VE$LGHQWLW\WR(F'VE$$VH[SHFWHGWKHUHGR[SURSHUWLHVVWUXFWXUHDQGVXUIDFHIHDWXUHVIURPFU\VWDO
DQG105GDWDRI.S'VE$ZHUHDOPRVWLGHQWLFDOWRWKRVHRI(F'VE$DQG6H'VE$0RUHRYHU.S'VE$DQG(F'VE$
ELQGSHSWLGHVGHULYHGIURPWKHLUUHVSHFWLYH'VE%VZLWKDOPRVWHTXDODIILQLW\VXSSRUWLQJWKHQRWLRQWKDWFRPSRXQGV
GHVLJQHG WR LQKLELW (F'VE$ZLOO DOVR LQKLELW .S'VE$ 7DNHQ WRJHWKHU RXU GDWD VKRZ WKDW'VE$V IDOO LQWR GLIIHUHQW
FODVVHVWKDW'VE$VZLWKLQDFODVVPD\EHSUHGLFWHGE\VHTXHQFHDQDO\VLVRIELQGLQJORRSVWKDW'VE$VZLWKLQDFODVV
DUH DEOH WR FRPSOHPHQW RQH DQRWKHU LQ YLYR DQG WKDW FRPSRXQGV GHVLJQHG WR LQKLELW (F'VE$ DUH OLNHO\ WR LQKLELW
'VE$VZLWKLQWKHVDPHFODVV
&LWDWLRQ.XUWK)5LPPHU.3UHPNXPDU/0RKDQW\%'XSUH]:HWDO&RPSDUDWLYH6HTXHQFH6WUXFWXUHDQG5HGR[$QDO\VHVRI.OHEVLHOOD
SQHXPRQLDH'VE$6KRZ7KDW$QWL9LUXOHQFH7DUJHW'VE$(Q]\PHV)DOOLQWR'LVWLQFW&ODVVHV3/R621(HGRLMRXUQDOSRQH
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(GLWRU9ODGLPLU18YHUVN\8QLYHUVLW\RI6RXWK)ORULGD&ROOHJHRI0HGLFLQH8QLWHG6WDWHVRI$PHULFD
5HFHLYHG$XJXVW$FFHSWHG6HSWHPEHU3XEOLVKHG1RYHPEHU
&RS\ULJKW.XUWKHWDO7KLVLVDQRSHQDFFHVVDUWLFOHGLVWULEXWHGXQGHUWKHWHUPVRIWKH&UHDWLYH&RPPRQV$WWULEXWLRQ/LFHQVHZKLFKSHUPLWV
XQUHVWULFWHGXVHGLVWULEXWLRQDQGUHSURGXFWLRQLQDQ\PHGLXPSURYLGHGWKHRULJLQDODXWKRUDQGVRXUFHDUHFUHGLWHG
)XQGLQJ7KLVZRUNZDVVXSSRUWHGE\DQ$5&ZZZDUFJRYDX$XVWUDOLDQ/DXUHDWH)HOORZVKLS)/WR-/0²ZKLFKDOVRVXSSRUWHG3K'
VFKRODUVKLSVWR).DQG:'²DQGDQ1+05&ZZZQKPUFJRYDX3URMHFW*UDQW$33WR0-6DQG%+-/0LVDOVRDQ+RQRUDU\1+05&
5HVHDUFK)HOORZ7KHIXQGHUVKDGQRUROHLQVWXG\GHVLJQGDWDFROOHFWLRQDQGDQDO\VLVGHFLVLRQWRSXEOLVKRUSUHSDUDWLRQRIWKHPDQXVFULSW
&RPSHWLQJLQWHUHVWV7KHDXWKRUVKDYHGHFODUHGWKDWQRFRPSHWLQJLQWHUHVWVH[LVW
(PDLOMPDUWLQ#LPEXTHGXDX-/0PDUWLQVFDQORQ#PRQDVKHGX0-6
͞D&XUUHQWDGGUHVV-DQVVHQ&LODJ3W\/WG0DFTXDULH3DUN1HZ6RXWK:DOHV$XVWUDOLD
͞E&XUUHQWDGGUHVV,QVWLWXWHIRU0ROHFXODU6FLHQFH/DWUREH8QLYHUVLW\0HOERXUQH9LFWRULD$XVWUDOLD
,QWURGXFWLRQ
$QWLELRWLFUHVLVWDQFHKDVLQFUHDVHGGUDPDWLFDOO\RYHUWKHODVW
GHFDGHDQGWKHFRQVHTXHQW ODFNRIWUHDWPHQWRSWLRQVSRVHVD
PDMRUWKUHDWIRUSXEOLFKHDOWK>@2QHDSSURDFKWRGHYHORSQHZ
FKHPLFDOFODVVHVRIDQWLEDFWHULDOV LV WR WDUJHWYLUXOHQFHIDFWRUV
WKDW FDXVH GLVHDVH LQ DQWLELRWLF UHVLVWDQW RUJDQLVPV >@ 0RVW
SDWKRJHQLF (QWHUREDFWHULDFHDH HQFRGH DQ R[LGDWLYH IROGLQJ
SDWKZD\ HVVHQWLDO IRU YLUXOHQFH IDFWRU SURGXFWLRQ >@
7\SLFDOO\ WKH R[LGDWLYH IROGLQJ PDFKLQHU\ LQFOXGHV D VROXEOH
WKLRUHGR[LQIROG SURWHLQ 'VE$ DQG DQ LQWHJUDO PHPEUDQH
SURWHLQSDUWQHU'VE%>@7KHGLVXOILGHIRUPRI'VE$LVKLJKO\
R[LGL]LQJDQGGRQDWHV LWV GLVXOILGHERQG WRXQIROGHG VXEVWUDWH
SURWHLQV >@ OHDYLQJ 'VE$ LQ WKH LQDFWLYH UHGXFHG IRUP 7KH
LQQHU PHPEUDQH SURWHLQ 'VE% LQ FRQFHUW ZLWK LWV FRIDFWRU
XELTXLQRQH LQWHUDFWVZLWK UHGXFHG'VE$ WR R[LGL]H WKH DFWLYH
VLWH F\VWHLQHV DQG FRQYHUW 'VE$ WR LWV IXQFWLRQDOO\ FRPSHWHQW
GLVXOILGH IRUP >@ ,QKLELWLRQ RI WKH LQWHUDFWLRQ EHWZHHQ'VE$
DQGVXEVWUDWHSURWHLQVRUEHWZHHQ'VE$DQG LWVSDUWQHU'VE%
FRXOGFRQVWLWXWHDPHDQVRIEORFNLQJYLUXOHQFHIDFWRUIRUPDWLRQ
DQG WKHUHE\ RI LQKLELWLQJ YLUXOHQFH RI EDFWHULDO SDWKRJHQV
6XSSRUWLQJ WKLV QRWLRQ GHOHWLRQ RI 'VE$ KRPRORJXHV LQ
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SDWKRJHQLF RUJDQLVPV UHVXOWV LQ GLPLQLVKHG YLUXOHQFH LQ
LQIHFWLRQ PRGHOV >@ DQG GHOHWLRQ RI GVE$ RU GVE% LQ
XURSDWKRJHQLF(FROL 83(&VHYHUHO\DWWHQXDWHG LWVDELOLW\ WR
FRORQL]HWKHEODGGHU>@
7KH FKDUDFWHULVWLF SURSHUWLHV RI (F'VE$ LQFOXGH DQ DFWLYH
VLWH&3+&PRWLIWKDWIRUPVDGHVWDELOL]LQJGLVXOILGH7PUHGXFHG
(F'VE$.7PR[LGL]HG(F'VE$. >@ WKHPRUH1
WHUPLQDORI WKH WZRF\VWHLQHV LVQXFOHRSKLOLFDQGKLJKO\DFLGLF
S.D XVXDOYDOXH IRUDF\VWHLQH LV >@DQG(F'VE$ LV
KLJKO\R[LGL]LQJUHGR[SRWHQWLDOP9>@7KHSDVW\HDUV
KDV VHHQ WKH FKDUDFWHUL]DWLRQ RI 'VE$ HQ]\PHV IURP PDQ\
RWKHU EDFWHULD LQFOXGLQJ 'VE$V ZLWK YDU\LQJ GHJUHHV RI
VHTXHQFH LGHQWLW\ WR (F'VE$ VXFK DV 1HLVVHULD PHQLQJLWLGLV
'VE$ 1P'VE$  LGHQWLW\ 3VHXGRPRQDV DHUXJLQRVD
'VE$ 3D'VE$  DQG9LEULR FKROHUDH 'VE$ 9F'VE$ RU
7FS*7KHVH'VE$VVKDUHDVLPLODUVWUXFWXUDO IROGZLWK
(F'VE$ WKRXJK WKHLU VXUIDFH SURSHUWLHV YDU\ >@ DQG WKH\
H[KLELWDZLGHUDQJHRIUHGR[SURSHUWLHV7DEOH,PSRUWDQWO\
WKH(F'VE$K\GURSKRELFJURRYHWKDWLQWHUDFWVZLWKLWVHVVHQWLDO
SDUWQHU (F'VE% LV FRQVLGHUDEO\ WUXQFDWHG LQ 1P'VE$
3D'VE$ DQG 9F'VE$ >@ 7KLV PRGLILFDWLRQ DQG RWKHU
VXUIDFH FKDQJHV LQ WKHVH'VE$V LQGLFDWH WKDW WKH\ IDOO LQWR D
VHSDUDWH FODVV GLVWLQFW IURP (F'VE$ DQG WKDW LQKLELWRUV
GHVLJQHG DJDLQVW (F'VE$ PD\ QRW LQKLELW PHPEHUV RI WKLV
FODVV RI 'VE$&RQYHUVHO\ 'VE$V FORVHO\ UHODWHG WR (F'VE$
VKRXOGEHVXVFHSWLEOHWRWKHVDPHPRGHRIFKHPLFDOLQKLELWLRQ
+HUHZHWHVWHGKRZFORVHWKHVHTXHQFHUHODWLRQVKLSPXVWEH
WR SURGXFH VLPLODU UHGR[ SURSHUWLHV DQG ELQGLQJ LQWHUDFWLRQV
:H LQYHVWLJDWHG WZR ZHOOFKDUDFWHULVHG 'VE$V VKDULQJ 
VHTXHQFH LGHQWLW\ IURP ( FROL . VWUDLQ (F'VE$ DQG 6
HQWHULFD 7\SKLPXULXP 'VE$ VWUDLQ 6/ 6H'VE$ E\
DSSO\LQJFRPSDUDWLYHVWUXFWXUDOVHTXHQFHDQGUHGR[DQDO\VHV
WR LGHQWLI\ SURSHUWLHV FRQVHUYHG DFURVV WKHVH WZR HQ]\PHV
7KH UHVXOWV DOORZ XV WR SODFH 'VE$V RI ILYH RWKHU *UDP
QHJDWLYHEDFWHULD(QWHUREDFWHULDFHDHQDPHO\6KLJHOODIOH[QHUL
7DEOH&RPSDULVRQRIVWUXFWXUHVDQGUHGR[SURSHUWLHVRI
'VE$V
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D >@  UHGR[ SRWHQWLDO UDQJH IRU1P'VE$  :S'VE$   S.D UDQJH
1P'VE$ 9F'VE$ 7PR[LGLVHG PLQ1P'VE$ PD[9F'VE$DQG
UHGXFHGPLQ1P'VE$PD[9F'VE$
E>@>@506'RI(F'VE$GHULYHGIURPWKHRYHUOD\RIPROHFXOHV$DQG%IURP
WKHDV\PPHWULFXQLWLQ)9.
F>@DQG>@
G>@
H>@
GRLMRXUQDOSRQHW
  6I'VE$  VHTXHQFH LGHQWLW\ WR (F'VE$
(QWHUREDFWHU FORDFDH 6&) (Q'VE$  &LWUREDFWHU
NRVHUL$7&&%$$&N'VE$&URQREDFWHUVDND]DNLL
63&V'VE$DQG.SQHXPRQLD.S'VE$
LQWR WKH VDPH 'VE$ FOXVWHU DV 6H'VE$ DQG (F'VE$ 7R
DVVHVV ZKHWKHU WKH UHGR[ DQG VWUXFWXUDO SURSHUWLHV DUH
PDLQWDLQHG LQ WKLV'VE$JURXSZH IRFXVHGRQ.S'VE$ZKLFK
VKDUHV WKH ORZHVW VHTXHQFH LGHQWLW\ ZLWK (F'VE$ :H
GHWHUPLQHG WKH KLJK UHVROXWLRQ FU\VWDO VWUXFWXUH RI UHGXFHG
.S'VE$DQG WKH105VROXWLRQ VWUXFWXUHRI R[LGL]HG.S'VE$
DQG ZH PHDVXUHG WKH UHGR[ SURSHUWLHV RI WKLV HQ]\PH $V
H[SHFWHG WKH UHGR[ SURSHUWLHV VXUIDFH FKDUDFWHULVWLFV DQG
ELQGLQJ SURSHUWLHV RI .S'VE$ DUH VLPLODU WR WKRVH RI (F'VE$
VXJJHVWLQJWKDWLQKLELWRUVGHYHORSHGDJDLQVW(F'VE$DUHOLNHO\
WR DOVR EH HIIHFWLYH DJDLQVW RWKHU PHPEHUV RI WKLV 'VE$
VXEFODVV
0DWHULDOVDQG0HWKRGV
3URWHLQSURGXFWLRQ
&RGRQRSWLPL]HG . SQHXPRQLDH GVE$ *HQ%DQN
DFFHVVLRQQXPEHU$&,ODFNLQJWKHVHTXHQFHFRGLQJIRU
WKH SUHGLFWHG VLJQDO VHTXHQFH  DD ZDV FORQHG LQWR D
PRGLILHG S0&6* 0LGZHVW &HQWHU IRU 6WUXFWXUDO *HQRPLFV
YHFWRU FRPSDWLEOH ZLWK OLJDWLRQLQGHSHQGHQW FORQLQJ 7KLV
PRGLILHGYHFWRUHQFRGHGDOHDGHUVHTXHQFHFRQVLVWLQJRIDQ1
WHUPLQDO +LVWDJ IROORZHG E\ D OLQNHU FRQWDLQLQJ WKH WREDFFR
HWFKYLUXVSURWHDVH7(9UHFRJQLWLRQVHTXHQFH.S'VE$ZDV
H[SUHVVHGLQ%/'(S/\VFHOOVXVLQJDXWRLQGXFWLRQPHGLXP
>@ DQG SXULILHGZLWK 7DORQ UHVLQ &ORQWHFK $XVWUDOLD 7KH
+LVWDJ ZDV UHPRYHG E\ 7(9 SURWHDVH OHDYLQJ WKH
HQJLQHHUHG.S'VE$ZLWKWZRDGGLWLRQDODPLQRDFLGV6±DQG
1 DW WKH1WHUPLQXV $ ILQDO VL]HH[FOXVLRQ FKURPDWRJUDSK\
VWHS XVLQJ D 6XSHUGH[ FROXPQ *( +HDOWKFDUH 86$
\LHOGHG KLJKO\ SXULILHG .S'VE$ DV MXGJHG E\ 6'63$*(
2[LGL]HG RU UHGXFHG .S'VE$ ZDV SUHSDUHG XVLQJ D IROG
PRODU H[FHVV RI FRSSHU,,SKHQDQWKUROLQH RU '77
UHVSHFWLYHO\2[LGL]LQJUHGXFLQJ DJHQWZDV WKHQ UHPRYHGDQG
WKH SURWHLQ EXIIHUH[FKDQJHG LQWR  P0 +(3(6 S+  LQ
RQH VWHS XVLQJ *( 6HSKDGH[ GHVDOWLQJ UHVLQ IRU
FU\VWDOOL]DWLRQDQGELRFKHPLFDOH[SHULPHQWV
3UHSDUDWLRQ RI ( FROL 'VE$ &$$ 6 HQWHULFD
7\SKLPXULXP'VE$$$%DQG(FROL'VE&$$$
ODFNLQJWKHSHULSODVPLFOHDGHUVLJQDOZHUHSXULILHGDVGHVFULEHG
IRU .S'VE$ )RU SHSWLGH R[LGDWLRQ H[SHULPHQWV( FROL 'VE%
$$& PHPEUDQH H[WUDFWV ZHUH SUHSDUHG DV GHVFULEHG
SUHYLRXVO\>@DQGUHVXVSHQGHGLQSKRVSKDWHEXIIHUHGVDOLQH
3%6  P0 1D&O  P0 .&O 1D+32  P0 DQG
.+32S+FRQWDLQLQJJO\FHURO
.S'VE$&RPSOHPHQWDWLRQRI(F'VE$
7KHDELOLW\RI.S'VE$WRUHVFXHQRQPRWLOH(FROLGVE$QXOO
-&% DQG GVE$GVE% GRXEOHQXOO -&% VWUDLQV ZDV
DVVHVVHG LQ D FHOOVZDUPLQJ DVVD\ DV GHVFULEHG SUHYLRXVO\
>@ 7KH PDWXUH .S'VE$ FRGLQJ VHTXHQFH ZDV FORQHG LQWR
S%$' XQGHU DQ DUDELQRVH LQGXFLEOH SURPRWRU ZLWK WKH
(F'VE$ SHULSODVPLF VLJQDO VHTXHQFH $ ZLOGW\SH (F'VE$
FORQHG LQWR S%$' YHFWRU ZDV XVHG DV D SRVLWLYH FRQWURO
&RPSDUDWLYH$QDO\VLVRI.OHEVLHOODSQHXPRQLDH'VE$
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1RQPRWLOH( FROL GVE$ GHILFLHQW -&% RU GVE$  GVE%
GRXEOHPXWDQW -&% >@ FHOOV [ WUDQVIRUPHG ZLWK D
.S'VE$ RU (F'VE$ S%$' LQGXFLEOH YHFWRU ZHUH VSRWWHG
RQWRWKHFHQWHURIDVRIW0PLQLPDODJDUSODWHFRQWDLQLQJ
PJP/ RI HDFK DPLQR DFLG H[FHSW /F\VWHLQH 3ODWHV ZHUH
LQFXEDWHG DW  & DQG PRWLOLW\ RI FHOOV PRQLWRUHG XVLQJ D
0ROHFXODU ,PDJHU *HO 'RF V\VWHP IURP %,25$' &$
86$DIWHU  K&RPSOHPHQWDWLRQH[SHULPHQWVZHUH
UHSHDWHGDVELRORJLFDOWULSOLFDWHV
.S'VE$'LVXOILGH5HGXFWDVH$FWLYLW\
8QGHU PLOG UHGXFLQJ FRQGLWLRQV 'VE$ SURWHLQV FDQ UHGXFH
WKH LQWHUPROHFXODU GLVXOILGH ERQGV IRUPHG EHWZHHQ LQVXOLQ
FKDLQV$DQG%>@7KHUDWHRIGLVXOILGHERQGUHGXFWLRQFDQEH
VSHFWURVFRSLFDOO\IROORZHGDW2'QPE\DQLQFUHDVHLQWXUELGLW\
UHVXOWLQJ IURPSURGXFWLRQRI WKH LQVROXEOH LQVXOLQFKDLQ% >@
6DPSOHVZHUHSUHSDUHG LQFPFXYHWWHVFRQWDLQLQJȝ0RI
SURWHLQ .S'VE$ (F'VE$ RU (F'VE&  P0 '77 DQG 
P0('7$ LQP01D+32 1D+32 WLWUDWHG WRS+
&DWDO\VLV ZDV LQLWLDWHG E\ WKH DGGLWLRQ RI  P0 LQVXOLQ
, 6LJPD$OGULFK $XVWUDOLD WR WKH VDPSOH PL[WXUH 7KH
DVVD\ZDVUHSHDWHGWKUHHWLPHVDQGGDWDZHUHSORWWHGVKRZLQJ
VWDQGDUGGHYLDWLRQV
0HDVXUHPHQWRI.S'VE$5HGR[3RWHQWLDO
7KH VWDQGDUG UHGR[ SRWHQWLDO RI .S'VE$ ZDV PHDVXUHG
XVLQJ LWV LQWULQVLF WU\SWRSKDQ IOXRUHVFHQFH DV GHVFULEHG
SUHYLRXVO\IRU(F'VE$>@2[LGL]HG.S'VE$ZDVLQFXEDWHGIRU
KDW&LQGHJDVVHGP01D+321D+32EXIIHU
S+   P0 ('7$ . FRQWDLQLQJ  P0 R[LGL]HG
JOXWDWKLRQH *66* DQG YDU\LQJ FRQFHQWUDWLRQV RI UHGXFHG
JOXWDWKLRQH *6+ ± P0 .S'VE$  / IURP HDFK
UHGR[ FRQGLWLRQZDVGLVSHQVHG LQWR D ZHOO SODWH 733$*
6ZLW]HUODQG  DQG WU\SWRSKDQ IOXRUHVFHQFH ZDV
PHDVXUHGH[FLWDWLRQDWQPHPLVVLRQVHWWRQPXVLQJ
D PLFURSODWH UHDGHU 6\QHUJ\ + DQG *HQ  VRIWZDUH
%LRWHN 86$ 'DWD ZHUH QRUPDOL]HG DQG WKH UHGR[ SRWHQWLDO
ZDV FDOFXODWHG DV GHVFULEHG IRU (F'VE$ >@ ,Q EULHI WKH
HTXLOLEULXPFRQVWDQW.HTZDVFDOFXODWHGXVLQJWKHHTXDWLRQ< 
>*6+@  >*66+@.HT  >*6+@  >*66+@ ZKHUH < LV WKH
IUDFWLRQ RI UHGXFHGSURWHLQ DW HTXLOLEULXP7KH UHGR[ SRWHQWLDO
IRU.S'VE$ZDVFDOFXODWHGIURPWKH1HUQVWHTXDWLRQ(¶.S'VE$ 
(¶*6+*66+57Q)OQ.HTZKHUH(¶*6+*66+ P95LVWKH
LGHDO JDV FRQVWDQW  -.PRO 7 LV WKH DEVROXWH
WHPSHUDWXUHLQ.QLVWKHQXPEHURIHOHFWURQVWUDQVIHUUHGQ 
) LV WKH)DUDGD\FRQVWDQW[&PRODQG.HT LV WKH
HTXLOLEULXP FRQVWDQW GHULYHG IURP WKH ELQGLQJ HTXDWLRQ $OO
PHDVXUHPHQWV ZHUH SHUIRUPHG DV ELRORJLFDO WULSOLFDWHV 7KH
JUDSKVKRZVDSORWRI WKHDYHUDJHYDOXHV LQFOXGLQJHUURUEDUV
UHSUHVHQWLQJWKHVWDQGDUGGHYLDWLRQIRUWKHUHSOLFDWHV
.S'VE$7KLRODWH$QLRQS.D'HWHUPLQDWLRQ
7KHS+GHSHQGHQWDEVRUEDQFHRIWKHFDWDO\WLFWKLRODWHDQLRQ
RI .S'VE$ ZDV IROORZHG DW  QP >@ XVLQJ D &$5< 
899,6 VSHFWURSKRWRPHWHU $JLOHQW 7HFKQRORJLHV 86$ 7KH
S+WLWUDWLRQPHDVXUHPHQWVRIR[LGL]HGRUUHGXFHG.S'VE$
ȝ0 LQ  P/ FRPSRVLWH EXIIHU  P0 7ULV  P0 VRGLXP
FLWUDWH P0.+32 P0.+32 P0.&O DQG
P0('7$ZHUHFRQGXFWHGDW&$EVRUEDQFHȜ DQG
 QP ZDV PHDVXUHG EHWZHHQ S+  DQG  LQ 
LQFUHPHQWV 7KH S.D YDOXH ZDV FDOFXODWHG IURP WKH ILWWHG
FXUYHV RI WKUHH UHSOLFDWHV XVLQJ WKH +HQGHUVRQ+DVVHOEDOFK
HTXDWLRQS+ S.DORJ>$»$@UHG»>$»$@R[LG
([SHULPHQWVZHUH UHSHDWHG DW OHDVW WKUHH WLPHV 3ORWWHG GDWD
UHSUHVHQW DYHUDJH YDOXHV DQG HUURU EDUV UHSUHVHQW WKH
VWDQGDUGGHYLDWLRQVDFURVVWKHUHSOLFDWHV
5HODWLYH6WDELOLW\RI2[LGL]HGDQG5HGXFHG)RUPVRI
'VE$(Q]\PHV
7HPSHUDWXUHLQGXFHG XQIROGLQJ RI QDWLYH 6H'VE$ DQG
.S'VE$ZDVGHWHUPLQHGDVGHVFULEHGSUHYLRXVO\ >@XVLQJD
-DVFR-FLUFXODUGLFKURLVP&'VSHFWURSRODULPHWHU-DVFR
86$ 7KH UHGR[ VWDWH RI WKH SURWHLQ ZDV FRQILUPHG XVLQJ
(OOPDQ¶VUHDJHQW>@7KHODUJHVWGLIIHUHQFHLQPRODUHOOLSWLFLW\
IRUR[LGL]HGRUUHGXFHGHQ]\PHVZDVFDOFXODWHGIURPLQLWLDOIDU
89&'VSHFWUDIURPQPWRQPUHFRUGHGDW&DQG
 & UHVSHFWLYHO\ 7KH XQIROGLQJ RI R[LGL]HG DQG UHGXFHG
SURWHLQ 6H'VE$R[    QP 6H'VE$UHG    QP DQG
.S'VE$R[ QP.S'VE$UHG QPZDVPRQLWRUHGDW
DKHDWUDWHRI.PLQIURP.WR.LQDPPTXDUW]
FXYHWWH$OOPHDVXUHPHQWVZHUHFDUULHGRXWZLWK0SURWHLQ
LQ  P0 1D+32  1D+32  P0 ('7$ DW S+ 
6DPSOHV IRUPHDVXUHPHQWRI UHGXFHGHQ]\PHFRQWDLQHG
P0'775DZGDWDZHUHDQDO\]HGLQ3ULVPDQGILWWHGWRDWZR
VWDWH XQIROGLQJ PRGHO DV GHVFULEHG SUHYLRXVO\ >@ 7KH
VWDQGDUGGHYLDWLRQZDVPHDVXUHGIURPWKUHHUHSOLFDWHV
.S'VE$'LWKLRO2[LGDWLRQ$FWLYLW\
$ SHSWLGH &44*)'*7416&. ZLWK D 
WHWUDD]DF\FORGRGHFDQHWHWUDDFHWLFDFLG'27$JURXS
DPLGHFRXSOHG WR WKH 1WHUPLQXV DQG D PHWK\OFRXPDULQ
DPLGHFRXSOHG WR WKH İDPLQR JURXS RI WKH &WHUPLQDO O\VLQH
ZDV SXUFKDVHG IURP $QD6SHF )UHPRQW &$ /\RSKLOL]HG
SHSWLGH ZDV UHVXVSHQGHG LQ  P0 LPLGD]ROH S+  DW D
FRQFHQWUDWLRQ RI  P0 (XURSLXP WULIOXRURPHWKDQHVXOIRQDWH
6LJPD$OGULFK$XVWUDOLDVROXWLRQP0ZDVDGGHGWRWKH
SHSWLGHDWDPRODUUDWLRRIDQGLQFXEDWHGIRUPLQDWURRP
WHPSHUDWXUHWRDOORZHXURSLXPFKHODWLRQ7KHSHSWLGHVROXWLRQ
ZDV WKHQ LPPHGLDWHO\DOLTXRWHG IODVK IUR]HQ LQ OLTXLGQLWURJHQ
DQGVWRUHGDW&$Q LQFUHDVH LQIOXRUHVFHQFHRFFXUVXSRQ
R[LGDWLRQ RI WKH SHSWLGH F\VWHLQHV WR IRUP D GLVXOILGH 7KXV
IOXRUHVFHQFH FDQ EH XVHG WR PRQLWRU WKH FDSDFLW\ RI 'VE$
HQ]\PHVWRFDWDO\VHGLWKLROR[LGDWLRQ
$VVD\VZHUHFRQGXFWHGXVLQJD6\QHUJ\+PXOWLPRGHSODWH
UHDGHU%LR7HN86$ZLWKWKHH[FLWDWLRQZDYHOHQJWKVHWWR
QP DQG HPLVVLRQ WR  QP $  ȝV GHOD\ EHIRUH UHDGLQJ
DQG  ȝV UHDGLQJ WLPH ZHUH XVHG IRU WLPHUHVROYHG
IOXRUHVFHQFH 7KH DVVD\ ZDV SHUIRUPHG LQ D ZKLWH ZHOO
SODWH3HUNLQ(OPHU2SWL3ODWH3DUW7KHEXIIHU
FRQVLVWHGRIP00(6P01D&ODQGP0('7$DWS+
 7KH UHDFWLRQ FRQVLVWHG RI D  ȝ/ VROXWLRQ LQ HDFKZHOO
FRQWDLQLQJ  Q0 (F'VE$ .S'VE$ RU 6H'VE$  ȝ0
(F'VE% FUXGH PHPEUDQH H[WUDFWV FRQWDLQLQJ XELTXLQRQH
DQGȝ0SHSWLGHVXEVWUDWHDGGHG ODVW WR LQLWLDWH WKHUHDFWLRQ
6DPSOHV FRQWDLQLQJ EXIIHU DQG 'VE$ RU EXIIHU DQG SHSWLGH
ZHUH XVHG DV FRQWUROV 'DWD ZHUH PHDVXUHG IRU WKUHH
&RPSDUDWLYH$QDO\VLVRI.OHEVLHOODSQHXPRQLDH'VE$
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UHSOLFDWHV DQG DUH SUHVHQWHG DV PHDQ YDOXHV ZLWK WKH
VWDQGDUGHUURURIWKHPHDQLQGLFDWHGE\HUURUEDUV
.S'VE$&U\VWDOOL]DWLRQDQG&U\VWDO6WUXFWXUH
'HWHUPLQDWLRQ
$IWHU LQLWLDOVFUHHQLQJXVLQJWKH8452&;IDFLOLWLHVFU\VWDOV
RI UHGXFHG .S'VE$ ZHUH JURZQ DW  & LQ 9';P ZHOO
SODWHV +DPSWRQ 5HVHDUFK XVLQJ WKH KDQJLQJGURS YDSRU
GLIIXVLRQPHWKRG6FUHHQLQJSODWHVZHUHLPDJHGDQGLQFXEDWHG
LQ D 5RFN,PDJHU  )RUPXODWUL[ 0$ 86$ 'URSV
FRQWDLQHGȝ/RIPJP/UHGXFHG.S'VE$DQGȝ/RI
FU\VWDOOL]DWLRQVROXWLRQ0VXFFLQLFDFLGS+ZY
SRO\HWK\OHQH JO\FRO  DQG   YY PHWK\O
SHQWDQHGLRO )RU GLIIUDFWLRQ GDWDPHDVXUHPHQW FU\VWDOVZHUH
IUR]HQ LQ OLTXLG QLWURJHQ ZLWKRXW DGGLWLRQDO FU\RSURWHFWDQW
'LIIUDFWLRQ GDWDZHUHPHDVXUHG DW WKH$XVWUDOLDQ6\QFKURWURQ
PLFURIRFXV 0; EHDPOLQH XVLQJ %OXH,FH VRIWZDUH >@
5HIOHFWLRQV ZHUH SURFHVVHG LQ 0RVIOP >@ DQG ;'6 >@
DQDO\]HGDQGFRQYHUWHGWR07=LQ3RLQWOHVV>@DQGVFDOHGLQ
6&$/$>@3KDVHVZHUHREWDLQHGE\PROHFXODUUHSODFHPHQW
05XVLQJ3+$6(5>@ZLWK(F'VE$DVWHPSODWH3'%FRGH
'6%  7KH LQLWLDO PRGHO ZDV LPSURYHG E\ LWHUDWLYH PRGHO
EXLOGLQJ LQ &227 >@ DQG UHILQHPHQW LQ 3+(1,; >@
+RZHYHUWKHSURJUHVVRIUHILQHPHQWZDVVWDOOHGZLWKDKLJK5
IDFWRU5IUHH RI      'LIIUDFWLRQ GDWD DQDO\VLV LQ
3KHQL[[WULDJH LQGLFDWHG WKDW WKH FU\VWDO ZDV PHURKHGUDOO\
WZLQQHG ZLWK D WZLQQLQJ IUDFWLRQ RI  )XUWKHU UHILQHPHQW
F\FOHV ZHUH SHUIRUPHG XVLQJ WKH WZLQ WDUJHW IXQFWLRQ DV
LPSOHPHQWHG LQ 3+(1,; ZLWK WKH WZLQQLQJ RSHUDWRU KKNO
7ZR IROG QRQFU\VWDOORJUDSKLF V\PPHWU\ 1&6 LV SUHVHQW
ZKLFKGRHVQRWDOLJQZLWKVSDFHJURXSD[HVWKRXJK1&6ZDV
QRW XVHG DW DQ\ VWDJH RI UHILQHPHQW 7KH UHILQHPHQW ILQDOO\
FRQYHUJHGDIWHUVHYHUDO7/6UHILQHPHQWF\FOHV1RDWRPVZHUH
PRGHOHG LQWR DGGLWLRQDOO\ VSKHULFDO GHQVLW\ ORFDWHG EHWZHHQ
FKDLQ'/DQGFKDLQ%7EHFDXVHLWZDVQRWREYLRXV
ZKDWZDVERXQG7KHVWHUHRFKHPLFDOTXDOLW\RIWKHILQDOPRGHO
ZDV DVVHVVHG XVLQJ0RO3URELW\ >@ $ VXPPDU\ RI WKH GDWD
SURFHVVLQJDQGUHILQHPHQWVWDWLVWLFVDUHSURYLGHGLQ7DEOH
0ROHFXODU ILJXUHV ZHUH JHQHUDWHG LQ 3\02/ 7KH 3\02/
0ROHFXODU*UDSKLFV6\VWHP9HUVLRQ6FKU|GLQJHU//&
DQGILJXUHVRI WKHHOHFWURVWDWLFSRWHQWLDOZHUHJHQHUDWHGXVLQJ
$3%6 >@ 7KH VXUIDFH LQFOXGLQJ WKH SURSRUWLRQ RI FDUERQ
DWRPV OLQLQJ WKH K\GURSKRELF JURRYH LQ .S'VE$ ZDV
FDOFXODWHG XVLQJ WKH&DVW3 VHUYHU >@ E\ DYHUDJLQJ RYHU DOO
VL[ PROHFXOHV ZLWKLQ WKH DV\PPHWULF XQLW 506' FDOFXODWLRQV
DQG VWUXFWXUDO DOLJQPHQWV ZHUH FRQGXFWHG XVLQJ 3\02/ DV
ZHOODV)$7&$7>@
1056WUXFWXUH'HWHUPLQDWLRQRI2[LGL]HG.S'VE$
$VDPSOHRIXQLIRUPO\&1 ODEHOHGR[LGL]HG.S'VE$
P0ZDVSUHSDUHGLQP00(6S++2DQG
+2105H[SHULPHQWVZHUHFRQGXFWHGDW.RQHLWKHU
 0+] RU  0+] VSHFWURPHWHUV HTXLSSHG ZLWK
FU\RJHQLFDOO\ FRROHG SUREHV $OO VSHFWUD ZHUH DFTXLUHG ZLWK
VWDQGDUG SXOVH VHTXHQFHV DQG SURFHVVHGXVLQJ72363,1
%UXNHU %LR6SLQ +1 1 &Į &Į &ȕ &ȕ SHDN OLVWV ZHUH
JHQHUDWHG PDQXDOO\ LQ &$5$ XVLQJ ' >1+@+64& '
+1&$'&%&$&21+DQG'+1&$&%VSHFWUDDQGXVHG
DVWKHLQSXWIRUDXWRPDWHGEDFNERQHDVVLJQPHQWVXVLQJ81,2
0$7&+ 7KHVH DVVLJQPHQWV ZHUH UHILQHG PDQXDOO\ DQG
H[WHQGHG XVLQJ ' 1UHVROYHG >++@12(6< +ȕ +Į
DVVLJQPHQWV ZHUH REWDLQHG XVLQJ D ' +%+$&%&$&21+
VSHFWUXP+11&ĮDQG&ȕDVVLJQPHQWV WRJHWKHUZLWK+ȕ+Į
ZHUH SURYLGHG DV LQSXW IRU 81,2$7126$6&$1 IRU
DXWRPDWHG VLGHFKDLQ DVVLJQPHQWV XVLQJ ' 1 &DOL  DQG
&DUR  UHVROYHG >++@12(6<GDWDVHWV >@8SSHU OLPLWV
IRU GLVWDQFH UHVWUDLQWV XVHG LQ VWUXFWXUH FDOFXODWLRQV ZHUH
DXWRPDWLFDOO\ JHQHUDWHG IURP 12(6< GDWDVHWV XVLQJ 81,2
$7126&$1',' DQG WKH VWUXFWXUH RI R[LGL]HG .S'VE$ ZDV
GHWHUPLQHG XVLQJ WKH WRUVLRQ DQJOH G\QDPLFV SURJUDP
&<$1$>@&RQIRUPHUVZLWKORZHVW&<$1$WDUJHWIXQFWLRQ
YDOXHV ZHUH HQHUJ\ PLQLPL]HG XVLQJ 23$/S DQG YDOLGDWHG
XVLQJ VWUXFWXUH YDOLGDWLRQ WRROV KWWSZZZSGERUJ DQG KWWS
ZZZQLKVHUYHUPELXFODHGX 6WUXFWXUHV ZHUH LQVSHFWHG DQG
7DEOH;UD\GDWDPHDVXUHPHQWDQGUHILQHPHQWVWDWLVWLFV
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E WK 0ROSURELW\ >@ SHUFHQWLOH LV WKH EHVW DPRQJ VWUXFWXUHV RI FRPSDUDEOH
UHVROXWLRQ WK SHUFHQWLOH LV WKH ZRUVW 7KH QXPEHU RI VWUXFWXUHV LQFOXGHG LQ WKH
FRPSDULVRQLVJLYHQLQSDUHQWKHVHVZLWKLQVTXDUHEUDFNHWV
GRLMRXUQDOSRQHW
&RPSDUDWLYH$QDO\VLVRI.OHEVLHOODSQHXPRQLDH'VE$
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DQDO\]HG ZLWK 02/02/ >@ 7DEOH  VXPPDUL]HV WKH 105
VWDWLVWLFV
%LQGLQJ$IILQLW\RI'VE$,QWHUDFWLQJ3HSWLGHV
&U\VWDOVWUXFWXUHVRI WKH(F'VE$(F'VE%FRPSOH[ UHYHDOHG
WKDW WKH 3 ORRS UHJLRQ RI (F'VE% LQWHUDFWV ZLWK (F'VE$
>@7ZRSHSWLGHVGHULYHG IURP WKH3 ORRSVHTXHQFHVRI
(F'VE%DQG.S'VE%(F±363)$7&'DQG.S±363)47&'
ZHUH V\QWKHVL]HG E\ VROLGSKDVH PHWKRGV XVLQJ )PRF
GHSURWHFWLRQRQ ULQNDPLGH0%+$UHVLQ OHDGLQJ WR&WHUPLQDO
DPLGDWLRQ DQG FDSSHG E\ 1WHUPLQDO DFHW\ODWLRQ $PLGDWLRQ
DQG DFHW\ODWLRQ HQVXUH WKDW WKHUH DUH QR FKDUJHV RQ WKH
SHSWLGH WHUPLQL DV WKHVH DUH QRW SUHVHQW LQ WKH QDWLYH 'VE%
7DEOH  3DUDPHWHUV IRU VWUXFWXUH FDOFXODWLRQ DQG
FKDUDFWHUL]DWLRQ RI  ORZHVW HQHUJ\ PLQLPL]HG 105
FRQIRUPHUVRIR[LGLVHG.S'VE$ņ
4XDQWLW\D 9DOXH
12(XSSHUGLVWDQFHOLPLWV 
LQWUDUHVLGXDO 
VKRUWUDQJH 
PHGLXPUDQJH 
ORQJUDQJH 
5HVLGXDOWDUJHWIXQFWLRQYDOXH>c@ 
5HVLGXDO12(YLRODWLRQV 
QXPEHUc 
PD[LPXP>c@ 
5HVLGXDOGLKHGUDODQJOHYLRODWLRQV 
QXPEHU 
PD[LPXP>@ 
$0%(5HQHUJLHV>NFDOPRO@ 
WRWDO 
YDQGHU:DDOV 
HOHFWURVWDWLF 
506'IURPPHDQFRRUGLQDWHVE>c@ 
)RUZHOOGHILQHGUHJLRQV 
EDFNERQH 
KHDY\DWRPV 
)RU75;GRPDLQ 
EDFNERQH 
KHDY\DWRPV 
)RUKHOLFDOGRPDLQ 
EDFNERQH 
KHDY\DWRPV 
5DPDFKDQGUDQSORWVWDWLVWLFVF 
PRVWIDYRXUHGUHJLRQV>@ 
DGGLWLRQDODOORZHGUHJLRQV>@ 
JHQHURXVO\DOORZHGUHJLRQV>@ 
GLVDOORZHGUHJLRQV>@ 
D ([FHSW IRU WKH WRS ILYH HQWULHV WKRVH UHODWLQJ WR 12(V DYHUDJH YDOXHV DQG
VWDQGDUGGHYLDWLRQVIRUWKHHQHUJ\PLQLPL]HGFRQIRUPHUVDUHJLYHQ7KHWRSVL[
HQWULHV UHSUHVHQW WKH RXWSXW JHQHUDWHG LQ WKH ILQDO F\FOH RI WKH 81,2$7126
&$1','&<$1$ FDOFXODWLRQ E 7KH QXPEHUV LQ SDUHQWKHVHV LQGLFDWH WKH
UHVLGXHVIRUZKLFKWKH506'ZDVFDOFXODWHGF$VGHWHUPLQHGE\352&+(&.
GRLMRXUQDOSRQHW
ORRS VHTXHQFH %LQGLQJ DIILQLW\ ZDV PHDVXUHG XVLQJ D
0LFUR&DO$XWRL7& IURP *(+HDOWKFDUH 86$ DW  &
7KHVDPSOHFHOOZDVORDGHGZLWKȝ/RIȝ0.S'VE$RU
(F'VE$ LQP0+(3(6P01D&OS+DQG'062
  7KH SHSWLGH  P0 GLOXWHG LQ WKH VDPH EXIIHU ZDV
WLWUDWHGZLWKDQLQLWLDOLQMHFWLRQRIȝ/LQWR'VE$IROORZHGE\
 FRQVHFXWLYH LQMHFWLRQV  ȝ/ RIIVHW E\  V ZKLOH WKH
VROXWLRQZDVFRQVWDQWO\VWLUUHGUSP'DWDZHUHILWWHGWRD
VLQJOHVLWHELQGLQJPRGHOXVLQJ0LFUR&DO2ULJLQVRIWZDUH
2ULJLQ  65 Y ([SHULPHQWV ZHUH FRQGXFWHG LQ
WULSOLFDWH DQG DIILQLW\ DQG WKHUPRG\QDPLF SDUDPHWHUV DUH
UHSRUWHGDVPHDQVDQGVWDQGDUGGHYLDWLRQV7DEOH
&RPSDUDWLYH6HTXHQFHDQG6WUXFWXUDO$QDO\VHV
7KH VHTXHQFH FRQVHUYDWLRQ RI WHQ YLUXOHQFH IDFWRUV
SUHYLRXVO\ LGHQWLILHG >@ DV VXEVWUDWHV RI'VE$ZHUH DQDO\]HG
KHUH6HTXHQFHVIURPSXEOLVKHGDQGYDOLGDWHG'VE$VXEVWUDWH
YLUXOHQFH IDFWRUV ZHUH WDNHQ IURP WKH RULJLQDO OLWHUDWXUH DQG
XVHGWRVHDUFKWKHSXEOLFO\DYDLODEOH8QL3URWGDWDEDVH>@IRU
SRWHQWLDO KRPRORJXHV LQ( FROL6 HQWHULFD7\SKLPXULXP DQG
.SQHXPRQLDH0RVWRIWKHIDFWRUVZHUHRULJLQDOO\LGHQWLILHG
LQWKRVHWKUHHRUJDQLVPVH[FHSW<VF&DQG&DI0ZKLFKZHUH
LQLWLDOO\ UHSRUWHG LQ <HUVLQLD SHVWLV $ SURWHLQSURWHLQ %/$67
VHDUFK ZDV SHUIRUPHG XVLQJ WKH 8QL3URW EDFWHULDO JHQRPH
GDWDEDVH ZLWK D WKUHVKROG RI 3   8QOHVV VWDWHG
RWKHUZLVH KRPRORJXHV ZHUH LGHQWLILHG LQ SDWKRJHQLF VWUDLQV
LH(FROL83(&2.+DQG(3(&2+ 2+
6 HQWHULFD 7\SKLPXULXP 6/ DQG QRQPRWLOH .
SQHXPRQLHDHKY.30*+178+.6HTXHQFH
LGHQWLW\ EHWZHHQ KRPRORJXHVZDV H[WUDFWHG IURP WKH8QL3URW
SURWHLQ%/$67UHVXOWV$OORWKHUVHTXHQFHDOLJQPHQWVUHSRUWHG
KHUHLQHJIRU7DEOHZHUHFRQGXFWHGXVLQJ&OXVWDO:>@
5HVXOWV
%LQGLQJ5HVLGXHVRI(F'VE$DUHFRQVHUYHGLQ6H'VE$
DQG'VE$VRI)LYH2WKHU(QWHUREDFWHULDFLDH
(F'VE$DQG6H'VE$VKDUHVHTXHQFHLGHQWLW\DQGERWK
KDYH EHHQ FKDUDFWHUL]HG SUHYLRXVO\ >@ 6H'VE$ FDQ
FRPSOHPHQW (F'VE$ >@ LQ D QXOO PXWDQW PRWLOLW\ DVVD\
LQGLFDWLQJ WKDW 6H'VE$ LV DEOH WR LQWHUDFW ZLWK WKH (F'VE$
ELQGLQJSDUWQHU(F'VE%DQGZLWKWKH(F'VE$VXEVWUDWH(FROL
)OJ, >@ %RWK DUH ZHDN GLVXOILGH UHGXFWDQWV LQ WKH VWDQGDUG
7DEOH  $IILQLW\ DQG HQWKDOS\ IRU 'VE%GHULYHG SHSWLGHV
ELQGLQJWR'VE$SURWHLQV
'VE$ 'VE%SHSWLGH 6WRLFKLRPHWU\ .Gȝ0 ǻ+NFDOPRO
(F'VE$ 363)$7&'   
 363)47&'   
.S'VE$ 363)$7&'   
 363)47&'   
 $SSDUHQW GLVVRFLDWLRQ FRQVWDQW .G DQG HQWKDOS\ RI ELQGLQJ ǻ+ DW  &
REWDLQHG IURP WKUHH LQGHSHQGHQW ,7& H[SHULPHQWV 6HH )LJXUH 6 IRU
UHSUHVHQWDWLYH,7&WUDFHV
GRLMRXUQDOSRQHW
&RPSDUDWLYH$QDO\VLVRI.OHEVLHOODSQHXPRQLDH'VE$
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LQVXOLQ UHGXFWLRQ DVVD\ IRU UHGR[ HQ]\PHV >@ %RWK DUH
VLPLODUO\ R[LGL]LQJ HQ]\PHV WKH UHGR[ SRWHQWLDOV RI (F'VE$
DQG 6H'VE$ DUH  DQG  P9 UHVSHFWLYHO\ >@
ZKHUHDVWKHUDQJHIRUDOO'VE$VLVWRP97DEOH,Q
ERWK (F'VE$ DQG 6H'VE$ WKH PHDVXUHG S.D RI WKH
QXFOHRSKLOLFF\VWHLQHLV>@WKRXJKYDOXHVYDU\DFURVVDOO
'VE$V IURP  WR  7DEOH  $OWKRXJK GLVXOILGH ERQGV
JHQHUDOO\ VWDELOL]H IROGHG SURWHLQV WKH GLVXOILGH IRUP RI 'VE$
HQ]\PHVLVGHVWDELOL]LQJ>@7KHPHOWLQJWHPSHUDWXUHVRIWKH
R[LGL]HG DQG UHGXFHG IRUPV RI (F'VE$ DQG 6H'VE$ DUH
DOPRVWLGHQWLFDOUHGXFHG.DQG.R[LGL]HG.DQG
 . UHVSHFWLYHO\ >@ )LJXUH 6 ZKHUHDV WKH UDQJH RI
PHOWLQJ WHPSHUDWXUHV DFURVV DOO 'VE$V YDULHV FRQVLGHUDEO\
7DEOH  ,PSRUWDQWO\ WKH FU\VWDO VWUXFWXUHV RI (F'VE$ DQG
6H'VE$FDQEHVXSHULPSRVHGZLWKDQ506'RIcIRU
&ĮDWRPVZKHUHDVDFURVVDOOVWUXFWXUDOO\FKDUDFWHUL]HG'VE$V
WKH506'ZLWK(F'VE$YDULHVIURPcWRcIRU
&ĮDWRPV7DEOH>@
7ZR FDWDO\WLFDOO\ UHOHYDQW (F'VE$ FRPSOH[ VWUXFWXUHV KDYH
EHHQ GHVFULEHG D FRPSOH[ EHWZHHQ (F'VE$ DQG (F'VE%
>@DQGRQHEHWZHHQ(F'VE$DQGDSHSWLGHVHJPHQWRI
6LJ$ DQ DXWRWUDQVSRUWHU SURWHLQ IURP 6KLJHOOD IOH[QHUL >@
$QDO\VLVRIWKHVHVWUXFWXUHVUHYHDOHGWKDWWKHELQGLQJLQWHUIDFH
FRPSULVHVWKH1WHUPLQDOUHJLRQVRIWKHDFWLYHVLWHKHOL[+DV
ZHOO DV ORRSV / WKH ILUVW RI WZR ORRSV FRQQHFWLQJ WKH
WKLRUHGR[LQDQGKHOLFDOGRPDLQV/ WKHVHFRQGRI WZR ORRSV
FRQQHFWLQJWKHWKLRUHGR[LQDQGKHOLFDOGRPDLQVDOVRUHIHUUHGWR
DVWKHFLV3URORRSDQG/+UHVLGXHVLQWKH ORRSSUHFHGLQJ
DQG DW WKH 1WHUPLQDO UHJLRQ RI KHOL[ + )LJXUH $ $
K\SRWKHVLVLVWKDW'VE$VVKDULQJRYHUDOOKLJKVHTXHQFHLGHQWLW\
ZLWK (F'VE$ DQG ZLWK KLJKO\ FRQVHUYHG ORRS OHQJWKV DQG
UHVLGXHVLQWKHVHUHJLRQVZLOOVKDUHVLPLODUELQGLQJDFWLYLWLHV$V
VKRZQ LQ )LJXUH % 6H'VE$ IDOOV LQWR WKLV FOXVWHU DV GRHV
6KLJHOOD IOH[QHUL 6I'VE$ 3 (QWHUREDFWHU FORDFDH
(Q'VE$(*/&LWUREDFWHUNRVHUL&N'VE$$$/DQG
&URQREDFWHUVDND]DNLL &V'VE$ ,('DQG.SQHXPRQLDH
.S'VE$ )LJXUH % 2I WKHVH WKH 'VE$ ZLWK ORZHVW
VHTXHQFHLGHQWLW\WR(F'VE$LV.S'VE$HQFRGHGE\DQ
LPSRUWDQW KXPDQ SDWKRJHQ UHVSRQVLEOH IRU PDQ\ DQWLELRWLF
UHVLVWDQWQRVRFRPLDOLQIHFWLRQV>@7RGHWHUPLQHZKHWKHU
.S'VE$ IDOOV ZLWKLQ WKH VDPH FODVV DV (F'VE$ ZH
LQYHVWLJDWHGLWVVWUXFWXUHVXUIDFHUHGR[DQGELQGLQJSURSHUWLHV
DQGFRPSDUHGWKHPZLWK(F'VE$
.S'VE$&RPSOHPHQWV(F'VE$LQYLYR
7KH(FROLSURWHLQ)OJ, LVUHTXLUHGIRU(FROLPRWLOLW\DQG LQ
WXUQ)OJ,UHTXLUHVWKH'6%PDFKLQHU\RI(FROLWRIXQFWLRQ)OJ,
IXQFWLRQ LV LPSDLUHG LQ ( FROL GVE$ GHILFLHQW -&% DQG
GVE$GVE% GRXEOHPXWDQW -&% VWUDLQV GXH WR WKH
DEVHQFHRI(F'VE$PHGLDWHGGLWKLROR[LGDVHDFWLYLW\>@$VD
FRQVHTXHQFHWKHVH(FROLVWUDLQVDUHQRQPRWLOH,QWULJXLQJO\
. SQHXPRQLDH LV QRQPRWLOH DQG GRHV QRW HQFRGH D )OJ,
KRPRORJXH:H WHVWHGZKHWKHU.S'VE$ZDVDEOH WR FDWDO\VH
GLVXOILGH ERQG IRUPDWLRQ RI ( FROL )OJ, XVLQJ DQ LQ YLYR
FRPSOHPHQWDWLRQVWUDWHJ\>@:HGHPRQVWUDWHGWKDW.S'VE$±
OLNH 6H'VE$ >@ ± FDQ IXOO\ UHVWRUH WKH PRWLOLW\ RI GVE$
GHILFLHQWVWUDLQVEXWQRWLQWKHGRXEOHGVE$GVE%PXWDQWFHOOV
)LJXUH 6 7KLV H[SHULPHQW VKRZV WKDW .S'VE$ LV DEOH WR
R[LGL]H )OJ, F\VWHLQHV DQG WKLV UHTXLUHV WKH SUHVHQFH RI
(F'VE%
6RPHGLVWDQWO\UHODWHG'VE$VGRQRWFRPSOHPHQW(F'VE$LQ
WKLV DVVD\ LQFOXGLQJ *UDPQHJDWLYH :ROEDFKLD SLSLHQWLV Į
'VE$ >@ DQG *UDPSRVLWLYH 6WDSK\ORFRFFXV DXUHXV 'VE$
>@ +RZHYHU UHVFXH RU SDUWLDO UHVFXH RI PRWLOLW\ KDV EHHQ
REVHUYHGIRUDZLGHUDQJHRI'VE$KRPRORJXHVVRPHVKDULQJ
TXLWHORZVHTXHQFHLGHQWLW\ZLWK(F'VE$VXFKDV9F'VE$
 3D'VE$   DQG 1P'VE$   >@
&RQVHTXHQWO\(F'VE$FRPSOHPHQWDWLRQPD\QRWEHDVXLWDEOH
JXLGHIRUFDWHJRUL]LQJ'VE$HQ]\PHVLQWRGLVWLQFWFODVVHV
.S'VE$KDVUHGR[SURSHUWLHVDOPRVWLGHQWLFDOWRWKRVH
RI(F'VE$DQG6H'VE$
(F'VE$ H[KLELWV ZHDN LQVXOLQ UHGXFWDVH DFWLYLW\ LQ WKH
SUHVHQFH RI GLWKLRWKUHLWRO >@ ZKHUHDV WKH ( FROL GLVXOILGH
LVRPHUDVH(F'VE&LVKLJKO\DFWLYH LQWKLVDVVD\5HGXFWLRQRI
WKHLQWHUPROHFXODUGLVXOILGHERQGVEHWZHHQWKH$DQG%FKDLQV
RILQVXOLQUHVXOWVLQSUHFLSLWDWLRQRIWKH%FKDLQDQGWKLVFDQEH
PRQLWRUHG E\ PHDVXULQJ WKH 2'QP :H IRXQG WKDW SXULILHG
UHFRPELQDQW .S'VE$ KDV WKH VDPH ZHDN LQVXOLQ UHGXFWDVH
DFWLYLW\DV(F'VE$)LJXUH$DQG6H'VE$ >@7KHDFWLYLW\
RI RWKHU FKDUDFWHUL]HG 'VE$ HQ]\PHV YDULHV 1P'VE$ IRU
H[DPSOHKDVDPXFKZHDNHUDFWLYLW\WKDQWKDWRI(F'VE$>@
DQG 'VE$ IURP 0\FREDFWHULXP WXEHUFXORVLV 0WE'VE$ LV
LQDFWLYH LQ WKLV DVVD\ >@ ,Q FRQWUDVW 7FS* 9F'VE$ IURP
9LEULR FKROHUDH FDWDO\VHV LQVXOLQ UHGXFWLRQ PXFK IDVWHU WKDQ
(F'VE$>@
:HQH[WGHWHUPLQHGWKHVWDQGDUGUHGR[SRWHQWLDORI.S'VE$
UHODWLYH WR JOXWDWKLRQH >*6+@*66* (¶    9 7KH
HTXLOLEULXP FRQVWDQW IRU .S'VE$ ZDV HVWLPDWHG IURP WKH
>*6+@*66*WLWUDWLRQH[SHULPHQWWREH0)LJXUH
%ZKLFK FRUUHVSRQGV WR D VWDQGDUG UHGR[SRWHQWLDO RI 
P9 7KLV YDOXH IDOOV YHU\ FORVH WR WKH YDOXHV UHSRUWHG IRU
(F'VE$P9>@DQG6H'VE$P9>@FRQVLGHULQJ
WKH ZLGH UDQJH RI YDOXHV UHSRUWHG DFURVV DOO 'VE$ HQ]\PHV
WRP9>@
7KHS.DYDOXHRI WKHQXFOHRSKLOLFF\VWHLQH LQ WKHDFWLYHVLWH
&;;& PRWLI LV D NH\ GHWHUPLQDQW RI 'VE$ UHDFWLYLW\ WRZDUGV
VXEVWUDWH SURWHLQV :H PHDVXUHG WKH S.D YDOXH IRU WKH
QXFOHRSKLOLF F\VWHLQH RI .S'VE$ XVLQJ S+GHSHQGHQW WKLRODWH
DEVRUEDQFH DW Ȝ    QP )LJXUH & 7KH S.D&\V IRU
.S'VE$ZDVIRXQGWREHQHDUO\LGHQWLFDOWRWKDWRI(F'VE$
DQG6H'VE$FRPSDUHGZLWKWKHREVHUYHGUDQJHIRURWKHU
'VE$V
:HDOVRFRQILUPHG WKDW UHGXFHG.S'VE$ 7PUHG 
. LVPRUH VWDEOH WKDQR[LGL]HG.S'VE$ 7PR[   .
)LJXUH ' 7KH PHOWLQJ WHPSHUDWXUHV IDOO EHWZHHQ YDOXHV
UHSRUWHGSUHYLRXVO\IRU(F'VE$7PUHG.7PR[
  . >@ DQG WKRVH IRU 6H'VE$ 7PUHG    . 7PR[
   . UHSRUWHG KHUH )LJXUH 6 $JDLQ WKH UDQJH
UHSRUWHG IRU DOO 'VE$V LV PXFK ZLGHU 7PUHG   7PR[
.>@
:HWKHQWHVWHGWKHGLWKLROR[LGDVHDFWLYLW\RI.S'VE$XVLQJD
IOXRUHVFHQWO\ ODEHOHG SHSWLGH VXEVWUDWH 7KH DFWLYLW\ ZDV
PRQLWRUHG E\ WKH LQFUHDVH LQ HXURSLXP IOXRUHVFHQFH UHVXOWLQJ
IURP F\FOL]DWLRQ RI WKH VXEVWUDWH SHSWLGH WKURXJK IRUPDWLRQ RI
DQ LQWUDPROHFXODU GLVXOILGH ERQG ,Q WKH SUHVHQFH RI (F'VE%
&RPSDUDWLYH$QDO\VLVRI.OHEVLHOODSQHXPRQLDH'VE$
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ZH IRXQG WKDW WKH UDWH IRU .S'VE$ DQG 6H'VE$ FDWDO\]HG
GLVXOILGHERQGIRUPDWLRQZDVDOPRVWLQGLVWLQJXLVKDEOHIURPWKDW
RI (F'VE$ PHDVXUHG DW WKH VDPH FRQFHQWUDWLRQ RI HQ]\PH
)LJXUH7KLVUHVXOWVXJJHVWV WKDW.S'VE$DQG6H'VE$ LV
DEOH WR LQWHUDFW LQ WKH VDPHZD\DV(F'VE$ZLWK WKHSHSWLGH
VXEVWUDWH DQG ZLWK (F'VE% 7FS* KDV D VLPLODU DFWLYLW\ WR
(F'VE$LQWKLVDVVD\>@ZKHUHDV0WE'VE$LVLQDFWLYHLQWKH
SUHVHQFHRI(F'VE%>@
&U\VWDOVWUXFWXUHRIUHGXFHG.S'VE$
:H GHWHUPLQHG WKH FU\VWDO VWUXFWXUH RI UHGXFHG .S'VE$
3'%0&8DW c UHVROXWLRQE\PROHFXODU UHSODFHPHQW
XVLQJ (F'VE$ DV WKH WHPSODWH $V H[SHFWHG WKH VWUXFWXUH LV
YHU\VLPLODUWRWKDWRI(F'VE$)LJXUH$7KHDV\PPHWULFXQLW
FRQWDLQVVL[.S'VE$PROHFXOHVHDFKDGRSWLQJWKHW\SLFDO'VE$
IROG 6WUXFWXUDO VXSHUSRVLWLRQ RI WKHVH VL[ LQGHSHQGHQW FRSLHV
\LHOGHGDURRWPHDQVTXDUHGHYLDWLRQ506'cIRU
&ĮDWRPVEHWZHHQUHVLGXHV*O\9DO/LNHZLVHVWUXFWXUDO
)LJXUH&RPSDULVRQRI(F'VE$DQG6H'VE$$6WUXFWXUDOVXSHUSRVLWLRQRI(F'VE$PDJHQWD3'%LG)9.DQG6H'VE$
EOXH 3'% ,G /6 1 DQG&WHUPLQL KHOLFHV +   DQG VWUDQGV ȕ DUH LQGLFDWHG ,Q DGGLWLRQ VXUIDFH ORRSV / ± /
SUHGLFWHGWREHLQYROYHGLQELQGLQJ(F'VE%SHULSODVPLFORRS3RUVXEVWUDWHDUHODEHOHGLQUHG$FWLYHVLWHF\VWHLQHVDUHVKRZQDV
RUDQJHVSKHUHVDQGWKHFLV3URPRWLI LQ WKH/ ORRS LV LQGLFDWHGE\D\HOORZVWDU%6HTXHQFHVRI(F'VE$ORRSVWKDWELQG'VE%
EOXHUHGRU6LJ$VXEVWUDWHEOXH+RPRORJXHVZLWKKLJKO\FRQVHUYHGORRSVHTXHQFHVDUHVKRZQ6IOH[QHUL6I'VE$36
HQWHULFD 7\SKLPXULXP 6H'VE$(:(& NRVHUL &N'VE$ $$/( FORDFDH (Q'VE$ (*/& VDND]DNLL &V'VE$
,('DQG.SQHXPRQLDH.S'VE$%;=-&RQVHUYHGUHVLGXHVDUHVKRZQLQJUH\DQGYDULDEOHUHVLGXHVLQEODFN
GRLMRXUQDOSRQHJ
&RPSDUDWLYH$QDO\VLVRI.OHEVLHOODSQHXPRQLDH'VE$
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DOLJQPHQWRI.S'VE$ZLWK(F'VE$)9.cPROHFXOH%
DQG6H'VE$/6cJDYH506'YDOXHVcIRUWKH
LGHQWLFDO UDQJH RI  &Į DWRPV %\ FRPSDULVRQ KLJK
UHVROXWLRQ FU\VWDO VWUXFWXUHV RI GLVWDQWO\ UHODWHG 'VE$V KDYH
PXFKKLJKHU506'VFRYHULQJDVPDOOHUUDQJHRIHTXLYDOHQW&Į
DWRPV HJ 3D'VE$ 3'% FRGH + DQG (F'VE$ )9.
PROHFXOH%&ĮDWRPV506'RIc>@7KHVHKLJKHU
YDOXHVDUHD FRQVHTXHQFHRI VWUXFWXUDO GHYLDWLRQV LQFOXGLQJD
WUXQFDWHGKHOL[+DQGDVKRUWHQHGK\GURSKRELFJURRYH
7KH VWUXFWXUH RI WKH FDWDO\WLF VLWH RI .S'VE$ LV VWULFWO\
FRQVHUYHGZLWKWKDWRI(F'VE$FRPSULVLQJWKHDFWLYHVLWHPRWLI
&\V3UR+LV&\V ORFDWHG DW WKH1WHUPLQDO HQG RI KHOL[+
DQG WKHDGMDFHQWFLV3UR 9DO3UR / ORRS )LJXUH%7KH
F\VWHLQH UHVLGXHV &\V DQG &\V DUH SUHVHQW LQ WKH
UHGXFHGVWDWHLQWKHFU\VWDOVWUXFWXUH$K\GURSKRELFSDWFKDQG
D ODUJH JURRYH VXUURXQGV WKH QXFOHRSKLOLF &\V DV DOVR
RFFXUV LQ (F'VE$ DQG 6H'VE$ )LJXUH & $V H[SHFWHG
WKHVHVXUIDFHIHDWXUHVDUHOLQHGZLWKUHVLGXHVFRQWULEXWHGIURP
WKH//DQG/ORRSV
7KH VL[ LQGHSHQGHQW FRSLHV RI .S'VE$ LQ WKH FU\VWDO
VWUXFWXUH DOORZ DQ DQDO\VLV RI FRQIRUPDWLRQDO YDULDELOLW\ RI WKH
ORRS UHVLGXHV IRUPLQJ WKH ELQGLQJ VXUIDFH 7KLV UHYHDOHG WKDW
WKH VLGH FKDLQVRI+LV3KH /HX*OQ7KUDQG
0HWDGRSWYDULRXVURWDPHUFRQIRUPDWLRQVZKHUHDVWKHUHLV
QR HYLGHQFH RI FRQIRUPDWLRQDO YDULDELOLW\ LQ 7\U &\V
3UR 9DO 3UR DQG 3KH )LJXUH $ 7KH VLGH
FKDLQYDULDWLRQVGRQRWLQIOXHQFHWKHVXUIDFHDFFHVVLELOLW\RIWKH
K\GURSKRELFJURRYHZKLFKZDVFDOFXODWHGWREHcE\
&DVW3>@DFURVVWKHPROHFXOHV0RUHRYHUWKHK\GURSKRELF
QDWXUH RI WKH JURRYH LV XQDIIHFWHG E\ WKH VLGH FKDLQ
FRQIRUPDWLRQDO YDULDELOLW\ DV LQGLFDWHG E\ WKH SURSRUWLRQ RI
FDUERQDWRPVOLQLQJWKLVJURRYH>@
1056ROXWLRQ6WUXFWXUHRI.S'VE$LV6LPLODUWRWKH
&U\VWDO6WUXFWXUH
3UHYLRXV VWXGLHVKDYHGHPRQVWUDWHG WKDW WKHUHDUHPLQLPDO
GLIIHUHQFHV EHWZHHQ UHSRUWHG VWUXFWXUHV FU\VWDO DQG105 RI
R[LGL]HG DQG UHGXFHG (F'VE$ 7R GHWHUPLQH LI WKLV ZDV DOVR
)LJXUH.S'VE$UHGR[SURSHUWLHV$'LVXOILGHERQGUHGXFWLRQDFWLYLW\RI.S'VE$Ÿ(F'VE$Ŷ(F'VE&ƔDQGDFRQWURO
ZLWKRXWHQ]\PH△ZDVPRQLWRUHGVSHFWURSKRWRPHWULFDOO\6H'VE$DFWLYLW\KDVEHHQSXEOLVKHGHOVHZKHUH>@%5HGR[HTXLOLEULD
RI.S'VE$ZLWKJOXWDWKLRQH*6+*66*&'HWHUPLQDWLRQRIWKHQXFOHRSKLOLF&\V&;;&S.D7KHS+GHSHQGHQWDEVRUEDQFH
RIWKHWKLRODWHDQLRQDWQPZDVILWWHGWRWKH+HQGHUVRQ+DVVHOEDFKHTXDWLRQ'7HPSHUDWXUHLQGXFHGXQIROGLQJRIR[LGL]HGR[
ŶDQGUHGXFHGUHGƑ.S'VE$ZDVGHWHUPLQHGE\IDU89&'VSHFWURVFRS\VKRZLQJWKDWWKHUHGXFHGIRUPLVPRUHVWDEOHWKDQWKH
R[LGL]HGIRUP
GRLMRXUQDOSRQHJ
&RPSDUDWLYH$QDO\VLVRI.OHEVLHOODSQHXPRQLDH'VE$
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WKH FDVH IRU .S'VE$ D VHPLDXWRPDWHG105 DSSURDFKZDV
XVHG WRGHWHUPLQH WKHVWUXFWXUHRIR[LGL]HG.S'VE$3'% ,'
0%6 %05% ,'  )ROORZLQJ 81,2$7126$6&$1
PDQXDOYHULILFDWLRQDQGUHILQHPHQWHQDEOHGDVVLJQPHQWRI
RIWKHQRQODELOHSURWRQUHVRQDQFHVLQ.S'VE$7KHVHZHUH
XVHGWRJHQHUDWHWKH12(EDVHGGLVWDQFHFRQVWUDLQWV IRU ILQDO
VWUXFWXUH FDOFXODWLRQ 7ZHQW\ FRQIRUPHUV ZLWK ORZHVW WDUJHW
IXQFWLRQDQGOHDVWYLRODWLRQVRI LQSXWUHVWUDLQWVZHUHFKRVHQWR
UHSUHVHQWWKHVWUXFWXUHRIR[LGL]HG.S'VE$)LJXUH6$%,W
ZDV QRW SRVVLEOH WR DVVLJQ VHYHUDO EDFNERQH DPLGH
UHVRQDQFHVFRUUHVSRQGLQJWRUHVLGXHVLQWKHȕȕORRS,OH
*O\ *OX *OQ 9DO /HX VR WKDW WKLV UHJLRQ
DSSHDUV WR EH ODUJHO\ GLVRUGHUHG LQ WKH 105 HQVHPEOH
FRPSDUHGZLWKWKHUHVWRIWKHVWUXFWXUH7KHEDFNERQH1&Į
&¶DQGDOOKHDY\DWRP506'IRUWKHZHOOGHILQHGUHVLGXHV
±RIWKH.S'VE$FRQIRUPHUVZHUH
c DQG    c UHVSHFWLYHO\ 6WUXFWXUDO VWDWLVWLFV DUH
VXPPDUL]HGLQ7DEOH$VREVHUYHGIRURWKHU'VE$VWUXFWXUHV
WKH LQGLYLGXDO WKLRUHGR[LQ DQG KHOLFDO GRPDLQV FDQ EH
VXSHULPSRVHG ZLWK KLJKHU SUHFLVLRQ WKDQ WKH HQWLUH VWUXFWXUH
7KLV LVPRVW OLNHO\GXHWR LQWHUGRPDLQPRWLRQZKLFKKDVDOVR
EHHQ UHSRUWHG LQ WKH VWUXFWXUHV RI (F'VE$ >@ DQG 9F'VE$
>@ 5HVLGXHV ZKLFK IDOO LQWR GLVDOORZHG 5DPDFKDQGUDQ
UHJLRQV LQFOXGHWKHXQDVVLJQHGUHVLGXHV*OX*OQ9DO
DQG +LV DQG UHVLGXHV LQ ORRS UHJLRQV LH /\V 3KH
/HX$VQDQG0HW
7KH RYHUDOO FRQIRUPDWLRQ RI WKH 105 VWUXFWXUH RI R[LGL]HG
.S'VE$ LV VLPLODU WR WKDW RI WKH FU\VWDO VWUXFWXUH RI UHGXFHG
.S'VE$)LJXUH&)RUH[DPSOHVXSHUSRVLWLRQRIPROHFXOH$
LQ WKH FU\VWDO VWUXFWXUH RI UHGXFHG .S'VE$ ZLWK WKH ILUVW
)LJXUH   ,Q YLWUR SHSWLGH GLWKLRO R[LGDWLRQ  $ 'LWKLRO
R[LGDVHDFWLYLWLHVRI(F'VE$Ŷ6H'VE$ƔDQG.S'VE$➉
ZHUHPRQLWRUHGXVLQJDIOXRUHVFHQWO\ODEHOHGSHSWLGHVXEVWUDWH
6DPSOHV ODFNLQJ WKHSDUWQHUSURWHLQ(F'VE%.S'VE$SHSWLGH
△(F'VE$SHSWLGHƑ6H'VE$SHSWLGHż RU EXIIHU DORQHź
VKRZHGQRLQFUHDVHLQVLJQDORYHUWKHVDPHWLPHSHULRG
GRLMRXUQDOSRQHJ
VWUXFWXUH LQWKH105HQVHPEOHRIR[LGL]HG.S'VE$\LHOGVDQ
506' RI  c RYHU  &Į DWRPV 7R PDNH D VLPLODU
FRPSDULVRQWKHFU\VWDOVWUXFWXUHVRIR[LGL]HG)9.PROHFXOH
%DQGUHGXFHG$/PROHFXOH%(F'VE$KDYHDQ506'RI
 c RYHU  &Į DWRPV DQG WKH FU\VWDO VWUXFWXUH RI
R[LGL]HG(F'VE$)9.PROHFXOH%DQGWKHILUVWVWUXFWXUH LQ
WKH105HQVHPEOHRIUHGXFHG(F'VE$$KDYHDQ506'
RIcRYHU&ĮDWRPV>@
7KHVWUXFWXUHVRIWKHFDWDO\WLFVLWHVDQGK\GURSKRELFVXUIDFH
IHDWXUHVDUHVLPLODUFRQVLGHULQJWKDWWKHF\VWHLQHVRIWKH&;;&
PRWLI DUH R[LGL]HG LQ WKH 105 VWUXFWXUH DQG UHGXFHG LQ WKH
FU\VWDO VWUXFWXUH )LJXUH6& $V KDV EHHQ QRWHG SUHYLRXVO\
IRU RWKHU 'VE$ VROXWLRQ DQG FU\VWDO VWUXFWXUHV >@ / RI
.S'VE$LVDUHODWLYHO\IOH[LEOHSDUWRI WKHSURWHLQ LQERWK105
DQG FU\VWDO VWUXFWXUHV )LJXUH % DQG & 7KXV RYHUDOO WKH
VWUXFWXUHV RI R[LGL]HG DQG UHGXFHG .S'VE$ DUH VLPLODU
QRWZLWKVWDQGLQJ WKH GLIIHUHQW FRQGLWLRQV DQG DSSURDFKHV XVHG
IRUVWUXFWXUHGHWHUPLQDWLRQ
%LQGLQJ$IILQLW\RI'VE%SHSWLGHVLVVLPLODUIRU.S'VE$
DQG(F'VE$
7KH VLPLODU VXUIDFH IHDWXUHV DQG VLPLODU SUHGLFWHG ELQGLQJ
UHVLGXHV RI .S'VE$ DQG (F'VE$ VXJJHVWHG WKDW WKHVH
HQ]\PHV ZRXOG LQWHUDFW ZLWK ELQGLQJ SDUWQHUV ZLWK VLPLODU
DIILQLW\7KHFU\VWDOVWUXFWXUHVRIWKH(F'VE$(F'VE%FRPSOH[
VKRZHGWKDW WKHVHFRQGSHULSODVPLF ORRS3RI(F'VE%ELQGV
GLUHFWO\ WR (F'VE$ >@ 7KH ELQGLQJ UHVLGXHV DUH 
363)$7&' DQG WKHVH DUH KLJKO\ FRQVHUYHG LQ .S'VE%
363)47&' 7KHVH WZR 3 SHSWLGHV ZHUH
V\QWKHVL]HGDQGLVRWKHUPDOWLWUDWLRQFDORULPHWU\,7&ZDVXVHG
WRDVVHVVWKHLUELQGLQJDIILQLW\ IRUERWKHQ]\PHV.S'VE$DQG
(F'VE$ ZHUH IRXQG WR ELQG WR 363)$7&' DQG 363)47&'
ZLWKVLPLODUDIILQLWLHV .G07DEOH)LJXUH6$:H
LQYHVWLJDWHG WKH LQWHUDFWLRQ RI .S'VE$ ZLWK 363)47&' E\
VWUXFWXUDO VXSHUSRVLWLRQ RI .S'VE$ RQWR WKH VWUXFWXUH RI
(F'VE$ LQ WKH (F'VE$(F'VE% FRPSOH[ VWUXFWXUH 5HVLGXH
$OD RI (F'VE% 363)$7&' ZDV PXWDWHG LQ VLOLFR WR
363)47&' XVLQJ WKHPRVW FRPPRQO\ REVHUYHG URWDPHU IRU
JOXWDPLQH7KHVXSHULPSRVHGPRGHOVKRZHG WKDW WKH3 ORRS
PDWFKHG WKH VXUIDFH RI .S'VE$ YHU\ ZHOO ZLWK QR FODVKHV
DSSDUHQWEHWZHHQWKH3UHVLGXHVDQG.S'VE$)LJXUH6%
'LVFXVVLRQ
:H KDYH VKRZQ WKDW WKH VWUXFWXUDO VXUIDFH UHGR[ DQG
ELQGLQJSURSHUWLHVRI(F'VE$6H'VE$DQG.S'VE$HQ]\PHV
DUH KLJKO\ FRQVHUYHG DQG WKDW WKHVH WKUHH 'VE$V DQG IRXU
RWKHU 'VE$V IURP (QWHUREDFWHU FORDFDH &LWUREDFWHU NRVHUL
6KLJHOOD IOH[QHUL DQG &URQREDFWHU VDND]DNLL PLJKW EH
FRQVLGHUHG DQ (QWHUREDFWHULDFHDH VXEFODVV RI 'VE$
&DUEDSHQHPUHVLVWDQW(QWHUREDFWHULDFHDH DUH UHVSRQVLEOH IRU
D ODUJHSURSRUWLRQRIGLIILFXOW WR WUHDWFRPPXQLW\DQGKRVSLWDO
DFTXLUHGLQIHFWLRQV>@DQGWKHUHLVDQXUJHQWQHHGWRGHYHORS
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7KHFU\VWDOVWUXFWXUHDQG105VROXWLRQVWUXFWXUHRI.S'VE$
WKH ODWWHU GHULYHG E\ VHPLDXWRPDWHG DSSURDFKHV UHSRUWHG
KHUH DUH LQ H[FHOOHQW DJUHHPHQW 7KH DYDLODELOLW\ RI VWUXFWXUDO
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IDOOLQWRWKH(F'VE$OLNHFODVV,PSRUWDQWO\RXUUHVXOWVVXJJHVW
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RXWOLQHGKHUHLQ
6XSSRUWLQJ,QIRUPDWLRQ
)LJXUH6 7KHUPDOXQIROGLQJRI6H'VE$$7HPSHUDWXUH
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The bacterial disulfide machinery is an attractive molecular
target for developing new antibacterials because it is required
for the production of multiple virulence factors. The arche-
typal disulfide oxidase proteins in Escherichia coli (Ec) are
DsbA and DsbB, which together form a functional unit: DsbA
introduces disulfides into folding proteins and DsbB re-
oxidizes DsbA to maintain it in the active form. In
Mycobacterium tuberculosis (Mtb), no DsbB homologue is
encoded but a functionally similar but structurally divergent
protein, MtbVKOR, has been identified. Here, the Mtb
protein Rv2969c is investigated and it is shown that it is the
DsbA-like partner protein of MtbVKOR. It is found that it
has the characteristic redox features of a DsbA-like protein: a
highly acidic catalytic cysteine, a highly oxidizing potential and
a destabilizing active-site disulfide bond. Rv2969c also has
peptide-oxidizing activity and recognizes peptide segments
derived from the periplasmic loops of MtbVKOR. Unlike the
archetypal EcDsbA enzyme, Rv2969c has little or no activity
in disulfide-reducing and disulfide-isomerase assays. The
crystal structure of Rv2969c reveals a canonical DsbA fold
comprising a thioredoxin domain with an embedded helical
domain. However, Rv2969c diverges considerably from other
DsbAs, including having an additional C-terminal helix (H8)
that may restrain the mobility of the catalytic helix H1. The
enzyme is also characterized by a very shallow hydrophobic
binding surface and a negative electrostatic surface potential
surrounding the catalytic cysteine. The structure of Rv2969c
was also used to model the structure of a paralogous DsbA-
like domain of the Ser/Thr protein kinase PknE. Together,
these results show that Rv2969c is a DsbA-like protein with
unique properties and a limited substrate-binding specificity.
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1. Introduction
The devastating disease tuberculosis (TB) caused by the
bacterium Mycobacterium tuberculosis (Mtb) is responsible
for approximately two million deaths annually. The loss of
effectiveness of the only available TB vaccine, Bacillus
Calmette–Gue´rin (BCG), for people of economically
productive age (15–59 years) has created an enormous drain
on the world economy (World Health Organization, 2011). A
major hurdle to eradicating TB is the requirement for multi-
antibiotic therapy administered over a period of six to nine
months (Connolly et al., 2007). Multidrug-resistant (MDR)
and extensively drug-resistant (XDR) Mtb strains have
evolved for which therapeutic options are limited to toxic and
expensive second-line and third-line reserved drugs (Phillips,
2013). Aside from MDR and XDR strains, Mtb has evolved
mechanisms to succeed as an intracellular pathogen by
manipulating the host immune signalling responses (Kumar &
Narayanan, 2012; Pieters, 2008). Mtb virulence factors can
avert host-cell apoptosis, phagosome maturation and auto-
phagy to gain intracellular persistence, hence restricting the
adaptive immune response (Vergne et al., 2004; Welin et al.,
2011; Songane et al., 2012; Kim et al., 2012). Considering that
one third of the world’s population is infected with TB, there is
a compelling need to identify new molecular targets for the
development of antituberculosis drugs as alternatives or
additions to the current broad-spectrum traditional antibiotics
(Raman et al., 2012; Murillo et al., 2007; Lou & Zhang, 2010).
Mtb cell-surface and secretory proteins are known virulence
components for mycobacterial growth during infection and for
continued survival in host cells (Zhou et al., 2010; Scherr et al.,
2007; Feltcher et al., 2010; DiGiuseppe Champion & Cox,
2007). Consequently, antivirulence approaches targeting
individual proteins responsible for mycobacterial virulence
are being intensively investigated (Feltcher et al., 2010). While
these approaches offer some advantages, there is also a case to
be made for a therapeutic strategy that interferes with the
early stages of Mtb infection and that affects multiple viru-
lence targets.
Periplasmic disulfide-bond forming (Dsb) enzymes catalyze
the oxidative folding and maturation of many toxins and
surface proteins required for virulence in a range of patho-
genic bacteria (Heras et al., 2009). Typically, Dsb proteins
include a soluble thioredoxin (Trx) fold protein DsbA, which
introduces disulfide bonds into newly translocated proteins in
the periplasm (Heras et al., 2009; Kadokura et al., 2003; Inaba,
2009), and its cognate inner membrane partner protein DsbB
that keeps DsbA in the functionally active oxidized form
(Inaba & Ito, 2008; Inaba et al., 2006). Deletion of DsbA or
DsbB has pleiotropic effects on virulence-factor production
and in some cases can provide a marginal increase in sensi-
tivity to conventional antibiotics (Hayashi et al., 2000). Both
DsbA and DsbB have therefore been identified as potential
antibacterial targets to combat virulence of pathogenic
bacteria (Heras et al., 2009; Yu, 1998). DsbA and DsbB
enzymes are not always conserved across bacterial species,
although the oxidative-folding pathway seems to be widely
required for bacterial virulence (Dutton et al., 2008).
Approximately 60% of Mtb exported proteins are esti-
mated to require a disulfide bond for activity, stability and
protease resistance (Chim et al., 2011; Goulding et al., 2004).
However, the mycobacterial genome is deficient in a DsbB
sequence homologue. Moreover, a DsbA-like protein
responsible for disulfide oxidase activity has not been
confirmed in Mycobacterium, although the Mtb gene product
of Rv2969c (annotated as uncharacterized) has been identified
as a potential candidate DsbA (Wang et al., 2011). DsbA
enzymes typically comprise two domains: a noncontiguous Trx
domain, which has a characteristic redox-active CXXC motif
and a cis-Pro motif, and a helical domain inserted into the Trx
domain. Aside from the Trx domain motifs, sequence
conservation among DsbA enzymes is very low. The Mtb
genome contains two genes encoding remote DsbA homo-
logues, Rv2969c and a transmembrane serine/threonine
protein kinase protein incorporating a DsbA-like domain
(PknE; Rv1743; I6YBI4).
A gene adjacent to the dsbA-like Rv2969c gene encodes a
mammalian homologue of vitamin K epoxide reductase
(VKOR; Rv2968c; Dutton et al., 2008). In humans, deficiency
of VKOR or administration of its antagonist warfarin inhibits
reduction of vitamin K 2,3-epoxide that is otherwise required
for blood clotting. In an elegant series of studies, the Beckwith
group proposed that MtbVKOR may represent the functional
equivalent of E. coli DsbB (EcDsbB) and showed that
MtbVKOR rescues motility of E. coli dsbB null cells (Dutton
et al., 2008; Wang et al., 2011). This notion was further
supported by the observation that some plants and bacteria
encode a Trx-VKOR fusion protein. A crystal structure of a
Cyanobacterium Trx-VKOR fusion confirmed that VKOR and
DsbB are functionally similar but structurally divergent (Li et
al., 2010).
Throughout Mycobacterium, Rv2969c and VKOR are
genetically linked. This may indicate that they are functionally
related genes. Genome-wide transposon-insertion mutagen-
esis studies showed that these two genes are essential for the
optimal growth of Mtb (Sassetti et al., 2003). This is in
agreement with the observation that deletion of VKOR in
M. smegmatis confers severe growth defects (Wang et al.,
2011). Moreover, the anticoagulant medication warfarin can
inhibit growth of Mtb in a VKOR-dependent manner (Dutton
et al., 2010).
Here, we present a detailed structural and functional char-
acterization of Rv2969c, the remote DsbA homologue
encoded by Mtb (which we refer to as MtbDsbA). The
structure of MtbDsbA reveals a number of modifications to
the archetypal EcDsbA structure and to the binding surface
surrounding the active-site cysteine. The in vitro activity of
MtbDsbA indicates that it is a mycobacterial disulfide oxidase
and its ability to bind peptides derived from MtbVKOR
supports the notion that MtbDsbA and MtbVKOR form a
functional redox pair. MtbDsbA may therefore represent an
important target for the development of antituberculosis
drugs that block oxidative folding of exported Mtb proteins
necessary for mycobacterial infection and survival within host
macrophages. The structure that we report may serve as a
starting point for rational drug design towards this end.
2. Experimental procedures
2.1. Cloning, expression and protein production
The N-terminal region of MtbDsbA is predicted to be a
secretion signal (SignalP; Emanuelsson et al., 2007) or trans-
membrane anchor (TMHMM; Krogh et al., 2001). A codon-
optimized synthetic gene corresponding to the soluble
MtbDsbA enzyme lacking this region (M. tuberculosis H37Rv,
residues 46–255) was inserted into the bacterial expression
vector pMCSG7 by ligation-independent cloning (Eschenfeldt
et al., 2009). An amino-terminal His6-tagged MtbDsbA was
expressed in E. coli BL21(DE3) cells using auto-induction
medium (Studier, 2005). Protein was purified using TALON
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cobalt resin (Clontech) and the His6 tag was removed by TEV
protease leaving three vector-derived residues (Ser-Asn-Ala)
at the N-terminus. For crystallization experiments, the protein
was incubated with 100 mM oxidized glutathione to generate
the oxidized enzyme, prior to final purification on a Superdex
75 gel-filtration column (GE Healthcare). Site-directed
mutagenesis was performed using the QuikChange method
and the mutation was confirmed by DNA sequencing. A
noncatalytic double cysteine mutant MtbDsbAm (Cys140Ala,
Cys192Ala) and an active-site single cysteine mutant
MtbDsbA (Cys92Ala) were expressed and purified in the
same way as for wild-type MtbDsbA.
2.2. Crystallization and diffraction data collection
MtbDsbA crystals were grown by the hanging-drop vapour-
diffusion method at 293 K; drops were set up using a Mosquito
crystallization robot (TTP Labtech) and were incubated and
imaged in a RockImager 1000 (Formulatrix). 250 nl MtbDsbA
solution concentrated to 55 mg ml"1 in 25 mMHEPES pH 7.4,
100 mM NaCl was mixed with 250 nl reservoir solution
consisting of 2.4M sodium malonate pH 5.5, 3.7% 1,4-
dioxane, 0.08% polyvinylpyrrolidone. Crystals grew as long
thin rods (#30 $ 500 mm) in 3–4 weeks and were flash-cooled
in liquid nitrogen after brief rinsing in 3.4M sodium malonate
pH 5.5. Diffraction data were collected on the MX2 beamline
at the Australian Synchrotron at a wavelength of 0.9537 A˚ and
were recorded using an ADSC Quantum 315r detector
controlled by Blu-Ice (McPhillips et al., 2002). Data were
integrated in XDS (Kabsch, 2010), space-group possibilities
were analyzed using POINTLESS (Evans, 2006) and data
were scaled in SCALA from the CCP4 suite (Winn et al.,
2011).
2.3. Structure determination and refinement
Molecular-replacement (MR) searches for MtbDsbA with
Phaser (McCoy et al., 2007) using intact DsbA templates (less
than 21% sequence identity) were unsuccessful. Regions
contributing to DsbA structural divergence were identified by
superposition of DsbA structures currently available in the
PDB and the structurally divergent regions were trimmed to
generate a collection of DsbA ‘Poly Ser’ MR templates
(nonglycine and non-alanine residues that were not conserved
were changed to serine) for MR trials in Phaser. A Poly Ser
conserved structural core search model derived from
Staphylococcus aureus DsbA (SaDsbA) (PDB entry 3bci;
Heras et al., 2008) gave an MR solution (TFZ = 8.0) with two
copies in the asymmetric unit. This trimmed MR search model
provided 39% coverage with 48% identity to the MtbDsbA
sequence (Supplementary Fig. S11). Iterative manual building,
density modification and refinement in PHENIX (Adams et
al., 2010) and Coot (Emsley & Cowtan, 2004) allowed tracing
of almost the entire MtbDsbA sequence. Final refinement
cycles involving TLS were carried out in phenix.refine.
Electron density was absent for the three vector-derived
residues and the N-terminal 11 residues of the MtbDsbA
construct in both molecules in the asymmetric unit. At the
interface of the two MtbDsbA molecules in the asymmetric
unit, two additional regions of electron density were observed
in the difference Fourier map contoured at 3.0!. These were
interpreted as 1,4-dioxane and HEPES, both of which were
present in the crystallization condition. A summary of the
data-processing and refinement statistics is presented in Table
1. The stereochemical quality of the final model was assessed
using AutoDep Input Tool (Yang et al., 2004), MolProbity
(Chen et al., 2010) and SFCHECK (Vaguine et al., 1999). The
coordinates and structure factors have been deposited in the
Protein Data Bank (PDB entry 4k6x).
2.4. Isothermal titration calorimetry (ITC)
Experiments were carried out on a Microcal Auto-iTC200
(GE Healthcare). Peptides with N-terminal acetylation and
C-terminal amidation were chemically synthesized manually
by classic solid-phase peptide synthesis using rink amide
MBHA resin (ChemImpex International, loading
0.65 mmol g"1) and Fmoc-protected amino acids (ChemImpex
International). Peptides were purified by reversed-phase
HPLC (C18, Phenomenex) and characterized by retention
times, electrospray mass spectrometry and 1H NMR spectro-
scopy. Each ITC titration involved an initial 0.5 ml injection
(not included in the subsequent analysis) followed by 19
injections of 2 ml of 2–4 mM peptide into cells containing
100 mMMtbDsbA in 25 mM HEPES pH 7.4, 100 mM NaCl at
research papers
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Table 1
Summary of data-collection and refinement statistics.
Values in parentheses are for the highest resolution shell.
Space group I4122
Unit-cell parameters (A˚) a = 92.05, b = 92.05, c = 232.76
Data-collection wavelength (A˚) 0.9537
Resolution range (A˚) 85.6–1.97 (2.08–1.97)
No. of observations 286100 (39641)
No. of unique reflections 35185 (5080)
Mean I/!(I) 14.9 (3.3)
Rmerge 0.096 (0.66)
Rp.i.m. 0.036 (0.246)
Multiplicity 8.1 (7.8)
Wilson B factor (A˚2) 26.1
Model and refinement statistics
Resolution range (A˚) 59.3–1.97
No. of unique reflections 35175
Completeness 98.4
Rwork (%) 14.5 (20.3)
Rfree† (%) 19.2 (28.4)
No. of non-H atoms
Protein 2996
Ligand 17
Water 415
R.m.s.d., bond lengths (A˚) 0.011
R.m.s.d., bond angles (%) 1.27
Ramachandran favoured/allowed (%) 97.5/99.5
Average B factor (A˚2)
Protein 23.7
Ligand 24.6
Water 34.6
† Rfree is calculated as for Rwork but for 5% of the total reflections chosen at random and
omitted from refinement.
1 Supplementary material has been deposited in the IUCr electronic archive
(Reference: TZ5033). Services for accessing this material are described at the
back of the journal.
298 K. Thermodynamic parameters were obtained from
nonlinear curve fitting using a single-site binding mode in
Origin 7.0 (SR4 v7.0552 beta, Microcal).
2.5. Thermal stability measurement
Temperature-induced unfolding of MtbDsbA was recorded
by far-UV circular dichroism (CD), with the temperature
increasing from 298 to 368 K at a rate of 1 K min"1 using a
Jasco J-810 spectropolarimeter. The normalized CD signal for
oxidized (219 nm) and reduced (220.5 nm) MtbDsbA in
100 mM phosphate buffer, 1 mM ethylenediaminetetraacetic
acid (EDTA) pH 7.0 was fitted to a two-state unfolding model
as described previously (Kurz et al., 2009). The redox status of
the oxidized and reduced protein preparation with oxidized
glutathione and DTT (dithiothreitol), respectively, was veri-
fied with Ellman’s reagent.
2.6. Insulin-reduction assay
The catalytic ability of MtbDsbA to reduce insulin in the
presence of DTTwas monitored by the increase in absorbance
at 650 nm over 80 min as described previously (Heras et al.,
2008). Briefly, the reaction mixture contained 131 mM insulin
and 10 mM of oxidized MtbDsbA or EcDsbA in 100 mM
phosphate buffer pH 7.0, 2 mM EDTA. The reaction was
initiated by adding DTT to a final concentration of 0.35 mM.
The noncatalyzed aggregation of insulin by DTT was moni-
tored in a control reaction without enzyme.
2.7. Isomerization of scrambled RNaseA
In vitro disulfide isomerase activity of MtbDsbA, EcDsbC
and EcDsbA was monitored using a scrambled RNaseA
refolding assay (Hillson et al., 1984). Scrambled RNaseA was
produced as previously described (Heras et al., 2008).
Isomerization of scrambled RNaseA (40 mM) was conducted
in 100 mM sodium phosphate buffer containing 1 mM EDTA
pH 7.0, 10 mM DTT and 10 mM DsbA or DsbC at 298 K
(750 ml). At various time intervals, 50 ml of refolded RNase
sample was taken to monitor the hydrolysis activity of cytidine
30,50-cyclic monophosphate (3 mM) using a BioTek H1 plate
reader at 296 nm. Native RNaseA and scrambled RNaseA in
the absence of DsbA or DsbC served as positive and negative
controls, respectively.
2.8. Ubiquinone-reduction assay
DsbB-catalyzed oxidation of DsbA can be monitored by
following the decrease in ubiquinone absorbance at 275 nm
(Bader et al., 2000). The reaction mixture (70 ml) contained
30 mM reduced MtbDsbA or EcDsbA, 30 mM ubiquinone-1
(UQ1) in 50 mM Tris pH 7.0, 100 mM NaCl and 0.01%
n-dodecyl "-d-maltoside. The decrease in absorbance was
recorded for 3 min at 303 K after addition of 57 nM EcDsbB
using a Varian Cary 50 UV–visible spectrophotometer.
2.9. Determination of redox potential
Oxidized MtbDsbAm (2 mM) was incubated in 200 ml
degassed buffer consisting of 100 mM phosphate buffer, 1 mM
EDTA pH 7.0, 1 mM oxidized glutathione (GSSG) for 1 h at
room temperature. The protein was then incubated in buffers
with a range of reduced glutathione (GSH) concentrations
(0.01 mM–1 mM) for 24 h at 298 K (10 ml per reaction
containing 2 mM protein concentration). After incubation, the
reactions were stopped with 10% trichloroacetic acid and the
precipitated protein pellets were collected by centrifugation at
14 000 rev min"1 for 10 min at 277 K. The pellets were washed
with 100% ice-cold acetone and dissolved in buffer consisting
of 50 mM Tris pH 7.0, 1% SDS, 4 mM 4-acetamido-40-male-
imidylstilbene-2,20-disulfonate (AMS) to label the free thiols.
Separation of reduced and oxidized forms was performed on a
NuPAGE 12% bis-tris gel (1.0 mm thick, 12 well; Invitrogen,
Australia). The gel was stained with Coomassie, scanned
(Perfection V700 Scanner, Epson) and intensities of the
reduced protein were analyzed using ImageJ v.1.42q
(Schneider et al., 2012). The fraction of the reduced protein
was plotted against the ratio [GSH]2/[GSSG] and the equili-
brium constant Keq was calculated using the binding equation
Y = ([GSH]2/[GSSH])/{Keq + ([GSH]
2/[GSSH])}, where Y is
the fraction of reduced protein at equilibrium. The redox
potential was calculated using the Nernst equation E0
0
=
E0
0
GSH/GSSG " (RT/nF)lnKeq, where E00GSH/GSSG is the standard
potential of "240 mV (Gilbert, 1995), R is the universal gas
constant 8.314 J K"1 mol"1, T is the absolute temperature in
K, n is the number of electrons transferred, F is the Faraday
constant 9.648 $ 104 C mol"1 and Keq is the equilibrium
constant.
2.10. Determination of pKa
The pH-dependent UV absorbance of the nucleophilic
cysteine thiol was followed at 240 nm (Nelson & Creighton,
1994). Measurements of oxidized or reduced MtbDsbAm
(lacking the second disulfide) of 24 or 16 mM in a total volume
of 200 ml buffer comprising 10 mM dipotassium phosphate,
10 mM monopotassium phosphate, 10 mM sodium citrate,
10 mM Tris, 1 mM EDTA, 200 mM KCl were performed at pH
values ranging from 2.2 to 7.5 using Greiner 96-well UV-Star
microplates. The redox status of the protein preparation was
verified with Ellman’s reagent. The absorbance at 240 and
280 nm was recorded on a BioTek Synergy H1 microplate
reader and corrected for blank absorbance. The pH-depen-
dent thiolate-specific absorbance signal [(A240/A280)reduced/
(A240/A280)oxidized] was fitted to the Henderson–Hasselbach
equation as described previously (Kurz et al., 2009).
2.11. Complementation assay
Complementation of EcDsbA by MtbDsbAwas monitored
in a cell-swarming assay as described previously (Kurz et al.,
2009). A chimeric gene encoding an EcDsbA signal peptide
fused to the mature form of MtbDsbA was cloned into the
arabinose-inducible pBAD33 vector (Guzman et al., 1995). A
nonmotile E. coli dsbA" mutant (JCB817) strain transformed
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with this chimera construct was stabbed into a minimal agar
(M63) plate supplemented with 40 mg ml"1 of each amino
acid and 1 mg ml"1 arabinose. The swarming of E. coli cells
was analyzed after incubating the plate for 4–6 h at 303 K.
JCB817 cells transformed with pBAD33::EcDsbA were used
as a positive control. A nonmotile dsbA"/dsbB" double-
mutant strain (JCB818) served as a negative control. Plates
without arabinose were used to monitor background
complementation.
2.12. Peptide-oxidation assay
A synthetic peptide substrate CQQGFDGTQNSCK with a
europium DOTA (1,4,7,10-tetraazacyclododecane-1,4,7,10-
tetraacetic acid europium) chelate at the N-terminus and a
methylcoumarin amide at the "-amino group of the lysine was
obtained from Anaspec, USA (for further details of the
peptide, see Vivian et al., 2009). Disulfide-bond formation of
the peptide was fluorometrically followed using time-resolved
fluorescence with excitation at 340 nm and emission at 615 nm,
a delay of 150 ms and a reading time of 100 ms in a Synergy H1
multimode plate reader (BioTek, USA). The assay was
performed in a 384-well white plate (PerkinElmer OptiPlate)
containing EcDsbA or MtbDsbA and 2 mM GSSG in 50 mM
MES, 50 mM NaCl, 2 mM EDTA at pH 5.5. The reaction was
initiated by the addition of substrate peptide at 4–8 mM in a
total volume of 50 ml. The reaction was performed in triplicate
and repeated at various concentrations of EcDsbA or
MtbDsbA. The reaction in the absence of enzyme was used as
a control.
3. Results
3.1. Putative Mtb DsbA-like proteins
To identify potential Mtb DsbA-like oxidases, we searched
the genome of the virulent strain Mtb H37Rv by using
keyword and BLASTP searches. 15 Trx-related gene products
were identified (Table 2) and nine of these were eliminated as
potential DsbA-like proteins as they are likely to be located in
the cytoplasm (on the basis of literature reports, the absence
of sorting signal/transmembrane region and sequence-to-
structure relationships). Of the remaining six predicted to be
extracytoplasmic Trx-related proteins, only the sequences of
hypothetical Rv2969c and the DsbA-like domain of PknE
(Rv1743) remotely resembled DsbA homologues. The
sequence identity of the nearest structurally characterized
neighbour, Bacillus subtilis DsbA (BsDsbA), is less than 19%
(by sequence-based alignment) to these two Mtb DsbA
paralogues. Rv2969c and Rv1743 share #50% sequence
similarity (31% identity) and both contain four conserved
cysteine residues. The sequence positions of two of the four
cysteines are similar to that of the characteristic redox-active
CXXC motif of the Trx fold, whereas the other two cysteines
are consistent with the structural (noncatalytic) cysteines
found in Wolbachia pipientis #-DsbA1 (Wp#-DsbA1; Kurz et
al., 2009).
The presence of a predicted sorting signal or trans
membrane helix in Rv2969c (currently annotated as
uncharacterized) indicates it is either secreted into, or
membrane-anchored with the catalytic domain facing, the
recently characterized mycobacterial periplasm (Patarroyo et
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Table 2
Survey of Trx-related proteins in M. tuberculosis strain H37Rv.
Summary of the 15 Trx-related proteins found using keyword and BLASTP searches. Only Rv2969c and Rv1743 could be considered similar to DsbA-like proteins.
Structural similarities to Trx-related proteins were identified using BLASTP and Fold and Function Assignment (FFAS; http://ffas.burnham.org/) searches against
PDB codes or % identity to reported structure (PDB code in parentheses) are given. The functional annotation, presence and location of signal peptide/
membrane-spanning region and operon are derived information from Target TB annotation (http://genome.tbdb.org/). The presence of signal sequence and
transmembrane region were also confirmed using SignalP3.0 and transmembrane prediction using hidden Markov models (TMHMM). DsbA-like (Rv2969c) is
predicted to have an N-terminal transmembrane (TM) helix or signal peptide (SP).
Protein Length Functional annotation Signal peptide Structural representative Operon
PknE-DsbA (Rv1743) 566 Ser/Thr kinase Integral
membrane
2h34 (kinase; Gay et al., 2006),
31% (DsbA-like)
Ser-Thr protein kinase, fused
DsbA-like
DsbA-like (Rv2969c) 255 Conserved, unknown TM or SP Present work Pyruvate carboxylase-like, VKOR,
Dsb-like
DsbE (Rv2878c) 173 Unknown Yes 1lu4 (Goulding et al., 2004) Rv2877c, DsbE
DsbF (Rv1677) 182 Unknown Yes 3ios (Chim et al., 2010) Rv1676, DsbF
ResA-like (Rv3673c) 227 Unknown Yes 30% (DsbE/F) Rv3673c, endonuclease III
Trx-related (Rv0526) 216 Unknown Yes 47% (3lwa; Midwest Center for
Structural Genomics, unpublished work)
HemeL, Rv0525, Rv0526, ccdA,
Rv0528, ccsA
TrxC (Rv3914) 116 Disulfide exchange No 3o6t (Hall et al., 2011) TrxB2, TrxC
TrxB2 (Rv3913) 335 Disulfide reductase No 2a87 (Akif et al., 2005) TrxB2, TrxC
TrxB1 (Rv1471) 123 Disulfide exchange No 36% (3hhv; Ruggiero et al., 2009) TrxA, TrxB1
TrxA (Rv1470) 124 Disulfide exchange No 32% (3hhv; Ruggiero et al., 2009) TrxA, TrxB1
Trx-like (Rv0816c) 140 Disulfide exchange ?? 28% (3ilu; Ptak et al., 2009) Rv0816c, Rv0817c
Trx-like (Rv2183c) 131 Conserved, unknown ?? 14% (3raz; New York SGX Research Center
for Structural Genomics, unpublished work)
Rv2183c, Rv2184c
Trx-fusion protein (Rv1324) 304 Disulfide exchange No 24% (3qdn; Center for Structural Genomics
of Infectious Diseases, unpublished work)
Rv1324
Trx-related (Rv2286c) 230 Conserved, unknown No 20% (3fz5; Midwest Center for Structural
Genomics, unpublished work)
Rv2286c
Trx-related (Rv2466c) 207 Unknown No 14% (3fz5; Midwest Center for Structural
Genomics, unpublished work)
Rv2466c
al., 2008; Sani et al., 2010) and may therefore represent a
potential candidate for a DsbA-like protein. Hereafter, we
refer to it as MtbDsbA. Its paralogue PknE is a single-pass
transmembrane Ser/Thr protein kinase that comprises an
extracytoplasmic DsbA-like domain and a cytoplasmic kinase
domain (Gay et al., 2006). PknE has been shown to regulate
cellular events in response to host-mediated apoptotic stimuli
such as nitric oxide (Jayakumar et al., 2008). As such, PknE
appears to promote the survival of Mtb in the latent state by
suppressing host apoptosis (Kumar & Narayanan, 2012).
3.2. MtbDsbA is highly oxidizing
Typically, DsbA enzymes have a highly acidic catalytic
cysteine and a highly oxidizing redox potential that enable its
participation in thiol–disulfide exchange reactions. To study
the redox characteristics of MtbDsbA, we created a double
noncatalytic cysteine mutant MtbDsbAm (Cys140Ala,
Cys192Ala). Similar to Wp#-DsbA1, this mutation did not
affect the solubility and integrity of MtbDsbA. Using a pH-
titration experiment (Fig. 1a), we found that the measured pKa
of the catalytic cysteine Cys89 is 4.2& 0.2, which falls between
the previously reported values for EcDsbA (pKa = 3.3) and
Vibrio cholerae DsbA (VcDsbA, pKa = 5.1). The redox
potentials of DsbA proteins also vary among characterized
DsbAs; the most reducing and oxidizing DsbAs reported to
date are Wp#-DsbA1 ("163 mV) and neisserial NmDsbA3
("80 mV), respectively. We measured the standard redox
potential by equilibration of MtbDsbAm with glutathione at
298 K and pH 7.0 (Fig. 1b). We found that the oxidizing power
of MtbDsbA ("99 mV) is comparable to that of Pseudomonas
aeruginosa DsbA (PdDsbA) ("94 mV; Shouldice et al., 2010),
somewhat more oxidizing than EcDsbA ("122 mM;
Wunderlich & Glockshuber, 1993) and a little less oxidizing
than BsDsbA ("80 mM; Crow et al., 2009).
Another characteristic feature common to DsbA enzymes is
that the catalytic cysteine disulfide bond reduces the stability
of the protein (Heras et al., 2008). A thermal unfolding
experiment comparing the stability of the redox forms showed
that the oxidized (disulfide) form of MtbDsbA is less stable
than its reduced form by 13 K (Fig. 1c), which is in agreement
with the findings for other DsbA enzymes.
Taken together, these results show that the putative DsbA
protein encoded byM. tuberculosis has the redox hallmarks of
a DsbA disulfide oxidoreductase.
3.3. MtbDsbA is a disulfide oxidase
An in vivo complementation experiment has been devel-
oped to demonstrate that the expression of a DsbA enzyme
can rescue the motility of E. coli cells deficient in EcDsbA
(Kurz et al., 2009; Paxman et al., 2009). However, MtbDsbA
does not restore the motility of E. coli DsbA null cells as
shown by the results of the cell-swarming assay (Fig. 2a). To
establish whether this might be a consequence of a lack of
interaction between MtbDsbA and EcDsbB (the essential
redox partner of EcDsbA), we monitored the ability of
EcDsbB to oxidize MtbDsbA in an EcDsbB-catalyzed
ubiquinone reduction assay (Fig. 2b). This experiment showed
as expected that EcDsbB can oxidize EcDsbA, but it failed to
redox couple with MtbDsbA. This could explain why
MtbDsbA does not complement EcDsbA in the motility assay,
but we cannot rule out the possibility that MtbDsbA is in-
active because it also does not recognize the P-ring protein
(FlgI) substrate of EcDsbA in the assay (Dailey & Berg,
1993).
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Figure 1
Characterization of the redox properties of MtbDsbA. (a) pKa determination of the nucleophilic cysteine of MtbDsbA. This is a representative plot of
three independent measurements of the pH-dependent thiolate-specific absorbance of the catalytic cysteine. The pKa was obtained from the nonlinear fit
to the Henderson–Hasselbach equation. (b) Determination of the redox equilibria of MtbDsbAwith glutathione at pH 7.0 and 298 K. The plot shows the
averaged fraction (three replicates) of reduced MtbDsbA at various ratios of reduced:oxidized glutathione. The resulting equilibrium constantKeq (17.37
& 0.1 mM) from the nonlinear curve fit for a one-site binding equation was used to calculate the redox potential of MtbDsbA relative to the glutathione
(GSH/GSSG) standard potential of "240 mV (Gilbert, 1995). (c) Relative thermal stability of oxidized (grey) and reduced (black) MtbDsbA at pH 7.0.
The normalized average far-UV CD signal from three measurements was fitted to a two-state unfolding model as described previously (Kurz et al., 2009).
The resulting melting temperature (Tm) of MtbDsbA shows that its reduced form (351.7 & 0.1 K) is more stable than its oxidized form (338.6 & 0.1 K).
We then set out to determine the redox-activity profile of
MtbDsbA in standard disulfide oxidase, reductase and
isomerase assays.
The disulfide oxidase activity of MtbDsbAwas investigated
using an in vitro peptide-oxidation assay with a fluorescently
labelled peptide substrate (CQQGFDGTQNSCK), using
GSSG as the electron donor to regenerate the oxidized DsbA
(Fig. 3a). MtbDsbA catalyzed peptide oxidation well above
the background rate [in the absence of enzyme or in the
presence of the catalytic cysteine mutant MtbDsbA
(Cys92Ala)]. However, EcDsbA-mediated peptide oxidation
was found to be faster than MtbDsbA as it required five times
more MtbDsbA to match the catalytic rate of EcDsbA. This
suggests the possibility that MtbDsbA and EcDsbA recognize
the substrate peptide with differing affinities or kinetics.
The reductase activity of MtbDsbA was assessed spectro-
photometrically by analyzing the ability of the enzyme to
reduce the interchain disulfides of insulin (measured as an
increase in turbidity through precipitation of the insulin B
chain; Fig. 3c). In contrast to EcDsbA, MtbDsbA did not show
any disulfide reductase activity against insulin, supporting the
possibility that the two enzymes have different substrate-
binding surfaces.
Finally, we tested the ability of MtbDsbA to isomerize, or
shuffle, the incorrect disulfides of scrambled RNaseA to form
the correctly folded RNaseA. Under the conditions of the
assay, MtbDsbA was able to generate just 10% of the activity
of fully folded RNaseA after 5 h (Fig. 3c). By comparison,
EcDsbA and EcDsbC (a disulfide isomerase enzyme)
produced #60 and #90%, respectively, of the activity of
correctly folded RNase over the same time period. These
observations are consistent with the view that MtbDsbA has
the characteristic redox properties of a disulfide oxidase but
differs functionally in other redox assays compared with the
prototypical EcDsbA oxidase.
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Figure 3
Disulfide oxidoreductase activities. (a) Disulfide oxidase activity. Representative fluorescence curves of peptide cysteine oxidation by MtbDsbA and
EcDsbA in the presence of glutathione as the electron donor. Enzyme-catalyzed peptide oxidation is significantly faster than the glutathione-mediated
reaction. Peptide oxidation in the buffer control or by the catalytically inactive MtbDsbA (Cys89Ala) or EcDsbA (Cys33Ala) was insignificant over the
duration of the assay (not shown for clarity). (b) Insulin disulfide-reduction assay. The precipitation of insulin by MtbDsbA or EcDsbA or DTT (trace
overlaps that of EcDsbA) was monitored as described in x2. (c) Scrambled RNase disulfide isomerization assay. Disulfide isomerization activity of
MtbDsbA, EcDsbA and EcDsbC was monitored using scrambled RNase as the substrate.
Figure 2
Ability of MtbDsbA to recognize EcDsbB. (a) Restoration of E. coli
motility. Constructs expressing MtbDsbA or EcDsbA (control) were
transformed into E. coli DsbA null (JCB817) and DsbA/DsbB double
null (JCB818) mutant cells. FlgI function is impaired in the absence of
EcDsbA or EcDsbB owing to the absence of disulfide-bonding activity
(Dailey & Berg, 1993). The ability to recognize EcDsbB and EcDsbA
substrates in vivo by MtbDsbA was evaluated by restoration of E. coli
motility in the agar, as seen in the induced EcDsbA control. Shown is the
summary of three replicates of induced (containing arabinose) and
uninduced bacterial swarming plates (not containing arabinose, as a
negative control). See Supplementary Fig. S2 for bacterial plate images.
(b) Ubiquinone reduction of EcDsbB–UQ1 by MtbDsbA. The data
presented here are the normalized mean absorbance of UQ1 from three
independent measurements. EcDsbB was added to the EcDsbA/UQ1
mixture to initiate the reaction.
3.4. The crystal structure of MtbDsbA reveals unique features
To explore the atomic details of MtbDsbA, we determined
its structure at 2.0 A˚ resolution. The structure was solved by
MR searches using trimmed ‘Poly Ser’ templates derived from
remote DsbA homologues (see x2 and Supplementary Fig.
S1). Two independent MtbDsbA molecules were well resolved
in the asymmetric unit (residues 57–255; 199 residues for each
monomer) and were refined to Rwork and Rfree values of 14.5
and 19.2%, respectively (Table 1). TheMtbDsbA structure has
a canonical DsbA-like architecture comprising a Trx domain
with a helical domain inserted into the middle of the Trx
domain (Fig. 4a). The two MtbDsbA molecules in the asym-
metric unit are very similar (r.m.s. deviation of 0.26 A˚ for all
C# atoms). However, the structure of MtbDsbA differs
significantly from the prototypical EcDsbA with an r.m.s.
deviation of 3.7 A˚ for 149 C# atoms (PDB entry 1fvk chain A;
3.7 A˚ for 148 C# atoms for 1fvk chain B; Guddat et al., 1997).
Notable differences from EcDsbA include the folding
topology of the central "-sheet, an additional helix H8 at the
C-terminus and a much shorter connecting loop between "5
and H7 (Fig. 4a) that forms part
of the binding interface between
EcDsbA and its redox partner
EcDsbB. As in all thioredoxin-
like proteins, the catalytic CXXC
motif is located at the N-terminus
of helix H1 in MtbDsbA.
A structural comparison of
MtbDsbA against all structures in
the PDB using DALI (Holm et
al., 2008) revealed similarities to
other DsbA structures, albeit
with relatively large r.m.s. devia-
tions (2.1–4.0 A˚ for 148–168 C#
atoms) and weak sequence
conservation (Supplementary
Fig. S3). The closest structural
similarity occurs with DsbAs
from Gram-positive organisms:
BsDsbA (r.m.s. deviation 2.6 A˚
for 168 C# atoms; 21% identity)
and SaDsbA (r.m.s. deviation
2.1 A˚ for 154 C# atoms; 21%
identity). The central four strands
of the core "-sheet have the same
topology (3–2–4–5) in the Trx
domains of this group of DsbAs.
However, a topological differ-
ence is noted in the arrangement
of strand "1 (Figs. 4 and 5a):
in MtbDsbA, BsDsbA and
WpDsbA1 "1 forms hydrogen
bonds to "5 (3–2–4–5–1), whereas
in the majority of DsbA struc-
tures "1 forms hydrogen bonds to
"3 on the opposite edge of the "-
sheet (1–3–2–4–5).
A unique feature of MtbDsbA
compared with all other structu-
rally characterized DsbAs is the
C-terminal extension that forms
an additional helix, H8, that
packs against helices H1 and H7
(Figs. 4b and 5a). Crystallo-
graphic B factors plotted onto
these helices suggest the possibi-
lity that the H8 helix may reduce
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Figure 4
Structural comparison of MtbDsbA. (a) The crystal structure of MtbDsbA (left) is compared with the
prototypical EcDsbA (right; PDB entry 1fvk; Guddat et al., 1998). Catalytic/noncatalytic cysteine residues
are shown as light grey spheres. The noncatalytic structural disulfide of MtbDsbA is absent in EcDsbA.
Helix H8 appears to be unique to MtbDsbA. The orientation of helix H5 dramatically varies in these two
proteins. Gly204 breaks the hydrogen-bonding pattern in the middle of helix H6 of MtbDsbA (helix H6 is
kinked in MtbDsbA compared with EcDsbA). MtbDsbA appears to be much smaller in size than EcDsbA
in this orientation. However, the molecular surface areas of MtbDsbA (8208 A˚2) and EcDsbA (8670 A˚2)
are comparable. The intramolecular interaction of helix H1 with the C-terminal region of (b) MtbDsbA, (c)
EcDsbA (PDB entry 1fvk; Guddat et al., 1998) and (d) VcDsbA (PDB entry 1bed; Hu et al., 1997) is also
shown. For (b), (c) and (d) the backbone colour is set to the temperature factor from the PDB. The side
chains of interfacing residues identified by PISA (Protein Interfaces, Surfaces and Assemblies; Krissinel &
Henrick, 2007) analysis are shown as sticks. Catalytic and noncatalytic cysteines are shown as grey spheres.
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Figure 5
Structural elements of DsbAs and the catalytic site of MtbDsbA. (a) Structure-based sequence alignment of DsbAs. Structurally equivalent positions
(upper case), variable regions (lower case) and insertions (dashes) are shown. PknE DsbA sequence alignment is based on MtbDsbA and BsDsbA (see
Supplementary Fig. S6 for the PknE hypothetical model). Secondary-structure assignments for MtbDsbA (top green), EcDsbA (bottom blue) and
topological variations originating at strand "1 in MtbDsbA and EcDsbA (orange) are presented. The catalytic motif and cis-Pro motif are highlighted in
cyan and the equivalent EcDsbA residues involved in partner/substrate interaction are highlighted in orange. A negatively charged residue (Glu165) in
the vicinity of the catalytic cysteine, a residue blocking the hydrophobic groove (Trp226) and a noncatalytic structural disulfide bond are marked with red
arrows (see text for details). (b) The structure of the catalytic face of MtbDsbA. Residues forming the putative binding surface and negatively charged
residues neighbouring the catalytic cysteine are shown. The inset displays the 2mFo" DFc electron-density map around the catalytic motif, the cis-Pro
loop and ordered active-site water molecules (1.0! contour level).
the mobility of the catalytic helix H1 in comparison to
EcDsbA and VcDsbA (Figs. 4b–4d). We then analyzed the
interface between helix H1 and the C-terminal H8 region
(Table 3). Compared with other structurally characterized
DsbAs, the presence of helix H8 in MtbDsbA buries a greater
proportion of helix H1 (buried surface area of 592 versus 401–
260 A˚2). The H8 helix interaction may restrict the conforma-
tional flexibility of helices H1 and H7. Similarly, the second
disulfide bond (Cys140–Cys192) of MtbDsbA that links
helices H2 and H5 may also restrict flexibility of the four-helix
bundle (Figs. 4 and 5a). The functional effects of these
conformational restrictions are unclear but might explain at
least in part the differences that we observe in the functional
assays for MtbDsbA and EcDsbA.
The highly conserved structural regions in these DsbAs are
the catalytic motif and cis-proline (cis-Pro) loop, both of which
are known to be critical for activity in other DsbA enzymes
(Kadokura et al., 2004). However, the catalytic motif (Cys89-
Pro90-Ala91-Cys92) in MtbDsbA differs from other structu-
rally characterized DsbAs, which are generally Cys-Pro-His/
Tyr/Ser-Cys. The catalytic cysteines Cys89 and Cys92 display
alternative side-chain conformations corresponding to
oxidized and reduced states (estimated approximately 50 and
65% for reduced states on the basis of crystallographic occu-
pancy), despite the fact that
oxidized protein was used for
crystal growth (Fig. 5b). The
active-site disulfides of DsbA
proteins are susceptible to radia-
tion damage in the crystal
(Guddat et al., 1998) and the
broken disulfide bond in
MtbDsbA is therefore likely to be
a result of the synchrotron
radiation used to measure the
diffraction data. In its reduced
form in the crystal, Cys89 of
MtbDsbA is likely to exist as the
thiolate (pKa 4.2, pH in the
crystal drop 5.5). Ordered active-
site water molecules are present
in the crystal structure at posi-
tions consistent with formation of
stabilizing hydrogen bonds to the
Cys89 thiolate and to Thr214, a
residue preceding the cis-Pro
loop. This hydrogen-bonding
network differs from that in
EcDsbA, which has a Val at the
equivalent position to Thr214, but
is similar to that in SaDsbA,
which also has a Thr prior to the
cis-Pro residue (Heras et al.,
2008).
3.5. The surface surrounding the
active site of MtbDsbA differs
from that of EcDsbA
The conformation and amino-
acid composition of the loop
connecting the Trx domain and
the helical domain ("3–H2, L1),
an inter-helix loop (H3–H4, L2),
the cis-Pro loop (H6–"4, L3) and
the connecting loop "5–H7 (L4)
create the surface features
surrounding the catalytic cysteine
(Cys89) of MtbDsbA (Fig. 5).
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Figure 6
Comparison of surface properties. (a) Hydrophobicity surface presentations for MtbDsbA and EcDsbA.
Surface colourings are mapped to the Kyte–Doolittle hydrophobicity scale from purple (most hydrophilic)
to white to tan (most hydrophobic). The MtbDsbA structure is shown (left) with the modelled VKOR
peptide (VPSCNV) and crystallographically identified artificial ligand 1,4-dioxane (see text and
Supplementary Fig. S4 for details). The EcDsbA–EcDsbB complex structure is shown on the right
(PDB entry 3e9j; Malojcic´ et al., 2008). For clarity only the periplasmic loop segment ‘PFATCDF’ of
EcDsbB is shown. Electrostatic surface comparisons of (b) MtbDsbA, (c) the hypothetical model of PknE
DsbA and (d) EcDsbA. Electrostatic surface potential is contoured between "6 (red) and +6 (blue) kT/e.
The homology model of PknE (template based on MtbDsbA and BsDsbA) was prepared inMODELLER
(Eswar et al., 2006) and atomic clashes were minimized in Chiron (Ramachandran et al., 2011).
Crystal structures of EcDsbA in complex with protein part-
ners have shown that the hydrophobic patch created by loops
L1 and L3, the active-site motif and the hydrophobic groove
formed by loop L4 and helix H1 contribute to interactions
with partner proteins (Paxman et al., 2009; Inaba et al., 2006).
The length and amino-acid identity of these loops are gener-
ally not conserved among DsbAs (Fig. 5a). The relatively long
L4 loop in EcDsbA creates a large hydrophobic groove
compared with the short loop found in MtbDsbA, SaDsbA
and BsDsbA (Fig. 6). In MtbDsbA, the side chain of Trp226
(L4 loop) sits in a shallow groove formed by Ile94, Phe95,
Gly98, Phe99, Ser227, Thr228 and Pro229 (Fig. 5b). The
hydrophobic nature of the surrounding catalytic residues is
largely preserved in MtbDsbA (Fig. 6). Unexpectedly, a
ligand, 1,4-dioxane from the crystallization solution, was
bound in this shallow groove, forming contacts with Ile94,
Gly98, Phe99 and Pro229 (Supplementary Fig. S4). MtbDsbA
also has two negatively charged residues near the catalytic
Cys89, similar to those observed in SaDsbA (Glu165 and
Glu225, see Fig. 5b). The SaDsbA glutamate equivalent to
Glu165 has been shown to influence the pKa of the catalytic
cysteine (Heras et al., 2008).
3.6. MtbDsbA binds a peptide derived from VKOR
Although the binding surface of MtbDsbA does not have
the distinct binding groove of EcDsbA that interacts with a
periplasmic loop of its membrane partner EcDsbB, we inves-
tigated whether a fragment of a periplasmic loop from the
putative binding partner MtbVKOR would interact with
MtbDsbA. We used ITC to assess the binding of MtbDsbA to
several peptides derived from MtbVKOR (see Supplementary
Fig. S5 for the quality of the ITC data). Topological prediction
indicated that MtbVKOR is comprised of five transmembrane
helices connected by two periplasmic loops. Cys57 from the
first periplasmic loop has been shown to form a mixed disul-
fide bond with EcDsbA (Wang et al., 2011), although a direct
interaction of MtbVKOR with any mycobacterial protein has
not been reported. We found that the MtbVKOR 11-residue
peptide segment surrounding Cys57 (51PIYVPSCNVNP61)
binds to MtbDsbA with an apparent Kd of 3.8 mM (Table 4).
Trimming from either end of this peptide showed that a
minimal hexapeptide (54VPSCNV59) binds to MtbDsbA with
Kd,app = 6.7 mM. Further, modelling of the 54VPSCNV59
peptide onto MtbDsbA suggested that Tyr53 of the VKOR
sequence might bind to the site occupied by 1,4-dioxane in the
crystal structure (Fig. 6a). Indeed, this heptapeptide
53YVPSCNV59 showed improved binding (Kd,app =2.9 mM) to
MtbDsbA. Binding of this VKOR peptide to MtbDsbA is
cysteine-dependent, as substitution of Cys with Ala or Leu or
mutation of the MtbDsbA catalytic Cys89 to Ala abolished
binding under the conditions tested.
3.7. Comparison with the predicted mycobacterial DsbA-like
domain of PknE
Aside from MtbDsbA, the H37Rv strain encodes five other
putative extracytoplasmic Trx-related proteins: DsbE
(Rv2878c), DsbF (Rv1677), Rv3673c, Rv0526 and the trans-
membrane protein kinase PknE (Rv1743). PknE is a clear
structural homologue of MtbDsbA and also contains a kinase
domain. Curiously, sequence searches suggest that PknE
orthologues are restricted to pathogenic mycobacteria and
PknE appears to be the only Mtb protein kinase fused to a
DsbA homologous domain. The PknE predicted DsbA
domain (residues 377–566) is linked to the intracellular
protein kinase domain (residues 1–289) through a single-pass
transmembrane helix (residues 337–359). Sequence compar-
ison and secondary-structure prediction are consistent with
the notion that PknE DsbA shares the same overall fold as
that of MtbDsbA. We generated a homology model for PknE
DsbA based on the MtbDsbA structure to compare the
sequence variation in the context of the three-dimensional
structure (Supplementary Fig. S6). Predicted differences from
MtbDsbA in the PknE DsbA domain include the absence of
helix H8 and a short helix H7 at the C-terminus. There are also
sequence variations in loops L1, L3 and L4 (Fig. 5a). Predicted
similarities in PknE DsbA include conservation of the Thr-cis-
research papers
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Table 3
Analysis of the interface between helix H1 and the C-terminal region of DsbA structures.
The buried surface area (BSA) in helix H1 (column 3) was determined using PISA analysis (Krissinel & Henrick, 2007). DsbAs, their PDB codes (column 1, in
parentheses) and the residue ranges in helix H1 (column 2, in parentheses) and the C-terminal region (column 4, in parentheses) included in the PISA analysis are
listed. The percentage of surface area buried in helix H1 relative to its total accessible surface area (#2000 A˚2) is given in column 3 (in parentheses). For MtbDsbA
and EcDsbA, BSA and the values reported for the percentage of surface area buried are an average of two MtbDsbA chains (molecule 1 and molecule 2 in the
asymmetric unit) and nine EcDsbA chains [PDB entries 1dsb (two chains; Martin et al., 1993), 1fvk (two chains; Guddat et al., 1997), 1a2m (two chains; Guddat et
al., 1998), 1a2l (two chains; Guddat et al., 1998) and 1a2j (one chain; Guddat et al., 1998)].
Protein (PDB code)
No. of interfacing
residues in helix H1 Helix H1 BSA (A˚2)
No. of interfacing residues
in C-terminal region
MtbDsbA 13 (89–109) 592 & 4 (29.6) 18 (226–255)
EcDsbA 9 (30–50) 401 & 42 (18.9) 10 (168–188)
BsDsbA (3eu3; Crow et al., 2009) 8 (69–91) 355 (15.9) 8 (205–222)
SaDsbA (3bci; Heras et al., 2008) 9 (26–46) 370 (15.8) 7 (167–178)
PaDsbA (3h93; Shouldice et al., 2010) 7 (37–55) 282 (14.3) 9 (166–192)
VcDsbA (1bed; Hu et al., 1997) 8 (30–48) 261 (13.7) 6 (164–181)
WpDsbA (3f4r; Kurz et al., 2009) 9 (51–71) 363 (16.5) 9 (196–218)
NmDsbA1 (3a3t; Vivian et al., 2009) 7 (57–74) 290 (15.5) 7 (189–212)
Pro motif, a glutamate equivalent of Glu225 and a tyrosine
equivalent of Trp226. The calculated electrostatic potential
surfaces are negative in the region surrounding the catalytic
site in both proteins (Figs. 6c and 6d). However, the CPPC
catalytic motif in PknE DsbA differs from that of CPAC of
MtbDsbA. These differences may contribute to a difference in
redox characteristics. In EcDsbA, mutation of CPHC to CPPC
dramatically increased its reducing potential ("122 mV to
"220 mV; Bessette et al., 2001). The native CPPC active site in
a DsbA homologue from Salmonella enterica (SeSrgA) has
also been linked to a more strongly reducing potential
("154 mV). Indeed, the insulin reductase activity of SeSrgA
was shown to be similar to that of the disulfide isomerase
EcDsbC (Heras et al., 2010).
4. Discussion
Novel drug targets are desperately needed to combat tuber-
culosis. Mycobacterial proteins exported across the cyto-
plasmic membrane play important roles in Mtb adhesion,
invasion, virulence, pathogenesis and survival inside host cells.
Drugs targeting export systems in Gram-negative bacteria
have been tested for their ability to block delivery of effector
proteins required for virulence (Moir et al., 2011). Likewise,
there are intensive efforts to develop antituberculosis drugs
that target the major mycobacterial protein-export systems:
the Sec pathway, the Tat pathway and the ESX pathways
(Feltcher et al., 2010; McCann et al., 2011).
Another approach is to target the disulfide pathways that
mediate disulfide-bond formation and correct folding of
exported proteins in Mtb (Chim et al., 2010, 2011; Goulding et
al., 2004). In bacteria, disulfide-bond formation in newly
exported proteins is commonly mediated through mechanisms
that rely on electron transfer between redox proteins. The
best-studied protein redox pair, DsbA/DsbB, is found in most
aerobic #-, "- and $-proteobacteria. However, in myco-
bacteria and other actinobacteria, cyanobacteria and %- and "-
proteobacteria, it has been proposed that DsbA/VKOR forms
a functional redox pair to catalyze disulfide-bond formation
(Dutton et al., 2008; Li et al., 2010; Wang et al., 2011). The
currently accepted mechanism is that the cysteine-containing
periplasmic loop of transmembrane protein DsbB or VKOR is
transiently drawn into the binding groove of DsbA (Fig. 6) to
drive the flow of electrons (Inaba & Ito, 2008). Oxidized DsbA
then exchanges its catalytic disulfide bond with newly
exported proteins by transiently interacting with them through
its catalytic cysteine and binding surface (Inaba & Ito, 2008;
Inaba et al., 2006; Kadokura et al., 2003). Thus, compounds
targeting the protein–protein interaction surface responsible
for interaction between DsbA and its substrate proteins or
between DsbA and DsbB/VKOR may inhibit virulence-factor
maturation in pathogens.
The data we present here show that Rv2969c has disulfide
oxidase activity, a highly acidic active-site cysteine, a desta-
bilizing active-site disulfide and a highly oxidizing potential.
Structurally, MtbDsbA has a canonical DsbA architecture
with a CXXC active-site motif. We therefore conclude that
Mtb Rv2969c is an authentic DsbA enzyme. Our data also
show that MtbDsbA is able to interact tightly with a seven-
residue peptide corresponding to the periplasmic loop of
MtbVKOR and these data support the notion that MtbDsbA
and MtbVKOR are a functional redox pair that could catalyze
disulfide-bond formation in newly translocated substrates.
Helix H8 at the C-terminus of MtbDsbA and its interaction
with active-site helix H1 are unique to MtbDsbA among
structurally characterized DsbAs. This feature appears to be
absent in the DsbA-like domain of PknE. Substrate binding
and mobility of DsbAs has been linked to the catalytic activity
of DsbA (Horne et al., 2007). In this context, restraint of helix
H1 by helix H8 in MtbDsbA may contribute to the catalytic
activity of MtbDsbA. Moreover, the relatively negative
surface potential surrounding the catalytic site of MtbDsbA
compared with EcDsbA suggests that these two enzymes have
very different substrate-binding specificities. This is supported
by our assay data showing the relative activities of these two
enzymes in assays for reductase (MtbDsbA no activity),
oxidase (MtbDsbA slower activity) and isomerase (MtbDsbA
marginal activity) activity. EcDsbA is known to be a promis-
cuous enzyme that interacts with many substrates. Our struc-
tural and functional data suggest that MtbDsbA may have a
more limited number of specific substrates.
Previous work has shown that the anticoagulant warfarin
that inhibits human VKOR can also inhibit MtbVKOR and it
interferes with the growth of Mtb in cell studies (Dutton et al.,
2010). Inhibiting MtbVKOR is an appealing strategy for
treating Mtb, but will require the design of selective inhibitors
that target MtbVKOR and not its human counterpart. Our
results suggest that MtbDsbA may represent an alternative
target for inhibiting disulfide oxidation in Mtb and for
preventing the production of virulence factors.
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Table 4
Thermodynamic parameters for VKOR-derived peptides binding to
MtbDsbA.
Kd,app, apparent dissociation constant; !H, enthalpy change; T!S, tempera-
ture (K)$ entropy change;N is the apparent stoichiometry. T!S is calculated
from the free energy equation (!H " T!S = "RTlnKd,app). Values reported
are the mean and standard deviation of the curve fits from two ITC runs in
each case. Representative ITC profiles are provided in Supplementary Fig. S5.
n.b., no binding detected. 1 cal = 4.184 J.
N
Kd,app
(mM)
!H
(kcal mol"1)
"T!S
(kcal mol"1)
PIYVPSCNVNP 1.0 3.8 & 0.2 "10.9 & 0.0 3.5
VPSCNVNP 1.0 5.9 & 2.6 "7.1 & 4.0 2.5
VPSCNV 1.0 6.7 & 0.0 "6.8 & 0.2 "0.1
VPSLNV n.b.
YVPSCNV 1.1 2.9 & 0.3 "7.0 & 0.4 "0.5
YVPSANV n.b.
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Figure S1: Thermal shift assay raw fluorescence measurements of peptide PSPFATCDF binding to 
oxidized EcDsbA. 
 
Figure S2: Isothermal titration calorimetry profiles of peptide PSPFATCDF binding to oxidized and 
reduced EcDsbA.  
 
Figure S3: characterization data of the 31 synthesized peptides including HPLC retention times and 
high-resolution mass spectrometry measurements.  
 
Figure S4: HPLC profiles of peptide PWATCDF. 
 
Figure S5: HPLC profiles of peptide PWATCDS. 
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Supplementary figure S1. Thermal shift assay raw fluorescence measurements of oxidized 
EcDsbA in presence of different concentrations of peptide PSPFATCDF (peptide 1). Positive 
control with no peptide is shown in red, negative control with no EcDsbA in pink (along the 
baseline), and dye only as a light green (also along the baseline).  
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Supplementary figure S2. Isothermal Titration Calorimetry profiles and curve-fitting of EcDsbA 
titration with peptide PSPFATCDF. A. Titration using oxidized EcDsbA. B. Titration using reduced 
EcDsbA. Graph is representative of three independent experiments. 
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Supplementary figure S3. Characterization of synthetic peptides  
N° Sequence RT (min)A Calculated mass 
MH+ 
Calculated mass 
M2H+/2 
Measured 
LCMS 
2020 
Measured 
Q-STAR 
HRMS 
1 PSPFATCDF 4.4 1025.4397	   513.2235 1025.5 N.D.*	  
2 PSPFATCD 3.7 878.3713	   439.6893 878.5 878.3717	  
3 PSPWATCDF 4.5 1064.4506	   532.7289 1064.6 532.7289	  
4 PSPWATCD 3.7 917.3822	   459.1947 917.5 459.1946	  
5 PSPWATC 3.8 802.3552	   401.6812 802.5 802.3548	  
6 PSP(hF)ATC 4.0 777.3600	   389.1836 777.5 777.3602	  
7 PSP(1Dip)ATC 4.6 839.3756	   420.1914 839.2 839.3754	  
8 PS(pip)WATC 4.1 816.3709	   408.6891 816.5 807.3705	  
9 PS(thiq)WATC 4.6 864.3709	   432.6891 864.5 864.3711	  
10 ASPWATCDF 4.3 1038.4349	   519.7211 1038.5 519.7207	  
11 PAPWATCDF 4.6 1048.4557	   524.7315 1048.6 524.7134	  
12 PSAWATCDF 4.4 1038.4349	   519.7211 1038.5 519.7207	  
13 PSPAATCDF 3.7 949.4084	   475.20785 949.5 949.4081	  
14 PSPWAACDF 4.5 1034.4400	   517.7237 1034.5 517.7239	  
15 PSPWATADF 4.3 1032.4785	   516.7429 1032.5 516.7429	  
16 PSPWATCAF 4.6 1020.4608	   510.734 1020.5 N.D.*	  
17 PSPWATCDA 3.7 988.4193 494.7133 988.5 494.7131	  
18 PSPWATCDFMV 5.0 1294.5595 647.7834 1294.7 677.7832	  
19 PSPWATCDFM 4.8 1195.4911 598.2492 1195.6 598.2492	  
20 SPWATCDF 4.3 967.3978 484.2026 967.5 484.2026	  
21 PWATCDF 4.7 880.3658 440.6866 880.5 880.3659	  
22 PWATCDS 3.9 820.3294 410.6684 820.4 820.3296	  
23 P(hF)ATCDS 3.5 795.3342 398.1708 795.3 795.3344	  
24 PSPWATSDF 4.1 1048.4734 524.7404 1048.6 N.D.*	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25 PSPWAT(hS) 3.5 800.3937 408.6891 800.5 800.3863	  
26 PSPWATN 3.5 813.3890 407.1981 813.5 813.3847	  
27 PSPWATVDF 5.0 1060.5098 530.7585 1060.6 N.D.*	  
28 PSPWATIDF 4.7 1074.5255 537.7664 1074.6 537.7668	  
29 PSPWAT(Nve) 3.1 798.4145 399.7109 798.6 798.4149	  
30 PSPWATM 4.0 830.3865 415.6969 830.5 830.3865	  
31 PWATSDS 3.6 804.3523 402.6798 804.5 804.3524	  	  
Aretention time in minutes using a 0-100% gradient of 90/9.9/0.1 acetonitrile/H2O/trifluoroacetic 
acid over 10 min. N.D.* the peptide mass was not detected in high resolution mass spectrometry. 	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Supplementary figure S4. HPLC profiles of peptide 21 PWATCDF. UV measurements at 214nm 
are shown along with gradient of solvent over time. A. Elution profile on a 0-100% gradient of 
90/9.9/0.1 acetonitrile/H2O/trifluoroactic acid over 10 minutes. B. Elution profile on a 0-50% 
gradient of 90/9.9/0.1 acetonitrile/H2O/trifluoroactic acid over 10 minutes.     
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Supplementary figure S5. HPLC profiles of peptide 22 PWATCDS. UV measurements at 
214nm are shown along with gradient of solvent over time. A. Elution profile on a 0-100% gradient 
of 90/9.9/0.1 acetonitrile/H2O/trifluoroactic acid over 10 minutes. B. Elution profile on a 0-50% 
gradient of 90/9.9/0.1 acetonitrile/H2O/trifluoroactic acid over 10 minutes.     
	  	  
